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Abstract 
The ubiquitin ligase Mdm2 targets proteins (including p53) for proteasomal 
degradation. Its tumour-promoting role is well-established, but its regulation and role 
in cardiac myocytes (terminally-differentiated cells that are not susceptible to 
neoplastic transformation) have not been investigated. Microarray studies showed 
significantly increased expression of the orthologous rat Mdm2 mRNA in cardiac 
myocytes following oxidative stress (H202). The aim here was to examine the 
underlying mechanisms. Consistent with microarray data, H202 (0.1-0.3 mM) 
significantly increased Mdm2 transcription (maximal at 2 h as determined by semi-
quantitative RT-PCR). This required de novo protein synthesis, thus Mdm2 is not an 
immediate early gene. H202 also significantly increased abundances of total Mdm2 
protein and phospho-Mdm2(Ser-166) (an Akt- or MAPKAPK2-mediated 
phosphorylation associated with increased stability and activity). The Mdm2 gene 
possesses constitutively-active (P1) and inducible (P2) promoters. H202-induced 
transcription of Mdm2 originated from P2. This region contains binding sites for 
several transcription factors including two p53 sites, two Ets sites [Ets(A) and Ets(B)] 
and an AP-1 site that forms a composite with the Ets(B) site. p53 is a well-established 
factor upregulating expression from P2. However, p53 was not detectably induced by 
H202 in cardiac myocytes as measured by immunoblotting or electrophoretic mobility 
shift assays (EMSAs). EMSAs using native oligonucleotide sequences showed that 
transcription factor binding to the P2 Ets(A) sequence increased at 15-45 min whereas 
binding to the AP-1 sequence increased at 1-2 h. With H202, supershift assays showed 
the presence of Jun family proteins in the AP-1 protein/oligonucleotide complexes. 
The role of this element in increased Mdm2 expression was investigated further using 
2 
chromatin immunoprecipitation assays. These suggested that JunB and JunD interact 
with the AP-1 sequence under basal conditions, presumably mediating repression. 
With H202, c-Jun mRNA and c-Jun protein expression increased and c-Jun displaced 
JunB/JunD from the Mdm2 P2 AP-1 element, presumably promoting expression. These 
studies increase our understanding of the regulation of Mdm2 expression in cardiac 
myocytes. 
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Chapter one 
Introduction 
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1.1 Cardiac myocytes 
Cardiac myocytes are the contractile cells of the heart and while constituting only 30% 
of the cardiac cell number, myocytes occupy approximately 75% of the normal 
myocardial tissue volume (Vliegen et al. 1991). Cardiac myocytes are terminally-
differentiated, having withdrawn from the cell cycle and become arrested in Go/G1 prior 
to birth (Capasso et al. 1992; Soonpaa et al. 1996). A second phase of DNA synthesis 
in the absence of cell division occurs following birth up to approximately neonatal day 
10 and results in two separate nuclei being present in the majority of adult cardiac 
myocytes (Soonpaa et al. 1996). In response to a demand for increased contractile 
power, cardiac myocytes undergo compensatory hypertrophic growth. Hypertrophy is 
an increase in the content of cellular components in the absence of cell division. 
Cardiac hypertrophy initially has beneficial effects, allowing cardiac output to be 
maintained or increased. However, chronic hypertrophy is associated with increased 
risk of dilated cardiomyopathy, heart failure, sudden death and ischaemic heart disease 
(Casale et al. 1986; Levy et al. 1990; Koren et al. 1991; Bolognese et al. 1994; Vakili et 
al. 2001). There is some evidence that a sub-population of cardiac myocytes is able to 
re-enter the cell cycle and replicate (Anversa et al. 2002). However, this is unlikely to 
be sufficient to compensate for any substantial cardiac myocyte death (Wencker et al. 
2003). 
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1.2 Cell death 
1.2.1 Forms of cell death 
There are two principal forms of cell death: necrosis and apoptosis. Necrosis is 
considered to be an unregulated process, producing cellular debris and an inflammatory 
response. In contrast, apoptosis is a highly-regulated ATP-dependent form of cell death 
(programmed cell death, PCD). Apoptosis results in the progressive dismantling of 
cellular contents with their absorption into the surrounding tissue in the absence of an 
inflammatory response. Other forms of cell death have been described and include 
autophagy (Shimizu et al. 2004; Yu et al. 2004), oncosis (Majno and Joris 1995) and 
necrapoptosis/para-apoptosis (Lemasters 1999; Sperandio et al. 2000). However, 
comparatively little is known about the importance and molecular mechanisms of these 
forms of death. 
1.2.2 Apoptosis 
1.2.2.1 	Caspases 
Caspases are a family of cysteine-dependent aspartate-directed proteases which are 
largely responsible for the regulated dismantling of cellular protein contents that occurs 
in apoptosis. Caspases are expressed as inactive pro-enzymes that require dimerization 
to become active. The caspase family can be divided into initiator caspases (caspases-
2, 9, 8 and 10) and effector caspases (caspases-3, 6 and 7). Activated initiator caspases 
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cleave and activate effector caspases to initiate a proteolytic cascade. More than 280 
cellular substrates for caspases have been reported (Fischer et al 2003). A classical 
caspase substrate is ICAD (inhibitor of caspase-activated DNase) (Liu et al. 1997; Enari 
et al. 1998). Cleavage of ICAD by caspase-3 activates CAD (caspase-activated DNase) 
which catalyses DNA fragmentation, considered a hallmark of apoptosis. Caspase-3 
also cleaves the anti-apoptotic proteins Bcl-2 (see Section 1.2.2.3) (Cheng et al. 1997) 
and c-IAP1 (see Section 1.2.2.4) (Clem et al. 2000). Cleavage inactivates their anti-
apoptotic function and yields a pro-apoptotic fragment. Other caspase-substrates 
include structural proteins [e.g. fodrin (Janicke et al. 1998)] and protein kinases that are 
activated [e.g. p21 activated kinase (PAK) (Walter et al. 1998; Rudel et al. 1998)] or 
inactivated [e.g. Ca2+/calmodulin-dependent protein kinase-like kinase (Kruidering et 
al. 2001)]. There is activation of caspase-3 in cultured cardiac myocytes undergoing 
apoptosis in response to a range of stresses, including H202 (Cook et al. 1999) or 
hypoxia/reoxygenation (Kang et al. 2000a). Two principal apoptotic pathways lead to 
caspase activation, the extrinsic and intrinsic. The extrinsic pathway (Figure 1.1) is 
activated by the binding of specific ligands to cell surface death receptors and allows 
cells to respond to the immediate external environment. The intrinsic pathway (Figure 
1.2) is driven by organelles, particularly the mitochondria, which detect and respond to 
unfavourable changes in the internal environment. 
1.2.2.2 The extrinsic pathways of caspase activation 
A subset of the tumor necrosis factor receptor (TNFR) superfamily possesses the 
intracellular death domain (DD) motif. This includes the Fas receptor (FasR also 
known as CD95 or Apo-1), TNFR1, TNF-related apoptosis-inducing ligand (TRAIL) 
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receptor 1 (DR4) and TRAIL receptor 2 (DR5). On binding their respective ligands, 
these receptors mediate caspase activation. Taking FasR as an example (Figure 1.1), 
binding of the Fas ligand (FasL) to FasR causes trimerization of the receptor (Banner et 
al. 1993). The FasR DD then recruits the adapter protein Fas-associated DD (FADD), 
which possesses a complementary DD in its C-terminal region (Chinnaiyan et al. 1995; 
Boldin et al. 1995). The N-terminus of FADD contains a death effector domain (DED) 
and this recruits pro-caspase-8 through the DED contained in its pro-domain (Boldin et 
al. 1996; Muzio et al. 1996). Together the DD and DED containing proteins form the 
death-inducing signalling complex (DISC) (Kischkel et al. 1995; Medema et al. 1997). 
The trimeric state of the receptor allows up to three caspase-8 molecules to exist in a 
single DISC and, in addition, receptors undergo high ordered oligomerization (Dhein et 
al. 1992; Kischkel et al. 1995). Oligomerization of pro-caspase-8 leads to its 
autocatalytic cleavage and activation (Martin et al. 1998; Muzio et al. 1998; Yang et al. 
1998). Chang et al. (2003) propose that following its recruitment by FADD, pro-
caspase-8 molecules form stable enzymatically-competent dimers that cleave and 
activate adjacent dimers in an oligomer (Figure 1.1). Pro-caspase-8 dimerization is 
determined to be essential for its activation (Boatright et al. 2003; Chang et al. 2003; 
Donepudi et al. 2003). However, cleavage is indicated to be neither necessary nor 
sufficient for pro-caspase-8 activation but serves to stabilise active dimers (Boatright et 
al. 2003). Activated caspase-8 cleaves and activates pro-caspase-3 (Srinivasula et al. 
1996; Chang et al. 2003). This probably occurs in the cytoplasm following the release 
of active caspase-8 from the membrane (Martin et al. 1998). 
cFLIP [cellular FLICE (caspase-8) inhibitory protein] is an important regulator of the 
FasL - caspase-8 pathway (Irmler et al. 1997). cFLIP is expressed as long (cFLIPL) and 
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short (cFLIPs) isoforms. Both possess two DEDs and cFLIPL possesses an additional 
catalytically-inactive caspase-like domain (Irmler et al. 1997). cFLIPs and cFLIPL bind 
to FADD and caspase-8 and inhibit FasL/FasR-induced caspase-8 activation and 
apoptosis (e.g. Irmler et al. 1997; Krueger et al. 2001). cFLIPL when expressed at 
lower levels can promote caspase activation, this is through its caspase-like domain 
which allows the formation of active heterodimers with pro-caspase-8 within the DISC 
(Chang et al. 2002; Micheau et al. 2002; Boatright et al. 2004). 
The involvement of the death receptor pathway in cardiac myocyte apoptosis has been 
demonstrated in several studies. FasR and FasL protein levels are increased in cultured 
cardiac myocytes undergoing apoptosis in response to stretch (Liao et al. 2005) or 
simulated ischaemia/reperfusion (Stephanou et al. 2001). Ischaemia/reperfusion in the 
isolated rat heart increases FasL, FasR, TNFa (tumor necrosis factor a) and TRAIL 
protein levels (Jeremias et al. 2000; Stephanou et al. 2001). In the cardiac myocytes of 
rabbit hearts subjected to ischaemia/reperfusion in vivo there is increased FasR protein 
expression and apoptosis (Yue et al. 1998). Mice lacking functional FasR have reduced 
cardiac myocyte apoptosis following ischaemia/reperfusion in the heart ex vivo 
(Jeremias et al. 2000) and in vivo (Lee et al. 2003). Human studies of Fas in the heart 
have been limited and conflicting. Yamamura et al. (1999) show that cardiac myocytes 
exhibit increased apoptosis together with increased FasR protein in samples from 
human patients with cardiomyopathy compared with controls. However, in examining 
biopsies of human failing hearts, Filippatos et al. (1999) show that regions of the 
myocardium that label positively for FasR protein do not show increased apoptosis 
compared with FasR negative regions. 
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Despite the strong evidence in support of a role for the Fas pathway in cardiac myocyte 
apoptosis, these cells in culture (Wollert et al. 2000; Badorff et al. 2002) and the murine 
heart in vivo (Wollert et al. 2000; Nelson et al. 2000) are generally resistant to apoptosis 
induced by FasL alone. Cardiac myocyte apoptosis is only detected following exposure 
to very high levels of FasL (Yamaoka et al. 2000; Lee et al. 2003). Cardiac myocytes 
express significant levels of cFLIP (Irmler et al. 1997; Imanishi et al. 2000; Yaniv et al. 
2002) and there is good evidence to support the hypothesis that this provides resistance 
to FasL. Downregulation of cFLIP together with augmentation of apoptosis induction 
by FasL occurs in cultured cardiac myocytes exposed to H202 (Nitobe et al. 2003; 
Yaniv et al. 2005), doxorubicin (an anti-neoplastic agent that causes cardiac myocyte 
apoptosis) (Nitobe et al. 2003) or hypoxia (Yaniv et al. 2002). Consistent with these 
findings, downregulation of cFLIP by RNAi increases apoptosis in cultured cardiac 
myocytes exposed to simulated ischaemia/reperfusion (Davidson et al. 2003). 
Furthermore, in rat hearts subjected to ischaemia/reperfusion in vivo (Rasper et al. 
1998) and in failing human hearts (Imanishi et al. 2000), apoptotic cardiac myocytes 
possess reduced amounts of cFLIP protein compared with non-apoptotic cardiac 
myocytes. 
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Figure 1.1 The Fas receptor pathway of caspase activation. 
Binding of Fas ligand (FasL) to the Fas receptor (FasR) causes receptor trimerization. 
Additionally, two or more FasR trimers co-localize. The FasR DD (death domain) 
recruits the adapter protein Fas-associated DID (FADD). FADD recruits pro-caspase-8 
through the DED (death effector domain) present in both proteins. Pro-caspase-8 
undergoes dimerization, and dimers within an oligomer cross-cleave and activate each 
other. Active caspase-8 then cleaves and activates pro-caspase 3. Adapted from Chang 
et al. (2003). 
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1.2.2.3 The mitochondria! intrinsic pathway 
The mitochondrial intrinsic pathway can be divided into two stages (Figure 1.2): 
1. Release of cytochrome c. 2. Formation of the apoptosome with activation of 
caspase-9 and caspase-3. 
Releasing cyctochrome c - the MPTP Opening of the mitochondrial permeability 
transition pore (MPTP) in the inner mitochondrial membrane causes massive swelling 
of the mitochondria, rupture of the outer membrane and release of intermembrane 
components that include cytochrome c (Figure 1.2) (Kantrow et al. 1997; Scarlett et al. 
1997; Yang and Cortopassi 1998). The MPTP opens under stress conditions, most 
notably as a result of calcium overload and oxidative stress. Opening of the MPTP and 
release of cytochrome c into the cytosol are detected in cultured cardiac myocytes 
undergoing apoptosis induced by hypoxia (Gurevich et al. 2001; Regula et al. 2002, 
2004) or stretch (Liao et al. 2004). MPTP opening also occurs following 
ischaemia/reperfusion in the isolated rat heart (Griffiths and Halestrap 1995; Javadov et 
al. 2003). Apoptosis is an ATP-dependent process and, therefore, it would seem likely 
that the cell must maintain some functional mitochondria for it to proceed, either 
through closing the MPTP or possibly only opening MPTPs in a subset of the cell's 
mitochondrial population. There is indeed evidence that the MPTP opens and then 
closes following ex vivo cardiac ischaemia/reperfusion in rat (Kerr et al. 1999). 
Releasing cyctochrome c - Bcl-2 proteins The Bcl-2 family are characterized by the 
Bcl-2 homology domains (BH1-4) and comprise anti- and pro-apoptotic members that 
regulate the release of cytochrome c from the mitochondria (reviewed in Willis and 
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Adams 2005). The anti-apoptotic Bcl-2 proteins (e.g. Bcl-2, Bcl-xl, Bcl-w and Mc1-1) 
possess domains BH1-4. Pro-apoptotic Bc1-2 proteins possess domains BH1-3 (Bak 
and Bax) or just BH3 (the BH3-only proteins e.g. Bad, Bim, Noxa and Bid). 
The BH3-only protein Bid is generally active as a truncated form (tBid) generated by 
its cleavage catalysed by proteases including caspase-8 (Li et al. 1998; Luo et al. 1998; 
Gross et al. 1999), the serine protease granzyme B (Sutton et al. 2000) and the cysteine 
protease calpain (Chen et al. 2001a; Mandic et al. 2002). Cleavage of Bid by caspase-8 
allows cross-talk between the intrinsic and extrinsic pathways (Yin et al. 1999). Bak is 
constitutively integrated into the mitochondrial outer membrane, whereas Bax is 
predominantly localised in the cytosol and translocates to the mitochondria in response 
to apoptotic stress (Wolter et al. 1997; Gross et al. 1998). Binding of tBid to Bak (Wei 
et al. 2000; Cheng et al. 2001; Wei et al. 2001; Letai et al. 2002) or Bax (Wang et al. 
1996; Desagher et al. 1999; Eskes et al. 2000; Cheng et al. 2001; Wei et al. 2001; Letai 
et al. 2002) initiates their oligomerization in the outer mitochondrial membrane to 
release cytochrome c. Release of cytochrome c by Bax has received considerable 
attention and can occur in the absence of mitochondrial swelling, loss of mitochondrial 
membrane potential or damage to the inner mitochondrial membrane (Rosse et al. 1998; 
Jurgensmeier et al. 1998; Finucane et al. 1999; Kluck et al. 1999; von Ahsen et al. 
2000). 
Several mechanisms have been proposed for the Bax-mediated release of cytochrome c 
from mitochondria (Figure 1.2). In vitro, Bax is able to form channels in artificial 
membranes (Antonsson et al. 1997; Schlesinger et al. 1997; Antonsson et al. 2000; 
Saito et al. 2000) or cause general destabilisation of a lipid bilayer (Basanez et al. 
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1999). Bax can also act synergistically with VDACs (voltage-dependent anion 
channels) to release cytochrome c through artificial membranes in vitro (Shimizu et al. 
1999, 2000a) and from the mitochondria in vivo (Shimizu et al. 2000b; Shimizu et al. 
2001; Godlewski et al. 2002). Release of cytochrome c by Bax has been associated 
with loss of mitochondrial membrane potential and opening of the MPTP (e.g. Narita et 
al. 1998; Pastorino et al. 1998; Pastorino et al. 2000). It is possible that these events are 
independent or downstream of cytochrome c release (Bossy-Wetzel et al. 1998; 
Goldstein et al. 2000; Ikemoto et al. 2000; Scorrano et al. 2000). Alternatively, under 
some conditions, Bax may directly activate opening of the MPTP (Marzo et al. 1998). 
The anti-apoptotic proteins Bcl-2, Bc1-xl and Mc1-1 prevent cytochrome c release by 
forming inhibitory complexes with their pro-apoptotic cousins e.g. Mc1-1 - Bak (Bae et 
al. 2000; Leu et al. 2004), Bcl-2 Bax (Oltvai et al. 1993; Yin et al. 1994), Bcl-xl - Bax 
(Sedlak et al. 1995; Yang et al. 1995; Chao et al. 1995), Bcl-2 - tBid (Cheng et al. 
2001) and Mc1-1 - tBid (Clohessy et al. 2006). Bcl-2 and Bcl-xl may also prevent 
cytochrome c release through directly closing VDACs (Shimizu et al. 1999; Shimizu et 
al. 2000c). 
The BH3-only proteins can bind anti-apoptotic Bcl-2 proteins to displace Bax or Bak 
and thus promote apoptosis. For example, under basal conditions Bak is bound to Mcl-
1, then in response to apoptotic stress there is increased expression of the BH3-only 
protein Noxa which binds to Mc1-1 and releases Bak (Willis et al. 2005). The 
association with Noxa promotes Mc1-1 degradation (Willis et al. 2005). Bak can also 
be displaced from Mc1-1 by binding of tBid to Mc1-1 (Clohessy et al. 2006). This 
indicates that tBid promotes Bax/Bak activation by direct binding to induce their 
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oligomerization (as detailed above) and by promoting their release from anti-apoptotic 
Bcl-2 proteins. 
Many of the Bcl-2 proteins are expressed in the heart including Bcl-2, Bcl-xl, Bad, Bax, 
Bak and Bid (Cook et al. 1999; Ing et al. 1999; Chen et al. 2001a). As expected, Bcl-2 
and Bcl-xl protect against apoptosis in cardiac myocytes [as shown by their 
overexpression (Kirshenbaum and de Moissac 1997; Kang et al. 2000a; Kunisada et al. 
2002)], while Bax promotes apoptosis in cardiac myocytes [as shown by targeted 
inactivation of the Bax gene (Hochhauser et al. 2003)]. Translocation of Bax from the 
cytosol to the mitochondria parallels release of cytochrome c in cultured cardiac 
myocytes subjected to a range of apoptotic stresses (von Harsdorf et al. 1999; Shiraishi 
et al. 2001; Gupta and Knowlton et al. 2002; Tatsumi et al. 2003; Grazette et al. 2004). 
Similar results are obtained in the rat heart subjected to ischaemia/reperfusion in vivo 
(Lundberg and Szweda 2004, 2006). Interestingly, Grazette et al. (2004) detected 
oligomerization of Bax at the cardiac myocyte mitochondria. Processing of Bid to 
tBID also parallels release of cytochrome c in isolated rabbit heart (Chen et al. 2001a) 
or rat heart (Scarabelli et al. 2002) subjected to ischaemia/reperfusion. 
Formation of the apoptosome On release into the cytosol, cytochrome c binds to 
WD40 repeats in the C-terminal region of the adaptor protein Apaf-1 (apoptotic 
protease activating factor-1) (Li et al. 1997; Zou et al. 1997; Srinivasula et al. 1998). 
Binding of cytochrome c promotes binding of dATP/ATP to the Walker A and B 
nucleotide binding sites in the central region of Apaf-1 (Zou et al. 1997; Zou et al. 
1999; Jiang and Wang 2000). Subsequently, Apaf-1 undergoes homo-oligomerization 
and recruits pro-caspase-9 through interaction between the caspase recruitment domains 
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(CARD) in each Apaf-1 molecule and each pro-caspase-9 molecule (Li et al. 1997; 
Srinivasula et al. 1998; Flu et al. 1998; Saleh et al. 1999; Zou et al. 1999; Jiang and 
Wang 2000). This molecular complex (the apoptosome) contains seven Apaf-1 
molecules held in a wheel structure with seven radiating arms (Figure 1.2) (Zou et al. 
1999; Acehan et al. 2002). Caspase-9 is present in a 1:1 ratio with Apaf-1 (Qin et al. 
1999; Zou et al. 1999). The oligomerization of pro-caspase-9 by Apaf-1 causes its 
autoproteolytic cleavage and subsequent activation (Hu et al. 1998; Srinivasula et al. 
1998). Later studies suggest that pro-caspase-9 dimerization rather than cleavage is the 
necessary step for activation (Stennicke et al. 1999; Renatus et al. 2001; Acehan et al. 
2002; Boatright et al. 2003). Active caspase-9 recruits, cleaves and activates pro-
caspase-3 in the apoptosome (Figure 1.2) (Li et al. 1997; Bratton et al. 2001). Active 
caspase-3 cleaves and activates pro-caspase-9, giving positive feedback (Srinivasula et 
al. 1998; Slee et al. 1999). 
There is activation of caspase-3 and caspase-9 subsequent to cytochrome c release in 
cultured cardiac myocytes subjected to serum/glucose deprivation (Bialik et al. 1999), 
stretch (Liao et al. 2004), hypoxia/reoxygenation (Kang et al. 2000a) or hypoxia alone 
(Gurevich et al. 2001; Regula et al. 2004). Ischaemia/reperfusion in the rat heart ex 
vivo (Scarabelli et al. 2002) or in vivo (Lundberg and Szweda 2004) also causes release 
of cytochrome c and caspase-9 activation. Cytosolic cytochrome c and activated 
caspase-3 are detected in the human failing heart (Narula et al. 1999). Scheubel et al. 
(2002) also showed release of cytochrome c in human heart failure and this was 
associated with activation of caspase-9 but, curiously, there was no detectable 
activation of caspase-3 despite detection of apoptotic cardiac myocytes. The 
importance of Apaf-1 in cardiac myocyte apoptosis is yet to be fully substantiated. In 
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the cardiac myocytes of canine hearts subjected to ventricular pacing, apoptosis is 
detected together with increased Apaf-1 protein and increased association of 
cytochrome c, Apaf-1 and pro-caspase-9 (Cesselli et al. 2001). Association of Apaf-1 
and caspase-9 is also increased in cultured cardiac myocytes induced into apoptosis by 
simulated ischaemia, although Apaf-1 protein levels remained constant (Takatani et al. 
2004a). Two studies suggest that cultured cardiac myocytes express low levels of 
Apaf-1 compared with other cell types and this, at least in part, results in some 
resistance to caspase-3 activation and apoptosis following the release of cytochrome c 
(Sanchis et al. 2003; Potts et al. 2005). These discrepancies remain to be explained. 
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Figure 1.2 The intrinsic pathway of caspase activation 
Cytochrome c (CytC) is released from the mitochondria following opening of the 
mitochondrial permeability transition pore (MPTP) in the inner membrane or pore-
formation in the outer membrane by Bak or Bax. Bax may form a pore independently 
or in combination with VDAC (voltage-dependent anion channel), alternatively Bax 
may release cytochrome c by causing a general permeabilisation of the outer 
membrane. Cytosolic cytochrome c stimulates formation of the apoptosome, an 
oligomer of Apaf-1 and pro-caspase-9. Caspase-9 is activated and then recruits and 
activates pro-caspase-3, resulting in the execution of apoptosis. 
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1.2.2.4 Other regulators and executors of apoptosis 
IAPs Members of the inhibitor of apoptosis protein (IAP) family expressed in cardiac 
myocytes include X-chromosome-linked IAP (XIAP), cellular IAP-1 (cIAP1) and 
cIAP2 (Bergmann et al. 2001). These IAPs bind to and directly inhibit caspases 
(Deveraux et al. 1997; Roy et al. 1997). The expression of cIAP1 and XIAP mRNA and 
protein is downregulated in failing human hearts, although the functional importance of 
this remains to be clarified (Scheubel et al. 2002). 
Other pro-apoptotic mitochondrial proteins 	In addition to cytochrome c, the 
mitochondria release other pro-apoptotic factors including Smac (second mitochondria-
derived activator of caspase)/Diablo, AIF (apoptosis-inducing factor), Omi/HtrA2 and 
endonuclease G. In the cytosol, Smac/Diablo forms inhibitory complexes with IAPs 
(Du et al. 2000; Verhagen et al. 2000). Smac/Diablo is released into the cytosol of 
cultured cardiac myocytes exposed to hypoxia (Regula et al. 2004), 11202 (Jiang et al. 
2005) or stretch (Liao et al. 2004). Translocation of Smac/Diablo to the cytosol also 
occurs in the isolated rat heart following ischaemia/reperfusion (Scarabelli et al. 2004). 
Omi/HtrA2 also binds and inhibits IAPs but, unlike Smac/Diablo, Omi/HtrA2 directly 
degrades IAPs (Martins et al. 2001; Suzuki et al. 2001; Hegde et al. 2002; Verhagen et 
al. 2002; Srinivasula et al. 2003; Yang et al. 2003). Omi/HtrA2 is released into the 
cytosol following ischaemia/reperfusion in the mouse heart in vivo (Liu et al. 2005). 
Administration of a pharmacological inhibitor (ucf-101) of Omi/HtrA2 to mice prior to 
in vivo cardiac reperfusion provides protection against the induction of apoptosis in the 
heart (Liu et al. 2005). Similarly, reduction in Omi/HtrA2 levels by siRNA reduces 
apoptosis in cultured cardiac myocytes subjected to hypoxia/reoxygenation (Liu et al. 
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2005). AIF and endonuclease G promote DNA fragmentation (Susin et al. 1996; Susin 
et al. 1999; Li et al. 2001; van Loo et al. 2001). AIF does not possess intrinsic nuclease 
activity (Susin et al. 1999) and probably synergises with endonucleases as 
demonstrated for endonuclease G in C. elegans (Wang et al. 2002). AIF undergoes 
nuclear translocation in cultured cardiac myocytes exposed to H202 (Chen et al. 2004) 
and in the isolated rat heart subjected to ischaemia/reperfusion (Kim et al. 2003; 
Varbiro et al. 2003). Endonuclease G is expressed in the heart (Cummings et al. 1987) 
but, as far as is known, has not been the subject of investigation in this organ. 
1.2.3 Cardiac myocyte death and the development of cardiac 
pathologies 
A large body of evidence supports the role of apoptosis in the development of heart 
failure. There is increased cardiac myocyte apoptosis in autopsy samples from patients 
who died subsequent to acute myocardial infarction (Itoh et al. 1995; Saraste et al. 
1997; Veinot et al. 1997; Piro et al. 2000; Olivetti et al. 1996; Ottaviani et al. 1999) and 
in the hearts of patients diagnosed with heart failure (Narula et al. 1996; Olivetti et al. 
1997; Saraste et al. 1999; Guerra et al. 1999; Rayment et al. 1999; Petrovic et al. 2000). 
In many studies, the severity of human heart failure correlates with the degree of 
apoptosis (Saraste et al. 1999; Baldi et al. 2002; Metzger et al. 2002; Abbate et al. 
2003; Zorc et al. 2003). Cardiac myocyte apoptosis is detected in canine models of 
heart failure induced by multiple intracoronary microembolizations (Sharov et al. 1996) 
or ventricular pacing (Liu et al. 1995; Leri et al. 1998a). Cardiac myocyte apoptosis is 
detected following cardiac ischaemia/reperfusion in several animal species [Gottlieb et 
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al. 1994 (isolated rabbit heart); Fliss and Gattinger 1996 (rat heart in vivo); Maulik et 
al. 1998a (isolated rat heart); Yaoita et al. 1998 (rat heart in vivo); Maulik et al. 1999a 
(isolated murine heart); Zhao et al. 2000 (canine heart in vivo)]. Some studies suggest 
that ischaemia alone is sufficient to induce apoptosis [Bialik et al. 1997 (mouse heart in 
vivo); Fliss and Gattinger 1996 (rat heart in vivo)], whilst other studies indicate that 
reperfusion is required [Gottlieb et al. 1994 (isolated rabbit heart); Maulik et al. 1999a 
(isolated murine heart); Zhao et al. 2000 (canine heart in vivo); Narayan et al. 2001 
(isolated cardiac myocytes)]. Apoptosis is an ATP-dependent process (Eguchi et al. 
1997; Leist et al. 1997) and, therefore, the diminished levels of ATP present during the 
ischaemic phase (e.g. Jennings et al. 1978) may explain the absence of apoptosis at this 
stage. Indeed, the prominence of necrosis relative to apoptosis increases with 
prolonged ischaemia without reperfusion in the human heart (Veinot et al. 1997), the in 
vivo rat heart (Kajstura et al. 1996) and isolated cardiac myocytes (Narayan et al. 2001). 
Furthermore, cell death is primarily necrotic in cultured cardiac myocytes under 
conditions of ATP-depletion, whereas cell death is primarily apoptotic under conditions 
of abundant ATP (Tatsumi et al. 2003). Apoptosis of cultured cardiac myocytes is 
induced following exposure to a range of physiologically-relevant stresses including 
H202 (Cook et al. 1999) and hypoxiaireoxygenation (Toth et al. 2006). 
Most studies have employed indirect methods such as TUNEL (terminal 
deoxynucleotidyl dUTP nick-end labelling) to detect apoptosis and direct ultrastructural 
evidence of apoptosis occurring during the acute or chronic stage of myocardial 
infarction is rare among cardiac myocytes. However, several studies evaluating the 
effects of pharmacological inhibition of apoptosis in cardiac pathologies have clearly 
demonstrated its importance. Administration of broad-spectrum caspase-inhibitors 
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reduces apoptosis and injury following ischaemia/reperfusion in the isolated rat heart 
(Mocanu et al. 2000; Kovacs et al. 2001) and in the rat heart in vivo (Yaoita et al. 1998; 
Huang et al. 2000). However, the use of inhibitors for individual caspases does not 
have the same protective effects [Okamura et al. 2000 (rat heart in vivo); Kovacs et al. 
2001 (isolated rat heart)]. In support of the results of general caspase inhibition, 
transgenic mice with cardiac-specific increased caspase-8 activity demonstrate that 
cardiac myocyte apoptosis (at levels below those observed in vivo) is sufficient to cause 
lethal heart failure (Wencker et al. 2003). 
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1.3 Oxidative stress and heart disease 
1.3.1 The importance of reactive oxygen species (ROS) in heart 
disease 
Reactive oxygen species (ROS) are generated in cultured cardiac myocytes during 
simulated ischaemia alone (Vanden Hoek et al. 1997; Becker et al. 1999) and following 
simulated reperfusion (Vanden Hoek et al. 1997). In a range of animal species, a burst 
of ROS occurs upon reperfusion of the ischaemic heart both ex vivo [Garlick et al. 1987 
(rat); Zweier et al. 1987 (rabbit); Henry et al. 1990 (rat); Ray et al. 2001 (murine)] and 
in vivo [Bolli et al. 1989 (dog); Mergner et al. 1991 (pig); Grill et al. 1992 (rabbit)]. 
ROS levels are also increased in canine models of heart failure induced by ventricular 
pacing (Ide et al. 1999, 2000). Administration of antioxidants can protect against injury 
resulting from cardiac ischaemia/reperfusion ex vivo [Nishikawa et al. 1991 (rat); 
Ambrosio and Flaherty 1992 (rabbit)] and in vivo [Riva et al. 1987 (rat); Werns et al. 
1988 (dog)]. Clinical data regarding the role of ROS in human heart failure have been 
conflicting. A major problem is the assessment of ROS production in vivo and clinical 
studies have employed indirect methods such as assessment of lipid peroxidation. 
However, patients often have confounding co-morbidities which could induce 
alterations in these biochemical markers independently of cardiac-specific ROS activity 
(Mak and Newton 2001). The measurement of isoprostanes in plasma or urine has 
emerged as the best marker of oxidative stress (Fam and Morrow 2003). 8-Isoprostane 
is generated by the ROS-catalysed non-enzymatic peroxidation of arachidonic acid 
present in membrane phospholipids (Morrow et al. 1990, 1992). 8-Isoprostane is 
increased in human patients following ischaemia/reperfusion caused by acute 
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myocardial infarction followed by thrombolytic therapy (Delanty et al. 1997) or 
angioplasty (Reilly et al. 1997; Guan et al. 1999; Kijima et al. 2001), and in coronary 
bypass surgery with cardioplegia (Delanty et al. 1997; Mehlhorn et al. 2003). 
Furthermore, levels of 8-isoprostane are positively correlated with the severity of heart 
failure in human patients (Mallat et al. 1998). Despite the strong evidence for a role of 
ROS in heart disease, clinical trials with antioxidants have yielded mixed and often 
disappointing results (Yusuf et al. 2000; Cappola et al. 2001; Doehner et al. 2002; Lonn 
et al. 2002, 2005). 
1.3.2 Sources and types of ROS in the heart 
Types of ROS Superoxide (02* -) is probably the initial ROS produced in the 
myocardium (Ide et al. 2000) and this is reduced to H202 by the action of superoxide 
dismutases [Cu2+/Zn2+-SOD in the cytoplasm and Mn2+-SOD in the inner mitochondrial 
space (Slot et al. 1986)] (Kerckaert and Roels 1986). Hydroxyl radicals (OH.) are 
formed in the heart through the iron-catalyzed Haber-Weiss reaction of H202 with 02.  - 
(02' + H202 ---> 011.  + OH- + 02 ) and/or the Fenton reaction of 14202 with iron (H202 
+ Fe2÷ --+ 	+ OH- + Fe3) (Ide et al. 2000). 
The mitochondria as a source of ROS In the process of mitochondrial electron 
transport, oxygen is reduced to water through several steps in which hydrogen atoms 
act as electron donors. Under normal physiological conditions, approximately 1-2% of 
the oxygen used by the electron transport chain forms 02' (Cadenas and Davies 2000). 
Cardiac myocytes possess an abundance of mitochondria (Dobson and Himmelreich 
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2002) and the mitochondria of the heart are a significant source of ROS generation 
(Cadenas et al. 1977; Turrens et al. 1985; Vanden Hoek et al. 1998; Chen et al. 2003). 
The mitochondrial electron transport chain contributes significantly to the increases in 
ROS levels that occur in cultured cardiac myocytes subjected to simulated ischaemia 
alone (Becker et al. 1999), in the rabbit heart subjected to ischaemia/reperfusion ex vivo 
(Ambrosio et al. 1993) and in the canine heart in failure due to ventricular pacing (Ide 
et al. 1999). 
NAD(P)H oxidases The NAD(P)H oxidases are membrane-associated enzymes that 
catalyze the one electron reduction of oxygen using NADH or NADPH as the electron 
donor: NAD(P)H + 202 --* NAD(P)+ + le + 202.  
NADPH oxidase is the major source of ROS production in phagocytes such as 
neutrophils and macrophages, where it forms an important part of the anti-microbial 
arsenal. In co-culture systems, activated neutrophils induce apoptosis in cardiac 
myocytes and this is prevented by carvedilol, a 13-adrenergic antagonist which also has 
antioxidant properties (Dun et al. 2002). In several animal species subjected in vivo to 
cardiac ischaemia/reperfusion, there is myocardial recruitment of neutrophils [Engler et 
al. 1983 (dog); Engler et al. 1986 (dog); Jolly et al. 1986 (dog); Albertine et al. 1994 
(cat); Hiss and Gattinger 1996 (rat); Hayasaki et al. 2006 (mouse)] and macrophages 
[(Bohle et al. 1991 (pig); Zhao et al. 2001 (dog); Hayasaki et al. 2006 (mouse)]. These 
recruited neutrophils and macrophages are a major source of ROS generation (Duilio et 
al. 2001; Hayasaki et al. 2006) and are associated with cardiac myocyte apoptosis (Fliss 
and Gattinger 1996; Nakamura et al. 2000a; Zhao et al. 2001). Administration of anti-
neutrophil antibody depletes the number of circulating neutrophils and reduces infarct 
size following in vivo ischaemia/reperfusion in dogs (Romson et al. 1983; Litt et al. 
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1989). Only a limited number of studies have examined the importance of macrophage 
recruitment in ischaemia/reperfusion injury and results have been conflicting (Dewald 
et al. 2005; Hayasaki et al. 2006). 
NAD(P)H oxidase activity is also a major source of 02— production in cardiac 
myocytes (Mohazzab-H et al. 1997; Li et al. 2002a), in cardiac fibroblasts (Colston et 
al. 2005), in vascular endothelial cells (Moha77ab-H et al. 1994a) and in vascular 
smooth muscle cells (Mohazzab-H et al. 1994b; Griendling et al. 1994). Estimates of 
02.- production in vascular cells suggest that the capacity of these enzymes is about 
one third of those expressed in neutrophils (Ohara et al. 1993; Griendling et al. 1994; 
Pagano et al. 1998). 
Despite the evidence for the contribution of neutrophils and macrophages to 
ischaemia/reperfusion injury and the presence of NAD(P)H oxidase activity in cardiac 
cells, there is a paucity of evidence for NAD(P)H oxidase having an important role in 
the injurious effects of cardiac ischaemia/reperfusion. NAD(P)H oxidase activity is not 
increased following ischaemia/reperfusion in the isolated rat heart (Oudot et al. 2005). 
Furthermore, mice homozygous or heterozygous for a non-functional p47-phox allele [a 
subunit of NAD(P)H oxidase] have similar levels of injury following in vivo cardiac 
ischaemia/reperfusion (Hoffmeyer et al. 2000). However, cardiac levels of p22-phox 
and gp91-phox mRNA [subunits of NAD(P)H oxidase] are increased in rats subjected 
to cardiac ischaemia in vivo (Fukui et al. 2001) and NAD(P)H oxidase activity is 
upregulated in the failing human heart (Heymes et al. 2003; Maack et al. 2003). 
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Xanthine oxidase Xanthine dehydrogenase plays an important role in the oxidative 
metabolism of purines (Holmes and Wyngaarden 1989) but is readily converted to 
xanthine oxidase (X0) by reversible sulphydryl oxidation or irreversible proteolytic 
modification (Waud and Rajagopalan 1976). XO generates 02— or H202 from 02 (e.g. 
Kellogg and Fridovich 1975; Pederson and Aust 1973). Expression of XO in the heart 
appears to be species-specific. X0 is consistently detected in the rat heart (e.g. 
Engerson et al. 1987; Chambers et al. 1987; Coudray et al. 1992; Ashraf and Samra 
1993) but not in the rabbit heart (Grum et al. 1986; Downey et al. 1987; Muxfeldt and 
Schaper 1987). Early studies suggested that the human heart does not contain 
detectable levels of XO (Eddy et al. 1987; Grum et al. 1989; Podzuweit et al. 1991; 
Linder et al. 1999). However, more recent studies indicate that the human heart does 
possess significant amounts of XO (Abadeh et al. 1992, 1993; Moriwaki et al. 1993; 
Cappola et al. 2001). Cardiac myocytes do not possess significant XO activity 
(Kaminski and Wolin et al. 1994; Moha77ab-H et al. 1997) and any XO activity in the 
heart is localised to endothelial cells (Jarasch et al. 1986; Phan et al. 1989; Moriwaki et 
al. 1993; Ashraf and Samra 1993). XO activity is increased in the rat heart subjected to 
ischaemia/reperfusion in vivo (Ashraf and Samra 1993). Studies of the canine heart in 
vivo (Chambers et al. 1985) and the rat heart ex vivo (Chambers et al. 1987; Thompson-
Gorman and Zweier 1990) demonstrate that administration of X0-inhibitors 
(allopurinol or oxypurinol) reduces ROS levels and injury resulting from cardiac 
ischaemia/reperfusion. Similar results are seen in mice subjected to in vivo cardiac 
ischaemia (Engberding et al. 2004; Naumova et al. 2006). Cardiac X0 protein level is 
increased in human heart failure (Cappola et al. 2001) and allopurinol protects against 
ischaemia/reperfusion injury during human coronary bypass surgery (Coghlan et al. 
1994; Gimpel et al. 1995) and human coronary angioplasty (Guan et al. 2003). There is 
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therefore significant evidence supporting an important role for XO in the generation of 
ROS in the human heart and the hearts of at least some animal species. 
1.3.3 Cardiac antioxidants 
Enzymatic and non-enzymatic pathways counter the production of ROS in the heart. 
SODs catalyse the reduction of 02— to H202, which is reduced to H2O by catalase or 
glutathione peroxidase. 	Non-enzymatic cellular antioxidants include reduced 
glutathione (the glutathione peroxidase substrate), and vitamins A, E and C. 
Several studies show decreases in antioxidant activity in the heart following 
ischaemiereperfusion or ischaemia alone. There is suppression of Cu2÷/Zn2+-SOD, 
catalase and glutathione peroxidase activities in the rodent heart subjected to 
ischaemia/reperfusion in vivo [Ko et al. 1990 (rabbit); Ji et al. 1993 (rat)]. In the rat 
heart subjected to in vivo ischaemia without reperfusion, SOD, glutathione peroxidase 
and catalase activities and the levels of vitamin E are initially marginally increased but 
significantly decrease with the onset of heart failure (Hill and Singal 1996; Khaper and 
Singal 1997). In the blood of human patients given reperfusion therapy following 
myocardial infarction, there is a reduction in the levels of vitamin E and the activities of 
SOD and catalase (Dusinovic et al. 1998; Bhakuni et al. 2005; Dwivedi et al. 2006). 
However, the relationship of heart disease and antioxidant status is complex. For 
example, increased catalase activity but unaltered activities of Mn2+-SOD, Cu2+/Zn2+-
SOD and glutathione peroxidase are detected in myocardial tissue from failing human 
hearts (Dieterich et al. 2000). That glutathione peroxidase and SOD are important in 
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protecting against ischaemia/reperfusion injury has been confirmed by overexpression 
or targeted inactivation of their respective genes. Targeted inactivation of the 
glutathione peroxidase gene (Yoshida et al. 1997; Maulik et al. 1999a) or the 
Cu2+/Zn2f  -SOD gene (Yoshida et al. 2000) in mice increases injury following 
ischaemialreperfusion in the isolated heart. Overexpression of Mn2÷-SOD (Chen et al. 
1998) or glutathione peroxidase (Yoshida et al. 1996; Maulik et al. 1999a) in transgenic 
mice protects against ischaemiaireperfusion in the isolated heart. 
1.3.4 Effects of ROS in the heart 
When cellular defences are overwhelmed, ROS can react directly with any organic 
component of the cell including proteins (Stadtman and Levine 2003), DNA (Breen and 
Murphy 1995) and membrane lipids. Indeed, lipid peroxidation has often been used as 
a marker of oxidative stress and correlates with the severity of human heart failure 
(Keith et al. 1998). Mitochondrial DNA is more susceptible to oxidative attack than 
nuclear DNA, possibly due to its proximity to the electron transport chain in the inner 
mitochondrial membrane, the lack of protective histone like proteins and its poor repair 
activity (Clayton 1984). Increased ROS production caused by in vivo ischaemia of the 
murine heart is associated with damage to the mitochondrial DNA and increased lipid 
peroxidation in the mitochondria (Ide et al. 2001). 
As detailed above, one ROS is readily converted to another ROS (Kerckaert and Roels 
1986; Ide et al. 2000). It is therefore difficult to determine the separate effects of 
individual ROS. H202 is an easily manipulated and physiologically relevant ROS. It is 
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therefore widely used to study the cellular effects of oxidative stress. The effects of 
H202 on cardiac myocyte viability vary with concentration. Low concentrations of 
11202 (<0.03 mM) are non-toxic (Cook et al. 1999) and may induce cytoprotection and 
hypertrophic growth (Ytrehus et al. 1995; Valen et al. 1998; Vanden Hoek et al. 1998; 
Chen et al. 2000; Kwon et al. 2003). Higher concentrations of H202 cause cardiac 
myocyte death. Concentrations of H202 in the range of 0.1 - 0.5 mM induce cardiac 
myocyte apoptosis (Cook et al. 1999). Still higher concentrations of H202 induce 
necrosis (Chen et al. 2000; Kwon et al. 2003). In response to 0.5 mM 14202, neonatal 
rat cardiac myocytes display signs of apoptosis within 5-15 minutes, including loss of 
cytochrome c and Bcl-2 from the mitochondrial fraction (Cook et al. 1999). DNA 
fragmentation is detectable by TUNEL at 8 h and cardiac myocytes are predominantly 
TUNEL-positive at 16 h (Cook et al. 1999). As detailed in Section 1.4 below, 
concentrations of H202 within the apoptotic range activate protein kinase signalling 
cascades that modulate the induction of apoptosis. 
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1.4 Protein kinase signalling cascades 
1.4.1 The MAPK superfamily 
1.4.1.1 The MAPK cascades 
The MAPKs (mitogen-activated protein kinases) are a superfamily of Ser/Thr kinases 
and are the final components of three member cascades (Figure 1.3). Each of the 
MAPKs contains a Thr-X-Tyr motif in the activation loop of the kinase domain. Both 
the Thr and Tyr residues of this motif must be phosphorylated for full activation of the 
kinase. Four groups of MAPKs have been well characterised in mammals. The 
extracellular signal-regulated kinases 1/2 (ERK1/2) have the activation motif Thr-Glu-
Tyr (Payne et al. 1991), the c-Jun N-terminal kinases (JNI(s) have the motif Thr-Pro-
Tyr (Lawler et al. 1998), the p38-MAPKs have the motif Thr-Gly-Tyr (Han et al. 1994) 
and ERK5 [also known as Big MAPK1 (BMK1)] has the motif Thr-Glu-Tyr (Mody et 
al. 2003). 
The ERK1/2 cascade is the best characterized of the MAPK pathways. ERK1 (p44 
MAPK) and ERK2 (p42 MAPK) are activated by the MAPKKs (mitogen-activated 
protein kinase kinases), MEK1 and MEK2 (MKK1 and MKK2) (Crews and Erikson 
1992; Zheng and Guan 1993), which are activated by upstream MAPKKKs (mitogen-
activated protein kinase kinase kinases) of the Raf family (c-Raf, A-Raf and B-Raf) 
(Kyriakis et al. 1992; Pritchard et al. 1995). ERK5 is activated by MEK5 (Zhou et al. 
1995), which is activated upstream by MEKK2 or MEKK3 (Chao et al. 1999; Sun et al. 
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2001a). ERK1/2 (e.g. Clerk et al. 2001) and ERK5 (Nicol et al. 2001; Kennedy et al. 
2006) are both expressed in cardiac myocytes. 
Three JNK genes (JA/K/-3) generate at least ten JNK protein isoforms by alternative 
splicing (Gupta et al. 1996). JNK1 and JNK2 proteins are expressed in most tissues 
and significant levels are present in cardiac myocytes (e.g. Hreniuk et al. 2001; Liang et 
al. 2003; Kaiser et al. 2005a). Expression of JNK3 is generally restricted to the brain 
(Mohit et al. 1995; Martin et al. 1996). One study detected JNK3 protein expression in 
cardiac myocytes (Strait and Samarel 2000) although this is in conflict with other 
findings (Liang et al. 2003). The p38-MAPK family consists of at least six isoforms, 
the alternatively spliced p38-MAPKa1/a2 (Lee et al. 1994) and p38-MAPK01/02 
(Kumar et al. 1997) isoforms, p38-MAPKy (Li et al. 1996; Mertens et al. 1996) and 
p38-MAPKS (Goedert et al. 1997; Jiang et al. 1997). Studies indicate that p38-
MAPKa, p38-MAPK8 and p38-MAPKy but not p38-MAPKI3 are expressed in the heart 
(Lemke et al. 2001; Liao et al. 2001; Court et al. 2002). 
JNKs are activated by MKK4 (also known as SEK1) or MKK7 (Derijard et al. 1995; 
Tournier et al. 1997). Unlike MKK7, MKK4 can also activate p38-MAPKs (Derijard 
et al. 1995; Tournier et al. 1997). However, it is unclear whether MKK4 is a 
physiologically relevant activator of p38-MAPKs, as p38-MAPKs are also activated by 
MKK3 and MKK6 (Derijard et al. 1995; Raingeaud et al. 1996; Jiang et al. 1996). 
There is a limited knowledge of the MAPKKKs acting upstream in the JNK and p38-
MAPK pathways in cardiac myocytes but they may include ASK1 (apoptosis-signalling 
kinase-1) (Izumiya et al. 2003; Yamaguchi et al. 2003). 
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MAPKKK 	 Raf 	 MAPKKKs poorly defined 
v v w 
MAPKK 	 MEK1/2 	MKK3 / MKK6 	MKK4 / MKK7 
v w 	 v v 
MAPK 	 ERK1/2 p38-MAPK 	 JNK 
  
MI 
Phosphorylation p9ORSK2/3 NFAT ATF6 MEF2 MAPKAPK2 c-Jun c-Fos 
Substrates 
The MAPKs phosphorylate and regulate an array of substrates. In cultured cardiac 
myocytes, ERK1/2 phosphorylate and activate p90 ribosomal S6 kinases 2/3 (p90 
RSK2/3) leading to phosphorylation and inhibition of Bad(Ser112) (Valks et al. 2002). 
p38-MAPKs activate MAPKAPK2 (MAPK-activated protein kinase 2) in cultured 
cardiac myocytes and the isolated heart (Clerk et al. 1998a, 1998b, 1998c; Lazou et al. 
1998; Maulik et al. 1998b). Each of the MAPK pathways are important regulators of 
transcription in cardiac myocytes through modulating the activity of TFs (transcription 
factors), as detailed in Table 1.1. 
Figure 1.3 The MAPK cascades 
MAPKs (mitogen-activated protein kinases) are the final components of three-member 
cascades and phosphorylate and regulate a range of substrates. The most studied 
MAPKs are ERK1/2, p38-MAPKs and JNKs. MAPKs are phosphorylated and 
activated by MAPKKs (MAPK kinases), which are in turn phosphorylated and 
activated by MAPKKKs (MAPK kinase kinases). 
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Table 1.1 Regulation of TFs by MAPK signalling cascades in cardiac myocytes 
MAPK pathways regulate the activity and abundance of TFs in cardiac myocytes. This 
is achieved by direct phosphorylation of the TFs and/or indirect regulation of 
transcription from the TF gene. 
TF MAPK Reference 
AP-1 
Activated 
ERK1/2 
(upregulates c-Jun mRNA) 
(upregulates c-Fos mRNA) 
Li et al. 2000a 
Clerk et al. 2002 
Babu et al. 2000 
JNK 
(phosphorylates c-Jun) 
(phosphorylates c-Fos) 
Li et al. 2000a 
Clerk et al. 2002 
Coronella-Wood et al. 2004 
ERK5 
(upregulates c-Jun mRNA) 
Nadruz et al. 2003 
ATF6 
Activated 
p38-MAPK 
(phosphorylates ATF6) 
Thuerauf et al. 1998 
Elk-1 
Activated 
ERK1/2 
(phosphorylates Elk-1) 
Babu et al. 2000 
p38-MAPK 
(phosphorylates Elk-1) 
Pikkarainen et al. 2003 
GATA-4 
Activated 
ERK1/2 
(phosphorylates GATA-4) 
Morimoto et al. 2000 
Kitta et al. 2003 
p38-MAPK 
(phosphorylates GATA-4) 
Charron et al. 2001 
Kerkela et al. 2002a 
MEF2 
Activated 
ERK5 
(phosphorylates MEF2) 
Nadruz et al. 2003 
p38-MAPK 
(phosphorylates MEF2) 
Kolodziejczyk et al. 1999 
Montessuit et al. 2004 
NFAT 
Activated 
ERK1/2 
(phosphorylates NFAT) 
Sanna et al. 2005 
NFAT 
Inhibited 
p38-MAPK Braz et al. 2003 
NF--KB 
Activated 
ERK1/2 Craig et al. 2001 
Li et al. 2000a 
JNK Li et al. 2000a 
p38-MAPK Craig et al. 2001 
Zechner et al. 1998 
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1.4.1.2 Response of MAPKs to oxidative stress in the heart 
In cultured cardiac myocytes, JNK.s and p38-MAPKs are activated by 
hypoxia/reoxygenation (Laderoute and Webster 1997; Seko et al. 1997) or 14202 
(Aikawa et al. 1997; Clerk et al. 1998a). In the perfused adult rat heart, JNKs and p38-
MAPKs are activated by H202 (Clerk et al. 1998b) or ischaemia/reperfusion 
(Bogoyevitch et al. 1996; Yin et al. 1997; Clerk et al. 1998b). p38-MAPK activation 
occurs during ischaemia and is maintained during reperfusion, whereas JNK activation 
only occurs upon reperfusion (Bogoyevitch et al. 1996; Clerk et al. 1998b). ERK5 is 
activated by H202 in cultured cardiac myocytes (Nicol et al. 2001) and the adult 
perfused guinea pig heart (Takeishi et al. 1999). In the adult perfused guinea pig heart, 
ERK5 is also activated by ischaemia but surprisingly the ERK5 activity is diminished 
to basal levels upon reperfusion (Takeishi et al. 1999). Study of ERK1/2 has focused 
on their activation following growth factor stimulation, but they are also activated 
following exposure of cells to a variety of stresses. Thus, ERK1/2 are activated in 
cultured neonatal rat cardiac myocytes in response to H202 (Aikawa et al. 1997; Clerk 
et al. 1998a; Sabri et al. 1998; Bogoyevitch et al. 2000). However, in the adult perfused 
rat heart H202 induces a comparatively weak activation of ERK1/2 (Clerk et al. 1998b). 
1.4.1.3 Regulation of cardiac myocyte apoptosis by MAPK pathways 
ERK1/2 have an anti-apoptotic role in cardiac myocytes. The anti-apoptotic effects of 
agonists such as cardiotrophin-1 (Sheng et al. 1997; Brar et al. 2001a, 2001b; Craig et 
al. 2001), insulin-like growth factor-1 (IGF-1) (Foncea et al. 2000), basic fibroblast 
growth factor (Iwai-Kanai et al. 2002) and serotonin (Nebigil et al. 2003) are mediated 
at least in part by the ERK1/2 cascade in cultured cardiac myocytes. Pharmacological 
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inhibition of the ERK1/2 cascade by application of PD98059 potentiates apoptosis 
induced by H202 or simulated ischaemia/reperfusion in cultured cardiac myocytes, and 
increases ischaemia/reperfusion injury in isolated perfused rat hearts (Aikawa et al. 
1997; Yue et al. 2000). Consistent with this, overexpression of a constitutively-active 
MEK1 mutant in cultured cardiac myocytes provides resistance to apoptotic stress 
(Bueno et al. 2000; Lips et al. 2004), whereas overexpression of a dominant-negative 
MEK1 mutant enhances apoptosis (Lips et al. 2004). Transgenic mice with cardiac-
specific overexpression of a constitutively-active MEK1 mutant have reduced injury 
and apoptosis following cardiac ischaemia/reperfusion ex vivo (Bueno et al. 2000) and 
in vivo (Lips et al. 2004). 
The role of JNKs in cardiac myocyte apoptosis is less clear and appears to differ 
between neonatal and adult cardiac myocytes as well as between JNK isoforms. 
Inhibition of JNK activity, by the pharmacological agent SP600125 (Engelbrecht et al. 
2004) or overexpression of dominant-negative JNK1 or MKK4 mutants (Andreka et al. 
2001; Dougherty et al. 2002), indicates that JNKs have an anti-apoptotic function in 
cultured neonatal rat cardiac myocytes. However, in cultured adult rat cardiac 
myocytes, JNK activation by overexpression of a constitutively-active MKK4 mutant is 
sufficient to induce apoptosis (Aoki et al. 2002), whereas apoptosis is reduced 
following JNK inhibition by overexpression of dominant-negative MKK4 or JNK1 
mutants (Aoki et al. 2002; Kwon et al. 2003; Remondino et al. 2003). In antisense 
studies, JNK1 is pro-apoptotic in cultured neonatal rat cardiac myocytes exposed to 
simulated ischaemia/reperfusion, while JNK2 does not significantly influence apoptosis 
(Hreniuk et al. 2001). Studies of the heart in vivo have also produced conflicting results 
as exemplified by the findings of Kaiser et al. (2005a). Mice with targeted inactivation 
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of the JNKI gene or the JNK2 gene showed reduced apoptosis of cardiac cells 
following ischaemia/reperfusion in the heart in vivo (Kaiser et al. 2005a). However, in 
contrast to expectation, transgenic mice with cardiac-specific overexpression of wild-
type MKK7 were similarly protected (Kaiser et al. 2005a). The majority of the data 
from other cells types, particularly neuronal cells, indicate that JNKs are pro-apoptotic 
(reviewed in Davis 2000). Interestingly, JNK1 partly localises to the mitochondria in 
cultured adult rat cardiac myocytes and activated JNK promotes release of cytochrome 
c from isolated rat heart mitochondria in a cell free system (Aoki et al. 2002). The 
precise role of the JNK. cascade in cardiac myocyte apoptosis remains to be established. 
There is a similar lack of consensus in the literature pertaining to the role of p38-
MAPKs in cardiac myocyte apoptosis. In cultured cardiac myocytes, pharmacological 
inhibition of p38-MAPK by application of SB203580 or SB202190 has indicated that 
p38-MAPK promotes apoptosis (Mackay and Mochly-Rosen 1999; Zhu et al. 1999; 
Kang et al. 2000b) and/or protects against apoptosis (Communal et al. 2000; Hoover et 
al. 2000). Overexpression of constitutively-active MKK6 in cultured cardiac myocytes 
has also indicated that p38-MAPKs may have pro-apoptotic (Kaiser et al. 2004) and 
anti-apoptotic functions (Zechner et al. 1998; Hoover et al. 2000; Craig et al. 2000). 
Acute application of SB203580 reduces cell death and functional impairment in the 
isolated rat heart subjected to H202 infusion (Meldrum et al. 1998) or 
ischaemia/reperfusion (Wang et al. 2005). Similar protective effects are provided by 
application of SB203580 to the isolated rabbit heart subjected to ischaemia/reperfusion 
(Ma et al. 1999) or application of SB202190 to the isolated rat heart subjected to 
ischaemia/reperfusion (Schneider et al. 2001; Wang et al. 2005). Results in pigs are 
more conflicting. Application of the pharmacological p38-MAPK inhibitor, SB239063, 
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reduces infarct size following in vivo cardiac ischaemia/reperfusion in mice but not pigs 
(Kaiser et al. 2005b). However, application of SB203580 has been shown to reduce 
(Barancik et al. 2000) or not affect (Schulz et al. 2002) infarct size resulting from in 
vivo porcine cardiac ischaemia/reperfusion. Several studies specifically implicate p38-
MAPKa in the induction of apoptosis in cultured cardiac myocytes (Saurin et al. 2000; 
Martin et al. 2001; Wang et al. 1998a; Kaiser et al. 2004). Transgenic mice with 
reduced p38-MAPKa activity [not cardiac-specific (Otsu et al. 2003) or cardiac-
specific (Kaiser et al. 2004)] have reduced infarct size and apoptosis following in vivo 
cardiac ischaemia/reperfusion. The majority of studies conducted to date therefore 
conclude that p38-MAPKa signalling is pro-apoptotic in cardiac myocytes. 
1.4.2 The PI3K-PKB pathway 
Phosphatidylinositol 3' kinase (PI3K) is activated by receptor tyrosine kinases or by 
heterotrimeric G-protein coupled receptors. 	Activated PI3K catalyses the 
phosphorylation of phosphatidylinositol 4,5-bisphosphate to phosphatidylinositol 3,4,5 
trisphosphate (PtdInsP3) and this activates PtdInsP3-dependent protein kinase (PDK1), 
which in turn phosphorylates and activates protein kinase B (PKB also known as Akt). 
The PI3K-PKB pathway protects against apoptosis of cardiac myocytes in culture 
(Matsui et al. 1999; Fujio et al. 2000; Wu et al. 2000) and in the heart in vivo (Fujio et 
al. 2000; Matsui et al. 2001) (Figure 1.4). The PI3K-PKB pathway also upregulates 
global protein synthesis and promotes hypertrophy in cardiac myocytes (Figure 1.4) 
(Morisco et al. 2000; Pham et al. 2000; Matsui et al. 2002). 
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In cultured cardiac myocytes, as in other cell types, the PI3K-PKB pathway activates 
mTOR (mammalian target of rapamycin), leading to phosphorylation of 4E-BP1 (4E-
binding protein 1) (Pham et al. 2000). The phosphorylation of 4E-BP1 reduces its 
association with eIF4E (eukaryotic initiation factor 4E) and this increases eIF4E - 
eIF4G complex formation (Wang et al. 2000), which is considered to be essential for 
cap-dependent translation (reviewed in Sonenberg 1996). Pharmacological inhibition 
of the PI3K-PKB-mTOR-4E-BPI pathway (using LY294002 or wortmannin to inhibit 
PI3K, or rapamycin to inhibit mTOR) reduces basal protein synthesis in cardiac 
myocytes and attenuates insulin induced upregulation of protein synthesis (Pham et al. 
2000). PKB is slightly activated by 0.1 mM H202 and substantially activated by 1 mM 
H202 in cultured cardiac myocytes (Pham et al. 2000). However, H202 (1 mM) 
activates a PP1/PP2A protein phosphatase which dephosphorylates 4E-BP1 increasing 
its association with eIF4E and inhibiting protein synthesis (Pham et al. 2000). The 
PI3K-PKB-mTOR pathway also activates p70 S6 kinase (p70 S6K) which 
phosphorylates the ribosomal S6 protein, again resulting in increased protein synthesis. 
This pathway is activated in cardiac myocytes by insulin or hypertrophic agonists 
(Sadoshima and Izumo 1995; Boluyt et al. 1997; Oh et al. 1998; Wang et al. 2000; 
Hiraoka et al. 2003; Chandrasekar et al. 2005). 
Another important PKB substrate is glycogen synthase kinase-3 (GSK-3), which is 
inactivated following its phosphorylation (Cross et al. 1995). In response to insulin, 
PKB phosphorylates and inactivates GSK-3 in the heart and this leads to 
dephosphorylation and activation of glycogen synthase (Mora et al. 2005). GSK-3 
represses the hypertrophic response in cultured cardiac myocytes (Haq et al. 2000; 
Morisco et al. 2000) and in the heart in vivo (Antos et al. 2002). This is achieved at 
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least in part through GSK-3 catalysed phosphorylation and inhibition of the TFs NFAT 
(nuclear factor of activated T-cells) (Beals et al. 1997; Haq et al. 2000; Antos et al. 
2002) and GATA-4 (Morisco et al. 2001). Repression of these TFs and the 
hypertrophic response by GSK-3 is silenced in cardiac myocytes following its PKB-
catalysed phosphorylation and inactivation (Haq et al. 2000; Morisco et al. 2000, 2001; 
Chandrasekar et al. 2005). 
PKB also directly regulates TFs by phosphorylation. PKB directly phosphorylates 
GATA-4 in vitro, although the functional significance of this is undetermined 
(Kathiriya et al. 2004). The FOXO (Forkhead box transcription factors of class 0) 
family of TFs are phosphorylated and inactivated by PKB in cultured cardiac myocytes 
and in the heart in vivo (Morris et al. 2005; Skurk et al. 2005). NF-x13 (nuclear factor 
of lc light chain gene enhancer in B cells) is also indicated to be activated downstream 
of PKB in cultured cardiac myocytes. Specifically, the NF-xl3 inhibitor Ii(B (inhibitor 
of lc light chain gene enhancer in B cells) is subject to PI3K-dependent phosphorylation 
and degradation in cardiac myocytes leading to NF-kB activation with anti-apoptotic 
effects (Craig et al. 2001; Nebigil et al. 2003). 
The PI3K-PKB pathway directly regulates components of the apoptotic machinery. In 
proliferating cell lines, PKB phosphorylates and inhibits Bad (Datta et al. 1997; del 
Peso et al. 1997), though more recent data indicate that this is mediated by p70 S6K 
downstream of PKB (Harada et al. 2001). Several studies indicate that Bad is 
phosphorylated downstream of the PI3K-PKB pathway in cardiac myocytes (Aikawa et 
al. 2000; Kuwahara et al. 2000; Negoro et al. 2001), however other studies indicate that 
this is not the case (Wu et al. 2000; Matsui et al. 2001). In proliferating cell lines, PKB 
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inTOR 
inhibits human caspase-9 by phosphorylating it at Serl 96 (Cardone et al. 1998). This 
site is however not conserved in mouse (Fujita et al, 1999) and PKB-dependent 
phosphorylation at this site is yet to be demonstrated in cardiac myocytes. 
Nevertheless, activation of PKB is essential for inhibition of caspase-9 activity 
following treatment of cultured cardiac myocytes with anti-apoptotic agonists taurine 
(Takatani et al. 2004b) or leukaemia inhibitory factor (Negoro et al. 2001). 
F`I3K 
PDK1 
PKB 
I N. 
eIF4E S6 
Protein synthesis 
1370 S6K 	Glycogen NFAT GATA-4 	NF-KB 
Synthase 
• • 	 \I • • 
Hypertrophy 
Figure 1.4 Regulation of apoptosis, protein synthesis and hypertrophy in cardiac 
myocytes by the PI3K-PKB pathway 
The PI3K-PKB pathway is activated in cardiac myocytes by hypertrophic agonists, 
insulin, H202 or other stimuli. Active PKB regulates the activity of TFs, kinases and 
other proteins by phosphorylation. The resulting cellular effects include protection 
against apoptosis, increased global protein synthesis and induction of hypertrophy. 
Proteins/responses downstream of PKB are highlighted in red or green, depending on 
whether they are inhibited or activated, respectively. 
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1.4.3 The PKC superfamily 
PKCs (protein kinase C) are a superfamily of Ser/Thr kinases with three principal sub-
families: the classical PKCs (a, 131, 02, y) require Ca2+, diacylglycerol and 
phosphatidylserine for activation; the novel PKCs (S, c, ii, 0) are Ca2+-independent but 
require diacylglycerol and phosphatidylserine for activation; the atypical PKCs (, kit) 
are Ca2+- and diacylglycerol-independent and their methods of activation are 
incompletely understood. Expression of PKC isoforms in the heart is developmentally 
regulated (Rybin and Steinberg 1994; Clerk et al. 1995). It is well established that both 
adult and neonatal cardiac myocytes express PKCa, PKCS and PKC8 (Clerk et al. 
1994; Disatnik et al. 1994; Puceat et al. 1994; Rybin and Steinberg 1997; Rybin and 
Steinberg 2006). Other isoforms that have been detected in cardiac myocytes include 
PKC (Clerk et al. 1994; Disatnik et al. 1994), PKCX/t (Goldberg et al. 1997), and 
possibly PKCI31 and PKCO2 (Disatnik et al. 1994; Wientzek et al. 1997). Identification 
of downstream PKC substrates has proved difficult. In cardiac myocytes, the ERK1/2 
pathway is activated by PKCc (Ping et al. 1999a; Li et al. 2000a; Heidkamp et al. 2001; 
Strait et al. 2001) or PKCa (Braz et al. 2002; Kerkela et al. 2002b; Pan et al. 2005). 
The INK and p38-MAPK pathways can also be activated by PKC isoforms in cardiac 
myocytes, although analysis of which specific isoforms activate each pathway has 
produced conflicting results (Ping et al. 1999b; Li et al. 2000a; Heidkamp et al. 2001; 
Braz et al. 2002; Pan et al. 2005). 
PKC isoforms are activated in the heart in response to oxidative stress. Exposure of 
cultured cardiac myocytes to H202 (50 ptM) activates PKC and PKC6 (Mangat et al. 
2006). PKC6 is activated following ischaemia/reperfusion in the isolated mouse heart 
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(Hahn et al. 2002), the isolated rat heart (Murriel et al. 2004; Churchill et al. 2005; 
Churchill and Szweda 2005) or the in vivo pig heart (Inagaki et al. 2003a). Perfusion of 
the isolated rat heart with H202 also activates PKC6 (Churchill et al. 2005; Churchill 
and Szweda 2005). Protein expression and activity of PKCa, PKC131 and PKCI32 are 
elevated in the failing human heart (Bowling et al. 1999). 
PKCE and PKC6 have been the focus of several investigations in the heart and are 
determined to be protective and injurious, respectively. A selective PKCE inhibitor 
peptide augments the decrease in viability caused by exposure of cultured cardiac 
myocytes to H202 (50 ptM) (Mangat et al. 2006). Overexpression of wild type PKCE 
protects cultured cardiac myocytes against simulated ischaemia/reperfusion in a manner 
dependent on downstream activation of the ERK1/2 pathway (Ping et al. 1999a). 
Similarly, a selective PKCE activator peptide protects the rat or the mouse heart from 
injury caused by ex vivo ischaemia/reperfusion (Dorn et al. 1999; Chen et al. 2001b; 
Inagaki et al. 2003b). Furthermore, at least some aspects of ischaemic preconditioning 
(the protection against prolonged ischaemia produced by preceding brief episodes of 
ischaemia) are dependent upon PKCE activity (Gray et al. 1997; Liu et al. 1999a; Saurin 
et al. 2002). In contrast to PKCE, overexpression of a constitutively-active PKC6 
mutant is sufficient to cause apoptosis in cultured cardiac myocytes (Heidkamp et al. 
2001) and a selective PKC6 inhibitor peptide protects cultured cardiac myocytes from 
simulated ischaemia (Chen et al. 2001b). The selective PKCS inhibitor peptide also 
reduces cardiac myocyte apoptosis and impairment of cardiac function, following ex 
vivo ischaemia/reperfusion in the rat or mouse heart (Chen et al. 2001b; Hahn et al. 
2002; Inagaki et al. 2003a, 2003b; Murriel et al. 2004) and in vivo 
ischaemia/reperfusion in the pig heart (Inagaki et al. 2003a). 
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1.5 Changes in gene expression and TF activity concomitant with 
cardiac myocyte apoptosis 
Changes in gene expression have an important influence on the progression of 
apoptosis. Microarray studies show that numerous changes in gene expression occur in 
the failing human heart (Yang et al. 2000; Barrans et al. 2001, 2002; Tan et al. 2002; 
Kam) et al. 2004) and in cultured cardiac myocytes exposed to concentrations of H202 
that induce apoptosis (Kemp et al. 2003). Consistent with this, the induction of 
apoptosis in cardiac myocytes can be modulated by the action of TFs, of which GATA-
4, NF-xB (see Section 1.5.1 below) and p53 (see Section 1.5.2) have received 
considerable attention in this respect. 
1.5.1 GATA-4 and NF-KB 
Apoptosis of cultured cardiac myocytes induced by doxorubicin is associated with 
suppression of GATA-4 activity and is attenuated by overexpression of GATA-4 (Aries 
et al. 2004). Consistent with this, overexpression of antisense to GATA-4 in cultured 
cardiac myocytes increases apoptosis following challenge with doxorubicin (Aries et al. 
2004). Similarly, doxorubicin injection into mice causes higher levels of cardiac 
myocyte apoptosis and a greater reduction in cardiac function, in mice heterozygotic for 
a non-functional GATA-4 allele compared with wild type mice (Aries et al. 2004). 
There is therefore significant evidence supporting a protective function for GATA-4 in 
cardiac myocytes. Indeed, expression of the anti-apoptotic Bc1-X1 gene is upregulated 
by GATA-4 in cardiac myocytes (Kitta et al. 2003; Aries et al. 2004). 
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NF-KB is activated in cultured cardiac myocytes exposed to H202 (Peng et al. 1995; 
Frantz et al. 2001), and in the rat heart (Chandrasekar and Freeman 1997; Yang et al. 
2003) and rabbit heart (Morgan et al. 1999; Kis et al. 2003) subjected to 
ischaemia/reperfusion in vivo. Inhibition of NF-KB activity by overexpression of a 
degradation resistant mutant of KB indicates that NF-KB has an anti-apoptotic function 
in cardiac myocytes in culture (de Moissac et al. 1999; Mustapha et al. 2000; Bergmann 
et al. 2001) and in the murine heart in vivo (Misra et al. 2003). However, studies in rat 
show that downregulation of NF-KB activity by transfection with decoy 
oligonucleotides reduces cardiac ischaemia/reperfusion injury in vivo (Morishita et al. 
1997; Sawa et al. 1997). The precise role of NF-KB in cardiac myocyte apoptosis 
therefore remains to be clarified. 
1.5.2 AP-1 
AP-1 (activating protein-1) is a subfamily of the dimerizing b-Zip (basic region-leucine 
zipper) TFs and is involved in the induction of both apoptosis and hypertrophy in 
cardiac myocytes (Taimor et al. 2001, 2004). AP-1 dimers are composed of members 
of the Jun (c-Jun, JunB and JunD) and the Fos [c-Fos, FosB, Fra-1 (Fos related antigen-
1) and Fra-2] families of proteins. Jun proteins form homodimers and also 
heterodimerize with each other, while Fos proteins cannot homodimerize but form 
heterodimers with Jun family proteins (Angel et al. 1987, 1988; Halazonetis et al. 1988; 
Sassone-Corsi et al. 1988a; Hirai and Yaniv 1989). 
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In cardiac myocytes, AP-1 activity is increased following exposure to H202 and this is 
in association with increased levels of c-Jun and c-Fos mRNA and protein (Peng et al. 
1995; Frantz et al. 2001; Tu et al. 2003; Coronella-Wood et al. 2004). Increased AP-1 
activity is also detected in cultured cardiac myocytes exposed to apoptotic stress in the 
form of nitric oxide (NO) (Taimor et al. 2001), doxorubicin (Nobori et al. 2002) or 
hypoxia/reoxygenation (Rui and Kvietys 2005). AP-1 activity is increased following in 
vivo cardiac ischaemiaireperfusion in several animal species [Chandrasekar and 
Freeman 1997 (rat); Sun et al. 200 lb (dog); Fan et al. 2002 (dog); Zingarelli et al. 2002, 
2004 (mouse)]. In humans, there is increased expression of c-Jun and c-Fos mRNA in 
the heart following ischaemia/reperfusion during coronary bypass surgery (Nelson et al. 
2002). 
Incubation of cardiac myocytes with decoy oligonucleotides containing an AP-1 
binding sequence demonstrates that AP-1 signalling is required for the induction of 
apoptosis following exposure to NO (Taimor et al. 2001). In cardiac myocytes exposed 
to NO there is interaction between AP-1 and members of the SMAD family of TFs 
(Schneiders et al. 2005). Furthermore, SMAD activity is essential for the induction of 
apoptosis under these conditions (Schneiders et al. 2005). In contrast to NO, the 
hypertrophic agonist phenylephrine while increasing AP-1 activity does not increase 
SMAD activity in cardiac myocytes (Schneiders et al. 2005). Thus, interaction with 
SMAD proteins may be a factor shifting AP-1 from the induction of hypertrophy to the 
induction of apoptosis. In addition to interaction with other TFs, the dimer composition 
of AP-1 may also determine the cellular response that it mediates. In support of this, c-
Jun, JunB and JunD can have opposite effects on cell cycle progression in proliferating 
cells under the same conditions (Pfarr et al. 1994; Szabowski et al. 2000). However, 
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Schneiders et al. (2005) showed by supershift assay that the AP-1 EMSA complexes 
induced in cardiac myocytes by NO and phenylephrine both consist of the same subset 
of AP-1 proteins, specifically c-Jun, JunB and FosB. 
1.5.3 p53 
The p53 TF accumulates in cells exposed to DNA-damaging stress and has two 
prominent cellular functions, induction of apoptosis or induction of cell cycle arrest 
(Maltzman and Czyzyk 1984; Yonish-Rouach et al. 1991; Kuerbitz et al. 1992; Khanna 
and Lavin 1993; Zhan et al. 1993). p2/ ciP1waf1 is a prominent example of a gene the 
product of which induces cell cycle arrest and the transcription of which is activated by 
p53 (el-Deiry et al. 1993; Harper et al. 1993; Xiong et al. 1993). As cardiac myocytes 
are terminally differentiated, it is p53-induced apoptosis rather than cell cycle arrest 
that is important to their biology. 
1.5.3.1 Induction of apoptosis by p53 
p53 induces apoptosis through upregulating transcription of pro-apoptotic genes such as 
Bax (Miyashita et al. 1994), FasR (Owen-Schaub et al. 1995; Muller et al. 1998) and 
FasL (Maecker et al. 2000). In addition, p53 represses transcription from anti-apoptotic 
genes such as Bc1-2 (Miyashita et al. 1994). p53 also promotes apoptosis independently 
of its TF activity (Caelles et al. 1994). In response to apoptotic stress, p53 translocates 
to the mitochondria and promotes release of cytochrome c (Marchenko et al. 2000; 
Sansome et al. 2001; Mihara et al. 2003). This is achieved by p53 binding to Bcl-xl 
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and thus relieving inhibition of Bak (Mihara et al. 2003) or Bax (Chipuk et al. 2004), 
resulting in their oligomerization. p53 also binds to Bcl-2 but the significance of this 
has not been tested (Mihara et al. 2003). In addition, p53 may be able to directly 
stimulate oligomerization of Bak (Leu et al. 2004) or Bax (Chipuk et al. 2004). 
1.5.3.2 Regulation of p53 activity 
p53 is mainly regulated through posttranslational modifications that change its stability 
and TF activity (Ko and Prives 1996). For example, ionising radiation increases 
phosphorylation of p53(Ser20) by Checkpoint kinase 1/2 (Chk1/2). This abrogates 
interaction with Mdm2 (the negative regulator of p53, see Section 1.6). The net effect 
is to stabilise p53 (Chehab et al. 2000; Shieh et al. 2000; Hirao et al. 2000). p53 is also 
subject to phosphorylation and regulation by MAPKs. In response to DNA-damaging 
stress, JNK phosphorylates p53 and this reduces Mdm2-p53 binding and increases p53 
activity and stability (Milne et al. 1995; Adler et al. 1997; Fuchs et al. 1998a; 
Buschmann et al. 2001). Similar results have been described for ERK1/2 (Persons et al. 
2000; She et al. 2000) and p38-MAPK (Bulavin et al. 1999; Huang et al. 1999; Keller 
et al. 1999; Sanchez-Prieto et al. 2000; She et al. 2000). DNA-damaging stress also 
promotes acetylation of p53 to increase its TF activity (Luo et al. 2004) and reduce 
interaction with Mdm2 (Li et al. 2002b). 
1.5.3.3 p53 in cardiac myocyte apoptosis 
The results of microarray studies by our group demonstrate that, in response to 0.1 mM 
or 0.2 mM H202, cultured cardiac myocytes show a significant increase in the 
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expression of Mdm2 mRNA and p21ciP141741 mRNA (Kemp et al. 2003) (Table 1.2). 
Expression of both these genes is regulated by p53 (Barak et al. 1993; el-Deiry et al. 
1993), suggesting that p53 may be involved in apoptosis induced by 0.1-0.2 mM H202. 
However, previous studies examining the importance of p53 in cardiac myocyte 
apoptosis have given conflicting results (Table 1.3). 
p53 is upregulated following the induction of apoptosis in cultured cardiac myocytes by 
a range of stresses (Long et al. 1997; Leri et al. 1998b; von Harsdorf et al. 1999; Toth et 
al. 2006). There is also upregulation of p53 together with increased cardiac myocyte 
apoptosis in the rat heart subjected to ischaemia/reperfusion ex vivo (Maulik et al. 
2000) or in vivo (Xie et al. 2000). Consistent with this, upregulation of p53 also occurs 
together with cardiac myocyte apoptosis in the failing canine heart (Leri et al. 1998a; 
Cesselli et al. 2001) and the failing human heart (Song et al. 1999). Furthermore, 
overexpression of p53 alone is sufficient to induce apoptosis in cultured cardiac 
myocytes (Kirshenbaum and de Moissac 1997; Long et al. 1997; Regula and 
Kirshenbaum 2001), whilst a reduction in p53 activity has been associated with 
decreased apoptosis in cultured cardiac myocytes (Leri et al. 2000; Nobori et al. 2002) 
and in the murine heart (Hu et al. 2000; Liu et al. 2004; Shizukuda et al. 2005). 
Several other studies indicate that p53 has a non-essential role in cardiac myocyte 
apoptosis. Apoptosis can occur in the absence of increased p53 activity in cultured 
cardiac myocytes (Webster et al. 1999; Galvez et al. 2001). Similarly, cardiac myocyte 
apoptosis can occur without p53 upregulation in the rat heart in vivo (Nakamura et al. 
2000b) and in the human heart in vivo (Petrovit et al. 2000). Furthermore, cardiac 
myocytes derived from p531- mice have been shown not to be impaired for their ability 
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to undergo apoptosis (Webster et al. 1999; Iwakura et al. 2001). Apoptosis of cardiac 
myocytes has also been shown to be induced with equal efficiency in the hearts of wild-
type and p534- mice subjected to in vivo ischaemia (Bialik et al. 1997) or ex vivo 
ischaemialreperfusion (Webster et al. 1999). 
Some of these conflicting data may be explained by the use of different stresses which 
may induce apoptosis in cardiac myocytes by the activation of distinct pathways, some 
involving p53 and some not. However, this cannot explain disparate results obtained 
using the same stress [e.g. hypoxia/reoxygenation (Webster et al. 1999; Toth et al. 
2006)]. Overall, it would appear that whilst not essential for induction of apoptosis in 
cardiac myocytes, p53 is induced under some conditions and, here, may play an 
important role. The factors determining whether or not p53 is induced remain to be 
delineated. 
Table 1.2 Changes in expression of p53-responsive genes following exposure of 
cardiac myocytes to H202 
Data taken from microarray studies (Kemp et al. 2003) show that H202-induces 
changes in the levels of Mdm2 mRNA and p2/ ciPilwafl mRNA (both p53-responsive 
genes). Results are the means of the fold stimulations relative to two controls. 
Significant changes (i.e. >2.53) are in bold. 
Time (h) 1 2 
H202 (mM) 0.04 0.1 0.2 0.04 0.1 0.2 
Mdm2 1.96 5.26 8.04 2.33 4.41 7.06 
p2/ ci1lmill  5.45 11.17 15.95 6.30 12.62 14.27 
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Table 1.3 The importance of p53 in cardiac apoptosis 
Studies examining changes in cardiac p53 levels/activity during apoptosis and/or the 
dependence of cardiac apoptosis on p53 have produced varying findings. These results 
are summarized in the Table below. Where results are indicated not to be cardiac 
myocyte-specific general cardiac tissue was examined for p53 levels/dependence, in all 
other cases cardiac myocytes were examined specifically. 
Stress Model Change in p53 
levels/activity 
Dependence of 
apoptosis on p53 
Reference 
Doxorubicin Cultured cardiac 
myocytes 
Upregulated Poizat et al. 2000 
Upregulated Nobori et al. 2002 
Upregulated Poizat et al. 2005 
Administered to 
mice 
Upregulated 
(not cardiac myocyte- 
specific) 
Liu et al. 2004 
p53-dependent 
(not cardiac myocyte- 
specific) 
Shizukuda et al. 
2005 
Not upregulated 
(not cardiac myocyte- 
specific) 
Kawamura et al. 
2004 
Administered to 
rats 
Not upregulated 
(not cardiac myocyte- 
specific) 
Nakamura et al. 
2000b 
Heart allograft Operated on mice Upregulated 
(not cardiac myocyte- 
specific) 
p53-dependent 
Hu et al. 2001 
Heart failure 
(human) 
Ventricular 
samples 
Not detected Petrovi6 et al. 
2000 
Upregulated Song et al. 1999 
Heart failure 
(animal, induced by 
ventricular pacing) 
Dog in vivo Upregulated Led et al. 1998a 
Upregulated Cesselli et al. 2001 
Rabbit in vivo Upregulated Qi et al. 2001 
Hyperosmotic stress 
(sorbitol) 
Cultured cardiac 
myocytes 
Not upregulated Galvez et al. 2001 
Hypoxia/ 
reoxygenation 
Cultured cardiac 
myocytes 
Not upregulated 
p53-independent 
Webster et al. 
1999 
Upregulated Toth et al. 2006 
Hypoxia Cultured cardiac 
myocytes 
Not upregulated 
p53-independent 
Webster et al. 
1999 
Upregulated Long et al. 1997 
Upregulated Toth et al. 2006 
Ischaemia/reperfusion 
following candesartan 
treatment 
Rat in vivo Upregulated Chen et al. 2001c 
72 
Table 1.3 continued 
Stress Model Change in p53 
levels/activity 
Dependence of 
apoptosis on p53 
Reference 
Ischaemia/reperfusion Rat in vivo Upregulated Xie et al. 2000 
Dog in vivo Upregulated 
(not cardiac myocyte- 
specific) 
Zhao et al. 2001 
Isolated rat heart Upregulated 
(not cardiac myocyte- 
specific) 
Maulik et al, 2000 
Isolated murine 
heart 
p53-independent Webster et al. 
1999 
Ischaemia Rat in vivo Upregulated 
(not cardiac myocyte- 
specific) 
Oskarsson et al. 
2000 
Upregulated 
(not cardiac myocyte- 
specific) 
Oie et al. 2002 
Upregulated 
(not cardiac myocyte- 
specific) 
Ruixing et al. 
2004 
Mice in vivo p53-independent Bialik et al. 1997 
Okadaic acid (100 
nM) 
Cultured cardiac 
myocytes 
Upregulated Long et al. 2002 
Pericardial fluid from 
human patients with 
ischaemic heart 
disease 
Cultured cardiac 
myocytes 
p53-independent Iwakura et al. 
2001 
Pressure overload Rat in vivo Upregulated 
(not cardiac myocyte- 
specific) 
Ikeda et al. 1999 
ROS 
[05 (0.1 mM I-1202 
+ 0.1 mM FeSO4)] 
Cultured cardiac 
myocytes 
Upregulated Von Harsdorf et 
al. 1999 
ROS [02 - 
(XO/X + catalase)] 
Cultured cardiac 
myocytes 
Upregulated Von Harsdorf et 
al. 1999 
ROS (NO donor 
SNAP) 
Cultured cardiac 
myocytes 
Upregulated Pinsky et al. 1999 
Staurosporine Cultured cardiac 
myocytes 
Upregulated Long et al. 2002 
Stretch Cultured cardiac 
myocytes 
Upregulated Len et al. 1998b, 
1999 arid 2000 
Liao et al. 2004 
Taurine depletion 13-alanine added 
to rat drinking 
water 
Upregulated 
al. 2003 
Golubnitschaja et 
VPATPase inhibitor 
(bafilomycin Al) 
Cultured cardiac 
myocytes 
Upregulated Long et al. 1998 
and 2002 
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1.6 Mdm2  
The Murine double minute 2 (Mdm2) oncogene was identified owing to its 
overexpression in a tumourigenic derivative of NIH-3T3 cells (Cahilly-Snyder et al. 
1987). Mdm2 was subsequently demonstrated to be overexpressed in numerous human 
sarcomas (Oliner et al. 1992). The Mdm2 protein contains several functional domains 
(Figure 1.5): a p53 binding domain (Chen et al. 1993), a nuclear localization sequence 
(NLS) (Chen et al. 1995), a nuclear export sequence (NES) (Roth et al. 1999), an acidic 
domain (Fakharzadeh et al. 1991; Ma et al. 2006), a zinc finger (Boddy et al. 1994), a 
RING finger (Boddy et al. 1994) and a nucleolar localisation sequence (NoLS) 
(Lohrum et al. 2000). 
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Figure 1.5 The functional domains of the Mdm2 protein 
The functional domains of the Mdm2 protein are shown. The numbers indicate the 
amino acid residues bordering each domain in the human Mdm2 protein. 
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1.6.1 Functions of Mdm2 
1.6.1.1 Inhibition of p53 TF activity by Mdm2 
The best defined function of Mdm2 is its regulation of the p53 TF. Mdm2 and p53 
bind via their N-terminal regions and this results in the downregulation of p53 TF 
activity (Momand et al. 1992; Oliner et al. 1993; Chen et al. 1993, 1995a; Leng et al. 
1995; Freedman et al. 1997). Binding of Mdm2 to p53 is thought to conceal the p53 
activation domain (located in the N-terminus) from the general transcription machinery, 
although this mechanism awaits formal demonstration (Oliner et al. 1993). Mdm2 may 
also possess an intrinsic transcription inhibition function (Thut et al. 1997). In addition, 
Mdm2 reduces p53 acetylation through several mechanisms with the result that p53 TF 
activity is reduced (Kobet et al. 2000; Ito et al. 2002; Jin et al. 2002) and the p53 
protein is destabilised (Ito et al. 2001, 2002). Mdm2 inhibits p300/CBP(CREB binding 
protein)-mediated acetylation of p53 in a manner that is dependent upon binding of 
Mdm2 to p53 and Mdm2 to p300, but is independent of the Mdm2 RING finger (see 
Section 1.6.1.2) (Kobet et al. 2000; Ito et al. 2001). Mdm2 also inhibits PCAF 
(p300/CBP-associated factor)-mediated acetylation of p53 (see Table 1.4) (Jin et al. 
2002). Furthermore, Mdm2 promotes deacetylation of p53 by recruitment of a complex 
containing HDAC1 (histone deacetylase 1) to p53 (Ito et al. 2002). 
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1.6.1.2 Ubiquitin-ligase activity of Mdm2 
The ubiquitin - proteasome degradation pathway The ubiquitin (Ub) - proteasome 
system is a major route for controlled protein degradation. El Ub-activating enzymes 
activate ubiquitin in an ATP-dependent manner, catalysing the formation of a transient 
linkage between a Cys residue in El and the C-terminus of ubiquitin. The activated 
ubiquitin is then transferred to an E2 Ub-conjugating enzyme. An E3 Ub-ligase then 
catalyses the linkage of the ubiquitin protein to a lysine residue in the target protein. It 
is the E3 Ub-ligase that allows the selective ubiquitinylation of substrate proteins. The 
formation of a polyubiquitin chain by ubiquitin-ubiquitin ligation targets the protein for 
degradation by the 26S proteasome. The 26S proteasome is a large (-2 MDa) ATP-
dependent protease complex consisting of a 20S catalytic core and two 19S regulatory 
complexes. E3 Ub-ligases utilize just one of two catalytic domains, a HECT 
(homology to E6AP C-terminus) domain or a RING (really interesting new gene) 
finger. 
Mdm2 possesses a RING finger domain and functions as an E3 ubiquitin-ligase 
Mdm2 is a RING finger E3 ubiquitin-ligase and ubiquitinylates p53 in a manner 
dependent upon binding of Mdm2 to p53. Ubiquitinylation of p53 by Mdm2 targets 
p53 for degradation by the proteasome (Kubbutat et al. 1997; Haupt et al. 1997; Honda 
et al. 1997; Fuchs et al. 1998b; Honda and Yasuda 2000; Fang et al. 2000a). Mdm2-
mediated ubiquitinylation of p53 is largely restricted to the six C-terminal lysine 
residues (Kubbutat et al. 1998; Rodriguez et al. 2000; Nakamura et al. 2000c; Lohrum 
et al. 2001). At least five of these six lysine residues in p53 are subject to acetylation 
which protects against Mdm2-mediated ubiquitinylation and degradation, at least in 
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part, by site competition (Gu and Roeder 1997; Sakaguchi et al. 1998; Liu et al. 1999b; 
Ito et al. 2002; Li et al. 2002b). 
In addition to p53, a growing list of other proteins are subject to Mdm2-targeted 
proteasomal degradation (Table 1.4). These include Mdm2 itself which is subject to 
autoubiquitinylation that destabilises the protein (Fang et al. 2000a; Honda and Yasuda 
2000). The majority of the identified substrates are targeted for degradation by Mdm2 
through ubiquitinylation but a minority are targeted through a ubiquitin-independent 
mechanism. For example, Mdm2 binds to p21ciP1fwan and facilitates its association 
with the proteasomal C8 subunit independently of ubiquitinylation (Zhang et al. 2004). 
While these additional Mdm2-substrates are involved in a range of cellular processes, 
proteins involved in the regulation of transcription are particularly well represented 
(detailed in Section 1.6.1.3). 
Efficient recognition by the proteasome requires the presence of a chain of at least four 
ubiquitin molecules (Thrower et al. 2000). Mdm2 itself may only be able to catalyse 
multi-site monoubiquitinylation of p53, which does not result in p53-degradation (Lai 
et al. 2001). In contrast, Mdm2-autoubiquitinylation results in the formation of 
polyubiquitin chains (Lai et al. 2001). 	Grossman et al. (2003) show that 
polyubiquitinylation of p53 is mediated by the combined actions of Mdm2 and p300. 
p53 is monoubiquitinylated by Mdm2 and then polyubiquitinylated by p300 acting as 
an E4 ubiquitin-ligase. p300 binds to the central acidic domain of Mdm2 and deletions 
in this region can limit p53-ubiquitinylation to the mono-form and prevent p53-
degradation (Grossman et al 1998; Kawai et al. 2003a; Meulmeester et al. 2003). 
However, two studies show that deletions in this Mdm2 region allow p53- 
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polyubiquitinylation (although p53-degradation was still prevented presumably as 
sequences in this region are required for another function in p53-degradation) 
(Argentini et al. 2001; Zhu et al. 2001). The deletions that inhibit polyubiquitinylation 
extend further towards the Mdm2 C-terminus than those allowing polyubiquitinylation 
(Table 1.5). Although all of these deletions extend C-terminal to the region essential 
for p300 binding (Grossman et al. 1998), it is possible that binding is only fully 
disrupted by the more C-terminal deletions. Li et al. (2003) show in vitro and in vivo 
that high levels of Mdm2 catalyze polyubiquitinylation of p53, but low levels of Mdm2 
only catalyze monoubiquitinylation. Hence, p300 may only be required for p53-
polyubiquitinylation at lower levels of Mdm2 expression. Thus, the discrepancies in 
the results of acidic domain deletions may be due to variation in the levels of 
overexpression achieved. 
Monoubiquitinylation of p53 by Mdm2 reduces the TF activity of p53 by promoting its 
nuclear exclusion (Li et al. 2003). This is consistent with studies demonstrating that 
Mdm2 promotes nuclear export of p53 in a manner dependent upon the Mdm2 RING 
finger domain (Boyd et al. 2000; Geyer et al. 2000). Furthermore, mutation of the six 
lysine residues of p53 that are ubiquitinylated by Mdm2 results in a p53 protein that is 
defective for Mdm2-driven nuclear export (Lohrum et al. 2001). Mdm2 also directly 
binds and monoubiquitinylates histone H2B. This is suggested to result in repression of 
transcription from promoters to which Mdm2 is recruited by p53 (see Section 1.6.1.3) 
(Minsky and Oren 2004). 
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Table 1.4 Proteins subject to Mdm2-mediated degradation 
Subsequent to the identification of p53 as a substrate for Mdm2-mediated degradation, 
at least 14 other proteins have been identified as being degraded in a Mdm2-dependent 
manner. 
Mdm2 substrate Effect of Mdm2 Reference 
Androgen receptor Ubiquitinylation and 
degradation 
Lin et al. 2002 
Gaughan et al. 2005 
13-arrestin Ubiquitinylation and 
degradation 
Shenoy et al. 2001 
E2F1/DP1 
Under conditions where the 
TF heterodimer promotes 
apoptosis 
E2F1 degradation in a manner 
dependent upon the presence 
of the DP1 subunit 
(ubiquitinylation not 
examined) 
DP1 degradation 
(ubiquitinylation not 
examined) 
Loughran 	and 	La 
Thangue 2000 
HDAC1 Ubiquitinylation and 
degradation 
Gaughan et al. 2005 
Insulin-like growth factor-1 
receptor (IGF-1R) 
Ubiquitinylation and 
degradation 
Girnita et al. 2003 
Mdm2 Ubiquitinylation and 
degradation 
Fang et al. 2000a 
Honda and Yasuda 2000 
Mdmx Ubiquitinylation and 
degradation 
de Graaf et al. 2003 
Kawai et al. 2003b 
Pan and Chen 2003 
Numb Ubiquitinylation and 
degradation 
Juven-Gershon et al. 
1998 
Yogosawa et al. 2003 
p21Cipl/Wail Ubiquitin-independent 
degradation 
Jin et al. 2003a 
Zhang et al. 2004 
p53 Ubiquitinylation and 
degradation 
Kubbutat et al. 1997 
Haupt et al. 1997 
Honda et al. 1997 
p300/CBP Ubiquitinylation and 
degradation 
Sanchez-Molina et al. 
2006 
PCAF Ubiquitinylation and 
degradation 
Jin et al. 2004 
Retinoblastoma protein (Rb) Degradation in a ubiquitin- 
independent or ubiquitin- 
dependent manner 
Sdek et al. 2005 
Uchida et al. 2005 
TCAP Ubiquitin-independent 
degradation 
Tian et al. 2006 
Tip60 Ubiquitinylation and 
degradation 
Legube et al. 2002 
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Table 1.5 The effect of deletions in the Mdm2 acidic domain on p53 
ubiquitinylation 
Mdm2-mediated degradation of p53 requires the Mdm2 acidic domain. However, the 
importance of this domain in p53-polyubiquitinylation is uncertain. 
Residues 	deleted 	in 
Mdm2 acidic domain 
p53 - 
degradation 
p53 - 
ubiquitinylation 
Reference 
222 - 303 Inhibited Monoubiquitinylation Kawai et al. 2003a 
202 - 302 Inhibited Monoubiquitinylation Meulmeester et al. 2003 
222 - 272 Inhibited Polyubiquitinylation Argentini et al. 2001 
217 - 246 Inhibited Polyubiquitinylation Zhu et al. 2001 
217 - 246 Inhibited Not examined Grossman et al. 1998 
1.6.1.3 Nuclear localisation of Mdm2 
Mdm2 shuttles between the nucleus and the cytoplasm Mdm2 possesses a NLS (Chen 
et al. 1995) and a NES (Roth et al. 1998), and shuttles between the nucleus and the 
cytoplasm (Roth et al. 1998). At any one time, the majority of Mdm2 is localised to the 
nucleus (Chen et al. 1995; Roth et al. 1998; Tao and Levine 1999; Boyd et al. 2000). 
Mdm2 promotes nuclear export of p53 which will reduce p53 TF activity (Boyd et al. 
2000; Geyer et al. 2000; Li et al. 2003). One study suggests that Mdm2 shuttles p53 
out of the nucleus in a manner dependent upon the Mdm2 NES (Toa and Levine 1999). 
As detailed above, other studies indicate that it is the RING finger domain and not the 
Mdm2 NES that is essential to promote nuclear export of p53 (Boyd et al. 2000; Geyer 
et al. 2000). Initial studies showed nuclear export to be essential for p53-degradation 
(Roth et al. 1998; Freedman and Levine 1998; Lain et al. 1999; Boyd et al. 2000; Geyer 
et al. 2000). However, later studies indicate that inhibition of nuclear export does not 
inhibit p53-degradation (Lohrum et al. 2001; Shirangi et al. 2002; Joseph et al. 2003). 
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It has now been explicitly demonstrated that Mdm2 can promote degradation of p53 
within both the nucleus and the cytoplasm (Yu et al. 2000; Lohrum et al. 2001; 
Xirodimas et al. 2001; Shirangi et al. 2002; Joseph et al. 2003). 
Mdm2 possesses a nucleolar localisation activity Mdm2 possesses a NoLS (Lohrum 
et al. 2000; Weber et al. 2000). The NoLS does not function in unstressed cells but is 
required for nucleolar re-localisation induced by pl4ARF/p19Arf and contributes 
significantly to the negative regulation of Mdm2 by this protein (detailed in Section 
1.6.2.2) (Weber et al. 1999; Lohrum et al. 2000; Weber et al. 2000). 
Mdm2 associates with promoters of specific genes Using EMSAs (electrophoretic 
mobility shift assays) and ChIP (chromatin immunoprecipitation) assays, Gu et al. 
(2002a) demonstrated that Mdm2 binds to the p65 NF-KB subunit promoter. The 
authors suggest that Mdm2 binds directly to the DNA and functions as a TF. Mdm2 
possesses a zinc finger domain, a motif present in many TFs that mediates DNA 
binding. However, given that Mdm2 is a well defined E3 ubiquitin-ligase, it would 
seem unlikely that it functions as a TF. Zhao et al. (2005) detect Mdm2 association 
with the human telomerase promoter by ChIP assay. No association was detected by 
EMSA and the authors suggest that this is because the interaction is indirect. ChIP 
assays detect binding of Mdm2 at the p21Cipl/Waf1 promoter only concomitant with 
binding of the regulating TF, p53, to this site (Jin et al. 2002; Minsky and Oren 2004). 
Therefore, Mdm2 association with a gene promoter is indirect and mediated through a 
TF. Following recruitment to p53-responsive promoters, Mdm2 represses transcription 
and this can be achieved independently of p53 (Thut et al. 1997; Minsky and Oren 
2004). This transcription-repression function is dependent upon the Mdm2 RING 
finger domain and is associated with a local increase in ubiquitinylation (Minsky and 
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Oren 2004). Mdm2 may exercise its regulation of transcription through a number of its 
known substrates, these include TFs, histones, histone acetyltransferases (HATs) and 
HDACs (Table 1.6). 
Table 1.6 Substrates through which Mdm2 may regulate transcription 
Mdm2 may regulate transcription indirectly through a number of its substrates as detailed 
below. 
Category Mdm2 binding 
substrate 
Effect of Mdm2 on 
substrate 
Reference 
HAT p300/CBP (also 
acetylates non-histone 
proteins including TFs) 
Ubiquitinylation and 
degradation 
Sanchez-Molina et al. 
2006 
PCAF (also acetylates 
non-histone proteins 
including TFs) 
Ubiquitinylation and 
degradation 
Jin et al. 2004 
Tip60 (also acetylates 
non-histone proteins 
including TFs) 
Ubiquitinylation and 
degradation 
Legube et al. 2002 
HDAC HDAC1 Ubiquitinylation and 
degradation 
Gaughan et al. 2005 
Histone H2B Monoubiquitinylation Minsky and Oren 2004 
TF Androgen receptor Ubiquitinylation and 
degradation 
Lin et al. 2002 Gaughan 
et al. 2005 
E2F1 Protein stabilised 
(when the TF promotes cell 
proliferation) 
Martin et al. 1995 
Zhang et al. 2005 
E2F1/DP1 Degradation promoted 
(when E2F1/DP1 promote 
apoptosis) 
Loughran and La 
Thangue 2000 
p53 TF activity reduced and 
ubiquitinylation and 
degradation promoted 
Oliner et al. 1993 
Honda et al. 1997 
SP1 Reduction in TF activity 
without a change in protein 
level 
Johnson-Pais et al. 
2001 
TFIID (specifically 
TAFII250 and TBP) 
Unknown Leveillard and Wasylyk 
1997 
TFIIE (specifically the 
34 kDa subunit) 
Unknown Thut et al. 1997 
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1.6.1.4 The essential function of Mdm2 is the regulation of p53 
As detailed above, Mdm2 downregulates p53 through several mechanisms (Figure 1.6). 
Indeed, overexpression of Mdm2 inhibits p53-induced apoptosis (and cell cycle arrest) 
(Chen et al. 1996). Furthermore, reduced Mdm2 expression is associated with 
increased p53 levels and apoptosis (Conforti et al. 2000). Thus, Mdm2 plays a 
cytoprotective role through the downregulation of p53. Targeted inactivation of the 
Mdm2 gene is embryonic lethal in mice (Jones et al. 1995; Montes de Oca Luna et al. 
1995). In contrast, mice deficient in both the Mdm2 and the p53 genes develop 
normally and are viable (Jones et al. 1995; Montes de Oca Luna et al. 1995). Hence, 
although Mdm2 regulates other proteins, the only essential function of Mdm2 is the 
downregulation of p53. 
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Figure 1.6 Regulation of p53 by Mdm2 
Mdm2 binds to and downregulates p53. Mdm2 binding directly inhibits p53 TF 
activity. The Mdm2 RING finger catalyses p53 monoubiquitinylation. 
Monoubiquitinylation promotes p53 nuclear export. Mdm2 may also shuttle 
p53 out of the nucleus in a manner dependent upon the Mdm2 NES. p53 is 
polyubiquitinylated by p300 or by Mdm2 directly. Polyubiquitinylated p53 is 
degraded by the proteasome. 
Dashed lines indicate where alternative pathways are proposed. 
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1.6.2 Regulation of Mdm2 protein 
1.6.2.1 Phosphorylation of Mdm2 
Several protein kinases phosphorylate and regulate Mdm2 (Figure 1.7). In response to 
survival signals, Mdm2 is phosphorylated by PKB at Ser166 and possibly Serl 86 or 
Ser188, and this is associated with decreased Mdm2-autoubiquitinylation and increased 
degradation and inactivation of p53 (Mayo and Donner 2001; Zhou et al. 2001; 
Ashcroft et al. 2002; Gottlieb et al. 2002; Ogawara et al. 2002; Feng et al. 2004; Milne 
et al. 2004). Ser166 may alternatively be phosphorylated by MAPKAPK2, which may 
additionally phosphorylate Ser157 (Weber et al. 2005). 	Phosphorylation by 
MAPKAPK2 is also associated with enhanced degradation of p53 by Mdm2 (Weber et 
al. 2005). GSK-3 phosphorylates Mdm2 at Ser254 and this also enhances p53-
degradation (Kulikov et al. 2005). In response to ionizing radiation, GSK-3 is 
inactivated which leads to accumulation of p53 (Kulikov et al. 2005). 
Ionising radiation causes phosphorylation of Mdm2 at Ser395 by ATM (ataxia-
telangiectasia mutated, a DNA-damage activated kinase), which reduces the ability of 
Mdm2 to promote p53-degradation (Khosravi et al. 1999; Maya et al. 2001). 
Phosphorylation of Mdm2 at Tyr394 by c-Abl also impairs the ability of Mdm2 to 
target p53 for degradation and inhibit p53 TF activity (Goldberg et al. 2002). This site 
is phosphorylated in response to 11202 (Goldberg et al. 2002). Other kinases that 
phosphorylate Mdm2 include casein kinase II (CK2) (Guerra et al. 1997; Gotz et al. 
1999; Hjerrild et al. 2001), CK18 (Winter et al. 2004), cyclin A-CDK2 (cyclin 
dependent kinase 2) (Zhang and Prives 2001), ATR (ataxia-telangiectasia and rad3- 
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related) (Shinozaki et al. 2003) and DNA-PK (DNA-dependent protein kinase) (Mayo 
et al. 1997) (Figure 1.7). Phopho-Mdm2 is subject to the action of phosphatases. A 
complex of cyclin G and the protein phosphatase PP2A acts at Ser166 and Thr216 of 
Mdm2 (Okamoto et al. 2002). 
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Domain L E Domain Finger Finger L 
S S S 
DNA-PK PKB 
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Ser 1 88) 
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GSK-3 	CK2 on.  murine) 	(Ser240, Ser242 	(Ser 254) 	(Ser269) 
and Ser246) 
Figure 1.7 Kinase target sites within the Mdm2 protein 
The residues of Mdm2 subject to phosphorylation are indicated. Amino acid numbers 
correspond to the human Mdm2 protein, unless indicated otherwise. Sites of 
phosphorylation which activate Mdm2 are highlighted in green and sites of 
phosphorylation which inhibit Mdm2 are highlighted in red. Sites of phosphorylation 
which are of undetermined effect are highlighted in grey. 
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1.6.2.2 Regulation of Mdm2 protein by p14ARF/p19Ad and Mdmx 
Mdm2 is regulated by interaction with several non-kinase proteins, of which Mdmx 
(also known as Mdm4) and p14ARF/p19Arr (Figure 1.8) have received the most attention. 
Mdmx is a homologue of Mdm2 and is expressed in all tissues tested including the 
heart (Shvarts et al. 1996). Mdmx (like Mdm2) is an essential negative regulator of p53 
activity (Shvarts et al. 1996; Parant et al. 2001). Mdmx suppresses both the apoptosis 
and growth arrest inducing functions of p53 (Rallapalli et al. 1999). Similar to Mdm2, 
Mdmx possesses a RING finger and a p53 binding domain (Shvarts et al. 1996). Mdmx 
is however unable to ubiquitinylate p53 in vivo (Stad et al. 2001) but does binds p53 to 
reduce the p53 TF activity (Shvarts et al. 1996; Rallapalli et al. 1999). Mdmx and 
Mdm2 bind through their RING finger domains and this stabilises the Mdm2 protein 
(Sharp et al. 1999; Tanimura et al. 1999), which increases Mdm2-mediated degradation 
of p53 (Gu et al. 2002b). 
In response to DNA-damaging stress, Mdm2 catalyses the ubiquitinylation of Mdmx 
resulting in degradation of Mdmx by the proteasome (Pan and Chen 2003; de Graaf et 
al. 2003; Kawai et al. 2003b). The downregulation of Mdmx in response to DNA-
damaging stress allows upregulation of p53 (Kawai et al. 2003b; Chen et al. 2005; 
Okamoto et al. 2005; Pereg et al. 2005; Jin et al. 2006; LeBron et al. 2006). Mdmx is 
targeted for Mdm2-dependent degradation through its phosphorylation by ATM (Chen 
et al. 2005; Pereg et al. 2005) and ChK2 (Chen et al. 2005; LeBron et al. 2006) and 
possibly ChK1 (Jin et al. 2006). It is demonstrated that the phosphorylation by ChK1 
or ChK2 increases association of Mdmx with 14-3-3 proteins which augments its 
degradation by Mdm2 (Jin et al. 2006; LeBron et al. 2006; Okamoto et al. 2005). 
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Arf (p14ARF in human and p19Arf in mouse) is encoded by the INK4a/Arf locus, which 
(as the name suggests) also encodes the p16 4a  CDK inhibitor. These two products 
have different first exons but share exons 2 and 3, containing different reading frames 
(Queue et al. 1995). pl4ARI/p19Arf binds to the central acidic domain of Mdm2 and 
blocks Mdm2-mediated degradation of p53 and inhibition of p53 TF activity 
(Pomerantz et al. 1998; Honda and Yasuda 1999; Midgley et al. 2000; Bothner et al. 
2001). p14ARF also promotes the degradation of Mdm2 (Zhang et al. 1998a). 
Furthermore, p14ARF stimulates Mdm2-mediated ubiquitinylation and degradation of 
Mdmx (Pan and Chen 2003). As detailed above (Section 1.6.1.3), pl4ARF/p19Arf can 
sequester Mdm2 in the nucleolus in a manner dependent on nucleolar localisation 
sequences in Mdm2 and p14ARF/p19Arf (Weber et al. 1999; Lohrum et al. 2000; Weber 
et al. 2000). This nucleolar localisation of Mdm2 by pl4ARF/p19Arf was initially shown 
to be essential for the upregulation of p53 (Weber et al. 1999, 2000). Later studies 
show that pl4ARF/p19Arf can stabilise p53, without inducing Mdm2-nucleolar re-
localisation (Lin and Lowe 2001; Llanos et al. 2001). The result of p14ARF/p19Ad - 
mediated augmentation of p53 activity is to promote the induction of apoptosis or cell 
cycle arrest by p53 (Kamijo et al. 1997; de Stanchina et al. 1998; Zhang et al. 1998a; 
Lu et al. 2002). Study of pl4ARF/p19Arf in the heart is limited to one study. pl9Arf  
levels in murine cardiac myocytes are found to increase with age and as expected this is 
concomitant with increased p53 protein levels and decreased formation of Mdm2 - p53 
complexes (Torella et al. 2004). 
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Figure 1.8 Regulatory interactions between Mdm2, Mdmx, p14ARF/p19Ad and p53 
Mdmx upregulates Mdm2 and Mdm2 downregulates p53. p1eRF/p19Ad downregulates 
Mdm2 to cause p53 activation. 
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1.6.3 The Mdm2 gene 
Mdm2 is transcribed from the P1 and P2 promoters The Mdm2 gene possesses two 
promoters, P1 and P2. P1 lies 5' of exon 1 and P2 lies 5' of exon 2 in intron 1 (Figure 
1.9). P1 gives rise to a longer mRNA isoform (L-Mdm2) containing exon 1 and P2 to a 
shorter mRNA isoform (S-Mdm2) that lacks exon 1. Expression from P1 is constitutive 
(Barak et al. 1994; Saucedo et al. 1998; Mendrysa and Perry 2000), whereas expression 
from P2 is inducible (Juven et al. 1993; Perry et al. 1993; Ries et al. 2000). It is well 
established that, in response to DNA-damaging stress, p53 is activated and binds to the 
two p53 response elements located 5' to the TATA box of P2 in intron 1 of Mdm2 
(Figure 1.9) (Barak et al. 1993; Juven et al. 1993; Otto and Deppert 1993; Perry et al. 
1993; Wu et al. 1993; Barak et al. 1994; Chen et al. 1994; Zauberman et al. 1995; 
Saucedo et al. 1998; Mendrysa and Perry 2000). In this way, p53 increases expression 
from the P2 promoter of Mdm2 and creates an autoregulatory feedback loop. 
In intron 1 of Mdm2 there are binding sites for TFs other than p53 (Figure 1.9). These 
are positioned 5' to the p53 response elements and allow expression from P2 to be 
regulated in a p53-independent manner. Activation of Raf increases expression from 
P2 of murine Mdm2 in a p53-independent manner (Ries et al. 2000). An Ets (E26 
transformation-specific) TF binding site and a 3' AP-1/Ets composite TF binding site 
are essential for this upregulation (Ries et al. 2000). Fli-1 (Friend leukaemia virus 
integration-1, an Ets TF) is demonstrated to bind the 5' Ets site of murine Mdm2 in 
vitro and in vivo (Truong et al. 2005). The overexpression of Fli-1 is sufficient to 
increase expression from P2 of murine Mdm2 in a manner dependent on this site. The 
functional importance of the AP-1/Ets composite site has been confirmed for human 
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Mdm2, where it is required for p53-independent increased expression from the P2 
promoter in the T47D breast cancer cell line (Phelps et al. 2003). A repeat sequence 
(nnGGGGC)5 located 5' to the AP-1/Ets composite site is also required, but this 
sequence is not conserved in mouse (Phelps et al. 2003). Expression from P2 is also 
subject to repression. In response to high doses of ultraviolet (UV) irradiation (greater 
than those inducing upregulation of Mdm2 expression in a p53-dependent manner), 
expression from P2 of murine Mdm2 is repressed in a manner independent of p53 (Wu 
and Levine 1997; Zeng et al. 2000). Results obtained using reporter constructs of 
murine P2 demonstrate that the region required for repression lies 5' to the p53 
response elements (Zeng et al. 2000). 
Translation of Mdm2 protein The translation initiation codon of full length Mdm2 
protein (p90) is located in exon 3 (Figure 1.10) (Barak et al. 1994). Therefore full 
length Mdm2 is translated from both L-Mdm2 mRNA and S-Mdm2 mRNA, as the only 
sequence that S-Mdm2 lacks is exon 1. However, S-Mdm2 mRNA is translated more 
efficiently than L-Mdm2 mRNA and so expression from P2 leads to higher levels of 
Mdm2 protein (Landers et al. 1997; Brown et al. 1999; Jin et al. 2003b). This is due to 
the presence of two upstream open reading frames (uORFs) in exon 1, which is unique 
to L-Mdm2 mRNA (Brown et al. 1999; Jin et al. 2003). uORFs encode short peptides 
[14 amino acids in the case of human Mdm2 (Jin et al. 2003)] and inhibit translation 
from the 3' main ORF (Morris and Geballe 2000). uORF1 of Mdm2 has a greater 
inhibitory effect than the 3' uORF2 (Jin et al. 2003). Inhibition of translation by Mdm2 
uORF1 is dependent on the sequence of the translated peptide, suggesting that it 
belongs to the class of "sequence-specific" uORFs (Jin et al. 2003). The sequence-
specific uORFs encode peptides that cause ribosome stalling which blocks access of 
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scanning ribosomes to downstream initiation codons (Wang and Sachs 1997; Wang et 
al. 1998b; Fang et al. 2000; Raney et al. 2000; Gaba et al. 2001). Translation inhibition 
by Mdm2 uORF2 also requires its translation but the importance of the encoded peptide 
sequence is undetermined (Jin et al. 2003). 
The Mdm2 gene gives rise to a second protein isoform, p76 Mdm2 (Saucedo et al. 
1999). p76 Mdm2 is generated by initiation of translation from an internal AUG at 
codon 50 in exon 4 (Figure 1.10) (Barak et al. 1994; Saucedo et al. 1999). This is 
achieved through either internal translation initiation or alternative splicing to remove 
exon 3 containing the p90 Mdm2 translation initiation codon (Saucedo et al. 1999). 
p76 Mdm2 protein is translated from both L- and S- Mdm2 mRNA. However, 
compared with L-Mdm2 mRNA, S-Mdm2 mRNA gives rise to a higher ratio of p90 to 
p76 Mdm2 protein (Barak et al. 1994; Saucedo et al. 1999; Mendrysa et al. 2001). p76 
Mdm2 lacks the N-terminal 49 amino acids that contain the p53 binding domain (Chen 
et al. 1993; Barak et al. 1994; Saucedo et al. 1999). Indeed, p76 Mdm2 cannot bind 
p53 or inhibit its TF activity (Barak et al. 1994; Haines et al. 1994; Saucedo et al. 
1999). Overexpressed p76 Mdm2 acts in a dominant-negative manner to inhibit p90 
Mdm2-mediated degradation of p53 (Perry et al. 2000). 
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Figure 1.9 Mdm2 possesses two promoters: P1 and P2 
The L- and S-Mdm2 mRNA isoforms are transcribed from the P1 and P2 promoters, 
respectively. Expression of L-Mdm2 mRNA from P1 is constitutive. Expression of S-
Mdm2 mRNA from P2 is regulated by several inducible TFs that have binding sites 5' 
within intron 1. 
Figure 1.10 The p90 Mdm2 and p76 Mdm2 translation initiation (AUG) codons 
The p90 and p76 Mdm2 protein isoforms are translated from both L- and S-Mdm2 
mRNA. The p90 Mdm2 AUG codon is in exon 3 and the p76 Mdm2 AUG codon is in 
exon 4. 
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1.6.4 Mdm2 in cardiac myocytes 
Both p76 and p90 Mdm2 protein isoforms are expressed in the murine heart (Perry et 
al. 2000). The p53-responsiveness of the Mdm2 promoter is maintained in cardiac 
myocytes (Regula and Kirshenbaum 2001) and Mdm2 mRNA and protein show p53-
dependent upregulation in the murine heart exposed to apoptotic stress in the form of 
doxorubicin (Liu et al. 2004). IGF-1 treatment (Leri et al. 1999) or overexpression of 
p300 (Kawamura et al. 2004) protects against cardiac myocyte apoptosis in association 
with upregulation of Mdm2 protein abundance. Furthermore, Mdm2 overexpression in 
cultured cardiac myocytes reduces apoptosis caused by hypoxia alone or 
hypoxia/reoxygenation (Toth et al. 2006). Consistent with this, a peptide inhibitor of 
the Mdm2 - p53 interaction elevates p53 levels and apoptosis in cultured cardiac 
myocytes exposed to hypoxia alone or hypoxia/reoxygenation (Toth et al. 2006). There 
is therefore considerable evidence that Mdm2 maintains its anti-apoptotic function in 
cardiac myocytes. The relevance to the diseased heart is demonstrated by the findings 
that ischaemia/reperfusion injury is increased in isolated murine hearts expressing low 
Mdm2 protein levels (Toth et al. 2006), and that decreased Mdm2 mRNA expression 
occurs in the failing human heart together with caspase-3 activation (Steenbergen et al. 
2003). Microarray studies performed by our group demonstrate that Mdm2 mRNA 
levels are significantly increased in cultured cardiac myocytes exposed to 0.1 mM or 
0.2 mM H202 after 2 and 4 h (Kemp et al. 2003) (Table 1.2). This suggests that Mdm2 
may play an important role in cardiac myocyte apoptosis induced by this stress. 
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1.7 Hypothesis 
Mdm2 expression is upregulated in cardiac myocytes exposed to H202 and it is 
therefore hypothesised that this protein has an important regulatory role in the 
progression of cardiac myocyte apoptosis and the development of cardiac pathologies. 
This study therefore examines the regulation of Mdm2 in cardiac myocytes by 
oxidative stress. 
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Chapter two 
Methods 
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2.1 Preparation of primary cultures of neonatal rat cardiac myocytes 
Primary cultures of ventricular cardiac myocytes were prepared from neonatal (2-4 
day-old) Sprague-Dawley rats (purchased from Harlan). Rats were culled by cervical 
dislocation and then decapitated. The bodies were sterilised [70% (v/v) industrial 
methylated spirit]. Hearts were removed and washed in sterile ADS Buffer [116 mM 
NaC1, 20 mM HEPES (pH 7.35), 0.8 mM Na2HPO4, 5.6 mM glucose, 5.4 mM KCI, 
0.8 mM MgSO4]. Ventricles were isolated and sequentially digested at 37°C with 
agitation in digestion buffer [0.4 mg/ml collagenase (Worthington Biochemicals) and 
0.6 mg/ml pancreatin (Sigma) in ADS Buffer]. The supernatant from the first digest 
(10 ml, 5 mM) was discarded. Cardiac myocytes were isolated by five further digests: 
10 ml, 20 mM; 8 ml, 25 min; 8 ml, 25 min; 6 ml, 15 min; 6 ml, 10 mM. The 
supernatants were added to foetal calf serum (FCS, 2 ml) (Invitrogen) to quench the 
digestion. Cells were recovered by centrifugation (room temperature, 5 min, 60 g), 
resuspended in 4 ml FCS (37°C) and stored (37°C, 5% CO2). The final cell 
suspensions were pooled, centrifuged (60 g, 5 min) and the pelleted cells were 
resuspended in plating medium [68% (v/v) Dulbecco's modified Eagle's medium 
(DMEM) (Invitrogen), 17% (v/v) M199 (Invitrogen), 10% (v/v) horse serum 
(Invitrogen), 5% (v/v) FCS (Invitrogen), 100 units/ml penicillin and streptomycin 
(Invitrogen)]. Cells (4 ml per dish) were plated onto uncoated 60 mm Primaria 
culture dishes (37°C, 30 min, 5% CO2) to allow attachment of non-myocytes. Non-
adherent cardiac myocytes were collected and counted using a haemocytometer [75111 
myocyte suspension, 175 µI plating medium and 250 IA Trypan blue solution 
(Invitrogen)] ignoring blue-stained non-viable cells. 	Cardiac myocytes were 
suspended in plating medium (106 myocytes/ml) and plated (4 ml per 60 mm dish; 2 
ml per 35 mm dish) onto gelatin-coated [1% (w/v) in Milli-Q filtered water] Primaria 
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culture dishes. Following overnight (17 h) incubation (37°C, 5% CO2), cardiac 
myocytes were placed in serum-free medium [80% (v/v) DMEM, 20% (v/v) M199, 
100 units/ml penicillin and streptomycin] for 24 h. 
2.2 Agonists and inhibitors used to treat cardiac myocytes 
Inhibitors (Table 2.1), H202 (Sigma) and endothelin (ET-1, Sigma) were added 
directly to the cardiac myocyte serum-free medium. 
Table 2.1 Inhibitors used to treat cardiac myocytes 
Inhibitor Supplier Concentration Pre-incubation 
time 
Inhibition 
target 
Actinomycin D Sigma 4 µM 60 min mRNA 
transcription 
Cycloheximide Sigma 20 !AM 30 min Protein 
translation 
GF109203X Alexis 
Biochemicals 
10 uM 15 min PKC 
LY294002 Alexis 
Biochemicals 
50 µM 15 min PI3K 
SB203580 Alexis 
Biochemicals 
10 µM 15 min p38-MAPK 
SP600125 Sigma 10 p.M 15 min JNK 
U0126  Sigma 10 µM 15 min MEK1/2 
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2.3 Extraction of total RNA 
Cardiac myocytes (2.0 x 106 cells) were scraped into ice-cold RNAzo1 BeeTM 
(Biogenesis) (500 111), incubated with chloroform (100 pl) on ice (5 min) and 
centrifuged (4°C, 10 min, 15300 g). The upper phase was incubated with an equal 
volume of isopropanol (on ice, 1 h). RNA was pelleted by centrifugation (4°C, 10 
min, 20800 g), washed [70% (v/v) ethanol] and resuspended in 15 pi Milli-Q filtered 
water. RNA concentrations were determined by spectrophotometry (X = 260 nm). 
The purity was assessed from the X260/X280 ratio. Values of 1.9-2.1 were acceptable. 
RNA was stored at -80°C. 
2.4 Semi-quantitative reverse transcriptase polymerise chain 
reaction (RT-PCR) 
PCR primer design - Oligonucleotide primers (Table 2.2) were designed to match 
published mRNA sequences or expressed sequence tags (Ests). Where possible, 
forward and reverse primers were designed in different exons. This ensured that the 
amplification product of any contaminating genomic DNA would include an intron 
and therefore be of a different size to the mRNAJcDNA amplification product. 
Primers were designed to have a length of 18-24 bp and a melting temperature of 
60°C. That the primers were gene-specific was confirmed using the NCBI Blast 
engine. The oligonucleotides were synthesised by MWG Biotech. 
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DNase treatment - Where the goal of RT-PCR was to determine if a sequence is 
transcribed in cardiac myocytes rather than only being present in the DNA, RNA was 
DNase treated to remove any contaminating genomic DNA. A reaction mix of RNA 
(3 jig in 15 Ill), 3µl commercial DNase I reaction buffer (Invitrogen), 3µl DNase I 
Amp Grade (1 U/111) (Invitrogen) and 9 Ill Milli-Q filtered water was incubated (15 
min, room temperature) and then the reaction terminated by addition of 3 ttl 25 mM 
EDTA and heating (10 min, 65°C). 
Reverse transcription - cDNA was synthesised using reagents supplied by Invitrogen. 
Cardiac myocyte RNA (1 jig) was mixed with random hexamers (0.5 ttg) and dATP, 
dCTP, dGTP and dTTP (0.74 mM each), in 13.5 pl. Following incubation (65°C, 5 
min), 6.5 ttl mixture A [15 mM dithiothreitol (DTT), 4 td commercial 5 x lst strand 
buffer, 200 units M-MLV reverse transcriptase and 0.5 ill RNaseOut®] was added and 
samples were incubated (37°C, 1 h). The reaction was then terminated (65°C, 3 min) 
and the cDNA stored at -20°C. 
PCR - Reactions were performed in 50 Al of 1 x Buffer IV® (AB Gene) containing 
0.5-1.0 ng cDNA, 1 Taq polymerase unit (AB Gene), dATP, dCTP, dGTP and dTTP 
(0.2 mM each) (Invitrogen), 100 pmol forward primer and 100 pmol reverse primer. 
Samples were heated (94°C, 10 s) and then subjected to 20-30 cycles of denaturation 
(94°C, 30 s), annealing (59°C, 30 s) and extension (72°C, 30 s). Samples were then 
heated (72°C, 2 min) and finally cooled (4°C). Samples were mixed with PCR 
sample buffer [0.25% (w/v) bromophenol blue, 40% (w/v) sucrose] at 10% (v/v) and 
subjected to electrophoresis (90 V, 20 min) on agarose gels [2% (w/v) agarose in 1 x 
TBE (90 mM Tris, 90 mM boric acid, 2 mM EDTA) containing 100 14/1 ethidium 
bromide] with PCR running buffer (1 x TBE containing 100 14/1 ethidium bromide). 
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Bands were detected under UV light. Band sizes were estimated by comparison to a 
9)(174 RF DNA Hae III digest ladder (AB Gene) or a 100 bp DNA ladder 
(Invitrogen). Densitometric analysis was performed using ImageMaster 1D Prime, 
version 3.0 (Amersham). Values were normalised to those of the RT-PCR product for 
the housekeeping gene GAPDH. For genes displaying constitutive expression it was 
confirmed that the PCRs were semi-quantitative. This was achieved by performing 
PCR for a range of cycle numbers with a single sample, followed by densitometric 
analysis and construction of amplification curves (Figure 2.1). The PCR cycle 
numbers employed in experiments lay within the exponential sections of the curves. 
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Table 2.2 RT-PCR primer sequences 
Gene-specific oligonucleotides for use as RT-PCR primers were synthesised by 
MWG Biotech. 
RT-PCR primer Sequence (5' - 3') Exon Predicted 
product 
size 
PCR 
cycle 
number 
p1941 forward 
pl 9Arf reverse 
TTCGTGGTCACTGTGAGGAT 
AGTCTCGCGTTGCCAGAAG 
1 
3 
587 bp 27 cycles 
CJBS Pre-TATA 
forward 
CJBS Post-TATA 
forward 
CJBS reverse 
TTTGAGGCCTCTGTCTTCTG 
GTTGTTGTCCTGTGTCATGG 
GATGGTGTAGGTACAGGAGA 
N/A 
N/A 
N/A 
246 bp 
146 bp 
30 cycles 
28 cycles 
c-Fos forward 
c-Fos reverse 
AGTGGTGAAGACCATGTCAG 
AATGTTCTTGACCGGCTCCA 
2 
4 
448 bp 25 cycles 
FosB forward 
FosB reverse 
ACCCCTGTGCAGTATTATGC 
CAGTATAAAGCGCTCCAGCA 
Est 
Est 
138 bp 27 cycles 
Fra-1 forward 
Fra-1 reverse 
AATTGCAGTGGATGGTGCAG 
ACTTAGCAGCTGCTAGCTTG 
2 
3 
219 bp 26 cycles 
Fra-2 forward 
Fra-2 reverse 
AATCAACGCCATCACCACCA 
GGTGGTACCAATGGTCTTGA 
Est 
Est 
178 bp 26 cycles 
GAPDH forward 
GAPDH reverse 
ACCACAGTCCATGCCATCAC 
TCCACCACCCTGTTGCTGTA 
N/A 
N/A 
452 bp 20 cycles 
c-Jun forward 
c-Jun reverse 
ATGACTGCAAAGATGGAAACG 
TATTCTGGCTATGCAGTTCAG 
N/A 
N/A 
376 bp 24 cycles 
JunB forward 
JunB reverse 
ATCACGACGACTCATACGCA 
TGGAGGCTAGCTTCAGAGAT 
N/A 
N/A 
225 bp 25 cycles 
JunD forward 
JunD reverse 
ATGGAAACGCCCTTCTATGG 
CTTTCTTCAGCATGCTGCTC 
N/A 
N/A 
157 bp 28 cycles 
Total Mdm2 
forward 
Total Mdm2 
reverse 
ATCCAGCTTCTCTCTGAACG 
AGACTAAGACAATGCTCCGG 
12 
3' 
UTR 
259 bp 27 cycles 
Mdm2 exon 1 
forward 
Mdm2 exon 2 
forward 
Mdm2 exon 4 
reverse 
TCGCTTCGCTCGACCTCC 
AGCGGAGACGGACACACC 
CTCTTTCATAGTGTAAATATCTTT 
1 
2 
4 
333 bp 
220 bp 
27 cycles 
27 cycles 
Mdmx forward 
Mdmx reverse 
GGTGTACTGTGGTGGAGA 
AGCCTAGATGTCTCATCTTGA 
2 
6 
339 bp 27 cycles 
p53 forward 
p53 reverse 
TTGAGGTTCGTGTTTGTGCC 
CACGGGCATCCTTTAATTCC 
6 
8 
255 bp 27 cycles 
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Figure 2.1 Amplification plots for genes displaying constitutive 
expression 
For genes displaying constitutive expression [(A) p./ef, (B) CJBS, (C) GAPDH, (D) 
JunD, (E) Mdmx and (F) p53], PCRs were performed for increasing cycle numbers 
with a single cDNA sample. Plotting of the densitometric analysis demonstrated that 
amplification followed the expected sigmoid curve. The PCR cycle numbers used in 
semi-quantitative RT-PCR lay within the exponential sections of the curves. The 
images (upper panels) and the densitometric analysis (lower panels) shown are 
representative of two independent experiments. 
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2.5 Purification and sequencing of PCR products 
PCR products were purified from the reaction mix using the Qiagen QlAquick PCR 
purification kit (catalogue number 28104), according to the manufacturer's 
instructions. Where two products were produced in a given PCR, samples were 
mixed with PCR sample buffer and subjected to electrophoresis (90 V, 20 min) on 
agarose gels [2% (w/v) agarose in 1 x TBE containing 100 µg/1 ethidium bromide] 
with PCR running buffer. The separated bands were visualised and excised under UV 
light. DNA was extracted from the gel slices using the Qiagen QlAquick gel 
extraction kit (catalogue number 28704), according to the manufacturer's instructions. 
For sequencing, approximately 100 ng of purified PCR product was mixed with 100 
pmol of forward or reverse primer and made up to a 12 µ1 volume with Milli-Q 
filtered water. Automated sequencing was then carried out by the Advanced 
Biotechnology Centre (ABC), Imperial College London, using the ABI 3100 Genetic 
Analyser. 
2.6 Preparation of protein extracts 
Total protein extracts - Cardiac myocytes (4.0 x 106 per sample) were rinsed twice in 
ice-cold phosphate-buffered saline (PBS) (Invitrogen). For preparation of total 
protein extracts, cardiac myocytes were scraped into 150 µI ice-cold Buffer G [20 
mM glycerophosphate (pH 7.5), 50 mM NaF, 2 mM EDTA, 0.2 mM Na3VO4, 10 mM 
benzamide, 0.2 mM leupeptin (Sigma), 10 µM trans-epoxysuccinyl-L-leucylamido-
(4-guanidino) butane (E64) (Sigma), 5 mM DTT (Sigma), 0.3 mM 
phenylmethylsulphonyl fluoride (PMSF) (Sigma), 2 p.M microcystin (Alexis 
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Biochemicals), 1% (v/v) Triton X100]. Samples were centrifuged (4°C, 5 min, 10600 
g) and the supernatants retained. A 2 p,1 volume of supernatant was used to determine 
the protein concentration (see below) and the remaining supernatant was boiled with 
0.33 volume of immunoblotting sample buffer [0.33 M Tris-HC1 (pH 6.8), 10% (w/v) 
sodium dodecyl sulphate (SDS), 13% (w/v) glycerol, 133 mM DTT, 0.01% (w/v) 
bromophenol blue]. Immunoblotting samples were stored at -20°C. 
Nuclear protein extracts - Cardiac myocytes (4.0 x 106 per sample) were rinsed twice 
in ice-cold PBS (Invitrogen) and scraped into 150 1.11 ice-cold Buffer A [10 mM 
HEPES (pH 7.9), 10 mM KCI, 1.5 mM MgC12, 0.3 mM Na3VO4 , 0.2 mM leupeptin 
(Sigma), 10 uM E64 (Sigma), 5 mM DTT (Sigma), 0.3 mM PMSF (Sigma), 2 µM 
microcystin (Alexis Biochemicals)]. Samples were centrifuged (4°C, 5 min, 10600 g) 
and the pellets washed in 100 gl Buffer A containing 0.1% (v/v) Nonidet P40 (NP40). 
Samples were centrifuged (4°C, 5 min, 10600 g) and the pellets resuspended in 50 
ice-cold Buffer C [20 mM HEPES (pH 7.9), 420 mM NaCI, 1.5 mM MgC12, 0.2 mM 
EDTA, 25% (v/v) glycerol, 0.3 mM Na3VO4, 0.2 mM leupeptin (Sigma), 10 p,M E64 
(Sigma), 5 mM DTT (Sigma), 0.3 mM PMSF (Sigma), 2 p.M microcystin (Alexis 
Biochemicals)]. Suspensions were incubated (on ice, 1 h), centrifuged (4°C, 5 min, 
10600 g) and the supernatants retained. A 2 gl volume of supernatant was used to 
determine the protein concentration (see below). Samples for use in EMSAs were 
snap frozen in liquid N2 and stored at -80°C. Samples for use in immunoblotting were 
boiled with 0.33 volume of immunoblotting sample buffer and stored at -20°C. 
Measurement of protein concentration - Protein concentrations were determined by 
Bradford assay (Bradford 1976). BioRad Bradford reagent [1/5 dilution in double-
deionised water, 1 ml] was added to samples (2 ul) in a final volume of 100 ill. 
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Absorbance at X=595 nm was measured and the protein concentration determined by 
comparison to a range of bovine serum albumin (BSA) dilutions (2-10 pig). 
2.7 Immunoblotting 
Cardiac myocyte protein extracts (25 ilg of total or 10 ptg of nuclear) were separated 
by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) (200 V, 
45 min). BioRad Protean II mini-gels were used with 10% polyacrylamide resolving 
gels [10% (w/v) acrylamide, 0.27% (w/v) bis-acrylamide, 0.1% (w/v) SDS, 0.375 M 
Tris-HC1 (pH 8.8), 0.1% (v/v) TEMED, 0.1875% (w/v) ammonium persulphate], 6% 
polyacrylamide stacking gels [6% (w/v) acrylamide, 0.160% (w/v) bis-acrylamide, 
0.1% (w/v) SDS, 125 mM Tris-HC1 (pH 6.8), 0.1% (v/v) TEMED, 0.1875% (w/v) 
ammonium persulphate] and SDS-PAGE running buffer [25 mM Tris-HCI, 192 mM 
glycine, 2% (w/v) SDS]. Proteins were transferred to nitrocellulose membranes using 
BioRad Trans-Blot semi-dry transfer cells (10 V, 1 h) with transfer buffer [25 mM 
Tris-HC1, 192 mM glycine, 20% (v/v) methanol]. Membranes were incubated (room 
temperature, 20 min, with agitation) in TBST [Tris-buffered saline (20 mM Tris-HC1 
(pH 7.6), 137 mM NaC1) with 0.1% (v/v) Tween 20] containing 5% (w/v) non-fat 
milk powder. Membranes were then incubated (4°C, 18 h) with primary antibodies 
(Table 2.3) in 2 ml TBST containing 5% (w/v) BSA. Membranes were washed in 
TBST (3 x 5 min, with agitation) and then incubated (room temperature, 1 h) with 
horseradish peroxidase-conjugated secondary antibodies (DAKO) [1/5000 in 10 ml 
TBST containing 1% (w/v) non-fat milk powder]. Membranes were then washed 
again in TBST (3 x 5 min, with agitation). Immunoreactive bands were detected by 
enhanced chemiluminescence (Santa Cruz Biotechnology) and exposure of the 
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luminescing immunoblots to Hyperfilm (Amersham). Bands were captured using a 
scanner calibrated against the Kodak photographic step tablet number 2. The digital 
band images were analysed semi-quantitatively by densitometry (ImageMaster 1D 
Prime, version 3.0, Amersham). 
Table 2.3 Immunoblotting primary antibodies 
Antibody Supplier Cat. 
No. 
Source Concentration Working 
dilution 
Protein 
extract 
used 
p 1 9Arr Santa Cruz 
Biotechnology 
7401 Goat 0.2 µg/µ1 1/500 Total 
c-Fos Santa Cruz 
Biotechnology 
52X Rabbit 2 tig/µ1 1/20000 Nuclear 
c-Jun New England 
Biolabs 
9162 Rabbit N/A 1/750 Nuclear 
JunB Santa Cruz 
Biotechnology 
46X Rabbit 2 [tg/g1 1/5000 Nuclear 
JunD Santa Cruz 
Biotechnology 
74X Rabbit 2 lig/g1 1/12000 Nuclear 
Mdm2 Santa Cruz 
Biotechnology 
965 Mouse 0.2 pg/iAl 1/750 Total 
P-Mdm2 
(Ser-166) 
New England 
Biolabs 
3521 Rabbit N/A 1/750 Total 
Mdmx Santa Cruz 
Biotechnology 
14740 Goat 0.2 tig/111 1/500 Total 
p53 Santa Cruz 	! 
Biotechnology 
6243 Rabbit 0.2 ttg/µ1 1/1200 Nuclear 
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2.8 Electrophoretic mobility shift assay (EMSA) 
Synthesis of double stranded EMSA probe - An EMSA probe containing a consensus 
p53 binding sequence was purchased from Santa Cruz Biotechnology as double-
stranded oligonucleotides (Table 2.4). EMSA probes designed to specifically match 
the transcription factor binding sequences in the Mdm2 promoter were synthesised by 
Sigma Genosys as complementary single-stranded oligonucleotides (Table 2.4). 
Complementary single-stranded oligonucleotides (10 pg of each) were incubated 
(95°C, 2 mM) with 2 ill Buffer DS [100 mM Tris-HC1 (pH 7.5), 500 mM NaC1, 100 
mM MgC12] in a total volume of 20 pl. The reaction mixture was allowed to cool 
slowly over a period of 6 h and then the (now double-stranded) oligonucleotides were 
diluted to 100 ng/µl in Milli-Q filtered water. To check the efficiency of the 
annealing reaction, 200 ng of single- and double-stranded oligonucleotides were 
mixed with PCR sample buffer at 10% (v/v) and subjected to electrophoresis (90 V, 
20 min) on agarose gels [2.5% (w/v) agarose in 1 x TBE containing 100 µg/1 ethidium 
bromide] with PCR running buffer. Bands were detected under UV light. Double-
stranded oligonucleotides migrated more slowly than the single-stranded 
oligonucleotides. The level of annealing efficiency achieved was 100%. 
Radiolabelling of EMSA probe - Oligonucleotide EMSA probes were radiolabelled in 
12 µ1 containing 30 ng double-stranded oligonucleotides, 10 units T4 polynucleotide 
kinase (Promega), 15 µCi [y32P] ATP (Amersham) and 1.2 µI of commercial 
(Promega) 10 x kinase buffer. The reaction mixture was incubated (37°C, 30 min) 
and the reaction then terminated by addition of 1 p.1 EDTA (13 µM). Excess [732P] 
ATP was removed by centrifugation (room temperature, 3 min, 700 g) through 
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Chromaspin columns (pore size 100) (BD Biosciences) in 1 x TE [10 mM Tris-HC1 
(pH 8.0), 1 mM EDTA]. Oligonucleotide EMSA probes were diluted to a working 
concentration of 0.4 ng/µ1. 
Binding assay of nuclear protein extracts to radiolabelled EMSA probe - Cardiac 
myocyte nuclear protein extracts (10 pg) were incubated (room temperature, 10 min) 
with 4 pl binding buffer [50 mM Tris-HC1 (pH 7.5), 250 mM NaC1, 5 mM EDTA, 1 
mM DTT, 25% (v/v) glycerol] and 1 pg poly dI-dC (Amersham), in a total volume of 
20 pl. Radiolabelled EMSA probe [1 pl (0.4 ng)] was added and the mixture 
incubated (room temperature, 20 min). Samples were subjected to electrophoresis 
(120 V, 3 h) on 5% non-denaturing polyacrylamide gels [5% (w/v) acrylamide, 
0.166% (w/v) bis-acrylamide, 0.05% (w/v) ammonium persulphate, 0.1% (v/v) 
TEMED in 1 x TBE] using 0.5 x TBE as running buffer. Gels were vacuum dried 
(80°C, 45 min) onto 3 mm Whatman paper and exposed to Hyperfilm (Amersham) for 
24-48 h at -80°C. Bands were captured using a scanner calibrated against the Kodak 
photographic step tablet number 2. The digital band images were analysed semi-
quantitatively by densitometry (ImageMaster 1D Prime, version 3.0, Amersham). 
For competition experiments, nuclear extracts were incubated in binding buffer with 
poly dI-dC as in the standard assay. Nuclear extracts were then incubated (room 
temperature, 10 min) with the required amount of unlabelled wild type or mutated 
double stranded oligonucleotide EMSA probe (Table 2.4), followed by addition of the 
radiolabelled wild type probe and continuation of the assay in the standard manner. 
For supershift assays, nuclear extracts (3 jig) were pre-incubated (4°C, 1 h) with 1-2 
pg of antibody (Table 2.5) and the EMSA then performed in the standard manner. 
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Table 2.4 Oligonucleotide EMSA probes 
Mdm2-specific oligonucleotide EMSA probes were synthesised as complementary 
single-strands by Sigma Genosys. p53 consensus double-stranded oligonucleotide 
EMSA probe was purchased from Santa Cruz Biotechnology. 
EMSA probe Sequence (5' - 3') 
Mdm2 AP-1 wild type GCCTAGTTGACTCAGCTTTTC 
Mdm2 AP-1 mutant GCCTAGTTGACTTGGCTTTTC 
Mdm2 3' Ets (EtsA) wild type GGACGTGGCTTCCGGGACGGGT 
Mdm2 3' Ets (EtsA) mutant GGACGTGGATTCCAGGACGGGT 
Mdm2 5' Ets (EtsB) wild type GACTCAGCTTTTCCTGTGGGGCTGG 
Mdm2 5' Ets (EtsB) mutant GACTCAGCTTTTCCCGGGGGGCTGG 
Mdm2 MZFlwild type ATGGAGGGAGGGGAGAGGAG 
Mdm2 MZF1 mutant ATGGAGGGAAGGTAGAGGAG 
p53 consensus TACAGAACATGTCTAAGCATGCTGGGGACT 
Table 2.5 Antibodies used in EMSA supershift assays 
Antibodies used in EMSA supershift assays were purchased from Santa Cruz 
Biotechnology 
Antibody Cat. no. Species Concentration Quantity used 
ATF-2 187X Rabbit 2 ps/µ1 2 pg 
P-Elk-1 7979X Goat 2 1.1g/µ1 2 ps 
Fli-1 356X Rabbit 2 pg/µ1 2 lig 
c-Fos 52X Rabbit 2 pg/µ1 1 µg 
FosB 48X Goat 2 pg/µ1 2 µg 
Fra-1 605X Rabbit 2 pg/µ1 2 pg 
Fra-2 171X Rabbit 2 µg/µ1 2 µg 
c-Jun 45X Rabbit 2 µg,/µ1 2 µg 
JunB 46X Rabbit 2 pg/µ1 2 µg 
JunD 74X Rabbit 2 pg/µ1 2 ps 
p53 126 Mouse 0.2 pg/g1 1 ps 
p53 6243 Rabbit 0.2 pg/p.1 1 µg 
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2.9 The chromatin immunoprecipitation (ChIP) assay 
2.9.1 Chromatin immunoprecipitation (ChIP) and PCR 
Cross-linking of transcription factors to DNA - To cross-link transcription factors to 
DNA, the plated cardiac myocytes (4.0 x 106 per sample) were incubated (room 
temperature, 10 min) in serum-free medium [80% (v/v) DMEM, 20% (v/v) M199, 
100 units/ml penicillin and streptomycin] containing 1% formaldehyde. 
Lysis of cardiac myocytes - Cardiac myocytes were rinsed twice in ice-cold PBS 
(Invitrogen) and scraped into 200 µI PBS containing 0.2 mM leupeptin (Sigma), 10 
1.1.M E64 (Sigma), 5 mM DTT (Sigma), 0.3 mM PMSF (Sigma) and 2 µM microcystin 
(Alexis Biochemicals). Suspensions were centrifuged (4°C, 10 min, 4000 g) and the 
pelleted cells resuspended in 0.8 ml ChIP lysis buffer [50 mM Tris-HC1 (pH 8.0), 85 
mM KC1, 0.2 mM leupeptin (Sigma), 10 µM E64 (Sigma), 5 mM DTT (Sigma), 0.3 
mM PMSF (Sigma), 2 AM microcystin (Alexis Biochemicals), 0.5% (v/v) NP40]. 
Suspensions were incubated (on ice, 10 min), centrifuged (4°C, 5 min, 4000 g) and the 
pellets resuspended in 0.8 ml SDS lysis buffer [50 mM Tris-HC1 (pH 8.0), 10 mM 
EDTA, 1% (v/v) SDS]. Suspensions were incubated (on ice, 10 min). 
Fragmentation of DNA by sonication - The cardiac myocyte extracts in SDS lysis 
buffer were sonicated on ice. Sonication was performed five times for 30 sec with 2 
min cooling time between each, using a Vibracell sonicator at amplitude 30. This was 
sufficient to break the DNA into fragments of 200-800 bp (see Section 2.9.2). 
Sonicated samples were centrifuged (4°C, 10 min, 4000 g) and the supernatants (800 
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µ1) retained. Two 350 IA volumes were taken from the supernatant and each 
subjected to immunoprecipitation. One 20 µI volume (designated the input sample) 
was taken from the supernatant to assess the DNA concentration in the sonicated 
sample prior to immunoprecipitation. 
Immunoprecipitation of transcription factors and cross-linked DNA - Each 350 µI 
sample of the sonicated cardiac myocyte extracts was diluted in 1.65 ml ChIP dilution 
buffer [20 mM Tris-HC1 (pH 8.0), 150 mM NaC1, 2 mM EDTA, 0.01% (w/v) SDS, 
1% (v/v) Triton X100]. The diluted samples were incubated (4°C, 30 min, with 
mixing by rotation) with 80 ill Protein A-Sepharose (Sigma) (4 mg/ml, 50% slurry 
equilibrated in ChIP dilution buffer) containing 1 µg/m1 sonicated salmon sperm 
DNA (Sigma). Protein A-Sepharose was pelleted (4°C, 1 min, 200 g) and discarded, 
removing cardiac myocyte proteins that bound non-specifically to the Protein A-
Sepharose. Antibody (5 µg) to the transcription factor of interest (Table 2.6) was 
added to the supernatants followed by incubation (4°C, 16 h, with mixing by rotation). 
Antibody-protein-DNA complexes were recovered by incubation (4°C, 1 h, with 
mixing by rotation) of the suspensions with 150 µI Protein A-Sepharose (4 mg/ml, 
50% slurry equilibrated in ChIP dilution buffer) containing 1 µg/m1 sonicated salmon 
sperm DNA. Protein A-Sepharose was recovered by centrifugation (4°C, 1 min, 200 
g) and then washed (room temperature, 3 min, with mixing by rotation) in 1 ml low 
salt wash [20 mM Tris-HC1 (pH 8.0), 150 mM NaCl, 2 mM EDTA, 0.1% (w/v) SDS, 
1% (v/v) Triton X100]. Protein A-Sepharose was recovered by centrifugation (4°C, 1 
min, 200 g) and then washed (room temperature, 3 min, with mixing by rotation) in 1 
ml high salt wash [20 mM Tris-HC1 (pH 8.0), 500 mM NaC1, 2 mM EDTA, 0.1% 
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(w/v) SDS, 1% (v/v) Triton X100]. Protein A-Sepharose was then similarly washed 
in 1 ml LiC1 wash [10 mM Tris-HC1 (pH 8.0), 250 mM LiC1, 1 mM EDTA, 1% (w/v) 
deoxycholic acid, 1% (v/v) NP40] and then twice in 1 ml TE [10 mM Tris-HC1 (pH 
8.0), 1 mM EDTA]. Protein-DNA bound to Protein A-Sepharose was removed by 
incubation (room temperature, 3 min) with 250 pi elution buffer [0.1 M NaHCO3, 1% 
(w/v) SDS]. Samples were then centrifuged (4°C, 1 min, 200 g) and the supernatants 
removed and retained. The supernatants contained the immunoprecipitated protein-
DNA and were designated the extract samples. The pelleted Protein A-Sepharose was 
incubated (room temperature, 3 min) with another 250 pi elution buffer and the 
samples re-centrifuged. The extract supernatants were pooled with those generated in 
the previous incubation. 
Extraction of DNA from the input and extract samples - The input samples (made up 
to 500 p.1 in lb) and the extract samples (500 pl) were uncross-linked by incubation 
(65°C, 4 h) with 20 gl 5 M NaC1 (final concentration 0.2 M NaCl). Following 
uncross-linking, the 500 p1 volumes of input and extract samples were incubated with 
500 pl phenol:chloroform:isoamyl alcohol (25:24:1, pH 8.0) (Sigma) (on ice, 5 min). 
Aqueous and organic phases were separated by centrifugation (4°C, 10 min, 15300 g). 
The upper aqueous phase was removed and incubated with 500 p1 isopropanol (on 
ice, 1 h). DNA was pelleted by centrifugation (4°C, 10 mM, 20800 g), washed [70% 
(v/v) ethanol] and then resuspended in 15 pl Milli-Q filtered water. 
PCR - Reactions were performed as described for RT-PCR (section 2.4) but using a 
higher number of Taq polymerase units and primers matching genomic DNA 
sequences (Table 2.7). Input samples (1 pl) were subjected to 35 PCR cycles with 2.5 
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Taq polymerase units/50 Id reaction. Extract samples (1 Ill) were subjected to 35 
PCR cycles with 2.5 Taq polymerase units/50 1.t1 reaction, followed by a further 20 
PCR cycles using an additional 2.5 Taq polymerase units/50 µ1 reaction. 
2.9.2 Optimisation of DNA sonication 
Cross-linking and cardiac myocyte lysis were performed as described in Section 2.9.1. 
Samples were then subjected to 0, 1, 2, 3, 4 or 5 rounds of sonication using the same 
conditions as those described in Section 2.9.1. Immunoprecipitation was not 
performed and the samples were immediately uncross-linked and DNA extracted as 
described in Section 2.9.1. DNA samples (5 1.11) were mixed with PCR sample buffer 
at 10% (v/v) and subjected to electrophoresis (90 V, 20 min) on agarose gels [2% 
(w/v) agarose in 1 x TBE containing 100 tigil ethidium bromide] with PCR running 
buffer. The DNA was visualised under UV light and compared to the cpx174 RF 
DNA Hae III digest ladder (AB Gene) (Figure 2.2). Four or five rounds of sonication 
broke the DNA into fragments of 200-800 bp. 
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Figure 2.2 Optimisation of DNA sonication 
Cardiac myocyte extracts on ice were subjected to 1-5 rounds of sonication (30 sec 
with 2 min cooling time between each) using a Vibracell sonicator at amplitude 30. 
DNA was extracted and subjected to electrophoresis on an ethidium bromide agarose 
gel. The image shown is representative of three independent experiments. 
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Table 2.6 Antibodies used in ChIP assays 
ChIP assay antibodies were purchased from Santa Cruz Biotechnology. 
Antibody Cat. No. Species of origin Quantity used 
c-Jun 45X Rabbit 5 .ig (2.5 ill) 
JunB 46X Rabbit 5 lig (2.5 ill) 
JunD 74X Rabbit 5 1.1g (2.5 ill) 
Table 2.7 PCR primers used in ChIP assays 
ChIP-PCR 
primer 
Sequence (5' - 3') Position Product 
size 
Mdm2 P2 promoter 
forward 
Mdm2 P2 promoter 
reverse 
CAGGGGTCGGGGAGGTAA 
TTAGCTCCTCCAACAGCCAA 
Intron 1 144 bp 
Arbitrary sequence 
forward 
Arbitrary sequence 
reverse 
TTGCTCAGGAGACATCCTTG 
CAAGAATATTTCAACAATATTCAC 
4000 bp 
3' to 
Mdm2 
gene 
144 bp 
GAPDH forward 
GAPDH reverse 
ACCACAGTCCATGCCATCAC 
TCCACCACCCTGTTGCTGTA 
Exon 1 452 bp 
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Chapter three 
Expression of Mdm2, Mdmx and p19Arf mRNA 
and protein in cardiac myocytes 
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3.1 Introduction 
Mdm2 is an essential negative regulator of the pro-apoptotic p53 TF (Momand et al. 
1992; Jones et al. 1995; Montes de Oca Luna et al. 1995; Honda et al. 1997). 
Expression of Mdm2 is regulated at the levels of mRNA transcription and protein 
translation, and the Mdm2 protein is subject to posttranslational modifications that 
increase or decrease its activity (reviewed in Section 1.6). 
Mdm2 was one of 22 genes identified as being upregulated following exposure of 
cardiac myocytes to 0.1-0.2 mM H202 (Table 1.2, Kemp et al. 2003). The time 
course examined was very limited and the dependence on H202 concentration was not 
determined. H202 inhibits total protein synthesis in cardiac myocytes (Pham et al. 
2000). It is therefore necessary to confirm that increased Mdm2 mRNA abundance 
translates into an increased protein level. Mdm2 is subject to autoubiquitinylation 
leading to proteasomal degradation (Fang et al. 2000; Honda and Yasuda 2000). As a 
result Mdm2 is an unstable protein with a half life of 15-30 mM under basal 
conditions (Olson et al. 1993; Trotta et al. 2003). In response to apoptotic stress, 
Mdm2 is cleaved by caspase-3 (Chen et al. 1997; Erhardt et al. 1997). Activation of 
caspase-3 occurs in cardiac myocytes exposed to 0.5 mM H202 (Cook et al. 1999). It 
is therefore of particular interest to compare changes in Mdm2 mRNA and protein in 
cardiac myocytes exposed to H202. 
The Mdm2 protein contains several sites targeted by protein kinases and 
phosphorylation of distinct residues positively (e.g. Mayo and Donner 2001; Zhou et 
al. 2001) or negatively (e.g. Khosravi et al. 1999) regulates Mdm2 activity. 
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Phosphorylation of Mdm2 at Ser166 by either PKB or MAPKAPK2 enhances the 
stability and activity of Mdm2 (Mayo and Donner 2001; Zhou et al. 2001; Ogawara et 
al. 2002; Feng et al. 2004; Weber et al. 2005). Mdm2 is also regulated by non-kinase 
proteins of which Mdmx and p14ARF(human)/p19nmurine) are the most established 
examples. Mdmx binds and stabilises the Mdm2 protein (Sharp et al. 1999; Tanimura 
et al. 1999) and increases Mdm2-mediated degradation of p53 (Gu et al. 2002b). 
DNA-damaging stress increases ubiquitinylation and degradation of Mdmx by Mdm2, 
leading to upregulation of p53 (Pan and Chen 2003; Kawai et al. 2003b). Mdmx is 
also subject to cleavage by caspase-3 (Gentiletti et al. 2002). Binding of 
pl4ARI/p19mf  to Mdm2 inhibits Mdm2-mediated downregulation of p53 (Pomerantz 
et al. 1998; Honda and Yasuda 1999; Midgley et al. 2000; Bothner et al. 2001). 
Furthermore, p14ARF promotes the degradation of Mdm2 (Zhang et al. 1998a). 
In this chapter, changes in the expression of Mdm2 mRNA and protein in cardiac myocytes 
challenged with H202 were examined in detail. Changes in the abundance of Mdm2-P(Ser166) 
were also assessed together with changes in the expression of Mdmx and p19Arf mRNA and 
protein. 
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3.2 Methods 
3.2.1 RT-PCR 
Cardiac myocytes were exposed to H202 (0.2 mM for 0-24 h or 0-10 mM for 2 h) 
added directly to the serum-free medium. Total RNA was extracted and cDNA 
synthesised (Sections 2.3 and 2.4). Semi-quantitative PCR was performed (Section 
2.4) to assess expression of p/9Arf mRNA, GAPDH mRNA, Mdm2 mRNA (using 
primers in exon 12 and the 3' UTR so that both the L- and S-Mdm2 mRNA isoforms 
are amplified) and Mdmx mRNA. PCR cycles were 94°C (30 s), 59°C (30 s) and 
72°C (30 s). Amplification products were analysed by electrophoresis on ethidium 
bromide-agarose (2% w/v) gels. Bands were captured under UV illumination, 
analysed by densitometry and normalised to GAPDH. Values are expressed as fold 
stimulations and analysed by one way ANOVA with Tukey post test (p<0.05). 
3.2.2 Gel extraction and sequencing of PCR products 
Amplification products separated by electrophoresis were visualised under UV light 
and excised. DNA was extracted from the gel slices using the Qiagen QlAquick gel 
extraction kit (Section 2.5). Automated sequencing was outsourced to the Advanced 
Biotechnology Centre (ABC), Imperial College London. 
3.2.3 Immunoblotting 
Cardiac myocytes were exposed to 0.2 mM H202 (0-8 h) added directly to the serum-
free medium. Total protein was extracted and immunoblotting performed (Sections 
2.6 and 2.7). Briefly, proteins (25 tig) were subjected to SDS-PAGE with a 10% 
polyacrylamide resolving gel. Proteins were transferred to nitrocellulose membranes 
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and probed with primary antibody to pl9Arf, Mdm2, phospho-Mdm2(Ser166) or 
Mdmx. Immunoreactive bands were detected by enhanced chemiluminescence and 
analysed semi-quantitatively by scanning densitometry. Values are expressed as 
arbitrary units and analysed by one way ANOVA with Tukey post test (p<0.05). 
3.2.4 Sequence analysis tools 
The Multialign tool (http://prodes.toulouse.inra.fr/multalin/multalin.html) was used to 
compare DNA and mRNA sequences. 	The ExPASy translation tool 
(http://us.expasy.org/tools/dna.html) was used to translate DNA sequences into 
peptide sequences. The NCBI Blast engine was used to search for complementary Est 
sequences (http://www.ncbi.nlm.nih.gov[BLAST/). 
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3.3 Results 
3.3.1 Mdm2 mRNA is upregulated in response to oxidative stress 
Changes in Mdm2 mRNA expression were examined by semi-quantitative RT-PCR. 
In response to 0.2 mM 11202, Mdm2 mRNA expression was significantly upregulated 
at 2 h [3.5 ± 0.5 fold (mean ± SEM, n=4)], and the levels remained elevated over at 
least 24 h (Figure 3.1). The dependence of this response on H202 concentration was 
determined at 2 h (Figure 3.2). Mdm2 mRNA expression was significantly 
upregulated by concentrations of H202 in the range of 0.1 mM to 0.3 mM. 
Concentrations <0.1 mM or >0.3 mM did not induce any change in expression. The 
abundance of Mdm2 mRNA was increased by 2.1 ± 0.4 fold (mean ± SEM, n=3) in 
response to 0.1 mM H202 (2 h) and by 3.3 ± 0.4 fold (mean ± SEM, n=3) in response 
to 0.3 mM H202 (2 h). Overexpressed Mdm2 negatively regulates the development of 
hypertrophy in cardiac myocytes (Toth et al. 2006) and it was therefore of interest to 
examine the effect of the hypertrophic agonist endothelin-1 (ET-1) on the expression 
of Mdm2. ET-1 (100 nM) did not cause any change in Mdm2 mRNA expression over 
0-6 h (Figure 3.3). 
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Figure 3.1 Mdm2 mRNA expression is increased in cardiac myocytes 
exposed to 0.2 mM H202 
Cardiac myocytes were exposed to 0.2 mM I-1202 (0-24 h). Mdm2 mRNA expression 
was assessed by RT-PCR and normalised to GAPDH. Representative images (upper 
panels) and the densitometric analysis (lower panels) are shown. Results are means + 
SEM for four independent experiments (*p<0.05, one way ANOVA with Tukey post 
test). 
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Figure 3.2 Mdm2 mRNA expression is increased in cardiac myocytes 
exposed to 0.1- 0.3 mM H202 
Cardiac myocytes were exposed to 0-10 mM H202 (2 h). Mdm2 mRNA expression 
was assessed by RT-PCR and normalised to GAPDH. Representative images (upper 
panels) and the densitometric analysis (lower panel) are shown. Results are means 
SEM for three independent experiments (*p<0.05, one way ANOVA with Tukey post 
test). 
124 
271 bp ____ 
234 by — 
603 by 
310 bp_ 
Mdm2 
259 by 
GAPDH 
452 by 
2.00 
1 75- 
8 1.50— 
E 
$2 
N .> 
leg 
1.25— 
1.00- 
0.75 
Time (h) 
0 0.5 
	
2 4 6 Blank 
0 
	
1 
	
2 	3 	4 
	
6 
Time (h) 
Figure 3.3 Mdm2 mRNA expression is not changed in cardiac 
myocytes treated with ET-1 
Cardiac myocytes were treated with ET-1 (100 nM, 0-6 h). Mdm2 inRNA expression 
was assessed by RT-PCR and normalised to GAPDH. Representative images (upper 
panels) and the densitometric analysis (lower panel) are shown. Results are means + 
SEM for three independent experiments. 
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3.3.2 The expression of total Mdm2 protein and phospho-Mdm2(Ser 
166) are increased in response to 0.2 mM H202 
H202 inhibits global protein synthesis in cardiac myocytes (Pham et al. 2000) and so 
immunoblotting was performed to confirm that the upregulation of Mdm2 mRNA 
translates into an increase in Mdm2 protein (Figure 3.4 A). Using total protein 
extracts and an antibody to total Mdm2, several closely migrating bands were 
detected with molecular masses close to that of the full length Mdm2 protein (90 
kDa). The detection of total Mdm2 protein as multiple bands may be the result of 
posttranslational modifications that alter its electrophoretic mobility. In response to 
0.2 mM H202, the levels of the detected bands were increased significantly at 2 h [7.5 
± 1.6 fold (mean ± SEM, n=3)]. After 2 h, levels declined and were only slightly 
elevated at 5 h. A second significant increase in total Mdm2 protein occurred at 8 h. 
The maximal level of total Mdm2 protein at 2 h is concomitant with the maximal 
upregulation of Mdm2 mRNA (Figure 3.1). However, in contrast to the total Mdm2 
protein there was no decrease in Mdm2 mRNA after 2 h up to at least 24 h (Figure 
3.1). 
Immunoblotting was next performed on cardiac myocyte total protein extracts using 
an antibody selective for phospho-Mdm2(Ser166) (Figure 3.4 B). This antibody 
produced a single band of —90 kDa. Following exposure of cardiac myocytes to 0.2 
mM 11202, the abundance of phospho-Mdm2(Ser166) protein was significantly 
elevated from 1.5 h. The levels of phospho-Mdm2(Ser166) reached a maximum 
increase at 2 h [25.1 ± 9.0 fold (mean ± SEM, n=4)]. From 2 h, levels decreased and 
only remained significantly elevated up to 3 h. 
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Figure 3.4 Total Mdm2 protein and phospho-Mdm2(Ser166) 
increase in cardiac myocytes exposed to 0.2 mM 11202 
Cardiac myocytes were exposed to 0.2 mM H202 (0-8 h). Total Mdm2 protein (A) or 
phospho-Mdm2(Ser166) (B) was examined by immunoblotting. Representative 
images (upper panels) and the densitometric analysis (lower panels) are shown. 
Results are means ± SEM for three independent experiments (*p<0.05, one way 
ANOVA with Tukey post test). 
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3.3.3 plef mRNA and protein levels are not altered in response to 
0.2 mM H202 
p19Arf binds to Mdm2 and inhibits Mdm2-mediated downregulation of p53 
(Pomerantz et al. 1998). p19Arf has not been the subject of investigation in cardiac 
myocytes exposed to oxidative stress. Expression of p1.9411 mRNA was examined by 
semi-quantitative RT-PCR and was unaltered following exposure of cardiac myocytes 
to 0.2 mM H202 (0-24 h) (Figure 3.5). The levels of p19Ad protein were assessed by 
immunoblotting of total protein extracts from cardiac myocytes and were also not 
altered in response to 0.2 mM H202 (0-5 h) (Figure 3.6). 
3.3.4 Mdmx mRNA and protein levels are not altered in response to 
0.2 mM H202  
Mdmx binds and stabilises the Mdm2 protein (Sharp et al. 1999; Tanimura et al. 
1999). Mdmx has not been the subject of investigation in cardiac myocytes. Semi-
quantitative RT-PCR was used to examine expression of Mdmx mRNA in cardiac 
myocytes exposed to 0.2 mM H202. Two products (-340 bp and —270 bp) were 
produced by RT-PCR using primers specific to exons 4 and 8 of Mdmx. Neither 
product changed in abundance following exposure of cardiac myocytes to 0.2 mM 
H202 (0-24 h) (Figure 3.7). The exon/intron boundaries of the rat Mdmx gene were 
determined by comparison of the mRNA sequence (accession number XM_222632.2) 
with the genomic sequence (chromosome 13, accession number Rn13WGA1917_3). 
The rat Mdmx gene contains eleven exons of which exon 6 has a size of 68 bp (Figure 
3.8). Hence alternative splicing of exon 6 could produce two products of the observed 
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-70 bp size difference. The two Mdmx PCR products were extracted from the 
electrophoresis gel and sequenced. The 340 bp product contained the full sequence 
between the primer binding sites (Figure 3.9 A) and the 270 bp product as expected 
lacked the sequence for exon 6 (Figure 3.9 B). Splicing out of the 68 bp exon 6 
causes a frameshift mutation that introduces 13 novel codons followed by a stop 
codon (Figure 3.10 A). This would be expected to result in the translation of a 
truncated Mdmx protein consisting of the N-terminal 176 amino acids of full length 
Mdmx followed by 13 novel amino acids (Figure 3.10 B). 
The levels of Mdmx protein were examined by immunoblotting of cardiac myocyte 
total protein extracts. The antibody used was raised against a peptide mapping near 
the C-terminus of Mdmx and was therefore expected to bind to the full length but not 
the truncated Mdmx protein. A single band was produced with the molecular mass of 
the full length Mdmx protein (80 kDa). The levels of full length Mdmx protein were 
unchanged in response to exposure of cardiac myocytes to 0.2 mM H202 (0-5 h) 
(Figure 3.11). 
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Figure 3.5 plef mRNA expression is unaltered in cardiac myocytes 
exposed to 0.2 mM H202  
Cardiac myocytes were exposed to 0.2 mM H202 (0-24 h). Expression of p194rf 
mRNA was assessed by RT-PCR and normalised to GAPDH. Representative images 
(upper panels) and the densitometric analysis (lower panels) are shown. Results are 
means + SEM for four independent experiments. 
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Figure 3.6 p19Arf protein abundance is unchanged in cardiac 
myocytes exposed to 0.2 mM 11202  
Cardiac myocytes were exposed to 0.2 mM H202 (0-5 h). pl9Arr protein was 
examined by immunoblotting. Representative images (upper panels) and the 
densitometric analysis (lower panels) are shown. Results are means ± SEM for four 
independent experiments. 
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Figure 3.7 Mdmx mRNA expression is unaltered in cardiac myocytes 
exposed to 0.2 mM11202  
Cardiac myocytes were exposed to 0.2 mM H2O, (0-24 h). Expression of Mdmx 
mRNA was assessed by RT-PCR and normalised to GAPDH. Representative images 
(upper panels) and the densitometric analysis (lower panels) are shown. Results are 
means ± SEM for five independent experiments. 
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Exon 1 (153 bp) 
ATGTTCAGTGTCGCCTGCTCCCTTCGCCCGCACCGCGGCFCTGGGATCCCCGCTGCACTGGGACCACACGGGCAAGC 
AACGGGCGTGGGGGACGGTCCGGGGCCCGGTGCTGTCTGCTGAAAGCGTGCACGAGCTCGCAGTCAGGCAGCCCC 
GG 
Exon 2 (114 bp) 
TTGCTAACTGAGTTTGGAATCTTCACTGCCAAAATGACATCACATTCCACCTCTGCCCAGTGTTCAGCATCTGACA 
GTGCTTGCAGAATTTCTTCGGAACAAATCAATCAGGTA 
Exon 3 (80 bp) 
CGACCAAAACTGCAGCTTCTCAAGATTTTGCAAGCAGCAGGTGCTCAGGGGGAAGTTTTCACCATGAAAGAGGTA 
ATGCA 
Exon 4 (126 bp) 
CTATCTAGGCCAGTATATAATGGTGAAGCAGCTCTATGATCAACAGGAGCAACATCTGGTGTACTGTGGTGGAGA 
CCTTTTGGGAGATCTACTTOGATGTCAGAGCTTTTCTGTGAAAGATCCAAG 
Exon 5 (56 bp) 
CCCTCTGTATGACATGCTAAGAAAGAACCTTGTTACGTCAGCCTCTGTTAACACAG 
Exon 6 (68 bp) 
ATGCTGCTCAGACTCTCGCTCTCGCACAGGATCACACTATGGATATTCCAAGTCAAGACCGACTGAAG 
Exon 7 (104 bp) 
CACGGTGCAACAGAGTGCTCCAACCCCAGAAAAAGAACTGAAGAAGATGATACTCACACACTGCCTACCTCACGA 
CGTAAATGCAGAGATTCCAGAGCAGATGA 
Exon 8 (158 bp) 
AGACTTGATAGAACATTTATCTCAAGATGAGACATCTAGGCTTGATCTTGATTTTGAGGAGTGGGATGTTGCTGGC 
CTGCCTTGGTGGTTTCTAGGGAATTTGAGAAACAACTATATACCTAGAAGTAATGGCTCAACTGATTTACAGACAA 
ATCAGG 
Exon 9 (146 bp) 
ATATAGGTACTGCCATTGTTTCAGACACTACGOACGATTTGTOGTTTTTAAATGAGACCGTGTCAGAGCAATTAGG 
TOTTGGAGTAAAAGTTGAAGCTGCTAACTGTGAGCAACCAAGTGAAGTAGGGAGAACAAGAGACAAGAAG 
Exon 10 (82 bp) 
ATGGTTGAAGGGGGAAAAGATGATGACCTTGAGGACTCCAAGTCCTTAAGTGATGATACTGATGTGGAAGTCACT 
TCTGAGG 
Exon 11 (569 bp) 
ATGAGTGGCAGTGTACGGAATGCAAGAAGTTTAATTCTCCAACT'CAAGAGGTACTOTTTTCGTTGCTGGOCCTTGAG 
GAAGGATTGGTATTCGGATTGCTCTAAATTAACTCATTCTCTCTCTACATCTAATATCACTGCCATACCTGAAAAGA 
AGGACAATGAAGGAATCGATGTCCCCGATTGTCGOAGAACCATTTCCGCTCCTGTGGTTAGGCCTAAAGATGGAT 
ATTTAAAGGAGGAAAAGCCCAGGTTTGACCCTTGCAACTCAGTGGAATTTTTGGATTTGGCCCATGGTTCTGAAAG 
CCAAGAGATCATCTCAAGCACAAGAGAACAAACAGATATTTTCTCTGAGCAGAAGACAGAAACAGAAAGTATGG 
AAGATTTCCAGAATGTCTTGAAGCCCTGTAGCTTATGTGAAAAAAGGCCTCGGGATGGGAACATTATTCATGGGA 
AGACGAGCCATCTGACTACATGTTTCCACTGTGCCAGGAGACTGAAGAAGTCTGGGGCTTCATGTCCTGCTTGTAA 
GAAAGAGATTCAGTTGOTTATTAAGGTTTTTATAGCATAG 
Figure 3.8 The exon structure of the rat Mdmx gene 
The exon structure of the rat Mdinx gene was determined by comparison of the 
mRNA sequence (accession number XM222632.2) and the genomic sequence 
(chromosome 13, accession number Rn13 WGA1917_3). PCR primer binding sites 
are highlighted. 
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A) 340 bp Mdmx RT-PCR product 
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391 400 410 420 430 440 450 460 470 480 490 500 510 518 
I 	-+ 	+ 	 + 	+  	+---------+ 	+ 	+---------+ 	+ 	+- 	I 340_bp_product 
Exons.4-8 68C0TCH6601ATETNITTITGRO6T6661111TTET66CCTUCTIGGT66TTEM6G6FIRTIT6flaIRCRITTOTOTIKOIRWORT66CTCORCT6RTITHCR6001118TCR66 
B) 270 bp Mdmx RT-PCR product 
1 	10 	20 	30 	40 	50 	60 	70 	80 	90 	100 	110 	120 	130 I-+---------+ 	+---------+ + 	+ 	+ + 	+ 	+ + 	I 270.bp.product 	 6GIGTIET6TGGIGGIOCCITITUMGRICIRCTTMUCHACTITTCT6T6RIMITCCHNUCT 
Exons.4-8 CHTMAGCCETFINTORTETGAA6CREETOTGATCORMAGCROCRETG6TGTRUGTETHRGACCUTTGGGIUTCTRCTTEATUCRGRETITTCHIGINGOTCCROGCCCT 
131 140 150 160 170 180 190 200 210 220 230 240 250 260 
I 	+---------+— 	+ 	-+ 	+ 	+--- 	+ 	+ 	+ 	+ 	+ 	+ 	-1 270.hp.product CIGTOTGACIII6CTMANCUTGTACGTCHCCTET6ITHOCIICH  	 CRCGGTGCRR Exons.4-8 CIGTATGACRTGCTARGROUICCTIGINCGTCHCCTCTUTMCUGHTET6CTUIGACTUNCICICERCO6611TUICIEBT660TRTICCHTCMCC611CM86C8CGGIUM 
261 270 280 290 300 310 320 330 340 350 360 370 380 390 
I+ 	+ 	+ 	+ 	+ 	+ 	+ 	+ 	+--..-----+ 	+ 	+.._.....-I 270.bp.product CRGIETGCTEURCUCCOHRHONCTUNIOGOIMICICHCRERCIGECACCTCOCK6TRRAT6CREATICCAGH6COGRINGIITTGRTOMICHTTIRETCHNIITGRUCHTC 
Exons.4-8 CA6116T6CTCCHRUCCONNKTIMMOTUTOCKIEFICACTGCCTOCCEIEGIUTHITGUIGHETCCAGAGUSTROGITTTGANGOACHTTTUCTCHWITGRUCATC 
391 400 410 420 430 440 450 460 470 480 490 500 51012 	+---------+  	+— 	+ 	+-I 
270.6p.product 1166CT 
Exons.4-8 TAGGCTUITTGRTITTGAGUETCHOTGTIGCTECCTUCTIGUGGITTCTROORTTTERARCINCTIITATRECIMUNTUCTURCTGRITTACOGRCARATCAG6 
Figure 3.9 Exon 6 of Mdmx is subject to alternative splicing 
The two Mdmx RT-PCR products were purified and sequenced. The sequence of the 
340 bp product (A) and the 270 bp product (B) were compared by Multialign to the 
published rat Mdmx rnRNA sequence (accession number XM222632.2). The 270 bp 
product lacks the sequence of exon 6 which is contained in the 340 bp product. 
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Mdmx exons 1-5 
5' ATG TTC AGT GTC GCC TGC TCC CTT CGC CCG CAC CGC GGC TCT GGG 
ATC CCC GCT GCA GGG GAC CAC ACG GGC AAG CAA CGG GCG TGG GGG 
ACG GTC CGG GGC CCG GTG CTG TCT GCT GAA AGC GTG CAC GAG CTC 
GCA GTC AGG CAG CCC CGG TTG CTA ACT GAG TTT GGA ATC TTC ACT 
GCC AAA ATG ACA TCA CAT TCC ACC TCT GCC CAG TGT TCA GCA TCT 
GAC AGT GCT TGC AGA ATT TCT TCG GAA CAA ATC AAT CAG GTA CGA 
CCA AAA CTG CAG CTT CTC AAG ATT TTG CAA GCA GCA GGT GCT CAG 
GGG GAA GTT TTC ACC ATG AAA GAG GTA ATG CAC TAT CTA GGC CAG 
TAT ATA ATG GTG AAG CAG CTC TAT GAT CAA CAG GAG CAA CAT CTG 
GTG TAC TGT GGT GGA GAC CTT TTG GGA GAT CTA CTT GGA TGT CAG 
AGC TTT TCT GTG AAA GAT CCA AGC CCT CTG TAT GAC ATG CTA AGA 
AAG AAC CTT GTT ACG TCA GCC TCT GTT AAC ACA G 1111 
Mdmx exon 6 spliced out 
AT GCT GCT CAG ACT CTC GCT CTC GCA CAG GAT CAC ACT ATG GAT ATT 
CCA AGT CAA GACCGACTG AAG 
Novel codons introduced into Mdmx mRNA 
CA CGG TGC AAC AGA GTG CTC CAA CCC CAG AAA AAG AAC 	3' 
Frameshift mutation introduced, 
A) Splicing of exon 6 from Mdnvc mRNA introduces a frameshift mutation 
B) The frameshift mutation will result in the translation of a novel 13 amino 
acid peptide. 
ARCNRVLQPQKKN 
Figure 3.10 Splicing of exon 6 from Mdmx mRNA introduces a 
frameshift mutation 
The effect of alternative splicing of exon 6 from Mdmx mRNA was examined. 
Splicing out of exon 6 introduces a frameshift mutation that creates 13 novel codons 
followed by a stop codon (A). The novel codons were translated using the ExPASy 
translation tool (B). 
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Figure 3.11 Mdmx protein abundance is unchanged in cardiac 
myocytes exposed to 0.2 mM I-1202  
Cardiac myocytes were exposed to 0.2 mM H202 (0-5 h). Mdmx protein was 
examined by immunoblotting. Representative images (upper panels) and the 
densitometric analysis (lower panels) are shown. Results are means ± SEM for four 
independent experiments. 
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3.4 Discussion 
3.4.1 Changes in Mdm2 mRNA, total protein and phosphoprotein-
(Ser166) levels 
Using semi-quantitative RT-PCR, it was shown that H202 (0.1 - 0.3 mM) promotes an 
increase in expression of Mdm2 mRNA in cardiac myocytes (Figures 3.1 and 3.2), in 
agreement with microarray studies (Kemp et al. 2003). This concentration range of 
11202 is apoptotic in cardiac myocytes (Cook et al. 1999). Higher necrosis-inducing 
concentrations of 14202 (>1 mM) (Chen et al. 2000; Kwon et al. 2003) and lower non-
lethal concentrations of H202 (<0.03 mM) (Cook et al. 1999) did not alter the 
expression of Mdm2 mRNA. 
The increases in Mdm2 mRNA translated into increased total Mdm2 protein as 
demonstrated by immunoblotting (Figure 3.4 A). Mdm2 is expressed as at least two 
protein isoforms, p90 and p76 (Barak et al. 1994; Saucedo et al. 1999). p76 Mdm2 
lacks the N-terminal 49 amino acids that contain the p53 binding domain (Chen et al. 
1993; Barak et al. 1994; Saucedo et al. 1999) and on overexpression behaves in a 
dominant-negative manner (Perry et al. 2000). The antibody to total Mdm2 employed 
here was raised against amino acids 154-167 of Mdm2 and is therefore able to detect 
both p76 and p90 Mdm2 (Eymin et al. 2002). However, only p90 Mdm2 was 
observed, suggesting that cardiac myocytes express relatively low levels of p76 
Mdm2. This is consistent with the finding that p90 Mdm2 is significantly more 
abundant than p76 Mdm2 in the murine heart (Perry et al. 2000). 
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The amount of phospho-Mdm2(Ser166) was upregulated by 0.2 mM H202 (Figure 3.4 
B), this may be due to an increase in the proportion of Mdm2 phosphorylated at this 
site and/or the increased amount of Mdm2 protein available for phosphorylation. 
Phosphorylation of Mdm2 at Ser166 is associated with enhanced Mdm2 activity and 
stability (Mayo and Donner 2001; Zhou et al. 2001; Feng et al. 2004). This site is 
phosphorylated by either PKB (Mayo and Donner 2001; Zhou et al. 2001; Feng et al. 
2004) or MAPKAPK2 (Weber et al. 2005). In neonatal rat cardiac myocytes exposed 
to 1 mM H202, PKB is activated (as determined by its phosphorylation) within 5 min 
(Pham et al. 2000). However, the PKB phosphorylation stimulated by 1 mM H202 is 
reduced to basal levels by 45 min and PKB phosphorylation is only slightly induced 
by 0.1 mM H202 (Pham et al. 2000). MAPKAPK2 is activated by p38-MAPK 
following exposure of neonatal rat cardiac myocytes to 0.1 mM H202. MAPKAPK2 
activity is increased within 5 min and then reduces but remains elevated up to at least 
30 min (Clerk et al. 1998a). Increased phosphorylation of Mdm2 at Ser166 was 
detected at 1.5 h and is therefore likely to have occurred subsequent to any increase in 
PKB activity and subsequent to the peak in MAPKAPK2 activity. Pharmacological 
inhibition of MAPKAPK2 activation (using SB203580) or PKB activation (using 
LY294002) did not have a consistent effect on the phosphorylation of Mdm2 at 
Ser166. The kinase catalysing the phosphorylation of this site remains to be 
identified. 
The levels of Mdm2 mRNA, total Mdm2 protein and phospho-Mdm2(Ser166) were 
all maximal within 2 h of exposure of cardiac myocytes to H202, a time which 
precedes DNA fragmentation (Cook et al. 1999). Overexpressed Mdm2 protects 
cardiac myocytes from apoptosis induced by hypoxia/reoxygenation (Toth et al. 
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2006). It is therefore possible that the upregulation of Mdm2 in response to apoptotic 
concentrations of H202 is an attempt by the myocytes to reduce apoptosis. 
Phosphorylation and activation of Mdm2 by PKB, would be consistent with an anti-
apoptotic role for Mdm2 as PKB promotes cardiac myocyte survival (Fujio et al. 
2000; Matsui et al. 2000). MAPKAPK2 is activated by p38 MAPK, which although 
the data is conflicting the majority of studies show to be pro-apoptotic in cardiac 
myocytes (Zhu et al. 1999; Mackay and Mochly-Rosen 1999; Kang et al. 2000b). 
Therefore phosphorylation and activation of Mdm2 by MAPKAPK2 would not be 
consistent with an anti-apoptotic role for Mdm2. Mdm2 expression was not increased 
by the hypertrophic agonist ET-1 (Figure 3.3). This suggests that while Mdm2 may 
protect cardiac myocytes from apoptosis it does not induce hypertrophy, in fact 
overexpression of Mdm2 inhibits the hypertrophic response (Toth et al. 2006). 
3.4.2 Expression of p19m1  
pl4ARF/p19Arf promotes p53 activity by binding to Mdm2 and inhibiting Mdm2-
mediated downregulation of p53 (Pomerantz et al. 1998; Zhang et al. 1998a; Honda 
and Yasuda 1999; Midgley et al. 2000; Bothner et al. 2001). In cardiac myocytes 
exposed to 0.2 mM H202, there was no change in the expression of pl 9Arf mRNA or 
protein (Figures 3.5 and 3.6). This may indicate that p53 is not activated in cardiac 
myocytes exposed to DNA-damaging stress in the form of 0.2 mM H202. However, 
in MEFs (murine embryonic fibroblasts) pl9Arf can contribute to an upregulation in 
p53 protein in response to DNA-damaging stress (ionising radiation) without a change 
in p19 protein level (Khan et al. 2004). Furthermore, p19Arf is essential for 
upregulation of p53 protein in MEFs exposed to oncogenic stress but not DNA- 
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damaging stress (ionising radiation) (Palmero et al. 1998; de Stanchina et al. 1998; 
Kamijo et al. 1997; Khan et al. 2000). In fact in most studies, increases in p53 protein 
level and activity following DNA-damaging stress are demonstrated to occur through 
p53 phosphorylation (Shieh et al. 1997; Chehab et al. 1999; Unger et al. 1999; 
Chehab et al. 2000; Hirao et al. 2000; Shieh et al. 2000). Therefore failure to detect 
upregulation of p19 in cardiac myocytes exposed to 0.2 mM F1202 does not 
establish whether or not p53 is activated. Studies of p53 activity in cardiac myocytes 
exposed to other apoptotic stresses have produced conflicting data (Table 1.3). The 
effect of exposing cardiac myocytes to 0.2 mM H202 on p53 activity is yet to be 
determined. Two studies demonstrate activation of p53 following exposure of cardiac 
myocytes to other forms of oxidative stress, specifically NO (Pinsky et al. 1999), OH' 
(0.1 mM 11202 plus 0.1 mM FeSO4) or 02.  (XO/X + catalase) (Von Harsdorf et al. 
1999). 
3.4.3 Expression of Mdmx 
RT-PCR of neonatal rat cardiac myocyte mRNA using primers specific to Mdmx 
exons 4 and 8 showed that exon 6 is subject to alternative splicing (Figures 3.7, 3.8 
and 3.9). The splice variant lacking exon 6 has been detected previously and is 
termed Mdmx-s (Rallapalli et al. 1999). Examination of the human, rat and mouse Est 
databases (NCBI) together with published analyses shows that Mdmx-s is expressed in 
a large range of tissue and cell types (see Table 3.1 for details, see appendix B for full 
sequence of each Mdmx-s Est). Rallapalli et al. (1999) could only easily detect 
Mdmx-s mRNA in cells that were actively proliferating, especially those that had been 
transformed. Mdmx-s expression was barely detectable in serum starved cells. It is 
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therefore of interest that this transcript was easily detected in cardiac myocytes, which 
are terminally-differentiated and had been serum starved. 
Splicing of exon 6 from rat Mdmx mRNA causes a frameshift mutation that 
introduces 13 novel codons followed by a stop codon (Figure 3.10 A). This should 
lead to the translation of a truncated rat Mdmx protein containing 13 novel amino 
acids (Figure 3.10 B). The human and murine orthologues of this splice variant are 
indeed translated into a shortened Mdmx protein (Mdmx-s) (Rallapalli et al. 1999; de 
Graaf et al. 2003). Mdmx-s contains only the p53 binding domain and compared with 
full length Mdmx binds to p53 more efficiently in vitro and inhibits p53 activity more 
effectively in vivo (Rallapalli et al. 1999). The 13 novel amino acids of murine 
Mdmx-s are essential for high affinity p53 binding in vitro and for efficient 
expression of the protein in vivo (Rallapalli et al. 2003). There is a high degree of 
conservation in the novel amino acids between rat and mouse (11/13), suggesting that 
this sequence may serve a similar function in rat. 
Expression of full length Mdmx or Mdmx-s mRNA did not change in response to 
exposure of cardiac myocytes to 0.2 mM H202 (Figure 3.7). Constitutive expression 
of Mdmx in cells exposed to apoptotic stress is consistent with previous studies 
(Shvarts et al. 1996; Jackson and Berberich 1999; Kawai et al. 2003b; Pan and Chen 
2003). The full length Mdmx protein was detected by immunoblotting and the levels 
were unchanged following exposure of cardiac myocytes to 0.2 mM H202 (Figure 
3.11). It could not be confirmed whether the Mdmx-s transcript is translated in rat 
neonatal cardiac myocytes, as the translated protein would only include the N- 
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terminal 176 amino acids of full length Mdmx and the commercial Mdmx antibodies 
bind to epitopes outside this region. 
Mdmx binds and stabilises Mdm2 (Sharp et al. 1999; Tanimura et al. 1999) and 
Mdmx protein is targeted for proteasomal degradation by Mdm2-catalysed 
ubiquitinylation in response to DNA-damaging stress (Pan and Chen 2003; Kawai et 
al. 2003b). The constitutive levels of Mdmx protein suggest that Mdm2 does not 
target Mdmx for degradation and that upregulation of Mdm2 protein is not through 
Mdmx-mediated stabilisation. It is possible that Mdm2-dependent degradation of 
Mdmx occurs but that this is compensated for by increased Mdmx protein synthesis. 
This, however, seems unlikely given that there were no changes in the levels of Mdmx 
mRNA (Figure 3.7). Mdmx is phosphorylated at several sites by a number of kinases 
which target Mdmx for Mdm2-mediated degradation (Chen et al. 2005; Pereg et al. 
2005; Jin et al. 2006; LeBron et al. 2006). Phosphorylation or dephosphorylation of 
residues within Mdmx might increase Mdmx activity without a change in protein 
level. It therefore remains a possibility that Mdmx is activated in cardiac myocytes 
following exposure to 0.2 mM H202 and does contribute to the increase in Mdm2 
protein level. 
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Table 3.1 Tissue and cell types expressing Mdmx-s mRNA 
The tissue/cell types that express Mdmx-s mRNA were determined by examination of 
Est databases (NCBI) and published analyses. 
Species Tissue/cell type Est accession number / 
publication 
Homo 
sapiens 
Bone marrow cell line K562 BP282772 
Brain BP310272 
Breast cancer cell line MCF-7 Rallapalli et al. 1999 
Cervical carcinoma cell line C33A de Graaf et al. 2003 
Cervical carcinoma cell line HeLa Rallapalli et al. 1999 
Chondrosarcoma tissue cell line BU619731 
Embryonic kidney cell line 293 Rallapalli et al. 1999 
Embryonic stem cells CN409878 
Fetal muscle BP231576 
Foreskin fibroblasts Rallapalli et al. 1999 
Glioblastoma cell line U87Mg Rallapalli et al. 1999 
Lung carcinoma cell line Calu-6 Rallapalli et al. 1999 
Myeloma cell line KMS-5 BM848342 
Squamous cell line TE7 BP353227 
Synovial membrane BP344167 
T cell Jurkat cell line BX383381 
Testis DR007225 
Mus 
musculus 
Embryonic fibroblasts cell line C3H10T1/2 Rallapalli et al. 1999 
Embryonic fibroblast cell line NIH3T3 
Myeloma/hybridoma cell line SP2/0 
Teratocarcinoma cell line F9 
Rattus 
norvegicus 
Placenta CV103442 
Vascular smooth muscle cell line A10 Rallapalli et al. 1999 
3.4.4 Summary 
In response to exposure of cardiac myocytes to apoptotic levels of H202 (0.2 mM), 
there is an increase in Mdm2 mRNA and Mdm2 protein. Furthermore, there is an 
increase in the level of Mdm2 phosphorylated at Ser166, a modification associated 
with increased activity. In contrast, there are no changes in the mRNA or protein 
abundances of the two Mdm2 regulators, Mdmx andp/gfri. 
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Chapter four 
Regulation of Mdm2 mRNA expression in 
cardiac myocytes 
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4.1 Introduction 
An increase in expression of mRNA may be mediated by increases in the rate of 
transcription and/or increases in mRNA stability. mRNA stability can be controlled 
by cis-acting motifs within the mRNA molecule that are recognised by trans-acting 
factors. The AU-rich element (ARE) is the most common cis acting motif causing 
niRNA instability and usually consists of AUUTJA repeats located in the 3' UTR 
(Caput et al. 1986; Shaw and Kamen 1986). ARE binding proteins (AUBPs) stabilize 
(e.g. Peng et al. 1998) or destabilize (e.g. Chen et al. 2001d) the mRNA molecule. An 
ARE is present in the 3' UTR sequence of murine Mdm2 mRNA (Barak et al. 1994), 
although there is limited evidence for changes in stability having a regulatory role in 
Mdm2 mRNA expression. Mdm2 mRNA stability is increased in MEFs exposed to a 
DNA-damaging aryl hydrocarbon with no change in the rate of transcription (Hsing et 
al. 2000). However, murine Mdm2 mRNA isoforms with long and short 3' UTRs 
have the same stability, despite the ARE only being present in the longer 3' UTR 
(Mendrysa et al. 2001). Furthermore, in the majority of studies, Mdm2 mRNA 
abundance is regulated at the transcriptional level (e.g. Barak et al. 1993; Ries et al. 
2000; Truong et al. 2005). 
Immediate early genes (IEGs) show rapid changes in transcription that are dependent 
on the activation of pre-existing TFs and are independent of de novo protein synthesis. 
Mdm2 can under some conditions behave as an IEG (Fambrough et al. 1999). The 
concentrations of H202 that increase Mdm2 mRNA expression in cardiac myocytes 
[0.1-0.3 mM H202 (Chapter 3, Figure 3.2)] activate protein kinase signalling cascades. 
These include the ERK1/2, JNK and p38-MAPK pathways (Clerk et al. 1998a) which 
145 
both activate existing TFs and promote their de novo synthesis (Table 1.1). The 
PI3K-PKB pathway also promotes TF activation (Figure 1.4) and is activated in 
cardiac myocytes by 0.1 mM H202, although the level of activation is weak compared 
with that induced by higher concentrations of H202 (0.5 mM - 3 mM) (Pham et al. 
2000). PKC isozymes act upstream of the ERK1/2, JNK and p38-MAPK pathways in 
cardiac myocytes (Heidkamp et al. 2001). Although PKC activation has not been 
studied in cardiac myocytes exposed to 0.1-0.3 mM 14202, there is activation of PKCS 
and PKCE in cardiac myocytes exposed to 50 i.tM H202 (Mangat et al. 2006). 
Selective pharmacological inhibitors of the protein kinase pathways have been 
developed and these used to determine the involvement of a pathway in a particular 
response [U0126: MEK1/2 - ERK1/2 (Favata et al. 1998); SP600125: JNK (Bennett 
et al. 2001); SB203580: p38-MAPK (Cuenda et al. 1995); LY294002: PI3K - PKB 
(Vlahos et al. 1994); GF109203X: PKC (Toullec et al. 1991)]. 
Two isoforms of Mdm2 mRNA are transcribed, L-Mdm2 from the P1 promoter and S-
Mdm2 from the P2 promoter (Barak et al. 1994). P1 is located 5' to exon 1 and P2 is 
located 5' to exon 2 in intron 1. Therefore, Mdm2 exon 1 is present in L-Mdm2 but 
not S-Mdm2. Transcription of S-Mdm2 from P2 is upregulated in response to DNA-
damaging stress, while expression of L-Mdm2 from P1 is constitutive (Barak et al. 
1994; Saucedo et al. 1998; Mendrysa and Perry 2000). 
In exon 1 of human and murine Mdm2 there are two upstream open reading frames 
(uORFs) (the 5' uORF1 and the 3' uORF2) (Brown et al. 1999; Jin et al. 2003b). 
uORFs encode short peptides and inhibit translation from a 3' ORF (Morris and 
Geballe 2000). Indeed, murine and human Mdm2 uORF1 and uORF2 inhibit 
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translation from reporter constructs (Brown et al. 1999; Jin et al. 2003b). As exon 1 is 
contained in L-Mdm2 but not S-Mdm2, the ORF encoding full length Mdm2 protein 
(located in exon 3) would be expected to be translated more efficiently from S-Mdm2 
mRNA than L-Mdm2 mRNA. This is indeed the case at least for human Mdm2 
(Landers et al. 1997; Brown et al. 1999). Translation inhibition by human Mdm2 
uORF1 requires its translation and is dependent on the sequence of the encoded 
peptide (Jin et al. 2003b). The peptides encoded by such "sequence-specific" uORFs 
cause ribosome stalling creating a block in translation (e.g. Wang and Sachs 1997). 
Similar to uORF1, translation inhibition by human Mdm2 uORF2 requires its 
translation (Jin et al. 2003b). However, translation inhibition by human Mdm2 
uORF2 is weak in comparison with uORF1 and the importance of the encoded 
peptide sequence is undetermined (Jin et al. 2003b). 
This chapter examines the mechanism of increased Mdm2 mRNA expression in 
cardiac myocytes exposed to 0.2 mM H202. Changes in Mdm2 mRNA stability and 
the levels of expression from the P1 and P2 promoters were assessed. The 
dependence of Mdm2 mRNA upregulation on de novo protein synthesis and protein 
kinase signalling pathways was examined using selective inhibitors. 
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4.2 Methods 
4.2.1 Treatments 
Cardiac myocytes were exposed to 0.2 mM H202 with or without prior addition of 
inhibitors to the serum free medium: actinomycin D (4 On, 60 min pre-incubation); 
cycloheximide (20 µM, 30 min pre-incubation); GF109203X (10 µM, 15 min pre-
incubation); LY294002 (50 µM, 15 min pre-incubation); SB203580 (10 µM, 15 min 
pre-incubation); SP600125 (10 µM, 15 min pre-incubation); U0126 (10 AM, 15 min 
pre-incubation). 
4.2.2 RT-PCR 
RNA was extracted from cardiac myocytes, cDNA synthesised and semi-quantitative 
PCR performed (Sections 2.3 and 2.4). PCR cycles were: 94°C (30 s), 59°C (30 s) 
and 72°C (30 s). Total S- and L-Mdm2 mRNA was examined using a forward primer 
in exon 12 and a reverse primer in the 3' UTR or a forward primer in exon 2 and a 
reverse primer in exon 4. L-Mdm2 mRNA was examined using a forward primer in 
exon 1 and the reverse primer in exon 4. PCR products were analysed by 
densitometry and normalised to GAPDH. Values are expressed as fold stimulations 
and analysed by Student's t-test (p<0.05) or one way ANOVA with Tukey post test 
(p<0.05). 
4.2.3 Sequence analysis 
PCR products were purified using the Qiagen QlAquick PCR purification kit and then 
sequenced by the Advanced Biotechnology Centre (ABC), Imperial College London 
(Section 2.5). DNA sequence comparisons were made using the Multialign tool 
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(http://prodes.toulouse.inra.frimultalin/multalin.html). The ExPASy translation tool 
(http://us.expasy.org/tools/dna.html) was used to translate DNA sequences into 
peptide sequences. 
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4.3 Results 
4.3.1 11202 does not alter Mdm2 mRNA stability 
The 3'UTR of murine Mdm2 contains a consensus ARE (Barak et al. 1994). 
Examination of the rat Mdm2 3' UTR showed it to contain an identical element 
(Figure 4.1). To test the importance of mRNA stability in Mdm2 mRNA expression, 
mRNA transcription in cardiac myocytes was inhibited by addition of actinomycin D 
(4 ttM) to the serum free medium with or without prior exposure of the myocytes to 
0.2 mM H202 (2 h). Total (S- and L-) Mdm2 mRNA levels were assessed by semi-
quantitative RT-PCR (primers in exon 12 and the 3' UTR) over 6 h following the 
addition of actinomycin D. To allow easier comparison, cDNA samples from the 
H202 treated group and the unstimulated group were amplified by 23 and 27 PCR 
cycles, respectively. 
Mdm2 mRNA in the unstimulated and 11202 treated groups followed a similar pattern 
of decay (Figure 4.2). GraphPad (San Diego, CA) Prism (version 4.0) software was 
used to calculate the Mdm2 mRNA half life from the data in each independent 
experiment. Mdm2 mRNA was assumed to have a one-phase exponential decay as 
described for the mRNA of other genes (Chia and McLaughlin 1979). The formula 
used was Y = Span x e e K x x) + Plateau, where Y = mRNA level, X = time, K = the 
decay constant, and half life =1n 2 / K. The half life of Mdm2 mRNA was 2.36 h ± 
0.26 (mean ± SEM, n=4) in unstimulated cardiac myocytes and 2.67 h ± 0.36 (mean ± 
SEM, n=4) in cardiac myocytes exposed to 0.2 mM H202 (2 h) (Figure 4.2). These 
half lives are not significantly different (p>0.05, two-tailed paired Student's t-test) 
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and therefore exposure of cardiac myocytes to 0.2 mM H202 (2 h) does not alter the 
stability of Mdm2 mRNA. 
Mdm2 3' UTR 5' ACGGCGCTGCAGACGCAGACCUUUACACUUCUAAUGUAUGACCCCCAAAUUAGACAA 
CAUGGGUAUUAUUUUCAUACAUUAAAGCCGGAGCAUUGUCUUAGUCUACAUAAAGUUCAUUUGUAAUUUAUCC 
UCGAGAGUAAGAAUAGUAACUGUUUUCUUCCUUUUAGGAAAAUUUCAGUUGAUUALTUUUAUAUUUGUGUUUU 
AACGUAAUUUGCAUUAGCUCUUUUCAUUUUCCUUACGUUUUAAGUAATJCUCCACUUGGAAGGACUUUUGAAAG 
UAUACUUUAUACAGUGAGAAGUCCUCUCCAUCUCUGUCUCUUGGAGAUAAUGAUAGGCUAUCGAAUUGUGCUU 
GAUUUCCUiJIJiUUIJUCCUUGUUAAUAUUUAAUUUAUUUAGUAUCUUUCAUGUAAAGAGUUAAAGACUAUGUG 
AAGGAUUGAGUGUAUALTUUAAGUUAUUGAAAUUCUGAACCUCCUUAGUUCUCUUAAGUGGGGGUUGUGGGCU 
GCAGAGAAGAGUCAGCCGGUAAAGGCGCCCACUGUGUAUGCCUAAUGACACACALTUUGAUCCUUGCAACGCCC 
AGAAAGAGAGAACCAGUUCCACAAAGUAGUUCUCGGAUCUCCAAAUGGAUUCAUAUACACAC 
UUUAAGGUCUGAGIJUGCAUCUGGUGAUACAUAAGUGAAAACACACACCUUGUUUUCCAGCUUULTUGUCAUAUG 
GIGGUGUGGCACGAGUGUUGCAGUCUGUCCCAGGUUGAAAAAGUCUGUGGCCCUUCGAAGCACCUUCAUGGCCC 
GCUCCAUGGUUCCUGAUGGCUGUUGAAGUUUCAGGCCUGUACUUAGUCUAGGUUAGAAACCAGUCCAUUCAGA 
AAGACUAAAUCAGAGCAUGGAUGAAGUGGAUCCUCCAACCGUGUAGAUGAGUCUCUUGAUUCAUAAUAAGAAU 
CUUCCAUUUUAAUUGAAGCTGUCAUGCCUAAGUGUAGAAAACAAGUUCCCUAACUGUAUGGAGUAACCAAAGGA 
UAGTJUCUGUAUUGAAGUUGACUUAAAGUAUCAAAGAUCACUCCCCACAUGAUUUAGCAGUUAAGUCGGAGGCA 
GCGCCUCAGCCUGGGCAUCCUAACUCUGGACUUUGAUUCCCCAUUUACAAUGUAAUACUGAGGUUAUAUCCUA 
GUAUUACUAGUUCUUAAAUGUUUAUUUAGGUGUGGUAGACAUACAUUAUUUAUUUGCAAAUAAAUGGU 
UUAUUGAAUUGLTUUCAAGAGAUUUGUCUUGCA 3' 
Figure 4.1 Identification of an AU-rich element (ARE) in the 3' UTR 
of the rat Mdm2 gene 
The sequence of the rat Mdm2 3'UTR was examined for the presence of an AU-rich 
instability element (ARE) that has been identified in the murine orthologue (Barak et 
al. 1994). 
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Figure 4.2 The stability of Mdm2 mRNA is not altered in cardiac 
myocytes exposed to 0.2 mM 11202 
Cardiac myocytes were unstimulated or exposed to 0.2 mM H202 (2 h). Actinomycin 
D (4 I.tM) was added and RNA extracted at the times indicated. Mdm2 mRNA levels 
were assessed by RT-PCR and normalised to GAPDH. cDNA samples from the H202 
exposed and the unstimulated groups were amplified by 23 and 27 PCR cycles, 
respectively. Representative images (upper panels), densitometric analysis (lower left 
panel) and calculated mRNA half lives (lower right panel) are shown. Results are 
means ± SEM for four independent experiments. 
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4.3.2 Expression from the Mdm2 P2 promoter is increased in 
response to 0.2 mM H202 
Mdm2 is transcribed from the P1 and P2 promoters to give the L-Mdm2 and S-Mdm2 
mRNA isoforms, respectively (Barak et al. 1994). The abundance of L-Mdm2 mRNA 
was assessed by semi-quantitative RT-PCR using a forward primer specific to exon 1 
(unique to this isoform) and a reverse primer specific to exon 4 (common to both 
isoforms), producing a predicted product of 333 bp (Figure 4.3 A). The amount of 
total S- and L-Mdm2 mRNA was assessed by semi-quantitative RT-PCR using a 
forward primer specific to exon 2 (common to both isoforms) and the reverse primer 
specific to exon 4 (common to both isoforms), producing a predicted product of 220 
bp (Figure 4.3 A). The PCR products were sequenced and it confirmed that the 
primer sets amplified the expected regions of Mdm2: from the primer site in exon 1 to 
the primer site in exon 4 for the L-Mdm2 PCR product; from the primer site in exon 2 
to the primer site in exon 4 for the total S- and L-Mdm2 PCR product (Figure 4.3 B). 
In unstimulated cardiac myocytes, there was significant expression of L-Mdm2 
mRNA (Figure 4.4). The expression of L-Mdm2 mRNA did not change in response to 
0.2 mM H202 (2 h) (Figure 4.4). In response to 0.2 mM H202 (2 h), the levels of total 
S- and L- Mdm2 mRNA significantly increased [4.5 ± 1.1 fold (mean ± SEM, n=6)] 
(Figure 4.4). As there was no change in L-Mdm2 mRNA levels, the increase in the 
total S- and L-Mdm2 mRNA levels must be due to increases in S-Mdm2 mRNA. 
In human and murine Mdm2 exon 1 (present in L-Mdm2 not S-Mdm2) there are two 
uORFs which inhibit translation (Brown et al. 1999; Jin et al. 2003b). Analysis of the 
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rat Mdm2 sequence demonstrates that the presence of two uORFs (the 5' uORF1 and 
the 3' uORF2) in exon 1 is conserved in this species (Figure 4.5 A). The nucleotide 
sequences of rat Mdm2 uORF1 and uORF2 were translated into peptide sequences 
using the ExPASy translation tool and these compared by Multialign to the murine 
and human orthologues. The length of the Mdm2 uORF1 peptide (14 amino acids) is 
conserved in rat, human and mouse (Figure 4.5 B). The length of the Mdm2 uORF2 
peptide does not show inter-species conservation (Figure 4.5 B). The sequence of the 
Mdm2 uORF1 peptide has a higher degree of conservation than that of the Mdm2 
uORF2 peptide between rat and mouse (79% vs. 22%) and between rat and human 
(36% vs. 14%) (Figure 4.5 B). 
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exon 1 
forward primer 
exon 2 
forward primer 
exon 
2 
exon 4 
reverse primer 
exon 
4 
exons 
5-12 5' 
exon 
3 
3' exon 
  
2 
  
   
Total S- and L-Mdm2 PCR product 
Exon 2 
AGCGGAGACGGACACACCGGGGACCTC 
TCCGACCACCGTGCTTCTGCTGCGCGCCTC 
Exon 3 
CAGGCCAATGTGCAATACCAACATGTCTGTGT 
CTACCGAGGGTGCTGCAGGCACCTCACAGAT 
TCCAGCGTCGGAACAAGAGACTCT 
Exon 4 
GGTTAGACCAAAACCATTGCTTTTGAAGTTGT 
TAAAGTCTGTTGGAGCACAAMMINIE 
A) 
L-Mdm2 (333 bp) 
— Total S- and L-Mdin2 (220 bp) — 
L-Mdm2 PCR product 
Exon 1 
TCGCTTC GCTC GACCTCCCGAGCGAAAT 
GGTCTCTCAAGTCCCGGCCACCGGGCCTCCGC 
GCTCCCCATGAAGGGTCGGAGGCCGCGCGGG 
GAGTA 
Exon 2 
GCAGCGGTCTGCAGGCGAGCGGAGACGGACA 
CACCGGGGACCTCTCCGACCACCGTGCTTCTG 
CTGCGCGCCTC 
Exon 3 
CAGGCCAATGTGCAATACCAACATGTCTGTGT 
CTACCGAGGGTGCTGCAGGCACCTCACAGAT 
TCCAGCGTCGGAACAAGAGACTCT 
Exon 4 
GGTTAGACCAAAACCATTGCTTTAGAAGTAGT 
TAAAGTNTGTGAGCACAAMIIIIIM 
Figure 4.3 The PCR primers used in the amplification of L-Mdm2 
mRNA and total S- and L-Mdm2 mRNA 
The positioning of the primers used to assess expression of L-Mdin2 mRNA alone and 
total S- and L-Mdm2 mRNA are shown (A). The sequences of the PCR products are 
given with the forward primers highlighted in green and the reverse primer 
highlighted in red (B). 
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Figure 4.4 Changes in the expression of L-Mdm2 mRNA and total S-
and L- Mdm2 mRNA in cardiac myocytes exposed to 0.2 mM H202 
Cardiac myocytes were exposed to 0.2 mM H202 (2 h). The levels of L-Mdm2 mRNA 
(333 bp PCR product) and total S- and L-Mdm2 mRNA (220 bp PCR product) were 
assessed by RT-PCR and normalised to GAPDH. Representative images (upper 
panels) and the densitometric analysis (lower panel) are shown. Results are means ± 
SEM for six independent experiments (*p<0.05, two-tailed paired Student's t-test 
between unstimulated and H202 stimulated levels of each PCR product). 
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A) uORFs in exon 1 of rat Mdm2 
GGCCTCCGAAGCCGGGGTAGCCTAGGAGCGGCCGCGTTCTACGTCAGGAG 
uORF1 
CCGCTGTCGCTTCGCTCGACCTCCCGAGCGAA ATG GTC TCT CAA GTC 
CCG GCC ACC GGG CCT CCG CGC TCC CCA 
GGC CGC GCG GGG AG TAG C AG  
uORF2 
AGG GTC GGA 
uORF I stop codon 
uORF2 stop codon 
B) Comparison of the peptides encoded by the rat Mdm2 uORFs with the murine and 
human orthologues 
Rat uORF 
Murine uORF1 
Rat uORF1 
Human uORF1 
Rat uORF2 
Murine uORF2 
Rat uORF2 
Human uORF2  
MV SQVPATGPPRSP 
MVAQAPAAGPPRSP 
MVSQVPATGPPRSP 
MEQEAEPEGRPRPL 
MKGRRPRGE 
MRGK 
MKGRRPRGE 
MIPEAQGVVLPRAP 
Murine uORF1 s e 'tide Human uORF1 peptide 
Rat uORF1 peptide 79% consensus 36% consensus 
Murine uORF2 peptide Human uORF2 peptide 
Rat uORF2 peptide 22% consensus 
(50% consensus in aligning 
region) 
14% consensus 
(22% consensus in aligning 
region) 
Figure 4.5 Two uORFs exist in exon 1 of rat Mdm2 
Two uORFs were identified in exon 1 of the rat Mdm2 gene (accession number: 
XM_235169.2) (A). The peptide sequences encoded by rat Mdm2 uORF1 and 
uORF2 were compared with the murine and human orthologues using the Multialign 
tool (B). 
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4.3.3 Mdm2 is not an LEG 
Expression of TEGs is rapidly increased in response to appropriate stimulus. This is 
achieved through the activation of pre-existing TFs and is independent of de novo 
protein synthesis. Cycloheximide (20 µM) inhibits protein synthesis (>90%) in 
cardiac myocytes (Clerk and Sugden 1997) and its effect on total (S- and L-) Mdm2 
mRNA upregulation was assessed by semi-quantitative RT-PCR (primers in exon 12 
and the 3' UTR). Pre-treatment of cardiac myocytes with cycloheximide (20 µM, 30 
min) reduced by 77.8% ± 4.2 (mean ± SEM, n= 4) the upregulation of Mdm2 mRNA 
induced by 0.2 mM H202 (2 h) (Figure 4.6). Therefore increased Mdm2 expression is 
dependent upon de novo protein synthesis and Mdm2 is not an lEG in cardiac 
myocytes under oxidative stress. Treatment of cardiac myocytes with cycloheximide 
alone (20 uM, 2.5 h) did not significantly affect Mdm2 mRNA expression (Figure 
4.6). 
4.3.4 The PKC inhibitor GF109203X inhibits upregulation of Mdm2 
mRNA 
H202 activates protein kinase signalling cascades in cardiac myocytes (Clerk et al. 
1998a; Pham et al. 2000; Mangat et al. 2006). Selective protein kinase inhibitors 
were used to determine the involvement of these pathways in the upregulation of 
Mdm2 mRNA in cardiac myocytes exposed to 0.2 mM H202. Total (S- and L-) 
Mdm2 mRNA expression was assessed by semi-quantitative RT-PCR (primers in 
exon 12 and the 3' UTR). The upregulation of Mdm2 mRNA by 0.2 mM H202 (2 h) 
was not prevented by pre-treatment (15 min) of cardiac myocytes with inhibitors of 
158 
MEK1/2 - ERK1/2 (U0126, 10 04), PI3K - PKB (LY294002, 50µM), p38-MAPK 
(SB203580, 10 RM) or JNK (SP600125, 10 IiM) (Figure 4.7). Pre-treatment (15 min) 
of cardiac myocytes with the PKC inhibitor GF109203X (10 p.M) significantly 
inhibited the increase in Mdm2 mRNA induced by 0.2 mM H202 (2 h) (Figure 4.7). 
Treatment (2.25 h) of cardiac myocytes with each inhibitor alone did not significantly 
affect Mdm2 mRNA expression (Figure 4.7). 
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Figure 4.6 Cycloheximide inhibits Mdm2 mRNA upregulation in 
cardiac myocytes exposed to 0.2 mM 11202 
Cardiac myocytes were treated with cycloheximide (CX) (20 µM, 30 min) and/or 0.2 
mM H202 (2 h). Mdm2 mRNA expression was assessed by RT-PCR and normalised 
to GAPDH. Representative images (upper panels) and the densitometric analysis 
(lower panel) are shown. Results are means ± SEM for four independent experiments 
(*p<0.05, one way ANOVA with Tukey post test). 
160 
GF UO LY SB SP 	GF UO LY SB SP Blank 
300— 	 mow ma WV IMP 	Mdin2 
200— 259 by 
500— GAPDH 
400— 	 452 bp 
Unstimulated H202 
49, 	3.0- I14  2.5- 
1 8 2.0- 
1 1 1.5- 
1.0- 
g 0.5- 
0.0 
GF UO LY SB SP 	GF UO LY SB SP 
Unstimulated H202 
Figure 4.7 The effects of selective protein kinase inhibitors on the 
upregulation of Mdm2 mRNA in cardiac myocytes 
Cardiac myocytes were treated with protein kinase inhibitors [10 uM U0126 (U0), 
50µM LY294002 (LY), 10 µM SB203580 (SB),10 tiM SP600125 (SP), 10 µM 
GF109203X (GF)] with or without subsequent exposure to 0.2 mM H202 (2 h). 
Mdm2 mRNA expression was assessed by RT-PCR and normalised to GAPDH. 
Representative images (upper panels) and the densitometric analysis (lower panel) are 
shown. Results are means ± SEM for five independent experiments (*p<0.05, one 
way ANOVA with Tukey post test). 
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4.4 Discussion 
4.4.1 Upregulation of Mdm2 mRNA results from an increase in 
transcription from the P2 promoter 
Mdm2 mRNA levels were increased in cardiac myocytes exposed to 0.2 mM H202 
(Chapter 3, Figure 3.1). This upregulation occurred in the absence of any change in 
Mdm2 mRNA stability (Figure 4.2) and must therefore be achieved through increased 
transcription. This is consistent with the large number of studies demonstrating that 
Mdm2 mRNA levels are regulated by the action of TFs (Barak et al. 1993; Juven et al. 
1993; Perry et al. 1993; Ries et al. 2000; Truong et al. 2005). The finding that Mdm2 
mRNA was not regulated at the level of stability indicates that the ARE instability 
element in the 3' UTR (Figure 4.1) is not of functional importance in cardiac 
myocytes under oxidative stress. 	Mendrysa et al. (2001) have previously 
demonstrated that this element does not affect the stability of murine Mdm2 expressed 
in U2OS cells. An identical element in the E2F1 gene is also demonstrated not to 
affect mRNA stability (Bartley et al. 1998). 
Mdm2 is transcribed from the P1 and P2 promoters to give the L-Mdm2 and S-Mdm2 
mRNA isoforms, respectively (Barak et al. 1994). L-Mdm2 mRNA abundance and 
total S- and L-Mdm2 mRNA abundance were examined in cardiac myocytes exposed 
to 0.2 mM H202. The results indicated that expression of L-Mdm2 mRNA from P1 
was constitutive while expression of S-Mdm2 mRNA from P2 was increased. This is 
consistent with the effects of DNA-damaging stress on expression from the P1 and P2 
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promoters of Mdm2 in other cell types (Barak et al. 1994; Saucedo et al. 1998; 
Mendrysa and Perry 2000). S-Mdm2 does not contain any sequence that is not present 
in L-Mdm2 and expression of S-Mdm2 mRNA could therefore not be directly assessed 
by RT-PCR. RNase protection assay where the region protected includes the 
sequence unique to L-Mdm2 (exon 1) and extends into the sequence contained in both 
L- and S-Mdm2 (exon 2) may allow both mRNA isoforms to be directly examined by 
virtue of the size difference in the protected fragments (Ralhan et al. 2000). 
In exon 1 of murine and human Mdm2 there are two uORFs and the human 
orthologues are demonstrated to reduce the translation efficiency of L-Mdm2 mRNA 
compared with S-Mdm2 mRNA (Landers et al. 1997; Brown et al. 1999; Jin et al. 
2003b). The presence of two uORFs in Mdm2 exon 1 is conserved in rat (Figure 4.5 
A), suggesting that rat S-Mdm2 mRNA will also show enhanced translation. 
Enhanced translation efficiency of the upregulated Mdm2 mRNA isoform may 
contribute to the upregulation of Mdm2 that occurs at the protein level (Chapter 3, 
Figure 3.4 A). The length and sequence of the peptide encoded by Mdm2 uORF1 has 
greater inter-species conservation than that encoded by the 3' uORF2 (Figure 4.5 B). 
This is consistent with studies demonstrating that compared with human Mdm2 
uORF2, human Mdm2 uORF1 has a stronger inhibitory effect which is dependent 
upon the sequence of the encoded peptide (Jin et al. 2003b). 
At least two protein isoforms of Mdm2 are translated. p90 Mdm2 is translated from 
an AUG codon in exon 3 and p76 Mdm2 is translated from an internal AUG at codon 
50 in exon 4 (Barak et al. 1994; Saucedo et al. 1999). Initiation of translation from 
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codon 50 is achieved through either internal translation initiation or alternative 
splicing to remove exon 3 containing the p90 Mdm2 translation initiation codon 
(Saucedo et al. 1999). Exon 3 was amplified across in the PCR examining L-Mdm2 
mRNA alone and the PCR examining total S- and L-Mdm2 mRNA (Figure 4.3 A). 
Both PCRs produced a single product containing exon 3 (Figures 4.3 B and 4.4). 
Therefore Mdm2 exon 3 is not subject to alternative splicing in neonatal rat cardiac 
myocytes. This is consistent with the failure to detect p76 Mdm2 by immunoblotting 
(Chapter 3, Figure 3.4 A) and together these findings suggest that neonatal rat cardiac 
myocytes may not express p76 Mdm2. Transcripts lacking exon 3 are detected in the 
murine heart (Perry et al. 2000). It is possible that these transcripts are produced in 
the heart by cells other than cardiac myocytes (such as fibroblasts) or that lack of 
exon 3 splicing is specific to neonatal rat cardiac myocytes. 
4.4.2 Upregulation of Mdm2 mRNA is dependent on de novo protein 
synthesis and PKC 
Upregulation of Mdm2 mRNA by exposure of cardiac myocytes to 0.2 mM H202 (2 
h) was inhibited by cycloheximide (Figure 4.6), demonstrating that the increase is 
dependent upon the de novo protein synthesis of a TF or other regulator of 
transcription. Protein kinases regulate TF activity by directly catalysing their 
phosphorylation and also by indirectly promoting their de novo synthesis (Table 1.1). 
Use of selective protein kinase inhibitors indicated that increased expression of Mdm2 
mRNA potentially required PKC activity in cardiac myocytes (Figure 4.7). 
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PKC-dependent upregulation of Mdm2 mRNA occurs in G1-101A cells treated with 
phorbol 12,13-dibutyrate (PDB) (Zell et al. 2002) and a number of studies are 
supportive of a potential role for PKC isozymes in the upregulation of Mdm2 
transcription in cardiac myocytes under oxidative stress. Thus, exposure of cultured 
cardiac myocytes to H202 (50 µM) activates PKC6 and PKCE (Mangat et al. 2006), 
and perfusion of the isolated rodent heart with H202 activates PKC6 [Churchill et al. 
2005 (rat); Churchill and Szweda 2005 (rat)] and possibly PKCa, PKCI32 and PKC 
[Takeishi et al. 1999 (guinea pig)]. PKC isozymes activate a range of TFs some 
which may regulate transcription of S-Mdm2 [e.g. Ets, AP-1 and p53 (Barak et al. 
1993; Ries et al. 2000)]. PKC6 directly phosphorylates and activates p53 in several 
non-cardiac myocyte cell types (Ryer et al. 2005; Perletti et al. 2005; Lee et al. 2006; 
Yoshida et al. 2006). In non-myocyte cell lines, PKC isozymes activate Ets TFs 
through the ERK1/2 pathway (e.g. Sharif and Sharif 1999). However, in cardiac 
myocytes exposed to 0.2 mM H202 (2 h), the upregulation of Mdm2 mRNA was 
ERK1/2-independent (Figure 4.7). It is well established that AP-1 is activated in 
cardiac myocytes downstream of PKC (Kariya et al. 1991; Shubeita et al. 1992; Li et 
al. 2000A; Li et al. 2005). However, this is dependent on the ERK1/2 (Li et al. 
2000a) and JNK pathways (Li et al. 2000a, 2005). The finding that Mdm2 mRNA 
upregulation was independent of ERK1/2 and JNK (Figure 4.7) therefore argues 
against a PKC - AP-1 mechanism. 
The PKC inhibitor employed here (GF109203X) inhibits p90 RSK as well as PKC 
isozymes in cardiac myocytes (Roberts et al. 2005). However, p90 RSK is activated 
by ERK1/2 (Sturgill et al. 1988) which were not required for the upregulation of 
Mdm2 mRNA (Figure 4.7). GF109203X inhibits a number of other protein kinases in 
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vitro (Alessi et al. 1997; Hers et al. 1999; Davies et al. 2000) and so the involvement 
of PKC in upregulation of Mdm2 mRNA is not conclusive. 
4.4.3 Summary 
Upregulation of Mdm2 mRNA in response to exposure of cardiac myocytes to 0.2 
mM H202 results from an increase in transcription from the P2 promoter. The 
increased transcription is dependent upon de novo protein synthesis and may involve 
PKC isozymes. 
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Chapter five 
p53 is not detected in cardiac myocytes exposed 
to H202 
167 
5.1 Introduction 
Mdm2 mRNA is transcribed from a constitutive promoter (P1) and from an internal 
inducible promoter (P2) in intron 1 (Barak et al. 1994; Saucedo et al. 1998; Mendrysa 
and Perry 2000). The data in Chapter 4 (Figures 4.2 and 4.4) demonstrate that the 
upregulation of Mdm2 mRNA in cardiac myocytes exposed to 0.2 mM 14202 results 
from an increase in transcription from P2. It is well established that active p53 binds 
to two p53 sites 5' to the P2 TATA box and activates transcription from P2 (Juven et 
al. 1993; Perry et al. 1993; Barak et al. 1994). p53 is a key inducer of apoptosis 
(Clarke et al. 1993; Lowe et al. 1993) and it is well established that its expression and 
activity are increased in response to DNA-damaging stress in the form of ionising or 
UV irradiation (e.g. Kondo et al. 1997; Li and Ho 1998). There is significant 
evidence to indicate a strong relationship between p53 and oxidative stress in non-
myocyte cell types. Thus, H202 increases p53 protein expression in aortic vascular 
endothelial cells (Niwa et al. 2002, 2003) and aortic vascular smooth muscle cells 
(Deshpande et al. 2002). Furthermore, targeted inactivation of the p53 gene results in 
enhanced survival following exposure of several non-myocyte cell types to 11202 (Yin 
et al. 1998; Kitamura et al. 1999; Buschmann et al. 2000). 
Exposure of cardiac myocytes to oxidative stress in the form of 01-1.  (0.1 mM 11202 
plus 0.1 mM FeSO4) or 02 (XO/X + catalase) has been shown to upregulate p53 
protein expression (von Harsdorf et al. 1999). Exposure of cardiac myocytes to H202 
alone causes apoptosis (e.g. Cook et al. 1999) but its effect on p53 activity is 
undetermined. In microarray studies of cardiac myocytes, 0.2 mM H202 increases the 
expression of Mdm2 mRNA and p2/ wqrl/cl-P / mRNA (Kemp et al. 2003). It is well 
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established that transcription of both these genes is activated by p53 (el-Deity et al. 
1993; Barak et al. 1993), suggesting that upregulation of p53 occurs. However, the 
data regarding the importance of p53 in cardiac myocyte apoptosis are conflicting. 
Some studies indicate that apoptosis in cardiac myocytes is not dependent on p53 
(Webster et al. 1999; Iwakura et al. 2001), whilst others indicate that there is p53-
dependence (Hu et al. 2000; Len et al. 2000; Nobori et al. 2002; Shizukuda et al. 
2005). Assays for changes in p53 protein levels and activity following induction of 
apoptosis in cardiac myocytes have produced inconsistent results even when the same 
stress was employed [e.g. hypoxia/reoxygenation (Webster et al. 1999; Toth et al. 
2006)]. Exposure to doxorubicin (an anti-neoplastic drug belonging to the 
anthracycline group) is the stress most consistently shown to upregulate p53 protein 
abundance in cultured cardiac myocytes (Poizat et al. 2000; Nobori et al. 2002; Poizat 
et al. 2005). However, administration of doxorubicin to mice in vivo has not been 
consistently shown to upregulate p53 protein expression in the heart (Liu et al. 2004; 
Kawamura et al. 2004). 
TFs other than p53 can regulate expression from the Mdm2 P2 promoter. Expression 
from P2 is increased in a p53-independent manner following overexpression of 
constitutively active Raf in a murine fibroblast cell line (Ries et al. 2000). This 
upregulation is dependent upon three TF binding sites: two Ets sites designated Ets(A) 
and Ets(B), and an AP-1 site that forms a composite with the Ets(B) site (Ries et al. 
2000). Truong et al. (2005) demonstrated that Fli-1 (an Ets TF) binds to the Mdm2 
Ets(A) site and activates Mdm2 mRNA expression in murine erythroleukaemia cell 
lines (Truong et al. 2005). The functional importance of the Mdm2 Ets(B) site has 
been confirmed for the human Mdm2 gene, where it is required for full p53- 
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independent expression from P2 in the T47D breast cancer cell line (Phelps et al. 
2003). 
In this chapter, the rat Mdm2 intron 1 sequence was examined for the presence of TF 
binding sites 5' to the P2 TATA box. The importance of these TF binding sites in the 
upregulation of Mdm2 mRNA transcription in cardiac myocytes under oxidative stress 
was systematically tested. 
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5.2 Methods 
5.2.1 DNA sequence analysis 
Potential TF binding sites in a DNA sequence were identified using the TFSearch 
programme (Akiyama 1995, http://www.cbrc.jp/research/db/TFSEARCH.html). The 
Multialign tool (http://prodes.toulouse.inrair/multalin/multalin.html) was used to 
align corresponding DNA sequences. 
5.2.2 RT-PCR 
Cardiac myocytes were exposed to 0.2 mM 1-1202 (0-24 h). Total RNA was extracted 
(Section 2.3) and semi-quantitative RT-PCR performed (Section 2.4) to assess the 
expression of p53 mRNA. PCR products were analysed by densitometry and 
normalised to GAPDH. 
5.2.3 EMSA 
Cardiac myocytes were exposed to 0.2 mM 11202 (0-8 h) or 0.5 µM daunorubicin (7.5 
h), nuclear proteins were extracted (Section 2.6) and then EMSAs performed (Section 
2.8). Nuclear protein extracts (10 pg) were incubated with radiolabelled double 
stranded oligonucleotide probes matching the sequence of a consensus p53 site, the 
Mdm2 Ets(A) site, the Mdm2 Ets(B) site or the Mdm2 MZF1 site. Samples were 
separated on 5% non-denaturing polyacrylamide gels. Bands were captured by 
exposure of the dried gels to Hyperfilm (Amersham) and analysed by semi-
quantitative scanning densitometry. For competition experiments, nuclear protein 
extracts (10 pg) were pre-incubated with the required amount of unlabelled wild type 
or mutant EMSA probe prior to the addition of the radiolabelled wild type probe. For 
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supershift assays, nuclear protein extracts (3 ps) were incubated with antibody to 
phospho-Elk-1 (2 .ig), Fli-1 (2 1.tg), p53 (cat. no. 126, 1 pz), p53 (cat. no. 6243, 1 pg) 
or JunD (2 pig) and then the EMSAs performed in the standard manner. 
5.2.4 Immunoblotting 
Cardiac myocytes were exposed to 0.2 mM 14202 (0-8 h) or 0.5 ttM daunorubicin (7.5 
h) and nuclear proteins extracted (Section 2.6). Immunoblotting was performed 
(Section 2.7) by subjecting nuclear protein extracts (10 ttg) to SDS-PAGE with a 10% 
polyacrylamide resolving gel. Proteins were then transferred to nitrocellulose 
membranes and probed with primary antibody to p53. Immunoreactive bands were 
detected by enhanced chemiluminescence and analysed semi-quantitatively by 
scanning densitometry. 
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5.3 Results 
5.3.1 Identification of TF binding sites upstream of the P2 promoter 
of rat Mdm2 
The rat Mdm2 intron 1 sequence was examined for the presence of the five TF 
binding sites identified in the murine orthologue 5' to the P2 TATA box (Juven et al. 
1993; Ries et al. 2000). The two Ets sites [Ets(A) and Ets(B)], the AP-1 site which 
forms a composite with the Ets(B) site, and the two p53 sites are conserved in rat 
(Figure 5.1). To identify other potential TF binding sites, rat Mdm2 intron 1 was 
examined for consensus TF binding sequences using the TFSearch programme. A 
MZF1 (myeloid zinc finger gene 1) site and a NF-E2 (nuclear factor erythroid 2) site 
were identified 5' to the P2 TATA box, the NF-E2 site is ignored as it overlaps with 
the AP-1 site (Figure 5.1). 
The intron 1 sequences of the human and murine Mdm2 genes were examined for 
conservation of the TF binding sites identified in rat Mdm2 intron 1 (Figure 5.2). 
Sites in the same region (determined by Multialign) and with a similar level of 
concordance to a consensus binding site for the TF (within 10% as determined by the 
TFSearch programme) were accepted as conserved. Figure 5.2 A shows the MZF1 
binding site is conserved in mouse, the previously identified binding sites for Ets(A), 
AP-1, Ets(B) and p53 (Ries et al. 2000; Juven et al. 1993) are also indicated. Figure 
5.2 B shows the AP-1 site and the Ets(B) site are conserved in human, the two 
previously identified p53 sites (Zauberman et al. 1995) are also indicated. The MZF1 
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and Ets(A) sites are not conserved in human, which may indicate that these sites are 
of lower functional importance. 
5' GTACCCGCCAGGAGCGACGCGACGTGCGGGGTTGGGCGGTGGCGAGTTCTGATCATTC 
CCGAGTCCTCTGGGGCCCACTCGCAGCCCGAGACGGCTCGCGGGGTCGCGGGGCGACGGT 
TTGTTGGCGCCGGGCCATGATGCCCTTATTCATCAGGGTGAGGTGGGGGGGTCTGGGTTA 
MZF1 
ACACAGCGCACGCGCGGAAGAGGATGACGGGGGTAATGGGGAGGGGAGAGGAGAAG 
AGCCGGGGTCTCCCGGCAGGCCCCGCGCCCGGGGGCGGCTCCGGGGTCGCGCTGGGCTCA 
Ets(A) 
CTGCAGGGGTCGGGGAGGTAACAGGTGCCTGGTGGTGGGACGTGGCTTCCGGGAcGG 
AP-1 	Ets(B) 	 p53 
GTGGGACTGGGCTGTGCCTAGTTGACTCAGCTTTTCCTGTGGGGCTGGTCAAG 
p53 
TTAGGACACGTTCAGcGTTGGcTGTTGGAGGAGCTAAGTCCTGACATGTCTc 
CAGCTGAGGC 	 CCCTGCTCGTTTC 3' 
Figure 5.1 TF binding sites in intron 1 of the rat Mdm2 gene 
TF (MZFl, Ets(A), AP-1, Ets(B) and p53) binding sites 5' to the P2 TATA box in rat 
Mdin2 intron 1 were identified using the TFSearch programme and by comparison 
with published analyses of the murine orthologue (Juven et al. 1993; Ries et al. 2000). 
The = 	box is indicated. 
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A) Conservation of TF binding sites in mouse Mdm2 intron 1 
5' GTACCCGCTCCGTGGGCGGCGGAGAGTCCCGATCATTCCCTCTTTTCCGCGCCCTCCG 
GGGCCTACTCGTAACCCGGGCCGGCTCGTGGGGTCGCGGGGCACGAGGCTGGGCGACCGT 
TTGCCCGCGCTGGGCCCTGATGTCATTCTGCGGCCGGGGGTGTGCGTGTGGGTGGGAGTG 
M2F1 
GGGGGTGGGGTGGGAGATGGCGCGGTTAGCACGGCGCATGCGCGGGAGGGGACGGAG 
GGAGGGGGAGGAGGGAAGAGCGGGGGTCTCCCAGCAGGCCCCGCGCGCGGGGGGCCCGC 
TCCGGGGTCGCGCTGGGCTCGTTGCTGGGGTCCAGGAGGTGACAGGTGCCTGGTCCCGGA 
Ets(A) 	 AP-1 
CTCGCCGGGATGCGGCTTCCGGGAcGGGTGGGAcTGGGcTGGGccGAGTTGACTCA 
Ets(B) 	 p53 
GCTCTTCCTGTGGGGcTGGICAAGTTGGGACACGTCCGGCGTcGGurGivGGAG 
p53 
GAGCTAAGTCCTGACATGTCTCCAGCTGGGGISEREMCGCTGCCCCGTTTCC 
3' 
B) Conservation of TF binding sites in human Mdm2 intron 1 
5' TACTGGCCCGGCAGCGAGCGGTCACTTTTGGGTCTGGGCTCTGACGGTGTCCCCTCTAT 
CGCTGGTTCCCAGCCTCTGCCCGTTCGCAGCCTTTGTGCGGTTCGTGGCTGGGGGCTCGGG 
GCGCGGGGCGCGGGGCATGGGGCACGTGGCTTTGCGGAGGTTTTGTTGGACTGGGGCTAG 
GCAGTCGCCGCCAGGGAGGAGGGCGGGATTTCGGACGGCTCTCGCGGCGGTGGGGGTGG 
GGGTGGTTCGGAGGTCTCCGCGGGAGTTCAGGGTAAAGGTCACGGGGGCCGGGGGCTGC 
GGGGCCGCTTCGGCGCGGGAGGTCCGGATGATCGCAGGTGCCTGTCGGGTCACTAGTGTG 
AP-1 
AACGCTGCGCGTAGTCTGGGCGGGATTGGGCCGGTTCAGTGGGCAGGTTGACTCAGCT 
Ets(B) 	 p53 
TTTCCTCTTGAGCTGGTCAAGTTCAGACACGTTCCGAAACTGCAGTAAAAGGAG 
p53 
	
TTAAGTCCTGACTTGTCTCCAGCTGGGGC 	 CCATGCATTTTCCCAGCTG 
TGTTCAGTGGCGATTGGAGGGTAGACCTGTGGGCACGGACGCACGCCACTTTTTCTCTGCT 
GATCCAGGTAAGCACCGACTTGCTTGTAGCTTTAGTTTTAACTGTTGTTTATGTTCTTTATA 
TATGATGTATTTTCCACAGATGTTTCATGATTTCCAGTTTTCATCGTGTCTTTTTTTTCCTTG 
T 3' 
Figure 5.2 Conservation of the TF binding sites in Mdm2 intron 1 
Murine (A) and human (B) Mdm2 intron 1 sequences were examined for conservation 
of the MZFl, Ets(A), AP-1, Ets(B) and p53 sites present in the rat orthologue. The 
Ell box is indicated. 
175 
5.3.2 p53 protein was not detected in cardiac myocytes exposed to 
H202 
Expression of p53 mRNA was examined by semi-quantitative RT-PCR and did not 
change following exposure of cardiac myocytes to 0.2 mM H202 (0-24 h) (Figure 
5.3). To assess p53 activity, cardiac myocytes were exposed to 0.2 mM H202 (0-8 h) 
or for a positive control to 0.5 IIM daunorubicin (7.5 h) (an anthracycline related to 
doxorubicin). EMSAs were then performed to assess binding of cardiac myocyte 
nuclear protein extracts to a radiolabelled oligonucleotide containing a consensus p53 
binding sequence (5' TACAGAACATGTCTAAGCATGCTGGGGACT 3'). 
Daunorubicin but not 0.2 mM H202 induced the appearance of a low mobility 
complex (Figure 5.4). EMSA supershift assays were performed to determine whether 
this low mobility complex was produced by binding of p53 to the EMSA probe. 
Nuclear protein extracts from cardiac myocytes exposed to 0.5 µM daunorubicin (7.5 
h) were incubated with either of two antibodies for p53 or an antibody for an 
irrelevant protein (JunD) and then the EMSAs performed. Each of the two p53 
antibodies but not the JunD antibody induced a supershift of the putative p53-probe 
complex (Figure 5.5). This confirms that the low mobility complex is produced by 
binding of p53 to the EMSA probe. Therefore active p53 was detected by EMSA in 
cardiac myocytes exposed to daunorubicin but not H202. Immunoblotting was 
performed to confirm the EMSA results. p53 protein was not detected by 
immunoblotting of nuclear protein extracts from cardiac myocytes exposed to 0.2 mM 
H202 over 8 h. In contrast, p53 protein was detected by immunoblotting of nuclear 
protein extracts from cardiac myocytes exposed to 0.5 p,M daunorubicin (7.5 h) 
(Figure 5.6). 
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Figure 5.3 p53 mRNA expression is unaltered in cardiac myocytes 
exposed to 0.2 mM 11202  
Cardiac myocytes were exposed to 0.2 mM I-1,02 (0-24 h). p53 mRNA expression 
was assessed by RT-PCR and normalised to GAPDH. Representative images (upper 
panels) and the densitometric analysis (lower panels) are shown. Results are means ± 
SEM for six independent experiments. 
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Figure 5.4 EMSA for p53 binding in cardiac myocytes exposed to 0.2 
mM 11202 or 0.5 pM daunorubicin 
Cardiac myocytes were exposed to 0.2 mM H202 (0-8 h) or 0.5 [iN4 daunorubicin (7.5 
h). EMSAs were performed using a probe containing a consensus p53 binding 
sequence. 	The autoradiograph shown is representative of three independent 
experiments. Unbound probe can be seen at the bottom of the autoradiograph. 
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Figure 5.5 Supershift of the p53-probe complex 
Cardiac myocytes were exposed to 0.5 p.M daunorubicin (7.5 h). Nuclear protein 
extracts were analysed by EMSA using the probe containing a consensus p53 binding 
sequence. EMSAs were performed in the presence or absence of two different p53 
antibodies (Ab) (126 or 6243) or an antibody to an irrelevant protein (JunD). The 
autoradiograph shown is representative of three independent experiments. 
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Figure 5.6 Changes in p53 protein levels in cardiac myocytes 
exposed to 0.2 mM H202 or 0.5 p.M daunorubicin 
Cardiac myocytes were exposed to 0,2 mM H202 (0-8 h) or 0.5 p.M daunorubicin (7.5 
h). p53 protein was detected by immunoblotting of nuclear protein extracts. The 
images shown are representative of three independent experiments. 
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5.3.3 11202 promotes an increase in binding to the Mdm2 Ets(A) 
sequence 
EMSAs were performed using cardiac myocyte nuclear protein extracts and an 
oligonucleotide probe matching the sequence of the Mdm2 Ets(A) site (5' 
GGACGTGGCTTCCGGGACGGGT 3'). Three complexes of different mobility 
were produced, designated 1 (lowest mobility), 2 (second highest mobility) and 3 
(highest mobility) (Figure 5.7). Following exposure of cardiac myocytes to 0.2 mM 
H202, the levels of complex 2 increased by a maximum of 7.94 ± 1.48 fold (mean ± 
SEM, n=5) at 30 min. Levels then decreased, remaining significantly elevated at 45 
min and returning to basal by 1.5 h (Figure 5.7). The amounts of complexes 1 or 3 
did not change in response to 0.2 mM H202 (0-2 h) (Figure 5,7). Competition 
experiments were performed to determine the specificity of the binding complexes. 
Using nuclear protein extracts from cardiac myocytes exposed to 0.2 mM H202 (30 
min), binding to the radiolabelled wild type Mdm2 Ets(A) probe was monitored in the 
presence of unlabelled wild type or mutant (5' GGACGTGGATTCCAGGACGGGT 
3') Mdm2 Ets(A) probe (Figure 5.8). A 10 fold excess of unlabelled wild type Mdm2 
Ets(A) probe completely depleted complexes 1 and 2. A 100 fold excess of 
unlabelled mutant Mdm2 Ets(A) probe was not sufficient to completely deplete 
complexes 1 and 2. Complex 3 was not significantly depleted by up to a 100 fold 
excess of unlabelled wild type or mutant Mdm2 Ets(A) probe. These results indicate 
that complexes 1 and 2 are the result of specific binding to the Mdm2 Ets(A) probe, 
but complex 3 is produced by non-specific interactions. 
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EMSA supershift assays were performed to identify the protein/s binding the Mdm2 
Ets(A) probe. Nuclear protein extracts from cardiac myocytes exposed to 0.2 mM 
H202 (30 min) were incubated with antibody to phospho-Elk-1 (Ets-like gene-1) or 
Fli-1 or an irrelevant antibody (to JunD) (Figure 5.9). Neither the phospho-Elk-1 
antibody nor the Fli-1 antibody induced a supershift of the Ets(A) EMSA complexes, 
indicating that these are not the binding proteins. 
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Figure 5.7 EMSA for the Mdm2 Ets(A) site: Changes in binding in 
cardiac myocytes exposed to 0.2 mM 11202 
Cardiac myocytes were exposed to 0.2 mM I-1202 (0-2 h). EMSAs were performed 
using the Mdm2 Ets(A) probe. A representative autoradiograph (upper panel) and the 
densitometric analysis for complex 2 (lower panel) are shown. Unbound probe can be 
seen at the bottom of the autoradiograph. Results are means ± SEM for five 
independent experiments (*p<0.05, one way ANOVA with Tukey post test). 
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Figure 5.8 EMSA for the Mdm2 Ets(A) site: Competition study to 
determine the specificity of binding 
Cardiac myocytes were exposed to 0.2 mM H20/ (30 min) and binding to the 
radiolabelled wild type Mdin2 Ets(A) probe was tested in the presence of increasing 
concentrations of unlabelled wild type probe or unlabelled mutant probe. The 
autoradiograph shown is representative of three independent experiments. Unbound 
probe can be seen at the bottom of the autoradiograph, 
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Figure 5.9 EMSA for the Mdm2 Ets(A) site: The binding protein/s 
are not supershifted by antibodies to phospho-Elk-1 or Fli-1 
Cardiac myocytes were exposed to 0.2 mM H202 (30 min). Binding to the Mdm2 
Ets(A) probe was monitored in the absence or presence of antibody (Ab) to phospho-
Elk-1, Fli-1 or an irrelevant protein (JunD). The autoradiographs shown are 
representative of three independent experiments. Unbound probe can be seen at the 
bottom of the autoradiographs. 
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5.3.4 H202 does not alter binding to the Mdm2 Ets(B) or MZF1 
sequences 
One complex was produced in EMSAs using an oligonucleotide probe matching the 
sequence of the Mdm2 Ets(B) site (5' GACTCAGCTTTTCCTGTGGGGCTGG 3'). 
The levels of this complex did not change in response to exposure of cardiac 
myocytes to 0.2 mM H202 over 8 h (Figure 5.10). Using nuclear protein extracts from 
unstimulated cardiac myocytes, competition experiments were performed to test the 
specificity of binding to the Mdm2 Ets(B) probe (Figure 5.11). The levels of the 
Ets(B) EMSA complex were not completely depleted by a 25 fold excess of 
unlabelled wild type Mdm2 Ets(B) probe. Only a 50 fold excess of unlabelled wild 
type Mdm2 Ets(B) probe was sufficient to completely deplete the complex. A 100 
fold excess of unlabelled mutant Mdm2 Ets(B) probe (5' 
GACTCAGCTTTTCCCGGGGGGCTGG 3') was sufficient to completely deplete the 
Ets(B) EMSA complex. These results indicate that the binding to the Mdm2 Ets(B) 
probe is of lower specificity than the binding of complexes 1 or 2 to the Mdm2 Ets(A) 
probe. 
One complex was produced in EMSAs using an oligonucleotide probe matching the 
sequence of the Mdm2 MZF1 site (5' ATGGAGGGAGGGGAGAGGAG 3'). The 
levels of the MZF1 EMSA complex did not change following exposure of cardiac 
myocytes to 0.2 mM H202 over 8 h (Figure 5.12). Competition experiments were 
performed to test the specificity of binding to the Mdm2 MZF1 probe (Figure 5.13). 
No significant depletion of the MZF1 EMSA complex occurred in response to up to a 
100 fold excess of either unlabelled wild type or unlabelled mutant (5' 
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ATGGAG GAGGAG 3') Mdm2 MZFl probe. This complex is therefore
the result of non-specific binding.
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Figure 5.10 EMSA for the Mdm2 Ets(B) site: Binding is not changed 
in cardiac myocytes exposed to 0.2 mM 11202  
Cardiac myocytes were exposed to 0.2 mM H202 (0-8 h). EMSAs were performed 
using the Alcim2 Ets(B) probe. The autoradiograph shown is representative of three 
independent experiments. Unbound probe can be seen at the bottom of the 
autoradiograph. 
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Figure 5.11 EMSA for the Mdm2 Ets(B) site: Competition study to 
determine the specificity of binding 
Using nuclear protein extracts from unstimulated cardiac myocytes, binding to the 
radiolabelled wild type Mdm2 Ets(B) probe was tested in the presence of increasing 
concentrations of unlabelled wild type probe or unlabelled mutant probe. The 
autoradiograph shown is representative of three independent experiments. Unbound 
probe can be seen at the bottom of the autoradiograph. 
189 
Time (h) 0 0.083 0.25 0.5 0.75 1 	1.5 	2 	4 	8 
Probe—
complex 
Unbound 
probe 
Figure 5.12 EMSA for the Mdm2 MZF1 site: Binding is not changed 
in cardiac myocytes exposed to 0.2 mM 11202 
Cardiac myocytes were exposed to 0.2 mM f1202 (0-8 h). EMSAs were performed 
using the Mdm2 MZF1 probe. The autoradiograph shown is representative of three 
independent experiments. Unbound probe can be seen at the bottom of the 
autoradiograph. 
190 
Unlabelled 	 Unlabelled 
wild type probe 	mutant probe 
lx 10x 25x 50x 100x 50x 100x 
Probe 
complex 
Unbound 
probe 
Figure 5.13 EMSA for the Mdm2 MZF1 site: Competition study to 
determine the specificity of binding 
Using nuclear protein extracts from unstimulated cardiac myocytes, binding to the 
radiolabelled wild type Mdm2 MZF1 probe was tested in the presence of increasing 
concentrations of unlabelled wild type probe or unlabelled mutant probe. The 
autoradiograph shown is representative of three independent experiments. Unbound 
probe can be seen at the bottom of the autoradiograph. 
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5.4 Discussion 
5.4.1 p53 protein was not detected in cardiac myocytes exposed to 
11202 
Active p53 was not detected by EMSA in cardiac myocytes exposed to 0.2 mM H202 
over 8 h (Figures 5.4-5.5). p53 protein was also not detected by immunoblotting in 
cardiac myocytes exposed to 0.2 mM H202 over 8 h (Figure 5.6). This indicates that 
the upregulation in transcription from the Mdm2 P2 promoter in response to 0.2 mM 
H202 (Chapter 4, Figure 4.4) is not mediated by p53. Several studies have shown that 
doxorubicin upregulates p53 protein expression in cultured cardiac myocytes (Poizat 
et al. 2000; Nobori et al. 2002; Poizat et al. 2005). The efficacy of the 
immunoblotting and EMSAs performed here was confirmed by the detection of p53 
following exposure of cardiac myocytes to daunorubicin (an anthracycline related to 
doxorubicin) (Figures 5.4-5.6). It is possible that cardiac myocytes exposed to H202 
possessed a low level of p53 that the EMSAs and immunoblotting performed here 
were not sensitive enough to detect. That transcription from the Mdm2 P2 promoter 
can be activated independently of p53 under these conditions could be confirmed by 
the observation of unimpaired upregulation in cardiac myocytes derived from p53 null 
mice. 
There is a lack of consensus in the literature as to the importance of p53 in cardiac 
myocyte apoptosis. Assessment of changes in p53 protein abundance or p53 activity 
has given disparate findings, as has determination of p53-dependence (Chapter 1, 
Table 1.3 and references therein). Some of these discrepancies may be due to the 
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problems reported in the detection of p53. Immunoblotting using commercial p53 
antibodies can produce unidentified extra bands (Bonsing et al. 1997; Nickels et al. 
1997; Danks et al. 1998; Harlozinska et al. 2000; Turpeinen et al. 2002) or even not 
detect p53 (Bonsing et al. 1997; Danks et al. 1998; Turpeinen et al. 2002). Similar 
criticisms have been levelled at the results of immunohistochemical staining with 
commercial p53 antibodies (Andrejco et al. 1996; Nickels et al. 1997). There is also 
uncertainty as to the validity of the results from EMSAs for p53. Several studies 
suggest that p53 inactive for binding to an EMSA probe in vitro may bind to DNA in 
vivo (Kim et al. 1999; Espinosa and Emerson 2001; Kaeser and Iggo 2002). 
Furthermore, p53 binding is strongly influenced by changes in DNA conformation 
(e.g. supercoiling) that are not replicated in an EMSA (Kim et al. 1997, 1999). 
EMSAs also indicate that p53 inactive for binding to promoters containing a single 
p53 binding site can bind to promoters that possess two p53 binding sites (Kaku et al. 
2001a, 2001b). The Mdm2 promoter contains two p53 binding sites (Figure 5.1) and 
the p53 probe employed here contains only a single p53 site. However, the results of 
the EMSAs performed here were confirmed by immunoblotting using an antibody 
that produced a single band with a molecular mass of the expected 53 kDa. 
5.4.2 Binding to the Mdm2 Ets(A), Ets(B) and MZF1 sequences in 
vitro 
EMSAs were performed using probes matching the Ets(A), Ets(B) and MZF1 sites in 
Mdm2 intron 1. In proliferating cell lines, the Mdm2 Ets(A) site is essential for p53-
independent upregulation of expression from P2 in response to overexpression of 
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constitutively active Raf (Ries et al. 2000) or overexpression of Fli-1 (Truong et al. 
2005). Three complexes were produced using the Mdm2 Ets(A) probe and cardiac 
myocyte nuclear protein extracts. Competition experiments established that only the 
two lower mobility complexes were produced by specific interactions (Figure 5.8). 
Only the level of the medium mobility complex was increased in response to 0.2 mM 
H202 (Figure 5.7), suggesting that it is this complex that is produced by specific Ets 
binding. Previous Ets EMSAs in cardiac myocytes have also produced three main 
complexes with the medium mobility complex being the one produced by specific 
Ets-probe binding (Pikkarainen et al. 2003). The activation of an Ets TF by 11202 in 
cardiac myocytes is consistent with findings in other cell types (e.g. Sanij et al. 2001; 
Liu et al. 2006). The Ets activity declined to basal levels prior to the upregulation in 
Mdm2 mRNA which occurred at 2 h (Chapter 3, Figure 3.1). This suggests that the 
increased Ets activity does not directly activate transcription of Mdm2. It is possible 
that in vivo, the detected Ets TF binds to a gene other than Mdm2 that possesses a 
similar element in its promoter and shows an earlier upregulation in response to H202. 
EMSA supershift assays indicated that the TF binding to the Mdm2 Ets(A) probe was 
not phospho-Elk-1 or Fli-1 (Figure 5.9). The functionality of these antibodies was 
however not confirmed by positive controls. Truong et al. (2005) identified Fli-1 as 
the Ets TF that binds to the Mdm2 Ets(A) site, however these studies were performed 
in erythroleukaemia cell lines, not cardiac myocytes. The identity of the binding Ets 
TF remains to be determined. 
The Mdm2 Ets(B) site is required for p53-independent upregulation of transcription 
from P2 in response to overexpression of constitutively active Raf (Ries et al. 2000). 
EMSAs using the Mdm2 Ets(B) probe produced one complex. The levels of this 
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complex did not change in response to 0.2 mM H202 over 8 h (Figure 5.10) and 
competition experiments indicated that binding was of relatively low specificity 
(Figure 5.11). This indicates that this site in Mdm2 is not bound by a TF in response 
to exposure of cardiac myocytes to H202 and so does not mediate the upregulation in 
Mdm2 mRNA. However, the Mdm2 Ets(B) site forms a composite with an AP-1 site, 
which was not included in the oligonucleotide EMSA probe. Combinational control 
is a characteristic trait of Ets TFs and members of other TF families can facilitate their 
binding to promoters (e.g. Fitzsimmons et al. 1996). Hence, failure to detect 
increased/specific binding to the Mdm2 Ets(B) probe may be a false negative. The 
importance of the Ets(B) site could be further tested by its mutation within a reporter 
gene construct. No specific binding was detected to the Mdm2 MZF1 probe using 
cardiac myocyte nuclear protein extracts (Figures 5.12 and 5.13). Although the 
functionality of the assay was not confirmed by a positive control, no MZF1 binding 
is an expected result as this TF is preferentially expressed in myeloid cells (Hromas et 
al. 1991). 
5.4.3 Summary 
p53 was not detected by EMSA or immunoblotting in cardiac myocytes exposed to 
0.2 mM H202 over 8 h but was detected in cardiac myocytes exposed to daunorubicin. 
This suggests that increased expression from the Mdm2 P2 promoter in response to 
0.2 mM H202 is not mediated by p53. In cardiac myocytes exposed to 0.2 mM H202, 
there is a rapid increase in the activity of an unidentified Ets TF that binds to the 
sequence of the Mdm2 Ets(A) site in vitro. This Ets activity declines prior to the 
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increase in Mdm2 mRNA, suggesting that it does not directly induce the Mdm2 
mRNA upregulation. 
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Chapter six 
Regulation of Ilidm2 expression by AP-1 in 
cardiac myocytes under oxidative stress 
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6.1 Introduction 
Following exposure of cardiac myocytes to 0.2 mM H202 there is increased 
expression from the P2 promoter of Mdm2 (Chapter 4, Figure 4.4). P2 is located in 
intron 1 of the Mdm2 gene and 5' to the TATA box there are binding sites for several 
TFs: MZF1, Ets, AP-1 and p53 (Chapter 5, Figure 5.1). The increased expression 
from P2 in response to 0.2 mM H202 is indicated not to be mediated by p53 (Chapter 
5, Figures 5.4-5.6) and not involve either of the two Ets sites (Chapter 5, Figures 5.7 
and 5.10) or the MZF1 site (Chapter 5, Figure 5.13). In other cell types, the AP-1 site 
can play a prominent role in regulating Mdm2 expression. Thus, the Mdm2 AP-1 site 
is essential for p53-independent upregulation of transcription from P2 in response to 
overexpression of constitutively active Raf in a murine fibroblast cell line (Ries et al. 
2000). The Mdm2 AP-1 site also contributes significantly to the p53-independent 
expression from P2 in the T47D human breast cancer cell line (Phelps et al. 2003). 
AP-1 is a subfamily of the dimerizing b-Zip TFs and binds a seven base-pair 
palindromic DNA sequence (5' T G A G/C T C A 3'). The AP-1 subfamily 
comprises Jun family proteins (c-Jun, JunB and JunD) and Fos family proteins [c-Fos, 
FosB, Fra-1 and Fra-2]. Dimerization is required for specific and high affinity DNA-
binding (Rauscher et al. 1988; Gentz et al. 1989; Hirai and Yaniv 1989; Ransone et al. 
1989; Schuermann et al. 1989; Turner and Tjian 1989). Jun proteins form 
homodimers and also heterodimerize with each other, while Fos proteins cannot 
homodimerize but form heterodimers with Jun family proteins (Angel et al. 1987, 
1988; Halazonetis et al. 1988; Sassone-Corsi et al. 1988a; Hirai and Yaniv 1989). Jun 
and Fos proteins also heterodimerize with members of other b-Zip subfamilies 
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including ATF/CREB (activating transcription factor/cAMP response element-
binding protein) (Hai and Curran 1991) and Maf (musculoaponeurotic fibrosarcoma) 
(Kerppola and Curran 1994). This results in a change in DNA-binding specificity, for 
example c-Jun/ATF-2 heterodimers have a higher binding affinity for the CRE 
(cAMP-responsive element) sequence (5' T G A C G T C A 3') than for the AP-1 
sequence (Hai and Curran 1991). Each of the Jun and Fos proteins can activate or 
repress transcription (c-Jun and JunB: Bakiri et al. 2000; Passegue and Wagner 2000. 
JunD: Hirai et al. 1989; Weitzman et al. 2000; Smart et al. 2001. c-Fos: Sassone-
Corsi et al. 1988b; Schutte et al. 1989. FosB: Mumberg et al. 1991. Fra-1 and Fra-2: 
Suzuki et al. 1991). 
Exposure of cultured cardiac myocytes to H202 increases AP-1 activity associated 
with upregulation of c-Jun and c-Fos mRNA and protein (Peng et al. 1995; Frantz et 
al. 2001; Tu et al. 2003; Coronella-Wood et al. 2004). AP-1 activity in the heart is 
increased following cardiac ischaemia/reperfusion in several animal species 
[Chandrasekar and Freeman 1997 (rat heart in vivo); Maulik et al. 1999b (isolated rat 
heart); Sun et al. 200 lb (dog heart in vivo); Fan et al. 2002 (dog heart in vivo); 
Zingarelli et al. 2002 (murine heart in vivo); Zingarelli et al. 2004 (murine heart in 
vivo)]. In the human heart, there is increased expression of c-Jun and c-Fos mRNA 
following cardiac ischaemia/reperfusion during coronary bypass surgery (Nelson et al. 
2002). Ischaemia alone also increases AP-1 activity in the rat heart ex vivo (Li et al. 
2000b; Maulik et al. 2000) and in vivo (Shimizu et al. 1998). 
Given that the Mdm2 AP-1 site can contribute significantly to transcription of Mdm2 
mRNA and that AP-1 activity is reported to increase in cardiac myocytes under 
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oxidative stress; it was hypothesised that AP-1 mediates the increase in Mdm2 mRNA 
expression following exposure of cardiac myocytes to 0.2 mM H202. This hypothesis 
was investigated in this chapter. 
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6.2 Methods 
6.2.1 RT-PCR 
Cardiac myocytes were exposed to 0.2 mM H202 (0-8 h) and semi-quantitative RT-
PCR performed (Sections 2.3 and 2.4) to assess mRNA expression from c-Fos, FosB, 
Fra-1, Fra-2, c-Jun, JunB, JunD and pre- and post- the CJBS TATA box. PCR 
products were analysed by scanning densitometry and normalised to GAPDH. For 
RT-PCR of CJBS sequences, RNA was DNase treated prior to cDNA synthesis 
(Section 2.4). 
6.2.2 Immunoblotting 
Cardiac myocytes were exposed to 0.2 mM H202 (0-8 h) and then immunoblotting of 
nuclear protein extracts (10 ps) performed (Sections 2.6 and 2.7). The primary 
antibodies used were to c-Jun, JunB, JunD or c-Fos. Bands were analysed by semi-
quantitative scanning densitometry. 
6.2.3 EMSA 
Cardiac myocytes were exposed to 0.2 mM H202 (0-2 h) and EMSAs performed 
(Sections 2.6 and 2.8) using 10 µg nuclear protein extract and a radiolabelled double 
stranded oligonucleotide probe matching the Mdm2 AP-1 site. Bands were analysed 
by semi-quantitative scanning densitometry. For competition experiments, nuclear 
protein extracts (10 jig) were pre-incubated with the required amount of unlabelled 
wild type or mutant Mdm2 AP-1 probe prior to the addition of the radiolabelled wild 
type probe. For supershift assays, nuclear protein extracts (3 µg) were pre-incubated 
with antibody to c-Jun (2 µg), JunB (2 gg), JunD (2 ttg), c-Fos (1 µg), FosB (2 µg), 
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Fra-1 (2 gg), Fra-2 (2 Rg), ATF-2 (2 lig) or phospho-Elk-1 (2 p.g) and then the 
EMSAs performed in the standard manner. 
6.2.4 ChIP (chromatin immunoprecipitation) assay 
Cardiac myocytes were unstimulated or exposed to 0.2 mM1-1202 (2 h) and then ChIP 
assays were performed (Section 2.9). 	The antibodies used in the 
immunoprecipitations were to c-Jun (5 pg), JunB (5 [tg) or JunD (5 gg) and the 
primers used in the PCRs were specific to the Mdm2 P2 promoter, the GAPDH coding 
sequence or an arbitrary sequence lying 4000 bp 3' to the Mdm2 gene. PCR products 
were analysed by scanning densitometry 
6.2.5 DNA cloning and sequencing 
DNA fragments immunoprecipitated by ChIP assay were cloned by Dr. TJ Kemp 
using the Invitrogen TA cloning kit (catalogue number KNM2040-01) according to 
the manufacturer's instructions. Cloned DNA was sequenced by the Advanced 
Biotechnology Centre (ABC), Imperial College London. 
6.2.6 Sequence analysis 
The NCBI Blast engine (http://www.ncbi.nlm.nih.gov/BLAST/) was used to search 
Est and genomic databases for sequences matching a cloned DNA fragment. Open 
reading frames (ORFs) were identified in a DNA sequence using the NCBI ORF 
finder (http://www.ncbi.nlm.nih.gov/gorf/). Peptide sequence was analysed for the 
presence of known motifs using the 	ExPASy 	prosite tool 
(http://www. expasy.org/tools/scanprosite/).  
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6.3 Results 
6.3.1 Changes in expression of the Jun family and Fos family 
mRNAs in response to H202 
Cardiac myocytes were exposed to 0.2 mM H202 (0-8 h) and mRNA expression from 
the Jun and Fos family genes assessed by semi-quantitative RT-PCR. Expression of c-
Jun mRNA increased from 30 min and reached a maximal 7.9 ± 1.5 fold (mean ± SEM, 
n=3) upregulation at 1 h. The amount of c-Jun mRNA then decreased but remained 
above basal levels up to 2 h (Figures 6.1.1 and 6.1.2). JunB mRNA expression was 
increased at 15 min and reached a maximum elevation of 3.8 ± 0.6 fold (mean ± SEM, 
n=3) at 1 h. JunB mRNA declined to basal levels by 4 h (Figures 6.1.1 and 6.1.2). 
JunD mRNA abundance was unaltered in response to 0.2 mM 11202 over 8 h (Figures 
6.1.1 and 6.1.2). Expression of c-Fos mRNA was upregulated from 30 min, maximally 
increased by 20.9 ± 3.6 fold (mean ± SEM, n=3) at 1 h and reduced to basal levels by 4 
h (Figures 6.2.1 and 6.2.2). FosB mRNA was increased from 30 min, maximal at 1.5 h 
and then reduced to basal levels by 8 h (Figures 6.2.1 and 6.2.2). The fold changes in 
FosB mRNA could not be calculated accurately as expression was too low under 
control conditions to allow precise measurement. Fra-1 mRNA expression was 
increased from 45 min and levels were maximally upregulated by 11.8 ± 2.2 fold (mean 
± SEM, n=3) at 1.5 h. Fra-1 mRNA abundance then decreased but remained 
moderately elevated over at least 8 h (Figures 6.2.1 and 6.2.2). A small but consistent 
increase in Fra-2 mRNA occurred between 1-2 h, levels were increased by a maximal 
2.4 ± 0.8 fold (mean I SEM, n=3) at 1.5 h (Figures 6.2.1 and 6.2.2). The change in 
Fra-2 mRNA was not statistically significant. 
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Figure 6.1.1 Expression of c-Jun, JunB and JunD mRNA in cardiac 
myocytes exposed to 0.2 mM H202: RT-PCR analysis 
Cardiac myocytes were exposed to 0.2 mM H202 (0-8 h). RT-PCR was used to 
assess the mRNA levels of c-Jun, JunB and JunD and the house keeping gene 
GAPDH. The images shown are representative of three independent experiments. 
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Figure 6.1.2 Expression of c-Jun, JunB and JunD mRNA in cardiac 
myocytes exposed to 0.2 mM H202: Densitometric analysis 
Cardiac myocytes were exposed to 0.2 mM H202 (0-8 h). c-Jun, JunB and JunD 
mRNA levels were assessed by RT-PCR and normalised to GAPDH. The 
densitometric analysis is shown. Results are means ± SEM for three independent 
experiments (*p<0.05, one way ANOVA with Tukey post test). 
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Figure 6.2.1 Expression of c-Fos, FosB, Fra-1 and Fra-2 mRNA in 
cardiac myocytes exposed to 0.2 mM H202: RT-PCR analysis 
Cardiac myocytes were exposed to 0.2 mM H202 (0-8 h). RT-PCR was used to 
assess the mRNA levels of c-Fos, FosB, Fra-1, Fra-2 and the house keeping gene 
GAPDH. The images shown are representative of three independent experiments. 
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Figure 6.2.2 Expression of c-Fos, FosB, Fra-1 and Fra-2 mRNA in 
cardiac myocytes exposed to 0.2 mM 11202: Densitometric analysis 
Cardiac myocytes were exposed to 0.2 mM H202 (0-8 h). c-Fos, FosB, Fra-1 and 
Fra-2 mRNA levels were assessed by RT-PCR and normalised to GAPDH. The 
densitometric analysis is shown. Results are means ± SEM for three independent 
experiments (*p<0.05, one way ANOVA with Tukey post test). 
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6.3.2 The protein levels of c-Jun, JunB and c-Fos but not JunD 
increase in response to 11202 
Immunoblotting was performed to examine c-Jun, JunB, JunD and c-Fos in nuclear 
protein extracts from cardiac myocytes exposed to 0.2 mM H202 (0-8 h). c-Jun 
protein was detected as a single band except at 1 h where multiple bands of similar 
mobility were detected (Figure 6.3.1). JunB protein and c-Fos protein were detected 
as multiple bands of similar mobility at all time points examined (0-8 h) (Figure 
6.3.1). The bands of lower electrophoretic mobility are presumed to be the result of 
phosphorylations, as described previously [e.g. Franklin et al. 1992 (c-Jun); Bakiri et 
al. 2000 (JunB); Coronella-Wood et al. 2004 (c-Fos)]. Two protein isoforms of JunD 
are expressed through the use of two different translation initiation sites in JunD 
mRNA (Short and Pfarr 2002) and both protein isoforms were detected by 
immunoblotting (Figure 6.3.1). Changes in the protein levels paralleled the changes 
observed at the mRNA levels for each gene. The abundance of c-Jun protein was 
increased from 45 mM and reached a maximal 10.3 ± 1.6 fold (mean ± SEM, n=5) 
upregulation at 1-2 h. c-Jun protein was close to basal levels by 4 h (Figures 6.3.1 
and 6.3.2). The levels of JunB protein were maximally increased by 2.31 ± 0.2 fold 
(mean ± SEM, n=5) between 1-2 h. JunB protein was reduced to basal levels by 4 h 
(Figures 6.3.1 and 6.3.2). The levels of neither JunD isoform (35 and 40 kDa) 
changed in response to 0.2 mM H202 (Figures 6.3.1 and 6.3.2). c-Fos protein was 
upregulated from 1 h, reached a maximum 15.6 ± 5.7 fold (mean ± SEM, n=5) 
increase at 2 h and then reduced to basal levels by 4 h (Figures 6.3.1 and 6.3.2). 
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Figure 6.3.1 Abundances of c-Jun, JunB, JunD and c-Fos protein in 
cardiac myocytes exposed to 0.2 mM H202: Immunoblotting analysis 
Cardiac myocytes were exposed to 0.2 mM 14202 (0-8 h). c-Jun, JunB, JunD and c-
Fos proteins were examined by immunoblotting of nuclear protein extracts. The 
images shown are representative of four independent experiments. 
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Figure 6.3.2 Abundances of c-Jun, JunB, JunD and c-Fos protein in 
cardiac myocytes exposed to 0.2 mM 11202: Densitometric analysis 
Cardiac myocytes were exposed to 0.2 mM H202 (0-8 h). c-Jun, JunB, JunD and c-
Fos proteins were examined by immunoblotting of nuclear protein extracts. The 
densitometric analysis is shown. Results are means ± SEM for four independent 
experiments (*p<0.05, one way ANOVA with Tukey post test). 
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6.3.3 11202 promotes binding to the Mdm2 AP-1 sequence 
Cardiac myocytes were exposed to 0.2 mM 14202 and then EMSAs performed to 
assess in vitro binding of nuclear protein extracts to a radiolabelled oligonucleotide 
probe matching the sequence of the Mdm2 AP-1 site (5' 
GCCTAGTTGACTCAGCTTTTC 3'). Cardiac myocyte nuclear proteins bound to 
the Mdm2 AP-1 probe to produce a single band (Figure 6.4). The level of binding 
was increased significantly after 1 h of exposure of cardiac myocytes to 0.2 mM 
H202. Binding was maximally increased by 2.3 + 0.3 fold (mean + SEM, n=4) at 1.25 
h and remained similarly elevated up to 2 h (Figure 6.4). Competition experiments 
were performed to test the specificity of binding to the Mdm2 AP-1 probe (Figure 
6.5). Using nuclear protein extracts from cardiac myocytes exposed to 0.2 mM H202 
(1.5 h), binding to the radiolabelled wild type Mdm2 AP-1 probe was completely 
depleted by addition of a 10 fold excess of the unlabelled wild type probe. Binding to 
the radiolabelled wild type Mdm2 AP-1 probe was not completely depleted by 
addition of a 100 fold excess of the unlabelled mutant probe (5' 
GCCTAGTTGACTTGGCTTTTC 3'). Therefore the binding to the Mdm2 AP-1 
probe was specific. 
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Figure 6.4 Binding to the Mdm2 AP-1 probe increases following 
exposure of cardiac myocytes to 0.2 mM 11202 
Cardiac myocytes were exposed to 0.2 mM H202 (0-2 h) and EMSAs were performed 
using the Mdm2 AP-1 probe. A representative autoradiograph (upper panel) and the 
densitometric analysis (lower panel) are shown. Unbound probe can be seen at the 
bottom of the autoradiograph. Results are means ÷ SEM for four independent 
experiments (*p<0.05, one way ANOVA with Tukey post test). 
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Figure 6.5 Competition study to determine the specificity of binding 
to the Mdm2 AP-1 probe 
Cardiac myocytes were exposed to 0.2 mM H202 (1.5 h) and binding to the 
radiolabelled wild type Mdm2 AP-1 probe tested in the presence of increasing 
concentrations of unlabelled wild type probe or unlabelled mutant probe. The 
autoradiograph shown is representative of three independent experiments. Unbound 
probe can be seen at the bottom of the autoradiograph. 
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6.3.4 A subset of the AP-1 proteins bind the Mdm2 AP-1 sequence 
under control conditions and in response to H202 
To identify the proteins that bound to the Mdm2 AP-1 probe, EMSA supershift assays 
were performed using antibodies to the AP-1 proteins and ATF-2. Using nuclear 
protein extracts from unstimulated cardiac myocytes, components of the AP-1 EMSA 
complex were induced to supershift by antibody to JunB or JunD but not by antibody 
to c-Jun (Figure 6.6). This indicates that, under basal conditions, cardiac myocytes 
possess significant levels of active/DNA-binding JunB and JunD but not c-Jun. Using 
nuclear protein extracts from cardiac myocytes exposed to 0.2 mM H202 (1.5 h), 
antibody to JunB, JunD or c-Jun induced a supershift of components of the AP-1 
EMSA complex. This indicates that c-Jun had been activated by exposure of cardiac 
myocytes to 0.2 mM H202 (1.5 h) and that activity of JunB and JunD had been 
maintained (Figure 6.7). The irrelevant antibody (to phospho-Elk-1) did not induce a 
supershift of this complex, confirming the specificity of the assay (Figure 6.7). 
Components of the AP-1 EMSA complex induced by 0.2 mM H202 (1.5 h) were also 
caused to supershift by antibody to c-Fos, FosB or Fra-1 but not by antibody to Fra-2, 
ATF-2 or the irrelevant protein (phospho-Elk-1) (Figure 6.8). Therefore, cardiac 
myocytes exposed to 0.2 mM H202 (1.5 h) possessed active/DNA-binding c-Fos, 
FosB and Fra-1 as well as active/DNA-binding c-Jun, JunB and JunD. The efficacy 
of the Fra-2 and ATF-2 antibodies was not confirmed by positive control. It therefore 
remains a possibility that failure to detect the presence of Fra-2 or ATF-2 by EMSA 
supershift assay is a false negative. Antibodies to c-Jun, JunB, JunD, c-Fos, FosB and 
Fra-1 were added together to nuclear protein extracts from cardiac myocytes exposed 
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to 0.2 mM 11202 (1.5 h). The six protein-specific antibodies were together sufficient 
to supershift the entire AP-1 EMSA complex (Figure 6.9). 
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Figure 6.6 Binding of JunB and JunD but not c-Jun to the Mdm2 
AP-1 probe is detected using nuclear protein extracts from 
unstimulated cardiac myocytes 
Nuclear protein extracts were prepared from unstimulated cardiac myocytes and 
binding to the radiolabelled Mdm2 AP-1 probe was monitored in the absence or 
presence of antibody (Ab) to c-Jun, JunB or JunD. The autoradiograph shown is 
representative of three independent experiments. Unbound probe can be seen at the 
bottom of the autoradiograph. 
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Figure 6.7 Binding of c-Jun, JunB and JunD to the Mdm2 AP-1 
probe is detected using nuclear protein extracts from cardiac 
myocytes exposed to 0.2 mM 11202 
Cardiac myocytes were exposed to 0.2 mM H202 (1.5 h) and binding to the 
radiolabelled Mdm2 AP-1 probe monitored in the absence or presence of antibody 
(Ab) to c-Jun, JunB, JunD or an irrelevant protein (phospho-Elk-1). 	The 
autoradiograph shown is representative of three independent experiments. Unbound 
probe can be seen at the bottom of the autoradiograph. 
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Figure 6.8 Binding of c-Fos, FosB and Fra-1 but not Fra-2 or ATF-2 
to the Mdm2 AP-1 probe is detected using nuclear protein extracts 
from cardiac myocytes exposed to 0.2 mM 11202 
Cardiac myocytes were exposed to 0.2 inM H202 (1.5 h) and binding to the 
radiolabelled Mdm2 AP-1 probe was monitored in the absence or presence of 
antibody (Ab) to c-Fos, FosB, Fra-1, Fra-2, ATF-2 or an irrelevant protein (phospho- 
Elk-1). 	The autoradiograph shown is representative of three independent 
experiments. Unbound probe can be seen at the bottom of the autoradiograph. 
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Figure 6.9 Antibodies to c-Jun, JunB, JunD, c-Fos, FosB and Fra-1 
together supershift all of the proteins that bind the Mdm2 AP-1 probe 
following exposure of cardiac myocytes to 0.2 mM 11202 
Cardiac myocytes were exposed to 0.2 mM H202 (1.5 h) and binding to the 
radiolabelled Mdm2 AP-1 probe was monitored in the absence or presence of 
antibodies (Ab) to c-Jun, JunB, JunD, c-Fos, FosB and Fra-1. The autoradiograph 
shown is representative of three independent experiments. Unbound probe can be 
seen at the bottom of the autoradiograph. 
219 
6.3.5 Binding of Jun family proteins to the Mdm2 AP-1 site in vivo 
changes in response to H202 
To examine binding of the Jun family proteins to the endogenous Mdm2 AP-1 site, 
ChJP (chromatin immunoprecipitation) assays were performed. Using antibody to c-
Jun, JunB or JunD, DNA was immunoprecipitated from cardiac myocytes which were 
unstimulated or exposed to 0.2 mM H202 (2 h). Mdm2 P2 promoter DNA was 
detected by PCR using primers specific to sequences either side of the Mdm2 AP-1 
site. c-Jun antibody immunoprecipitated the Mdm2 P2 promoter from cardiac 
myocytes exposed to 0.2 mM H202 but not unstimulated cardiac myocytes (Figure 
6.10). JunB and JunD antibody each immunoprecipitated the Mdm2 P2 promoter 
from unstimulated cardiac myocytes but not cardiac myocytes exposed to 0.2 mM 
H202 (Figure 6.10). These results indicate that the endogenous Mdm2 AP-1 site is 
bound by JunB and JunD under basal conditions and is bound by c-Jun following 
exposure of cardiac myocytes to 0.2 mM H202 (2 h). 
To confirm the specificity of the ChM assays, immunoprecipitated DNA samples 
were subjected to PCR using primers specific to GAPDH or to an arbitrary sequence 
4000 bp 3' to the Mdm2 gene. Unexpectedly, product was obtained using both of 
these primer sets and in the same pattern as that seen with the Mdm2 P2 promoter 
specific primers (Figure 6.11). This result suggests that the CEP assays may not 
have been gene specific. 
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Immunoprecipitated DNA 
Input DNA 
Figure 6.10 ChIP of the Mdm2 P2 promoter with antibody to c-Jun, 
JunB or JunD 
Cardiac myocytes were unstimulated (unstim.) or exposed to 0.2 mM H202 (2 h). 
DNA was immunoprecipitated by ChIP assay using antibody (Ab) to c-Jun, JunB or 
JunD. Mdm2 P2 promoter DNA was detected by PCR (representative image, top 
panel). DNA from samples prior to immunoprecipitation (input DNA) was used as a 
positive control (representative image, middle panel). The densitometric analysis is 
shown with values normalised to the input DNA (lower panel). Results are means 
SEM for three independent experiments (*p<0.05, two-tailed paired Student's t-test 
between unstimulated and H202 stimulated levels of Mdm2 DNA immunoprecipitated 
by each antibody). 
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Figure 6.11 Determination of the ChIP assay specificity through 
PCR of control sequences - GAPDH and an arbitrary sequence 3' to 
the Mdm2 gene 
Cardiac myocytes were unstimulated (unstim.) or exposed to 0.2 mM H202 (2 h). 
DNA was immunoprecipitated by ChIP assay using antibody (Ab) to c-Jun, JunB or 
JunD. PCR was performed to detect GAPDH DNA or an arbitrary DNA sequence 
4000 bp 3' to the Mdm2 gene. DNA from samples prior to immunoprecipitation 
(input DNA) was used as a positive control. Representative images of three 
independent experiments are shown. 
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6.3.6 Sequencing of a novel c-Jun binding sequence (CJBS) 
ChIP assays were performed to identify novel genomic loci bound by c-Jun. Cardiac 
myocytes were exposed to 0.2 mM H202 (2 h) and DNA immunoprecipitated by the 
c-Jun antibody. The immunoprecipitated DNA was cloned by Dr. TJ Kemp using the 
Invitrogen TA cloning kit. Cloned DNA was sequenced by the Advanced 
Biotechnology Centre, Imperial College London. One DNA fragment was 
successfully cloned and sequenced; this c-Jun binding sequence (CJBS) contains a 
consensus AP-1 binding site 5' to a TATA box (Figure 6.12). RT-PCR was 
performed to determine whether the TATA box was a transcription start site. RNA 
was treated with a DNase to remove any contaminating genomic DNA. RT-PCR was 
then performed using a reverse primer annealing 3' to the TATA box and two 
different forward primers, one annealing 5' and one annealing 3' to the TATA box 
(Figure 6.13 A). An RT-PCR product was obtained using the forward primer 
annealing 3' to the TATA box but not the forward primer annealing 5' to the TATA 
box (Figure 6.13 B). The functionality of both primer sets was confirmed by PCR of 
genomic DNA (Figure 6.13 B). This result shows that the identified CJBS TATA box 
is a transcription start site. Using the primer set annealing 3' to the TATA box, 
expression of CJBS mRNA was examined in cardiac myocytes exposed to 0.2 mM 
H202 (0-8 h) and found not to change (Figure 6.14). 
The Est databases (NCBI) were searched for the expressed section of CJBS (3' to the 
TATA box). The expressed sequence was not present in any of the NCBI Est 
databases indicating that it may not have been previously detected. Using the NCBI 
Blast engine, CJBS was found to lie on rat chromosome 15. The first 20,000 bp of 
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genomic sequence 31 to the CJBS TATA box (Appendix C) were searched for ORFs 
using the NCBI ORF finder. The longest ORF identified is 324 bp in length (Figure 
6.15 A) and is 18,530 bp 3' to the CJBS TATA box (Appendix C). The peptide 
sequence encoded by this ORF (Figure 6.15 B) was analysed using the ExPASy 
prosite tool and found not to contain any known motifs. The human and murine 
genomes were searched for conservation of CJBS using the NCBI Blast engine. No 
significantly similarity was detected in the human genome but CJBS is conserved in 
the murine genome. There is sequence conservation (>80%) in the murine genome 
up to 9631 bp 5' to the CJBS TATA box and up to 1098 bp 3' to the CJBS TATA box 
(Appendix D). 
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5' AGTCTGTTGTCAAGATAAAGCTAATGCACCTTAGCAATTTGTTAAAA 
TTGGTCCTTTGTCTTAGGGTTTCTGCTGCAGGAACAAACCACCATGACC 
AAAAAAAGCAAATTGGGGAGGA A A GGGTTTGTTCAACTTTTAC A CTGT 
TCATCACCAAAGGAAGTCAGGACAGGAATTCAACAGTACAGGATCCTG 
GAGGCAGGAGCTGATGCAGGAGCCATGGAGGAGTTCTGCTTACTGGTT 
TGTTTCCCATG GCTTACTTGAATGTGCGCTCTCGCGCTCTCTCTCACACT 
CACTCACACACACGTTTTAAAAACTTCTTATTTGTTAATTTCACATCATA 
CACTCGAATTCCACTCATCTCCAGTCCCTTCATACCAGCCTCTGTCCCTT 
GCAATATCCCCCTCTTAAAGAAAAAAATGTGGAAGTTTGTAGTGTGTGA 
CAGTGTGTCCCACAGTTATTTGCCTTGTGTTCACACTTTACTTGCAAATG 
AP-1 site 
TTCATTGCTATGAGTCATTG GTCTGATTTGAGGCCTCTGTCTTCTGCTAN 
NTC 	CTGGGTCCTCAATAGGACTCCTCACAGATANCCCTGTT 
GTTGTCCTGTGTCATGGAGATCCTTCAGCTTTGGATCTGCAGGACCAGC 
CCTTCACATCCTCCAGTTCACTGATTGGGTAGAAACCTTGGATCTGGGC 
TGGTTGAACTGGTGAGCCTGTTAACTCTCCTGTACCTACACCATCAGGG 
AAAACCCTCTAGTCCTGTCCCGGGTAGCTA 3' 
Figure 6.12 Cloning of a novel c-Jun binding sequence (CJBS) 
Cardiac myocytes were exposed to 0.2 mM H202 (2 h) and then DNA bound to c-Jun 
was immunoprecipitated by ChIP assay. Immunoprecipitated DNA was cloned and 
the sequence obtained is shown. This c-Jun binding sequence (GIBS) contains a 
consensus AP-1 binding site and a 3' 11.1 box, as highlighted. 
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A) Positioning of PCR primers relative to the CJBS TATA box 
AP-1 site 	 Forward primer 5' to TATA 
5' TGAGTCATTGGTcTGATTTGAGGCCTCTGTCTTCTGcTANNTc 
Forward primer 3' to TATA 
CTGGGTCCTCAATAGGACTCCTCACAGATANCCCTGTTGTTGTCCTGTGTCATGGAG 
ATCCTTCAGCTTTGGATCTGCAGGACCAGCCCTTCACATCCTCCAGTTCACTGATTGGGTA 
Reverse primer 
GAAACCTTGGATCTGGGCTGGTTGAACTGGTGAGCCTGTTAACTCTCCTGTACCTACA 
CCATCAGGGAAAACCCTCTAGTCCTGTCCCGGGTAGCTA 3' 
B) Transcription occurs 3' but not 5' to the CJBS TATA box 
Forward primer 3' to TATA Forward primer 5' to TATA 
(146 bp) 	 (216 bp) 
I 
cDNA Genomic Blank cDNA Genomic Blank 
DNA 	 DNA 
310, 271 
234, 194 
118 
Figure 6.13 The c-Jun binding sequence (CJBS) contains a 
transcription start site 
RT-PCR was performed to assess whether the CIBS TATA box is a transcription start 
site. cDNA was synthesised from RNA treated with a DNase to remove any 
contaminating genomic DNA. One reverse primer was used, annealing 3' to the 
TATA box (A). Two forward primers were used, one annealing 5' and one annealing 
3' to the TATA box (A). Genornic DNA was used as a positive control. The PCR 
image shown is representative of three independent experiments (B). 
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Figure 6.14 CJBS mRNA expression is unaltered in cardiac 
myocytes exposed to 0.2 mM 11202  
Cardiac myocytes were exposed to 0.2 mM H202 (0-8 h). CUBS mRNA levels were 
assessed by RT-PCR and normalised to GAPDH. Representative images (upper 
panels) and the densitometric analysis (lower panels) are shown. Results are means ± 
SEM for three independent experiments. 
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A) ORF nucleotide sequence 
5' ATGTTAAAAACGATGAATAAAATGATAAATAGGTGTTTGTGCTACACA 
GTTTTATTTCTTTTTCCCCCCACAGTTAATTTTTTTACATTACATCACACTC 
CTGCCCCTGCAGATCTCTCCCCTTCCCCTGCTCTAACTCATACCCTGCTC TT 
CAGCGAAGGGGAAGCCCTTGCCCCCACCTGGGTGCCCCTCCACCCTGGGG 
GTCAGTCTCAGCAGGACTATGCGTCTTGTCTTCCACTGAGGCCCAGCCAG 
GAAGTCCAGGTAGGAGAAGGGGATGCAGTGGCAGGCCACAGAGTCAAAG 
ACAGTCCCCGCTTCAATTGTTAG 3' 
B) Peptide sequence encoded by ORF 
MetLKTMetNKMetINRCLCYTVLFLFPPTVNFFTLHHTP A 
PADLSPSPALTHTLLFSEGEALAPTWVPLHPGGQSQQD 
YASCLPLRPSQEVQVGEGDAVAGHRVKDSPRFNC Stop 
Figure 6.15 The longest ORF present within 20,000 bp 3' to the 
CJBS TATA box is 324 bp in length 
The first 20,000 bp of genomic sequence 3' to the CJBS TATA box was searched for 
ORFs using the NCBI ORF finder. The longest ORF (324 bp) identified (A) and the 
peptide sequence encoded (B) are shown. 
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6.4 Discussion 
6.4.1 Changes in expression of the AP-1 TFs in response to 11202 
In cardiac myocytes exposed to 0.2 mM H202, c-Jun and JunB mRNA were 
upregulated, while JunD mRNA showed constitutive expression (Figures 6.1.1 and 
6.1.2). A similar response is seen in non-myocyte cell lines following serum or 
growth factor (PDGF or FGF) stimulation (Hirai et al. 1989; Ryder et al. 1989). 
Immunoblotting demonstrated that the changes observed at the mRNA level were 
reflected at the protein level. The levels of both c-Jun and JunB protein were 
increased, while protein levels of both JunD isoforms (35 and 40 kDa) were 
constitutive (Figures 6.3.1 and 6.3.2). Upregulation of c-Jun mRNA and protein in 
cardiac myocytes exposed to H202 has been previously demonstrated (Peng et al. 
1995). c-Fos mRNA and protein were increased in cardiac myocytes exposed to 0.2 
mM H202 (Figures 6.2.1, 6.2.2, 6.3.1 and 6.3.2), which is consistent with previous 
studies (Peng et al. 1995; Coronella-Wood et al. 2004). Fra-1 mRNA upregulation 
was also detected and this is consistent with the results of microarray studies (Kemp 
et al. 2003). Increases in FosB and Fra-2 mRNA expression also occurred, although 
induction of Fra-2 mRNA was comparatively weak and did not show statistical 
significance (Figures 6.2.1 and 6.2.2). 
c-Fos protein was detected as multiple bands of similar mobility at all time points 
examined (Figure 6.3.1). This is consistent with previous studies of cardiac myocytes 
exposed to H202 (0.1 mM), where treatment of immunoprecipitated c-Fos with a 
phosphatase (PP2A) showed that the higher mobility bands were produced by 
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phosphorylations (Coronella-Wood et al. 2004). Immunoblotting detected multiple 
bands of similar mobility for c-Jun at the 1 h time point and for JunB at all time points 
examined (Figure 6.3.1). Previous studies indicate that the higher mobility bands are 
also likely to result from phosphorylations that reduce the electrophoretic mobility of 
c-Jun (Franklin et al. 1992) and JunB (Bakiri et al. 2000). 
6.4.2 Binding to the Mdm2 AP-1 sequence in vitro 
In response to 0.2 mM H202, there was increased binding to an EMSA probe 
corresponding to the AP-1 site in the P2 promoter of the Mdm2 gene (Figure 6.4). 
Previous studies have also demonstrated increased AP-1 activity in cardiac myocytes 
exposed to H202 (Peng et al. 1995; Frantz et al. 2001; Tu et al. 2003). EMSA 
supershift assays demonstrated that exposure of cardiac myocytes to 0.2 mM H202 
(1.5 h) induced a change in the composition of active/DNA-binding Jun proteins, 
from JunB and JunD to JunB, JunD and c-Jun (Figures 6.6 and 6.7). The activation of 
c-Jun detected by EMSA is consistent with the increases detected in c-Jun mRNA and 
protein (Figures 6.1.1, 6.1.2, 6.3.1 and 6.3.2). Compared with JunB and JunD, c-Jun 
is a more potent activator of transcription from promoters containing a single 
consensus AP-1 site (Hirai et al. 1989; Ryseck and Bravo 1991; Deng and Karin 
1993). Therefore a change in the composition of the Jun proteins to include c-Jun will 
have a significant impact on the expression of genes regulated by AP-1. 
EMSA supershift assays showed that cardiac myocytes exposed to 0.2 mM H202 (1.5 
h) also possessed active/DNA-binding c-Fos, FosB and Fra-1 (Figure 6.8). Fra-2 was 
not detected by EMSA supershift assay (Figure 6.8), however the efficacy of the 
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antibody was not confirmed by positive control. Antibodies to c-Jun, JunB, JunD, 
FosB and Fra-1 were together sufficient to cause supershifting of the entire AP-1 
EMSA complex (Figure 6.9). Other proteins may have been present in the AP-1 
complex and these caused to supershift by virtue of their association with the proteins 
targeted by the supershifting antibodies. Binding of ATF-2 to the Mdm2 AP-1 probe 
was not detected (Figure 6.8) but this is an expected result as, although ATF-2 can 
heterodimerize with Jun proteins, its consensus binding sequence differs from that of 
AP-1 (Hai and Curran 1991). 
6.4.3 Binding to the endogenous Mdm2 AP-1 site 
EMSAs employ a large excess of oligonucleotide probe which will allow unrestricted 
binding of all the active TFs recognising the contained DNA sequence. This explains 
why six different Jim/Fos proteins were demonstrated to bind the Mdm2 AP-1 EMSA 
probe, while only a single AP-1 dimer would be expected to bind to an endogenous 
AP-1 site. ChIP assays were performed to assess binding to the endogenous Mdm2 
AP-1 site and these indicated that the site is bound by a JunB/JunD heterodimer under 
basal conditions and by a c-Jun containing dimer following exposure of cardiac 
myocytes to 0.2 mM H202 (Figure 6.10). This is consistent with the finding that 
untreated cardiac myocytes possessed active JunB and JunD but not c-Jun, which was 
only activated in response to 0.2 mM H202 (EMSA supershift assays, Figures 6.6 and 
6.7). 
The EMSA and ChIP assay results therefore indicate a mechanism whereby under 
basal conditions a JunB/JunD heterodimer occupies the Mdm2 AP-1 site and represses 
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expression. Then, following exposure of cardiac myocytes to 0.2 mM H202, c-Jun is 
activated and binds (either as a homodimer or as a heterodimer with an unidentified 
Fos protein) to the Mdm2 AP-1 site, displaces JunB/JunD and activates transcription. 
This is consistent with the finding that overexpression of c-Jun in a fibroblast cell line 
is sufficient to activate transcription from the Mdm2 P2 promoter (Ries et al. 2000). 
The Mdm2 AP-1 site is single and consensus [TGACTCA (Chapter 5, Figure 5.1)]. c-
Jun has a higher DNA-binding affinity than JunB or JunD for a single consensus AP-1 
site (Ryseck and Bravo 1991; Deng and Karin 1993) and this should allow c-Jun to 
displace a JunB/JunD heterodimer from the Mdm2 AP-1 site. c-Jun is a more potent 
activator of transcription than either JunB or JunD at promoters containing a single 
consensus AP-1 site (Hirai et al. 1989; Ryseck and Bravo 1991; Deng and Karin 
1993). Therefore, exchange of a JunB/JunD heterodimer with c-Jun would be 
expected to increase transcription from the Mdm2 P2 promoter. 	Indeed, 
overexpression of JunB inhibits activation of transcription by overexpressed c-Jun 
from promoters containing a single consensus AP-1 binding site (Chiu et al. 1989; 
Deng and Karin 1993; Bakiri et al. 2000). 
Neonatal cardiac myocytes have withdrawn from the cell cycle but in other cell types 
Mdm2 positively regulates cell cycle progression (Fakharzadeh et al. 1991; Oliner et 
al. 1992). Antagonistic regulation of transcription by c-Jun and JunB has been 
previously described for genes the products of which regulate cell cycle progression. 
Cyclin DI positively regulates cell cycle progression and its promoter contains a 
single consensus AP-1 site and a single consensus CRE sequence. In a manner 
dependent on both these sites, overexpression of c-Jun activates transcription of cyclin 
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DI and overexpression of JunB represses basal and c-Jun induced cyclin DI 
expression (Bakiri et al. 2000). An inverse response occurs at the promoter of 
p I 6INK 4A , which is a negative regulator of cell cycle progression. JunB activates 
transcription of p16INK4A , whereas c-Jun represses basal and JunB induced p1eNK4A  
expression (Passegue and Wagner 2000). The p1eK4A promoter contains five non-
consensus AP-1 sites, including TGACTGA, TGACTTCA, and TGACACA 
which are demonstrated to be required for activation by JunB (Passegue and Wagner 
2000). The described control of Mdm2 transcription by c-Jun and JunB is therefore 
consistent with the function of Mdm2 in cell cycle progression. Mdm2 promotes cell 
cycle progression by inhibiting the p53 TF which is a key inducer of cell cycle arrest 
(Momand et al. 1992; Chen et al. 1996; Honda et al. 1997). The p53 promoter 
contains a single non-consensus AP-1 site (TGACTCT) and c-Jun can bind to this site 
causing repression of p53 transcription (Schreiber et al. 1999). Therefore c-Jun may 
promote cell cycle progression by both activating expression of the p53-inhibitor 
Mdm2 and by directly repressing expression of p53 mRNA. 
To test the specificity of the ChIP assay, PCR was performed using the 
immunoprecipitated DNA and primers annealing to control sequences not expected to 
be AP-1 responsive (GAPDH and an arbitrary sequence 4000 bp 3' to the Mdm2 
gene). Unexpectedly, this PCR produced the same pattern as that given using the 
Mdm2 specific primers (Figure 6.11). This indicates that either the ChIP assay was 
not gene specific or that the same pattern of Jun binding occurred at these sites. The 
AP-1 binding sequence is only 7 bp in length and occurs throughout the genome. 
Indeed, there are AP-1 binding sites within 455 bp of the GAPDH sequence and 
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within 546 bp of the arbitrary sequence 3' to the Mdm2 gene. Therefore binding of 
AP-1 in the regions of the control sequences is a possibility. 
Several studies have examined chromosome wide TF binding by combining ChIP and 
microarray technology. These demonstrate that TF binding is not restricted to genes 
showing altered expression in response to the TF activating stimulus [Martone et al. 
2003 (NF-KB); Hartman et al. 2005 (STAT1 and STAT2)]. This indicates that TFs do 
bind to genes that are not responsive to them at least under the conditions tested. In 
support of this conclusion, ChIP assays performed using a p53 antibody 
immunoprecipitated DNA from the promoters of p53 responsive genes but also from 
the GAPDH coding sequence (Kaeser and Iggo 2002). 
In several studies examining DNA binding of Jun proteins by ChIP assay, results were 
not validated by performing PCR to control sequences not expected to be responsive 
to AP-1 [e.g. Katabami et al. 2005 (c-Jun); Tsuji 2005 (JunD); Zhang et al. 2006 (c-
Jun)]. However, other studies of Jun protein binding by ChIP assay have 
demonstrated that of the limited number of genes tested, Jun binding is restricted to 
those genes that are responsive to AP-1 [e.g. Nateri et al. 2005 (performed ChIP for c-
Jun using c-Myc as a control sequence); Wang and Jaiswal 2006 (performed ChIP for 
JunD using GAPDH as a control sequence)]. Furthermore, ChIP assays for the Jun 
proteins have demonstrated specific binding to promoter regions and not 3' or 5' 
sequences [e.g. Petz et al. 2004 (c-Jun); Ghosh et al. 2005 (c-Jun); Sreeramaneni et al. 
2005 (JunB and JunD)]. This indicates that Jun protein binding is restricted to sites 
where there is a functional role. It would therefore seem unlikely that the indicated 
binding of c-Jun, JunB and JunD to the control sequences is genuine. This brings into 
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question the validity of the ChIP assay results pertaining to binding of the Jun proteins 
to the Mdm2 AP-1 site. 
It is possible that the identification of Jun protein binding to the control sequences by 
ChIP assay was caused by methodological problems. Sonication was initially 
optimised to produce DNA fragments of 200-800 bp (Chapter 2, Figure 2.2). The 
degree of DNA fragmentation was however not examined with the performance of 
each ChIP assay. The size of the DNA fragments may have varied due to factors 
including the concentration of DNA in the sample, the depth of the sonicator within 
the extraction buffer and the development of foaming in the extraction buffer. The 
occurrence of DNA fragments that were longer than expected may have placed the 
control sequences on the same fragments as genes showing the indicated regulation by 
the Jun proteins. Thus, the detection of the control sequences by ChIP assay may 
have been due to their co-immunoprecipitation with genes that genuinely bind to the 
Jun proteins. The protein specificity of the immunoprecipitations can also be 
questioned as the antibodies used were not tested in this respect. Thus, the detection 
of the control DNA sequences by ChIP assay may have been due to their association 
with proteins other than c-Jun, JunB and JunD. 
The potential experimental errors identified above mean that the ChIP assay results 
cannot be accepted as conclusive at this point. To be accepted the experiments should 
be repeated ensuring that these errors do not apply. Other techniques that examine in 
vivo DNA binding by TFs [e.g. protein position identification with nuclease tail (PIN* 
POINT) (Lee et al. 1998)] may allow the ChIP assay results to be confirmed or 
disproved. The regulation of expression from the Mdm2 P2 promoter by AP-1 as 
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indicated by the ChIP assays should be confirmed by overexpression and selective 
inhibition of c-Jun, JunB and JunD. 
6.4.4 Identification of a novel c-Jun binding sequence 
To identify novel genomic loci bound by c-Jun, ChIP assays were performed using 
the c-Jun antibody and extracts from cardiac myocytes exposed to 0.2 mM H202 (2 h). 
The immunoprecipitated DNA was cloned. A single sequence was produced and 
termed the c-Jun binding sequence (CJBS). CJBS possessed the characteristics of an 
AP-1 responsive promoter, a consensus AP-1 binding sequence 5' to a TATA box 
(Figure 6.12) demonstrated to be a transcription start site (Figure 6.13). Expression of 
CJBS mRNA was assessed by semi-quantitative RT-PCR and did not change 
following exposure of cardiac myocytes to 0.2 mM H202 over 8 h (Figure 6.14). This 
is an unexpected result given the upregulation of c-Jun activity (Figures 6.6 and 6.7). 
It is possible that CJBS expression is upregulated but to a low degree that may only be 
detectable by more accurate techniques such as Real-Time PCR. Alternatively, it may 
be that c-Jun binds to this site but does not activate transcription, possibly due to a 
requirement for additional factors activated under different conditions. Indeed, as 
described above, TF binding alone is not sufficient to activate transcription from all 
sites (Martone et al. 2003; Hartman et al. 2005). CJBS is conserved in the murine 
genome but not the human genome (appendix D), which may indicate that the 
sequence is not of high functional importance. 
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6.4.5 Summary 
In response to exposure of cardiac myocytes to 0.2 mM H202, there is an increase in 
the mRNA levels of c-Jun, JunB, c-Fos, FosB, Fra-1 and possibly Fra-2. It is 
confirmed that the increases in c-Jun, JunB and c-Fos mRNA translate into increases 
at the protein level. JunD mRNA and protein levels are constitutive in cardiac 
myocytes exposed to 0.2 mM H202. H202 (0.2 mM) induces an increase in AP-1 
activity. EMSA supershift assays showed that unstimulated cardiac myocytes possess 
active JunB and JunD and that cardiac myocytes exposed to 0.2 mM H202 possess 
active JunB, JunD and c-Jun. Examination of binding to the endogenous Mdm2 AP-1 
site by ChIP assay suggests that under basal conditions it is bound by JunB and JunD 
and following exposure of cardiac myocytes to 0.2 mM H202 it is bound by c-Jun. 
This suggests that expression from the Mdm2 P2 promoter is repressed under basal 
conditions by a JunB/JunD heterodimer. Then in response to H202, c-Jun is activated 
and binds to the Mdm2 AP-1 site to displace JunB/JunD and activate transcription. 
However, the gene specificity of the ChIP assay could not be confirmed. 
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Chapter seven  
General discussion 
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Ets(A) 5' — MZF1 
7.1 Summary of results 
1. H202 increased the expression of total Mdm2 mRNA and protein in neonatal rat 
cardiac myocytes. There was also an increase in the level of Mdm2 phosphorylated at 
Serl 66, a modification associated with increased Mdm2 protein stability. Mdm2 is 
regulated positively and negatively by Mdmx and p19 1, respectively. Mdmx and 
p/9-4rf mRNA and protein were expressed in unstimulated cardiac myocytes but their 
abundance did not alter in response to H202. 
2. Mdm2 mRNA is expressed as two isoforms, L-Mdm2 and S-Mdm2 which are 
transcribed from the P1 and P2 promoters, respectively. RT-PCR was used to assess 
changes in the expression of L-Mdm2 mRNA and total S- and L- Mdm2 mRNA. 
Upregulation of total Mdm2 mRNA in response to H202 was determined to result 
from an increase in expression of S-Mdm2 mRNA from the P2 promoter. 
3. The P2 promoter contains binding sites for several TFs: a MZF1 site, an Ets site 
[Ets(A)], an Ets [Ets(B)]/AP-1 composite site and two p53 sites (Figure 7.1). 
AP-1/Ets(B) p53 	p53 
Figure 7.1 The TF binding sites of the rat Mdm2 P2 promoter 
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In cardiac myocytes exposed to H202, p53 was not detected by either immunoblotting 
or EMSA. This is indicative of the increased expression from the Mdm2 P2 promoter 
not being mediated by p53. Binding to the MZF 1, Ets(A) and Ets(B) sites was 
examined by EMSA. No specific binding was detected to an EMSA probe containing 
the sequence of the Mdm2 MZF1 site. Only low specificity binding that did not 
change in response to H2O2 was detected to an EMSA probe containing the sequence 
of the Mdm2 Ets(B) site. Specific binding was detected to an EMSA probe containing 
the sequence of the Mdm2 Ets(A) site and the levels of this binding increased in 
response to H202 . However, binding to the Mdm2 Ets(A) EMSA probe declined to 
basal levels prior to the upregulation in Mdm2 mRNA, suggesting that binding to the 
Ets(A) site did not directly activate Mdm2 mRNA transcription. 
4. Exposure of cardiac myocytes to H2O2 increased specific binding to an EMSA 
probe containing the sequence of the Mdm2 AP-1 site. AP-1 activity was increased 
between 1-2 h and this time coincides with the upregulation of Mdm2 mRNA 
expression, possibly indicative of a causal relationship. The identity of the proteins 
binding the AP-1 EMSA probe was examined by supershift assay. Unstimulated 
cardiac myocytes contained active JunB and JunD which could bind the Mdm2 AP-1 
sequence. No active c-Jun capable of binding the Mdm2 AP-1 sequence was present 
in unstimulated cardiac myocytes. Cardiac myocytes exposed to H202 possessed 
active JunB, JunD and c-Jun which could bind the Mdm2 AP-1 sequence. Active c-
Fos, FosB and Fra-1 that could bind the Mdm2 AP-1 sequence were also present in 
cardiac myocytes exposed to H202. Exposure of cardiac myocytes to H202 increased 
expression of c-Jun, JunB, c-Fos, FosB and Fra-1 mRNA. Expression of Fra-2 
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mRNA was also increased but the induction was comparatively weak and did not 
show statistical significance. Expression of JunD mRNA was constitutive. c-Jun, 
JunB and c-Fos proteins were confirmed to be upregulated, while JunD protein 
expression was constitutive. 
5. ChIP assays indicated that the endogenous Mdm2 AP-1 site was bound by JunB 
and JunD in unstimulated cardiac myocytes and by c-Jun in cardiac myocytes exposed 
to H202. This indicated that a JunB/JunD heterodimer repressed Mdm2 transcription 
under basal conditions. Then, in response to H202, c-Jun was activated and bound (as 
a homodimer or a heterodimer with an unidentified Fos protein) to the Mdm2 AP-1 
site to displace JunB/JunD and activate transcription. This is consistent with the 
activity of c-Jun, JunB and JunD in unstimulated cardiac myocytes and in cardiac 
myocytes exposed to H202, as demonstrated by EMSA supershift assays. However, 
the gene specificity of the ChIP assays could not be confirmed. 
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7.2 p53 was not detected in cardiac myocytes exposed to 112.(h 
In cardiac myocytes exposed to H202, p53 was not detected by either EMSA or 
immunoblotting (Figures 5.4-5.6). Binding of pl9Arf to Mdm2 inhibits Mdm2-
mediated downregulation of p53 (Pomerantz et al. 1998). Although p19Arf is not 
essential for upregulation of p53 in response to DNA-damaging stress, an increase in 
p19Arf protein may allow for a more sustained upregulation of p53 protein (Khan et al. 
2000). Thus, the finding that p19Ai f mRNA and protein levels were unaltered in 
cardiac myocytes exposed to 11202 (Figures 3.5 and 3.6) is consistent with the absence 
of detectable levels of p53 protein (Figures 5.4-5.6). Mdmx binds directly to p53 and 
inhibits its TF activity (Shvarts et al. 1996; Rallapalli et al. 1999). Mdmx also 
directly binds Mdm2 which increases the stability of Mdm2 protein thus augmenting 
Mdm2-mediated downregulation of p53 (Sharp et al. 1999; Tanimura et al. 1999; Gu 
et al. 2002b). DNA-damaging stress increases Mdm2-mediated degradation of Mdmx 
leading to upregulation of p53 (Kawai et al. 2003b). Therefore, the finding that 
Mdmx protein levels were unaltered in cardiac myocytes exposed to H202 (Figure 
3.11) is also consistent with the absence of detectable levels of p53 protein (Figures 
5.4-5.6). The failure to detect p53 in cardiac myocytes exposed to H202 suggests that 
the changes in gene expression that occur under these conditions (Kemp et al. 2003) 
are not mediated by p53. This includes increased expression of p2/ c/11 ali mRNA 
and Mdm2 mRNA, which is classically activated by p53 (Barak et al. 1993; el-Deiry 
et al. 1993). 
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7.3 The probable function/s of Mdm2 in cardiac myocytes exposed to 
H2O2  
The essential function of Mdm2 is the negative regulation of p53 (Jones et al. 1995; 
Montes de Oca Luna et al. 1995). Mdm2 inhibits the TF activity of p53 and targets 
p53 for degradation by the proteasome through catalysing its ubiquitinylation (Oliner 
et al. 1993; Leng et al. 1995; Kubbutat et al. 1997; Haupt et al. 1997; Honda et al. 
1997; Fuchs et al. 1998b). p53 is a key inducer of apoptosis and its downregulation 
by Mdm2 is thus cytoprotective (Chen et al. 1996; Conforti et al. 2000). p53 protein 
was not detected in cardiac myocytes exposed to H202 (Figure 5.6). It is possible that 
the upregulated Mdm2 acts to keep p53 protein abundance at an undetectable level. 
Alternatively, the failure to detect p53 protein may indicate that Mdm2 regulates an 
alternative substrate in cardiac myocytes exposed to I-1202. Mdm2 regulates a 
growing list of substrates, more than half of which directly or indirectly control 
transcription (Tables 1.4. and 1.6). Furthermore, Mdm2 can be recruited to specific 
gene promoters where it can repress transcription in association with a local increase 
in ubiquitinylation (Thut et al. 1997; Minsky and Oren 2004). Thus, Mdm2 may have 
a role in regulating the increases and decreases in the expression of specific genes that 
occur following exposure of cardiac myocytes to H202 (Kemp et al. 2003). 
Maximal expression of Mdm2 protein occurred within 2 h of exposing cardiac 
myocytes to H202 (Figure 3.4 A). This time precedes DNA fragmentation (Cook et 
al. 1999) and it is therefore probable that the upregulation of Mdm2 is an attempt by 
the myocytes to reduce apoptosis. Indeed, overexpression of Mdm2 protects against 
apoptosis in cultured cardiac myocytes exposed to hypoxia alone or 
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hypoxia/reoxygenation (Toth et al. 2006). Significant apoptosis occurs in cardiac 
pathologies and this may contribute to their progression (Itoh et al. 1995; Narula et al. 
1996; Saraste et al. 1999; Wencker et al. 2003). Thus, through reducing apoptosis, 
Mdm2 would be expected to protect the heart from injurious effects. This is 
supported by the findings that isolated murine hearts expressing low Mdm2 protein 
levels suffer greater injury following ischaemia/reperfusion (Toth et al. 2006) and that 
a downregulation of Mdm2 mRNA occurs in the failing human heart (Steenbergen et 
al. 2003). 
7.4 AP-1 regulates Mdm2 transcription in cardiac myocytes exposed 
to 2.2  
Mdm2 is transcribed from the P1 and P2 promoters giving rise to the L-Mdm2 and S-
Mdm2 mRNA isoforms, respectively. Expression of L-Mdm2 mRNA and total S- and 
L-Mdm2 mRNA in cardiac myocytes was assessed by semi-quantitative RT-PCR. 
H202 induced an increase in expression of total L- and S-Mdm2 mRNA (Figure 4.4). 
Expression of L-Mdm2 mRNA was constitutive (Figure 4.4) and therefore the 
increase in total levels must be due to an increase in expression of S-Mdm2 mRNA 
from the P2 promoter. This finding is consistent with previous studies showing 
expression from P1 and P2 to be constitutive and inducible, respectively (Juven et al. 
1993; Perry et al. 1993; Barak et al. 1994; Saucedo et al. 1998; Mendrysa and Perry 
2000; Ries et al. 2000). 
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The rat P2 promoter contains six TF binding sites: an MZF1 site, a single Ets [Ets(A] 
site, an Ets [Ets(B)] site that forms a composite with an AP-1 site, and two p53 sites 
(Figure 7.1). EMSAs were performed to systematically assess the importance of these 
sites in the expression of Mdm2 in cardiac myocytes exposed to H202. EMSAs using 
a probe containing a consensus p53 binding sequence did not detect active p53 in 
cardiac myocytes exposed to H202 (Figures 5.4 and 5.5). Similarly, immunoblotting 
did not detect p53 protein in cardiac myocytes exposed to H202 (Figure 5.6). EMSAs 
using a probe containing the sequence of the Mdm2 MZF1 site detected only non-
specific binding that was unchanged in response to H202 (Figures 5.12 and 5.13). 
EMSAs using a probe containing the sequence of the Mdm2 Ets(B) site detected only 
binding of low-specificity that was unchanged in response to 11202 (Figures 5.10 and 
5.11). Specific binding was detected to an EMSA probe containing the sequence of 
the Mdm2 Ets(A) site and this increased in response to 11202 (Figures 5.7 and 5.8). 
However, the increased Ets activity declined to basal levels prior to the upregulation 
of Mdm2 mRNA (Figures 5.7 and 3.1). This indicates that binding to the Ets(A) site 
did not directly activate Mdm2 mRNA transcription. Following exposure of cardiac 
myocytes to H202, there was an increase in specific binding to an EMSA probe 
containing the sequence of the Mdm2 AP-1 site (Figures 6.4 and 6.5). The detected 
increase in AP-1 activity (Figure 6.4) was coincident with the upregulation of Mdm2 
mRNA (Figure 3.1). The results of EMSAs therefore suggest that the increase in 
Mdm2 expression from the P2 promoter is mediated by an increase in TF binding to 
the AP-1 site and not the p53, MZF1 or Ets sites. 
ChIP assays were performed to examine binding to the endogenous Mdm2 promoter 
in vivo. The ChIP assay results indicated that JunB and JunD bound the Mdm2 AP-1 
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site under control conditions and that c-Jun bound the AP-1 site following exposure of 
cardiac myocytes to H202 (Figure 6.10). This suggests that a JunB/JunD heterodimer 
represses Mdm2 expression under basal conditions. Then, following exposure of 
cardiac myocytes to H202, JunB/JunD are replaced by a c-Jun containing dimer which 
activates expression. The results of the ChIP assays are consistent with the results of 
EMSA supershift assays, which demonstrated that only JunB and JunD were activate 
in cardiac myocytes under basal conditions, while JunB, JunD and c-Jun were active 
in cardiac myocytes exposed to H202 (Figures 6.6 and 6.7). The gene specificity of 
the ChIP assays could however not be confirmed (Figure 6.11) as discussed in Section 
6.4.3. The regulation of Mdm2 expression by the Jun proteins as indicated by the 
ChIP assays can be tested by other techniques as described in Section 7.6.1. 
It is well established that p53 activates Mdm2 expression in proliferating cell lines 
exposed to DNA-damaging stress in the form of UV or ionising radiation (Perry et al. 
1993; Barak et al. 1994; Chen et al. 1994; Saucedo et al. 1998). 11202 is a DNA-
damaging stress in cardiac myocytes (Cook et al. 1999). Hence, the results presented 
here suggesting that increased Mdm2 expression is mediated by AP-1 and not p53 
provide further understanding of the mechanisms controlling Mdm2 mRNA 
abundance. Further insight into the mechanisms by which AP-1 proteins regulate 
transcription is provided by the ChIP assays. These indicate that one AP-1 dimer can 
be exchanged for another at an endogenous AP-1 site resulting in a change in 
transcription. Antagonistic control of transcription by c-Jun and JunB has been 
previously indicated by overexpression assays and targeted gene inactivation (Bakiri 
et al. 2000; Passegue and Wagner 2000). 
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The ChIP assays indicate that it is activation of c-Jun that causes upregulation of 
Mdm2 expression. Activation of c-Jun in cardiac myocytes exposed to H202 was 
mediated at least in part by increased c-Jun mRNA and protein expression (Figures 
6.1.1, 6.1.2, 6.3.1 and 6.3.2). In cardiac myocytes treated with ET-1, PKC activity 
and ERK1/2 activity are required for increased expression of c-Jun mRNA, while 
JNK activity is required for stabilisation of the c-Jun protein (Clerk et al. 2002). 
Activation of Mdm2 expression in response to H202 would be expected to show a 
similar dependency. The activation of Mdm2 expression was dependent upon PKC 
activity but was independent of ERK1/2 and JNK (Figure 4.7). The reason for 
ERK1/2 and JNK independence is unclear, it is possible that c-Jun is activated by 
distinct pathways in cardiac myocytes exposed to H202 or ET-1. 
7.5 The dimer composition and effects of AP-1 in cardiac mvocvtes 
exposed to Ha 
7.5.1 The composition of the AP-1 dimers active in cardiac myocytes exposed to 
11202 
AP-1 TFs are any one of 18 homo/heterodimers of the Jun and Fos families of 
proteins (c-Jun, JunB, JunD, c-Fos, FosB, Fra-1 and Fra-2). EMSA supershift assays 
showed that exposure of cardiac myocytes to H202 caused a change in the 
composition of active Jun proteins, from JunB and JunD to c-Jun, JunB and JunD 
(Figures 6.6 and 6.7). c-Jun is a more potent activator of transcription than JunB or 
JunD at promoters containing a single consensus AP-1 sequence (Hirai et al. 1989; 
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Ryseck and Bravo 1991; Deng and Karin 1993). In contrast, at the p16INK4A promoter 
which contains five non-consensus AP-1 binding sites, JunB can potently activate 
transcription, while c-Jun represses expression (Passegue and Wagner 2000). Thus 
the change in the composition of the active Jun proteins to include c-Jun will 
significantly impact on the expression of genes regulated by AP-1. 
Changes in the mRNA expression from each of the Fos genes were examined 
following exposure of cardiac myocytes to 11202 (Figures 6.2.1 and 6.2.2). An 
increase in expression occurred for each of the Fos genes but compared to c-Fos, 
FosB or Fra-1, the induction of Fra-2 was weak and did not show statistical 
significance. In agreement with these findings, EMSA supershift assays showed that 
cardiac myocytes exposed to 11202 possessed active c-Fos, FosB and Fra-1 protein but 
no active Fra-2 protein (Figure 6.8), although the efficacy of the Fra-2 antibody was 
not confirmed by positive control. Heterodimerization of a given Jun protein with 
different Fos proteins produces AP-1 dimers with distinct activities. For example, the 
human collagenase promoter contains a single consensus AP-1 site and expression of 
a reporter gene under its control is activated more potently by a c-Jun/c-Fos 
heterodimer than a c-Jun/Fra-1 or a c-Jun/Fra-2 heterodimer (Bakiri et al. 2002). In 
contrast, the c-Jun promoter contains two non-consensus CRE sites and expression 
from a reporter gene under its control is more potently activated by c-Jun/Fra-1 or c-
Jun/Fra-2 than c-Jun/c-Fos (Bakiri et al. 2002). The p/4ARF promoter contains three 
non-consensus AP-1 sites and its expression is also activated by c-Jun/Fra-1 
heterodimers. However, c-Jun/Fra-2 heterodimers do not activate expression from the 
p14ARF promoter (Ameyar-Zazoua et al. 2005). The higher levels of active c-Fos, 
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FosB and Fra-1 compared with Fra-2 in cardiac myocytes exposed to H202 will 
therefore influence the expression of genes regulated by AP-1. 
Differential induction of AP-1 proteins has been demonstrated in the intact heart. In 
human heart failure, JunD mRNA (Pollack et al. 1997) and protein (Hilfiker-Kleiner 
et al. 2005) levels are depressed, while c-Jun mRNA levels are unchanged (Pollack et 
al. 1997). In the murine heart subjected to ischaemia/reperfusion ex vivo, EMSAs 
demonstrate that there is increased JunB and FosB activity but no change in the 
activity of c-Jun, JunD or Fra-2 (Alfonso-Jaume et al. 2006). Consistent with this, in 
the porcine heart subjected to ischaemia/reperfusion in vivo, JunB mRNA expression 
is more potently upregulated than c-Jun mRNA expression (Brand et al. 1992). 
However, other studies indicate that c-Jun is activated following cardiac 
ischaemia/reperfusion (Mizukami et al. 1997; Sun et al. 2001b; Nelson et al. 2002; 
Zingarelli et al. 2004). The importance of AP-1 dimer composition in cardiac 
myocytes and the heart is yet to be clearly defined. 
7.5.2 The probable effects of AP-1 activation in cardiac myocytes exposed to 
11202 
EMSAs performed using a probe containing the sequence of the Mdm2 consensus AP-
1 site showed that there was an increase in AP-1 activity in cardiac myocytes exposed 
to H202 (Figure 6.4). The timing of the increased AP-1 activity (1-2 h) coincides with 
increases and decreases in the expression of a number of specific genes (Kemp et al. 
2003). AP-1 may be important in mediating these changes. Indeed, 14 of the 22 
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genes identified as being upregulated in cardiac myocytes exposed to H202 (2 h) have 
been previously demonstrated to be regulated by AP-1 (Table 7.1). 
The activation of AP-1 following exposure of cardiac myocytes to H202 (Figure 6.4) 
may have a role in controlling the induction of apoptosis. AP-1 is activated in cardiac 
myocytes exposed to a range of apoptotic stresses including doxorubicin (Nobori et 
al. 2002), hypoxia/reoxygenation (Rui and Kvietys 2005) and NO (Taimor et al. 
2001). Induction of apoptosis in cardiac myocytes exposed to NO is prevented by the 
quenching of AP-1 activity through pre-incubation of cells with decoy 
oligonucleotides containing an AP-1 binding sequence (Taimor et al. 2001). 
Therefore AP-1 signalling is essential for the induction of apoptosis in cardiac 
myocytes at least under some conditions. 
As discussed in Section 7.5.1 the effects of an AP-1 TF are dependent on its dimer 
composition. It is therefore possible that distinct AP-1 dimers have anti- or pro-
apoptotic functions in cardiac myocytes. This possibility is supported by studies in 
proliferating cells showing that c-Jun, JunB and JunD can have opposite effects on 
cell cycle progression under the same conditions (Pfarr et al. 1994; Szabowski et al. 
2000). The effects of AP-1 proteins are also changed by their dimerization with 
members of other bZIP families e.g. ATFs (Hai and Curran 1991) and by synergism 
between AP-1 and non-bZIP TFs e.g. SMADs (Zhang et al. 1998b; Liberati et al. 
1999; Wong et al. 1999). Interaction between AP-1 and SMAD proteins occurs in 
cardiac myocytes exposed to NO, and SMAD activity is essential for the induction of 
apoptosis under these conditions (Schneiders et al. 2005). That the cellular effects of 
an AP-1 protein will depend on a range of factors is exemplified by the findings that 
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c-Jun promotes apoptosis or hypertrophy in cardiac myocytes exposed to different 
stimuli. In response to phenylephrine, c-Jun promotes hypertrophy in cardiac 
myocytes (Omura et al. 2002). While, c-Jun promotes apoptosis in cardiac myocytes 
exposed to hypoxia and burn serum (extracted from the blood of rats given third-
degree burns) (Huang and Hu 2004). 
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Table 7.1 Genes with increased expression in cardiac myocytes 
exposed to H202 
Microarray studies (Kemp et al. 2003) identified increased expression of 22 genes in 
cardiac myocytes exposed to 0.2 mM H202 (2 h). A literature search identified those 
genes previously shown to be regulated by AP-1. 
Gene (accession number) Evidence for 
regulation by 
AP-1 
Reference 
Cu2'-/Zn2+-superoxide dismutase 
(M25157) 
No 
y-Glutamylcysteine synthetase 
(J05181) 
Yes Tomonari et al. 1997 
Sekhar et al. 1997 
Glutathione synthetase 	(L38615) Yes Yang et al. 2002 
Heme oxygenase 
(AI179610, J02722) 
Yes Alam et al. 1995 
Camhi et al. 1995 
Oguro et al. 1996 
Hsp70 	(AA818604, Z75029, 
AA848563 L16764, Z27118) 
No 
CD44 	(M61875) Yes Hofmann et al. 1993 
Fit-1S 	(U04319) Yes Braselmann et al. 1992 
Bergers et al. 1994 
mdr mRNA 	(M81855) Yes Scanlon et al. 1994 
Daschner et al. 1999 
Ledoux et al. 2003 
u-PAR I 	(X71898) Yes Lengyel et al. 1996 
Syndecan-1 	(S61865, X60651) Yes Jaakkola et al. 1997 
Tumour-associated glycoprotein E4 
(L12025) 
Yes Hirota et al. 2005 
Dynorphin 	(M32783) Yes Messersmith et al. 1994, 1996 
Follistatin 	(AA858520) No de Groot et al. 2000 
ATF-3/LRF-1 	(M63282) Yes Liang et al. 1996 
Fra-1 	(M19651) Yes Braselmann et al. 1992 
Bergers et al. 1995 
MKP3 	(X94185) No 
p21C.11)1/Wall 	(L41275, U24174) Yes Chung et al. 2002 
Tyrosine phosphatase-like protein 
(D38222) 
No 
Mdm2 
( AA108308, AA875509, rx02811) 
Yes Ries et al. 2000 
Clone 59 FSH-regulated protein 
(L26292) 
No 
Plasminogen activator inhibitor 2A 
(X64563) 
Yes Dear et al. 1997 
Unknown (AA900476) N/A 
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7.6 Future work 
7.6.1 Further examination of the regulation of Mdm2 expression by c-Jun, JunB 
and JunD 
The regulation of Mdm2 expression by c-Jun, JunB and JunD in cardiac myocytes as 
suggested by the ChIP assays (Figure 6.10) can be tested by their overexpression and 
inhibition. Overexpression of c-Jun would be expected to upregulate Mdm2 mRNA 
expression. However, if c-Jun activates Mdm2 expression as a heterodimer with a Fos 
protein, overexpression of that Fos protein may also be required. Inhibition of c-Jun 
using either siRNA or antisense oligonucleotides would be expected to inhibit 
upregulation of Mdm2 mRNA in response to H202. Inhibition of JunB and JunD 
would be expected to increase Mdm2 expression under basal conditions, although it is 
possible that JunB/JunD only repress activation in response to low levels of c-Jun 
activity. Overexpression of JunB/JunD would be expected to repress activation of 
Mdm2 transcription in response to H202. 
Overexpression of c-Jun, JunB or JunD has been previously employed to determine 
their individual functions (e.g. Pfarr et al. 1994; Bakiri et al. 2000). However, the 
results of such experiments must be interpreted with caution as the behaviour of 
overexpressed c-Jun, JunB and JunD may differ from that of the endogenous proteins. 
For example, although c-Jun and JunB differ in their promoter specificity and 
transcription activation activity (e.g. Chiu et al. 1989; Ryseck and Bravo 1991), 
overexpression of JunB largely compensates for targeted inactivation of the c-Jun 
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gene in mice and in cultured MEFs (Passegue et al. 2002). Thus, overexpressed JunB 
may behave more like endogenous c-Jun than endogenous Jun13. 
7.6.2 Identification of the Mdm2-substrate/s 
EMSAs and immunoblotting did not detect p53 in cardiac myocytes exposed to H202 
(Figures 5.4-5.6). This may indicate that Mdm2 has substrates other than p53 under 
these conditions or it may indicate that the upregulated Mdm2 maintains p53 protein 
below detectable quantities. The latter possibility could be tested by determining 
whether p53 protein is detectable in cardiac myocytes exposed to H202 concomitant 
with inhibition of the proteasome by a pharmacological agent e.g. MG-132. 
Alternative substrates regulated by Mdm2 have been previously identified by yeast 
two-hybrid screening (Juven-Gershon et al. 1998; Vlatkovic et al. 2000) and this 
technique could be applied here. 
7.6.3 Identification of the Ets TF activated by H202 
In cardiac myocytes exposed to H202, EMSAs suggested that there was increased 
activity of an Ets TF capable of binding the sequence of the Mdm2 Ets(A) site (Figure 
5.7). Twenty six different murine Ets TFs have been identified (reviewed in Hsu et al. 
2004). EMSA supershift assays indicated that the activated TF was not phospho-Elk-
1 or Fli-1 (Figure 5.9). The identity of the binding Ets TF could be determined by 
performing EMSA supershift assays using antibodies against each of the Ets TFs. 
Alternatively, it may be possible to examine the components of the EMSA band by 
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mass spectrometry as described in a number of methodologies (Nordhoff et al. 1999; 
Woo et al. 2002; Stenger et al. 2004). 
7.6.4 Further characterization of the c-Jun binding sequence (GIBS) 
With the aim of identifying novel genomic loci bound by c-Jun, an antibody to c-Jun 
was used to immunoprecipitate DNA from extracts of cardiac myocytes exposed to 
H202. The immunoprecipitated DNA was cloned and a single sequence produced, 
termed the c-Jun binding sequence or CJBS. CJBS has the characteristics of an AP-1 
responsive promoter, a consensus AP-1 binding sequence 5' to a TATA box (Figure 
6.12). Furthermore, the TATA box was shown to be a transcription start site (Figure 
6.13). The sequence of the full length mRNA transcript for CJBS could be obtained 
by RACE PCR or probing of a cDNA library. Semi-quantitative RT-PCR indicated 
that expression of CJBS mRNA was not increased in cardiac myocytes exposed to 
11202 (Figure 6.14). This is an unexpected result given the upregulation of c-Jun 
activity (Figures 6.6 and 6.7). This result could be confirmed by Real-Time PCR, 
which is a more accurate technique. The c-Jun responsiveness of CJBS could be 
tested by assessment of its transcription following overexpression of c-Jun or 
treatment of cardiac myocytes with other c-Jun activating stimuli e.g. ET-1 (Clerk et 
al. 2002). 
255 
Appendix 
256 
Appendix A The rat Mdm2 gene 
Exon 1: 156 by 
GGCCTCCGAAGCCGGGGTAGCCTAGGAGCGGCCGCGTTCTACGTCAGGAGCCGCTGTCGCTTCGCTCGACCTCCCGAGCGA 
AATGGTCTCTCAAGTCCCGGCCACCGGGCCTCCGCGCTCCCCATGAAGGGTCGGAGGCCGCGCGGGGAGTAGCAG 
Intron 1: 490 bp 
GTACCCGCCAGGAGCGACGCGACGTGCGGGGTTGGGCGGTGGCGAGTTCTGATCATTCCCGAGTCCTCTGGGGCCCACTCG 
CAGCCCGAGACGGCTCGCGGGGTCGCGGGGCGACGGTTTGTTGGCGCCGGGCCATGATGCCCTTATTCATCAGGGTGAGGT 
GGGGGGGTCTGGGTTAACACAGCGCACGCGCGGAAGAGGATGACGGGGGTAATGGAGGGAGGGGAGAGGAGAAGAGCCGG 
GGTCTCCCGGCAGGCCCCGCGCCCGGGGGCGGCTCCGGGGTCGCGCTGGGCTCACTGCAGGGGTCGGGGAGGTAACAGGT 
GCCTGGIGGTGGGACGTGGCTTCCGGGACGGGTGGGACTGGGCTGTGCCTAGTTGACTCAGCTTTTCCIGTGGGGCTGGT 
CAAGTTAGGACACGTICAGCGTTGGCTGTTGGAGGAGCTAAGTCCTGACATGICTCCAGCTGAGG 
C 	 CCCTGCTCGTTTCC 
p53-response elements 
Exon 2: 78 by 
GCAGCGGTCTGCAGGCGAGCGGAGACGGACACACCGGGGACCTCTCCGACCACCGTGCTTCTGCTGCGCGCCTCCAGG 
Intron 2: 168 by 
TAAGGAATCGTTTCGCTAATGCGGTTTTGCACTTGGAAGCTACTGTTGAAAGACGTTTTCTGTTGTCTCTTTTCGTAAATGCATTT 
ATTTGCTGTGTTTTTCGCAGATATTTTGCTATTTCAAGTTTTTATCGTGTATGTTGTTTTCTTTCTCTTTTTTTCCTACTTG 
Exon 3: 91 bp 
CAGGCC 	GCAATACCAACATGICTGTGICTACCGAGGGIGCTGCAGGCACCTCACAGATTCCAGCGTCGGAACAAGA 
GACTCTGGTT 
Intron 3: 4365 bp 
GGTATTTCTGTCTTTAGTGTGTAAAAAAAAAGCTTGCTTTTACCAGGTAATTAAGGAAACAAAATTTAAACCTGAATTATAGCGCA 
GTCCTTTAAGTATTTACCTACAAACTTGTAACTCTCTCAGTTGTAATTGCATTAGAGAGTGGTCACTATGATCTGTATTCCCATAG 
CCCTTCACCTGACGCTGGCTTTAGAAAGGCATTCACATTGTG TGGATGCTGCCGTTCAAGACATCACTGTTTAACTTTCTAAATG 
GTAATCTGAAAGTTATAGAAGTATCCGTGCTITTITGTGAAGATTITAGTTAGAGGAATGCATAAAATATATCAAGTTCCAGTCTT 
TGCTCTGGATCTCTCGTTTTCTACTTTATATTAACATATAAAGGTGTTGTACAGCTTGTCAGTAAATTACAAAGTTACTTTTAATAG 
CTGCATAGGATTTGATATTGTGATTGAACCTCAGCTTTIGGGGIGTGTGTATGCAAGTACTGTACTACTGAGCTGAGCTACATTC 
ATAGTCTCATGACTACGGGTAGATGTAAAAGTCGATTCATGTTTTTGAATAAAATAAGGGTGCGATTATTCTGTAATGAAGATAG 
GGAAATAGAAATCCTAAGTCCTGATTGCAAACTGCTAACTGCTCAGCAAAGGTTAAGGCAGTCTTCACTGCTGCCAGCACCGAA 
TATTACCTGCCTTCTTGTTTTCTTTTTGGTGTAATTTTGTACATATTTGTGAAGAATACATGTATGCAAGTTAAGTAGTTTTCCATTT 
CITTAAATTTTAGCATTTCTTTGTTAGAAATCTTCAGACTCTTACTICTTTATAAAATATGTCCTAAAACCGTAGGICAGTTTTTAGC 
ATTTCTACTTTATGGAGTAAGATATATTGTAATATTGITTCAGGGTACATATCCCAGATTTAAGTAGCCIGTTTATTCTGGGTTTAC 
CCAATTTCTGTCTCCCTTTTCCTTTTCTCCCCCCCATTCTTTTTTTTTTTTAAAGATTTATTTATTTATTATATATAAGCACACTGTA 
GCTGTCTTCAGAAACCAGAAGGAGTCATCAGATCACATTGTAGATGGTTGTGAGCCACCATGTGGTTGCTGGGATTTGAACTCA 
GGACCTCTGGAAGAGCAGTCAGTGCTCTTAACCGCTGAGCCATCTCTCCAGCCCTTTTTTTTTTTTTTTAAACTTCTTTATTTTAT 
TTCTATGAGTACACTGTGGCTGICTICAGACACACTAGAAGAGGTCATCAGATTCCGTAACAGATGGTTGTGAGCCACCCTGTG 
GTTACTGAGAACTGACTTCTGGAAGAGCAGTCAGTGCTCTTAACTGCTGAGCCATCTCTCCAGCCCCCTCCTCCCCATCTTTTG 
CATGTITTTAGTAGCTTGCATAATTCTCTTTTAAGTATAGTTAGCCTAAAAATTITTTTTTAACAAGTACTGTAACTTGATGTCTTCC 
CCATTGAGGATATCTTTAAAGAGTCAAATTTATTTATTTTGATAATTTTTGAATTTTCTTATAATGCTTTGTAGGAATTCTTCCATTT 
CAAGATTATGCACATGTTTAAAGTATTTTCATGTAGCATTTTAAAAAACTTTTCCATTTAGATCTTTACTCAGAACTGTCTTTGTTAA 
GTATGAGATTACAGTGTTGTCTTTTTATAGTAGTTTTAAAAATCAACTCTTTATCTTCTAAACTTTGATAAGAAACTAGCTTTCCATT 
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GTAGAGTTTTGATTTGACTTAATTTAATATG TAAAGATTTAGAACTTGCTTGGGCAG TAC GTACG CTAAAGTTGATACACTAAGGA 
GACTAGCGTGACTTCTACATAAGTTACATGAGAAAATTAAGGATTAAAAAGTAATTTTCAGGGGTTGGG GATTTGCTCAGTGGTA 
AGGCG CTTGCCTAGGAAGCGCAAGGCCCTGGGTTCGGTCCCCAGCTCCGAAGAGAAGAACCAAAAAAAAAAAAAAAAAAGAAA 
AGTCTTTAG AATACCAAAACAATACACAAAAATGATGGTTC C GGT GGTGG TGTCAAATTAAAACAGTTGAGTTTTGCAGATAGAA 
AGAGCATAGTCAGGTTACATGCTTICCATCCTAGTTTICCAAACATTTTCAACCTAGTCAACCCAGTGTACTTACCGTCCITCAAG 
CTCTTAATGGTATTTTAAAAATAAACTAAATGTCATCTAAAGTTGATGTTTAGTCCTGTTTGTCCTCACAGCCTATTCTAGCCACGT 
GTACATAAAGGGCTAGACCATGTGAACTACAGCCATTGCAACAACAGAGTCATAAAAATGACTGTCCTGATAGAGACAGGCGG C 
TGAGTAGCTAG GAGCATGACTACTTAGAGGACCTGG CTTCCATTCTCAGTACCCACACAGTGGCTCTTCTAAGCCATCTGTAAC 
TCCAGTTCCAGG GGGTCCAACACTCTTTTGTGGCCTCCCTGGAGACCAGGGACACAAATGGTACCTAGAAGTACACACAGGCA 
AAACATCCGTATGCATGAAACAAACAAAACTCTGTCCTTACTGGGCAACCATAGTTACAGAACACAAGCGAGTAGAAGCAACAC 
TCATTAAAGCTGTGATG CACAGGAGCACCTTCAGAGTATTTATTGCCGATGGTAAGAAGCTTTGATTTCAGACTTAGGTGG CTGT 
AGCAAGTTCAGTG CCACTTTATCATGGTGTTTATTG GTATTGGCTGTACTGG CTGCCAGGCTGGGCTCACTAGTGGCTTCGTGG 
GTAACAGCTTGCTAGTTAGGTGACAGTTGTCCAAGMTATTTCITTAAGGATTCATTTCTTAMTATGTATATGAATGAATGITT 
TGTCTGCATTGTATATGTATACCATGTAGGTGTCTGGIGCTTACAGAAGCCAGAAGAGGGTGTCAGATCCCTTGGAACCACAGT 
TACAG GTGGTTTTGATCTATCATATG GGTTCTGAGAACTAAATTCAGGGTCTCTATAAGAACAGCAAGTGCTTTTMMITTITT 
TCTIGGTTCTITTTTTTTMCGGAGCTG GGGACCAAACCCAG GGCCTTGTG CTTCCTAGGCAAGCGGTCTACCACTGAGCTAA 
ATCCCCAACCCCACAGCAAGTGCTCTTAACCTCTAAGCTTCAGCTCCATCAACTATTATCTCACTACTGGGAAAGCTAGATTAGA 
GTCAGACAAATTGTGGCTGGCTACCTTTTTTTTATAAATAAAGTTTATTGTTATATATTAACTCCTATAGTTTATGTAGTACTTTG CT 
TTTAAGTTGGCTAGATATGGAAAAAAATGCCTTTTGGCTCCTCTGATCTTACTGGCACGCTCTTCAAAGATCATGTATCATGATTT 
TTATG TCTGTCTATATGTCTATATCTAGCTTTTTTGAG TGTGAGTGATAAATAAATGATTATAAATGGTGTTGAAGG CATAAACCAC 
ATG CACAGAAAATAGTTGTAGTTGAGGGGCCATGATTGTACTCTGAATTACTCATTACCTTGTGACTTGGATTCATTCTCTAGCA 
GTCAGGAACATGGTATATGGTAGTCG GTGATAGGTTGTTCTAAGAGACATTCTTGTCTCCTGTGTTCTTCTGTAAGTTCCCTTTC 
AGTAGGTTTATACAATATGGTAAG CAAATTGGATCTCAACTAGATTGTGTGGTAGTAAG CAGATGATACAGTTAGAGGAAGAAAA 
CAGTGCTCTGTGTGTGTATGTGTGGTGTGTGTGTGTGTGTGTGTAGTTCCTGCAGAGGCCACAGTGGTTGTTGGATCGCCTAG 
AAAGAACTGGAATTTCAGGCACTTCTGGTGGCCATTG GAATTTGGACTTGGGTCCTCTGCAAAAGCAGCAAGTGCTTTTACTCT 
CTCAGCCATTTCTCCAGCCTCTTTTTTITTTTTTTTMTUTTTTCTTTTTTTCG GAGCTGGGGACCGAACCCAGGGCCTTGCGC 
TTGCTAAGCAAGCGCTCTACCACTGAGCTAAATCCCCAACCCCTCTCCAGCCTCTTGATACTGTTTTTTTMTTTTITCCTCCGG 
AGCTG GGGATC GAACCCAGGGC CTTGCGCTTGC TAGGCAAGCGCTCTAC CACTGAGCCAAATC C CCAACCCCTCTTGATACTG 
ITTTGATCACAACAAATTGTATTTGATTATTTGACATGACATCAAGGATTTGATGATTTCATGATAACGTCATAATAGCMTCCAA 
AAACATTTTCTGTCCTAACTCTTAGTGATGAGCATTTGTACTTAGTATAAAACCAACCTTTTGAAGTACAGCTTG GTAACAAATTG 
TTGAACACAGCATTTGCTGCCTGTATGG GGCTAGTGCTGGAGAGGACTCATGGGTGTAACATCAGCTCTTTTCTTTTTCTTCTAC 
A 
Exon 4: 48 by 
GGTTAGACCAAAACCATTGCTTTTGAAGTTGTTAAAGTCTGTTGGAGCACAAAAAGATATTTACACTATGAAAGAG 
Intron 4: 2911 bp 
GTGAGCAGGACTGAGGGGTGGAGAATGGATGTCTTAGTGGTTACATATAGGCATCTATGGTG GTTTTCTTAAGTTTATGAGTGA 
GATTGGGGGGTCATAGAGATTTTGTAATAAGCAAGGACATTACGTTTTGTGATCATTTGAACTATATTTTGAAGGTAAAAATCCTA 
ATTTACATGAATTTCTCCCTCCCTTITTCCCTCCCTCTGTCCTTTCCITTCTTCCITTTMI iiiiiAAGACAAGGTCTTACCCTG 
GCTGTCCTGAAACTCACTTTGTAGAACAGCTGGCTTCAAACTCAAGAGAGCTCTACCTGCTTCTGCCTCTG CCTCTGCCTCTG C 
CTCTG CCTCTGCCTCTGCCTCTG CCTCTGCCTCTGCCTCTGCCTCTGCCTCTGCCTCTG CCTCTGCCTCTGCCTCTGCCCCTGC 
CCCTGC CC CTG CC CCTGCCCCTG CC C CTGCCCCTG C CCCTGCC CCTGCCCCTGC C CCTGC C CCTGCCC CTGC CC CTGC CCCT 
G CCCCTGC C CCTGC C CCTGC CC CTGCCCCTGCCCCTGC CCCTGCCCCTGC C C CTGC CCCTGCC CCTGCC C CTGC CC CTGCC 
CCTGCCCCTGCCCCTGCCCCTGCCCCTGCCCCTGCCCCGAGTACTG GGATTAAAGGCATGTGCCACCAGACACATTAGCAM 
TGTTTCAATTCTTAACTAGAAACCCAGTAGAATTCTTG GTATTTTTGTGTTGTGAACTTATTTG GCAGACTGGTAAAAGTCTCAGG 
AACAAAAGAATTATATTGATGAGTTTGTTTCTGG CATACTAGAGTAGAAAAGCATTTCGATGTTTAATGGTGACAAAATCAAAAGG 
CACTACAAATGTTAGTTTGTTTCCTATATTCATAATCGAGGAGAAACCAGCCAGTTGAGATTTAGTGAAATGAAGATAATTTTTCC 
CCCATCCAAGTTACTG GATTCCCTCAGTTTTATCCAAGGACTTCTTGGGCATCCCTGGACCCCAGTTTGGACTTGTACAACTGTG 
CTGGAATG CTCAGGTGGGCTGATTGATGGACAAAACCTIGTATTCATCATTGCCTTACATTGGTTAGTAAAGAATCGCTTTCAGA 
GACTAGGCAATTGTAGACAGAATTGGAGATGCAAGTGTTTATCTTTCACTTAAGTTAAGGCTTGTTTACTTAAAACACTCAAGTTC 
TTGTGATAG GCTAGTGACTTCTCCTCAGTTATACTTCTTGAAGCATCTCAAAGGATACTTTCTAAGAGAAACCCAGGTACCCTTC 
CTGTCCCACTGACTGTCAACAGTTGTGACCCATAGGCATGGAAGAATTTCCTTTAAGATTGATTGGCTCCTGCTTAGCTAAAGTC 
TCTTTATGIGTTAAGTGATGTTTTCAGGGATATTAACTTIGGATTGACCMATAAATGTTACACAGACATTAAACGAGTATGGATT 
TAGCAGTAGATG TGAGAAAATAGATGAAGGCCATTAAAAAGATTTAGTGCTTATGCTAAG CCGTATGCG GCAACTCAGCTCTAG 
GTTATTGCTT'TTAGGACACTGCCTGCCAAGTCTCTTACTTAAAACATGAAACTGGGGTTGGGGATTTAGCTCAGTGGTAGAGTG 
GTTGCCTAGCAAGCGCAAGGCCCTGGGTTCGGTCCCCAGCTCCAAAAAAAAAAAAAAGAAAAGGAGTAAAAAAAACATGAAACT 
GTCTTTGTATGTTCATCATCTCTTATACTTTAAATTATCTCTAGATTACCTATAATACATAGTATACATAGTTGCTGTACTGTATCAC 
TTAAGGGATATCAACAAGGAAAAACATTACTACATTCAGGATGGATGTCAGGAATAGTTTTAGATCCATAGTCAAAAGAGTCTGT 
GGAGGTGGGACTTACAGATTGTTTATGTCTGATACCAGTTITCAGTTACAAGAGCTTTATTCTGGGACTCTTGAGGAAGTAGTGA 
ACCAGTGTGGTAGATAGTACACTGGGGTAGGTGTCCGG GCCTGAGTTAGMCTCATCTTTITTGTTTTTGTTUTTTTTTTTTCC 
GTGTGCTGGGTGTCAGACCAAGG GAACACATTTTACTACTGAACAACACTCGTGACCTTATTTTCATACAGTATTGACAATTCTG 
TGGGGTGICAGGATGATGAGACTACTGACAAAACTGCACCTGCACTGTAAATGCTATATAGATTATGTTGTTGATGGGCTAGTTT 
TGGAATAACAAAGTCTGTTGITTAAACTGATGTAATAGAGCAAATAGAATATAATTTAACTGAATAGTGATGGTTTGG GC CATGGA 
CTATTTGGTGTAGACTACATTAGTAACTGAGAACTGGGAGATGTCTCTAATGATGICCTGTCCTCCTCTGAGGICAGAG CTGTTG 
AAGTATATGTTTGTGACATGTCACTATTCTAATTCATTGCTGTATTTTATTTGATTTTTTTAACTCAAMTTTTTGTATTACCTCTTT 
TTMCCMCCTAGTATATTGAATGTTAGTAAATCTAGGTTTCTGGGCAGAATTAAAATTTATAAGAAAAAAAACAGAAAATACAT 
TTAAGTAATGTGGAGAAACAGTTATTTCTTTTTTTTTTTTTTTTTTGTTCTTTTTTTCGGAGCGG GGGACCGAACCCAGG GC CTTG 
CGCTTCCTAGGCAAGCGCTCTACCACTGAGCTAAATCCCCAACCCCGAAACAGTTATTTCTATTTTCATCAACTTGGAAGTATTT 
258 
AAAAGAAGCTTCTACAATACCAAATGTTTGGTCTTGTACATGGATGGTTGTGGATTTGGTTGTTAGTGTAATCTTGTTCAGATAAG 
TGOCATTGCTAAATGTATATGAAACTGATATGTAATTTGITTAATACTTAGAAACCATAMCTGITCC 
Exon 5: 137 by 
AGATTATATTTTATATTGGACAGTATATTATGACTAAAAGATTATATGATGAGAAGCAGCAGCACATTGTGTATTGCTCAAATGAT 
CTCCTAGGAGATGTGTTCGGAGTCCCAAGTTTCTCTGTGAAGGAGCACAGG 
Intron 5: 1035 bp 
TGAGCCITCTGTGAGGTTGGTTATAAAAATGCCTGCTGTACATGGGCCIGGAGAGATGGCTCAGTGGTTAAGAGCAATGGCTG 
CTCTTCCAGAGGTCCTGAGTTCAATTCCCAGTAGCTATATGATGGCTCACAGCTGTTGGTAATGTCAGTTCCCAAGGATCTGGT 
ACCCTCACACAGATAGACATGCAGGTAAACATCAGTGCATATATAAATAAAAATACATCTTAAAAAGAAGCACCAGGGGTTGGG 
GATTTAGCTCAGTGGTAGAGCGCTTGGGCCCTGGGTTCGGTCCCCAGCTCCGAAAAAAAAAAAAAAAAAAAGAAAAAAGAAGCA 
CCAGCTGGGCAATCATTGGATCTCACCTCTGTCAGAGAGGTCTGTCACCTCTGTCTGTGTACAGAATGCTAAAATTTAGATTCAT 
TTTTGGGGCCCTGCTTCTGTTAACAGTAGTGGCCTTGGTATTTTGAGGGGAGGGGTAATTGTAGTATATCGTGTGGAATCCCAA 
ACTCCAGAGTCTTAACTTMTGTTGTAGGGTTTMGTGTGIGTGGITTTGTTTTGTTTTTAACCTGTICAGCGGTGTGCCCTGT 
CCACTGGGCTCAGTTTTGGGTCTTTTTTTTTTMTCGTMTATTTAATGTATATGAATACACTGICACTGTCTTCAGTCACACCA 
GAAGAAGACATCAGATCCCATTATAGATGGTTGTGAGCCACCATGTGGTTGTTGGGAATTGAACTCAGGACCTCTGGAAGAGCA 
GTCAGTGCTCTTAACCATTGAGCCATCTTTCCAGCCTGTGTGGTTTGTTTTTGTGTGCATGCATGTGCACATGCCACTGTGAATG 
TGGAGATCAGAAGCCCACATTCAGGAGTCAGTCCTCTCCTTCCACGATTTGGGTACTAGGGATTGAACTCAGGICACCAAGCTT 
GATCTATTTTGAGACAAGCCCTGTCACTAGTTTGTGTAGGTGTATAAATAACTCTAATTTCCCTCAGCTGTGGGTTCTCTACTTAC 
AAMCTTTTTTCCTTACA 
Exon 6: 52 by 
AGGAAAATATATGCAATGATCTACAGAAACTTAGTGGTTGTAAGTCAACAAG 
Intron 6: 5486 bp 
GTAAGTTAATTTTGAATATTATAAGCGTACTATAAATTTAAAAAGAGTTCTTTGTGGGGTTGGGGATTTAGCTCAGTGGTAGAGTG 
CTTGCCTAGCAAGTGCAAGGCCCTGGGTTTAGTCTCCAGCTCTGAAAAAAATTAAAAAAAAAAAAAAAAAAAAAGAGTTCTTTGT 
GACACAAGGTCTTATGTATTGTAGICTAATTTCAAACTCTGTAGCAAAGGACCCTTGAGCTTTAAAAAAACTMGAGTAGMTG 
TGTATGTATATGIGTGTCITTGTAGCACGGGACACAGATACCATGCTGTACATGTGGAAGTCAGAAAACAACTTTGTGGAATTGG 
TTCTACCITTTACGTGGGTTCTGGTATCCAGCTCAGATCMAGGCTTGCATGGCAAGCACTCTTACCTTCTGAGCTGTCTCGCC 
AGTCCCTTAGTAATGMTAAAGGCTIGGGIGTGTATTTAGIGGTAGAGTGCTCTCCTAGCATGTATGCAGCTCTGTTAATCCTT 
GGCACTGTAAACTACAAAGGCAAATCTTACAGACACATGGCCACTATGTGCTGCTTTCATTTCAGGTTTGTTTTTGGCTCTCTCT 
AGTATGITTTGAATTAGCTCTTTGAATTCCACCTGTTTGTGTTTTTTTITTTTTITTITTTTTGTAATTATTTTTGTGTGTATTAGTGT 
MGCCTGCATGTATGTCTGTGTATTATCTGTGTGCAGTGCCTTTGGAGGACAGAAGAGGCCATCAGGTCTCCTTACAGACAGT 
TATGAATGCTGTGTGGGGGCTGGGAATTGATGCTAGAACCTCTGGCAGAGCAGCCAGGGCTCTTAATCATGGAGCTGTATTTC 
CAGCCTCTTTTTTTMTTMTITTCCGGAGCTGGGAACCGAACCCAGAGCCTIGTGCTTGCTAGGCAAGCGTTCTACCACTGA 
GCTAAATCCCCAGCCCCTCCAACCTCITTTTTTTTTTTMTTMTTMGGGTTCTMTITCGGAGCTGGGGACCGAACCCAG 
GGCCITGCGCTTCCTAGGCAAGCGCTCTACCACTGAGCTAAATCCCCAACCCUTTITTTTGTTTTTTTTTTTGGTTCTTTTTTTTT 
TMTMTTTTTTTTTTTTGGAGCTGGGGACCGAACCCAGGGCCTTGCGCTTCCTAGGTAAGCGCTCTACCACTGAGCTAAATC 
CCCAGCCCTCCAACCTCMITTATGTTGITTTGAGACCTGTCAATTATCCAGTGICAMGGAACCCAGICTTCCTGCTCCCCT 
CCTAAGTAGCTGGCAMGCTCATTTATTCAGCACTGCTGGAAGTTGAACTCAAGACTCACCOTTGCTMAGAAAGTACTGTAC 
TAGTTAGCTACCCCAGCCAGCCTTTGATTCATCTCATTCTCTCTICAAAAGTTAAAGTGGCTTCMCATTTTATTTGTATGGGTG 
CITTTCCTGTCTGCATGTATGCATGCATGTATGTATGTATATGCACCATCTGTGCAGTGCCCAGCAAGGTCAGAAGAAGGGCAT 
GGAGTCTCCTAAGACTGGAGTTAGACTATTGCAAGTGAGTTGCCTGTTACCTCTGGAAGAATCCAGTGCTCTTAAGTCATCTCTC 
CAGCTCCTCMGGAAAAAAACGTTTAATTATAGGGCCTAGTGTGGTAATGCATACCTICAGTCTCAGCAGTTGGGAGGCAGAG 
GCAGAGGAACTTGTCCATCCAAGITTATGTAATGAGACTCTGTCTCCAAAAAGAAAAAAGAAAGTTTTAATTATGTGTGCGCCCC 
ITTATGTGGGTATGTGTGCCTGAGTGTAAATGTGGACAGAGGCCAGACGTGTTAGGTTCTCTAGAGCTGGAATTATGGTGGTTT 
TGAGCTATGGCAGTTGGACACTGGACTTAGATCTGCTGTAAGAGCAATATGTGCTCTTAATCACTGAGTCATCTCCTCAGCCCC 
ATGATTATTCTTMTTTCCCCCCCCCTTIGGAGCTGAGGACCGAACCCAGGGCCTTGAGCTTGCTAGGCAAGCGCTCTACCAC 
TGAGCTAAATCCCCAGCCCCTCCCATGATTATTCTTTAAAAAAATTACATTGATTCATGMATGAGCATTTITGTGCCTTGATGT 
GCATTGGAAAGTCAAAGGACAGCTTGGGAGAGTCAGGICTCCTTCCATTGTGGGGGTCAGTCCTGGAGCTCAAGTTCTGGATT 
GAACTTAGGTCTTTTACTTAAAGGCCAAGGCCAAGTGGTTCTTACTGAAAGTTACTTTGTACATAGTTATATTAGGACTATACACT 
TGAGTAGGAAATGTATGTGAACTAAAACTGTTCTATGAAAATAATACAAAATTGAATGTCCTGCTATCTATTGAAACCTTGGGTTG 
TCAGGAMCTTCTGAAGAACAGACAGTGTCAAACGTTGCTCGGTAGAAGTGGTATCAAACCTCAGAATGCATTGAATTACCTAG 
GCAGGACCTTGAAAGAACGGGGTTTCATCTCTTCTCTTCTCTTGCCCCTUTTCTATTCTTTCTCTTGITCTTGATGGACACTTAC 
CAMTTAGGTAAGCACCATTTTAGCTCTCTACTIGGCAGTTGTTCTTTAGTGAATGGAGCACAGGTCCTCATGTGTGGTTCACA 
AGCACTCTGACGCTGAGCTCCATACCTAGACTGATGTAATTCATATTTTGGGGATGCAGCCTTMGAGAATCTAGTAAAGGTAC 
TTGATTTTCATTCTATAAGTGTACACATGTGGATAGTATTTTAATTGTCTTTCTTCCMCTTCCTTTCTTTCTTTCTTTCMCITTC 
MCTTTCTTICITTCMCTTTCTTTCTTTCTTTCTTICTTTCAAGAGTTTCTCTITAGATTCATCCACCTGCCTCTGCMCCAGG 
CTTTCACACCACCATACCTGCTAGTAGTTGTATTTGAATACTAGTAGGTGTGGGCTCTGAAACACCATAAACCTTACAGTTTATC 
CTTATAAATACTGTGTTCAGAAGCTTGCTTGGTTTCTAGACTGAACCGAGCACTCTCTTGTGATCCCACTATATTTCATICCACAT 
TCAGGATTCAATGTGTTATGTACACATTGTGTTGTAAAAGGCACCAGGATCTTCCCTTAACAAAGAACAAAGTAATGATTAGITTG 
GCAACTGAGACTATGATTTTTGGCTTCTGCCTCATGATGCTGAGATTACTGGGACCGCTCCTTATGTTGTTAGATGGCACAATAT 
259 
ACAGTTACAGGATCCGATAGTATTTTGAATATTCTCAAGTATCTAATAGTCATTCACTTAGTAAATTTTGACAGAATTAAAGGATAA 
CCTGTAGATTACTGACATTTTCTCTTTCGGTTTTGTGTTTCAGTTTAGTTAAAGTAATTTTGAAAATCCTAGATGAGTCTTGTCAGC 
CTTGTCAGACCTATTACTTTATTACGTGTTTTTTAACTATTACACATCCTAAGACAGAGTTCCCAGATATATAGCCTATCTATGTAT 
TCACTTTAAAATTTGTATAATGCCATAACACAAGACAGTTAACCGTGGGGTTGGGGATTGGCTCAGTGGTAGAGCAAAAAAAAGA 
CAGTTAACTGTGGTAGCTCATTGTTTGGAGGCGCTCAGTCAGTGCCTAACCATGACTTCACTGTTGATGGAAGTGTGTTAGGGT 
GGTAGTGTAGGGTATTTGATTATGACTTTTGAGTAATTTTATCCATTCCAATTCTGGAACTTGGATGTTTTGAGAGCTTGGTCCGT 
AAAACTACACCTGTCTATCTGTATAACTCATTTAAATTCATTATTTTTCCAAGCTAAATCTTTGACCTTGTTACAGTTCTCTCCTGG 
TAAGTGGTAACCACCTTTTTCATCTAGTTAGACTCTTTTTTTTTTTTCGGAGCTGGGGACCGAACCCAGGGCCTTGTGCTTGCTA 
GGCAAGCGCTCTACCTCTGAGCTAAATCCCCAACCCTTCTAGTTAGACTCTTAGGATCCTCTTTAACACTTTTTTCTTACAAACAC 
CTGATCTTAATTTTTCTTAAGTTGATTGTCTTAGTTAGGGTTTGCATTGCTGTGAAGAGGCACCATGACCAAGGGGGGCCCACCC 
GCCCCCCCTGAGCTGAGGACCGAACCCAGGGCTAGCGCTCTACCACTGAGCTAAATCCCCAACCCCATAGGCAACTCTTATGA 
TIGGGACTGGCTTACACTTCAGAGGATAAGTCCATTATCCTCAAGGCAGGAATCATGGAGATGGAGGAGCTGAGAGTTCTATAG 
CTTGTTCCAAAGGIGGGAACTGGCTTAGGAAAGCAAGCAAGAGGCTGGTTTCTCCACACTTGAGCAGAGGAGCCTCAGAGCCC 
AGCCCCACGGTGAGGCACTTCCTCCAACAAGGCCACACCTCCTAATAGTACCACTCCCTGCGACAAGCTTATTCAAACCACCAC 
TTGGTTTAATACAGTTTTGTATTTCAAATACTGTTTGCTTGCTTCTGTACTCTACTGTTTGTTTTCCCATATGGACATGGGGTCCA 
GGACCTCCCACATGCTGAGGACTCTTCCACTGAATCACTACAGCCCTTTTTTCCCTTTGACAGTCTCACTGAGTTGCCCAGGCT 
GGCCTGGGATTTGTAATCCTTCTGTCTAAGCCTGCTGGAGATGATTGGTGTAAATCACCATGCCCAGTGGGTTIGTTGTTGTTG 
GTTTCTGTGGTTTTGATGTTGTTATTGGTTTTGTTTTTTAAATTCTATTTTGTCAGAGTGGTTTGTTGTTTATTTAGGAGTTTTATGA 
TTGCTCCCTGGGGAGAATAGTTCTTGAGCTAGAAAATTATCTCTTGCACTAAAGCACTTTAATGATGAGAGGTTGCAAGATGGCC 
TCCCGCAAGATTAAATAATTGCTTAAATAACTGTTGAGAAGAACGACATITTATGCTGTTAGGCTGAACACCCATGGCTCTGTGC 
ACAGCGACTCTGCATITTACTGITTCAGTACAAATGAATTAATTTTAAGMGTGCCACAGGAATTGTTTGTGTCTGCATGCTTTC 
TTCAGTATGTAGACATACTCCTTCAGTCTGGAGTGCCTTTTTTTTTTTTTTTCCTTCTTTTTTTCCGGAACTGGGGACCGAACCCA 
GGGCC1TGCGCTTGCTAGGCAAGCGCTCTACCACTGAGCTAAATCCCCAACCCCTGGAGTGCCMCATGTACCAGCTTCAAC 
ATAGGCCATTCCAGAATCTGTCCTGGTAGTTCTTCAGAATTCCTTTCCCCTGTGTATACTAAACAATACTTTTGTTTCCTCTGCTA 
GTATATCTTAAAATTTGCTTATTTTACTTCATAATTCCTGTTTAATTTATATCTCTATCATGCAGATGACATTTAACACAAATGGTTA 
ATATTTGTTAAAAGGTTAAATTTTGTACAGGGCATGTGTTAGACTGGTATATGTTGAATTCTTGCTTTCTTTGTTTTGATTCAGTTT 
TTACTTTTTCTTACAATCCTC 
Exon 7: 62 by 
AGACTCTGGAACATCGCCGAGTGAGAGCAGATGTCAGCCTGAAGGTGGGAGTGACCTGAAGG 
Intron 7: 272 bp 
TAATACTCCGTAAAGTTCTTATCTCTGTGTGIGTGTGIGTCCTCCAGCCAGAAGACGGTGTCAGATCACCTGGAGCTGCAGTTA 
CCCCAGACATGACGGAAACCAAACTCATCTAGGCAAAAGCAGCACACGTTCTTAATCTCTGAGCCACCTCTCCAACTTCATGAC 
AAACAGTTCTTGAAAATTGGGAGGGTTATATAAAACAGAATTTGGAACAGCCACTGTTTTATGIGTGCAATACTTTGCAATATTTT 
ACTTTTTATTATGTATTT 
Exon 8: 99 by 
AGGACCCCGTGCAAGCATCACAAGAAGAGAAACCTTCATCTTCTGATGTAGTTTCTAGACCATCTACCTCATCTAGAAGGAGAGC 
AATTAGTGAAACAG 
Intron 8: 704 bp 
GTACATAAGGAATATTTATGTGACATACTAAACAGTTGCTTGGTGTTTCCUTTAGGGICAAATGACCCTTTCACAGGGGICTCC 
TAAGACCACTTAAAACCAGATATTTAATTCATTATGATTCATGTTAGCAAAATTATGGTTATGAAGTAGGAATTGTATTAAAGGATC 
CATAGCATTAGGAAGGTTGAGAGCCCCTGCACTAGACTCCCAATAGAAGATGAAGCTTAGCTTAGCTTAGCTTAGCTTTCCTTTC 
ATTTCCTTTCCTTTCCTTTTCTTTCCTTTCCTTTCCTTTCCTTTCCTTTCCTTTCCTTTCCTTTCCTTTCCTTTCCTTTCCTTTCCTTT 
CCTTTCCTTTCCTTGTCTTTTTTTTGAGACAGGGCTTCTATATAGACCAGACCAGCCTCACGTAGTTTTATTTTTAGAGCTTAATG 
TTGACAGGAAAACTGTACACTGCTGGATCAGTAAAAGCTCTAGATGGATTACACCTCCCTAACTTGTGCAGGTAAAGGTCACAA 
AGAAGGTTGCAAGCTCATAAGTAGAGCTTGTACTTAGTTGAACACATCCAATGAAACTCTGTTGACTGATATTCATGGTTGACTT 
TTCTGTTTAATGTAATTGAAATTAAATTTTGTTGCAAATAGGTGCTGMGTAAATCAGTCACAATACAGGGATTTTTAACTACCCA 
TTTGTCTTTCCTATCT 
Exon 9: 152 by 
AGAAGAGAACACAGATGAACTACCTGGGGAACGACAGAGGAAGCGCCACAGAGCCCTGTCCTTTGATGAGAGCCTGGGTCTG 
TGTGTGCTCAGGGAGATATGCTGTGAAAGAAGCAGCAGCAGCGAGGCCACAGACAC 
CCCCTCACATCAGG 
260 
Intron 9: 3334 bp 
TACTGCTCGGCTTTAAGACAMTATTTTGTAATATGTAAGTCTTGCCTGCCAGAATGCATACCACATGCATGCAGTGCCATTGG 
ATGCCAGAAGAGGTTGTGGAATCCCCCGGAACTGGAGTCAGGGATGGTTGTGAGCTACTATGTGGGTAATGGGAGTAGAACCT 
GGGTCCTCTCCAAGAGCAGCAAACCATCTAAAGTCCTGCATTCTG GTTTTAAATAAAACAAGTCTTTAAAAAAATTTAACTATTCT 
CTACAGTCTTMTTITTTICTTTTTCTTTTTCTITTTTTCGGAGCTGGGGACCAAACCCAGGGCCTTGCGTTTGCTAGGCAAGAG 
CTCTACCACTGAGCTAAATCCCCAACCCCTATTCTCTACAGTCTTAAGAAGCCTATAAATAAAATGCCTGTTTTTGATGTGAGATT 
GTTGCTGAACACAGCAGTGGTAAATITTAATCTCACATCCAGTCCTGGTTAGGAGATAAGTTAGTAGAGGAGAGGAGCTCTGCT 
CCTGGTAAAGTTAACACAGAGTCCATCCCTGCTGACGTCATCCCTTATACTAGAGAGCCTTTGTGGAACACGGTGCTAGTAGTC 
AGTCAGGTGGGTTGTAGCATAAAGTCAGCTGAACAMAGAAGACTTTTTGAATAACAGAAGGTAACTGGAAATTTAGCTCAATT 
ATATACCATAGAAATCTAAAGCAAATTTGTTTTGATTGATTGATTICTTGCCAAGAATCCAGTCCAGGICACATGTACTAGGCAAG 
CACTGTACCATTATAACCTAACCCTTGAGTGCTTAAAGGGCTCACAGGGTAAATGCTGGCTGGCCTGGAACTTTCTATGGAAGC 
TCACCTTGAACCTCAGAGACCCGCCGCTCTCTGCTTCCCCAGTITTGGAGTAAAAGGAATGTGCTTGCTAAAGACTCCCTTCAA 
ACACTGGGAGGGTTACCTGAGCTGGAGTCCTGTATCAGTAAGGACAGTGCTGATGGTCATTCTCTGTTAGTAGACCTACATTGT 
ACACAGCTAAAGACTAGTAAATAGGCCICTGATTTCTAGATCTATGTATGACATATTAACTGTGTGTGTATACATACAACATATCT 
ATGTATGACAGATAGTAAATTAGGGCCATGCTTATTTAMATTGAAAACTGGGCTGTAATAAAAAGGGTTGIGITTTTGTGGGGA 
CTGAATAGATGGCTCAGTGGTTAAGAGCACTTGGAGCCACACCTATTCCAACAAGACCACACCTCCTGACTTTGCCACTTCTAC 
AGGCTAAGCATTAAGCATATTTAAATCACCACAACATCTAGACACATATGAATAAGAAAAAATATGAAAAAGAAAAAATTITAAAG 
GGTGATGTTGTTTGAMTTTTTTTTTTTTTAATGTGGCACTGGACAATGCACTATGTCCTCAACCTACTGCCTTCCAACATGCTA 
GGCAGACTTCTTTTCAAAGGACTTTAGCATTCAAACAAACAAATAAAAACAAAACCAACTACCAAAACAACTGCAGCCTTGGTGT 
TTCAGTTTCTTTTTGGTTGCTGTGACCAAGGCAGCTTACCTAAGGAGGAGCTCTGCTTGGCTGACACTCCAGAGTGCTGAGAGT 
CCATCAGGTTGGGGAGGCGTGGCAGAGGGAGGAGCGGTGTCAAAGTGGGAAACTGAAAACTTGGATCCTTAACTTCAAGCGT 
GAAGCAGAAAGACCAAGTGGAAATTAGCAAGGTGTTTTAAATCTCCAAGCTCTCTCTCAGTGATGTACTTGTAGTAAGGCTACTC 
CTCCTAGGCCTTTCCAGACATTGCCACCCACTGATACCAAGCATTCACCACCACACTAGCTATATGACAGTGTCTCGTGGTCAC 
TGTTCAGATATTGTTAAATTTAGCTAACAMTCAAAACAGTTTCTTTGCGTATACCAGGCTGGATTTTAACTCAAGAGATCCACC 
TGCCICTGTTTCCTGAGTGCTGGGATTAAAGGCATGTGCCACCATCTCCTGATTTCAAAACAATTTCTATATTATATTTAAAAAAA 
ACA'TTTTTTTGTGTATGTGTTACAGGTGTTTATGTCTGCCACAATTGGTTTTTGGGGATAGTGAGAGTCAAAGGACAGTTTGAGA 
AAATCCCTAGTTCTTAATGAGTTCTTAATGCTTCTCCAGTTTTATCATTACTTGGAAGICITGACTTAGAAATTTATTAAATAATAC 
ACTTTATMTGTTGATTGCATATAGACCAMTATACCTCAAGCTGACTATATTTTCCAGAAGAGAAATGATTATGTCTGACGTTA 
AGCAGCATTITGGTAGCAAATTGAGAATGCCTGTGTTCTAAATTCTAGAGTAATATATTTTTCTTAATTGTAAATAAGTTCATTTGC 
AGATCAACTTAGTGTATGATTTGAAGTTGAATCTCTTTTGTGTTTTTTGAGACAGGGTCTCTATTTAGTCCTGGCTCTTGGTTATC 
CTGGAGCTCACTGTGTAGACCAGGCTGATCTTGAACTCTCAGAGATCTTCCTGTCTCTGTCTCCTGAATGCTAGGATTAAAGAC 
ATACACCATCATGCCTGGTCTTGAAATTGAATCMTAATCTCAGCACTCAGGCAGCAGGGACAGCAGAACTCTCTGAGGTAATA 
GCCAATATGGIGTACATAGCAAGTTCCAGGCCAACCAAGGCTACTTCAGAAACCCAGATGCCATCTTTGIGTTTGTGTCTAACT 
GCATTCTACCACACTAATAGTGTGAGGAGGGAGGCCMACCTIGTATCTTAGTAGGAATGCGGGTGTATATAATCACACATGTA 
GGAAAGACCATTAAATGTAGAAGAACTTTTATTTATGGTATTGTGAGAAGCTTAGCCAAAGGAAGATGAGCAGGACTCAGATTAT 
CTTAGTGAGGAAAAGTTAGTGTGCAGATTGGTTTAGAAAACAAGATCTGGGGGTTGGGGATTTAGCTCAGTGGTAGAGCGCTTC 
TAGCAAGCACAAGGCCCTGGGTTCAGTACCCAGCTCCAAAAAAAAGAAAAAAAAAAAAAAAACCAAAAAAACAAGATCTGGCTG 
GAGCATGGTGTCGAGTAGGGTGAAGGATGTGTTTAGCAGACATTTAAAAATTTTAATGCAGTCATACTCGGGACCTCGGGGCTA 
AGGGGCMTGATTTTMTCCTICATGAAGTAGAATTTGGAGCAGGGAAAATTCAATATTAATGTAATAACCTTAACCTAGTACT 
TATCTATGTAGTATGAGGCTGAGAAGGAAGTAGTGGCCCAGGATGAATCAGGAAGCTCTGAATGAGGCCCAGAGGCAATGTAT 
TTACATTTACTTTATTCTTT 
Exon 10: 166 bp 
CTCCATAGGATCTTGATGATGGCGTAAGTGACCATTCTGCTGATTGCCTGGATCAGGATTCAGTTTCTGATCAATTCAGTGTAGA 
ATTTGAAGTTGAGTCTCTTGACTCAGAAGATTACAGCCTGAGTGATGAAGGGCATGAGCTCTCAGATGAGGATGATGAGGT 
Intron 10: 1271 bp 
GGGCTTCCATGTTTATTAGCCTTTTTTTTTTTTTTTTMTTTTTTTGGAGCTGGGGACCAAACCTAGGGCCTTGCGATTCTTAGG 
CAAGCGCTCTACCACTGAGCTAAATATCCCCAACCCCTTATTAGCCTTTTAATAAGATGAAGAAGTGGTCTATGTAGATTCTCTT 
GAATTCTTGCTTTTCCATTTGTTCAAGATAGAATATTGCTTTGTGGTCTTGAGGTGAAATTTTATAATTTCMGCTTGCTGGCTTG 
CTTGCTTGATTTATTTATAAAGATGTATTTATTTGTTATGIGTACAGCATTCTGTCTGCATGTATGCCTGCAGGCCAGAAGAGGGC 
ACCAGATCTCATAGATGGITATTAGCCACCATGTGTTTGCTGGGAATTGAACTCAGAACCTTTGGAAGAACAGTCGGTGCTCTTA 
ACCTCTGAGCCATCTCTCCAGCCCTTTGCTTGATTTATTATAGTCTCATATTATTAAGTAAAAACCTTAGGAGAGTTTGAACAGTG 
TTTTTAAACMTTGAGTTGACTGGGTGTTTTTGCTGCTTTTTTMTTTTTTTTTGAGACTTGGTTTCTCTATGTAGCCTTAGCTAT 
CCTGGAACTTGCMGTAGACCAGGCTGGCCTCACATCTGCCTGTGTCTGCCTCCCAAGTCCTGGGACTAAAGACGGGCACTG 
CCACTGCTCTGCTAAAGATGAACATTCTTAGAATGGCTTGCCCACAGAACTCTCCATTTGTCTTCCCATTTATGTATTTATGTATG 
TATGTGTTTATTTGTTTTTGAGACAGAGTATCGCAATGTATCCCIGGCTGATCCCGAACTGGCTATCTAGACCAGGCTGGCCTCG 
AACTCACAGGAATACTTTTGCCTCTTCCTTCTGAGTGCTGGGACCAAAGGTGTGAGCCTTCTGCCCCTCCCTTCTCAGTACTGA 
CTTGTMTCACAAATGAAAACGTGCAGCAAACAGTGTCACATGGAACCTGGATATCMCTTGGAGTTACTTTATCTTTACTATT 
TCCAGTTGTTTTCTGGCTAATGACTCCTACATTTATAAAATGTTCTCTTGAGMTCTGITTGGTTCTAAATATTTAACAATTCTTG 
CCATGTGAGAAAAGATTTTACTTTGCTGCCTGACTTGAACTGCATTTAACTTTCTTTCAGAACTTCTCATGGCTCAAGCTATTTGT 
TTAAGACTTACTAAGAATTCAGGCCTICTGGTTGAAGGGTTAAATTGATGAATTAATGAATTTGTCTTATT 
261 
Exon 11: 81 bp 
AGGICTATCGGGICACAGTCTATCAGGCAGGAGAAAGCGATGCAGACTCTITTGAGGGAGATCCTGAAATTICCTTAGCTG 
Intron 11: 1257 by 
TAAGTATATAGATTCTICAAAGAAATAAAAACACAATGTTGAGATCAGAATTAGGAAAATATGGTTAATTTACTTMCAAGTGAGG 
TAGITTCA'TACTGTTAAAACTTTAAAACTCTTATGACTTAAAGCATTICTTTCTTTGTTGTAGTGAGATCTGTTGCTICATTTGTTGT 
GGTGGAACAACAACTTGAACAACCTGGAAACTGGATATATTTATTCAGGGTACACTAGGAAATGTCCTCAGTTTATGCAAGGATA 
TAGAGTATGTTCAATAATGAGGCAGGGATCGGGAAGAGTTTGCCTTTCTAGGTGIGTAAAGAGAAGTCGGGATAAGGAAGAGA 
CACTGGGCGGTTGGAGAGAGCACAGGACGACACTGACAAGGACGGGCATATAGTGGATTGTGGTGAGAAGAGTAGATTTCAG 
TTCCAGTAGCTGACAGGGATTGTGCGCAACTTGICTTCCAGGIGGAAACAGGATCTTTAGCTGCACTGGGGCCITTAGAGCATG 
TCTTAACGAGTCCTAGCAACTG CTATGTTGGAAGTGGTTCTCTAG GAAGAGCAGGTTTCATCTAGATTTATCATATAATGICTTTG 
CACTGTCCAGGATTGAGCTTTGAAGGAAGCGGGTATAGACCTTAGATACAGAGGAGAAGGTGCTGTACTTGAGCTAAGTGGAT 
GAGCTCATCTATCTGTATCCTIAAACAAATAAAACTTGAACAGATATACAGTACAGTACATTTTGAGGGTCTATAATITTTTTTAGG 
TTTTTTCTTTCTTTCTTTCTTTTTTTTTAAAAAACCCTCTTTTTACTGTGCTAGGGATTGATATTAGGCCTGCAGTCAAACCAACATC 
TTTTTTTTTAAAGGATTATTTGATGTATATGAGAACACTAACTGTGGCTGTCTTCAGACACACCAGAAGAGGGCATCGGTTCCCA 
TTACAGGTGGTTGCGGGCCACCATGTGGTGCTGGGAAGAGCAGCCAGTGCCTGGAACCTCTGAGCCATCTCTICAGCCCGAA 
ACTAACACCCCTTATTCCATATAGTGCACCGTTITGTGTGTATGIGTAGGGAAGGTACCTGAAGTCCGCTCTGTTGGCTAATTTG 
TGGTCTGTAGTATTAGCTATAGTCCTCATGTTCTTTGCCTGCTTATGTGAAATATGAGTGCTGAGCATTAACCATGGTCTACCTCA 
GCCCTATTGACGTTAATTAGTCTTGCTATGAATACTAGTTAAGAGTTGCTGTCTTTTTTATTGAAG 
Exon 12: 573 bp 
GACTATTGGAAATGCACCTCGTGCAATGAAATGAATCCTCCCCTTCCATCACACTGCAACAGATGTTGGACCCTTCGTGAGAAC 
TGGCTTCCAGACGATAAGGGGAAAGATAAAGTGGAAATTTCTGAAAAAGCCAAACTGGAAAGCTCAGATCAGGCAGAAGAAGG 
CTTAGATGTGCCTGATGGCAAAAAAGTGACAGAGGATGATGCTAAGGAGTCATCTGCTGAGGATAGCGAGGAAAAAGTGGCCC 
AGATGCTCCTGTCACAGGAGAGTGACGACTATTCCCAGCCGTCGACTTCCAGTAGCATTGTTTACAGCAGCCAAGAAAGTGGC 
AAAGAGTTGAAGGAGGACACACAAGACAAAGAGGAAAGTATG GAATCCAGCTTCTCTCTGAACGCCATCGAGCCATGTGTGAT 
TGCCAGGGG CGGCCTAAAAATGGTTGCATTGTTCACGGCAAAACCGGACACCTGATGTCATGITTCACGTGTGCAAAGAAGCT 
AAAGAAGAGGAATAAGCCCTGCCCCGTGTGCAGACAGCCGATCCAAATGATTGTGCTCACGTACTTCAACTAG 
Translation termination codon 
3' UTR: 1248 bp 
ACGGCGGGCAGACGCAGACCTTTACACTTCTAATGTATGACCCCCAAATTAGACAACATGGGTATTATTTTCATACATTAAAGCC 
GGAGCATTGTCTTAGTCTACATAAAGTTCATTTGTAATTTATCCTCGAGAGTAAGAATAGTAACTGTTTTCTTCCTITTAGGAAAAT 
TTCAGTTGATTATTTTATATTTGTGTTTTAACGTAATTTGCATTAGCTCTTTTCATTTTCCTTACGTTTTAAGTAATCTCCACTTGGA 
AGGACTITTGAAAGTATACITTATACAGTGAGAAGTCCTCTCCATCTCTGTCTCTTGGAGATAATGATAGGCTATCGAATTGTG CT 
TGATTTCCTTTTTTTTCCTTGTTAATATTTAATTTATTTAGTATCTTTCATGTAAAGAGTTAAAGACTATGTGAAGGATTGAGTGTAT 
ATTTAAGTTATTGAAATTCTGAACCTCCTTAGTTCTCTTAAGTGGGGGTTGTGGGCTGCAGAGAAGAGTCAGCCGGTAAAGGCG 
CCCACTGTGTATGCCTAATGACACACATTTGATCCTTGCAACGCCCAGAAAGAGAGAACCAGTTCCACAAAGTAGTTCTCGGAT 
CTCCAAATGGATTCATATACACACTITTITTTUTTTTAAGGICTGAGTTGCATCTGGTGATACATAAGTGAAAACACACACCTTGT 
ITTCCAGCTTTTTGTCATATGGGGTGTGGCACGAGTGTTGCAGTCTGTCCCAGGTTGAAAAAGTCTGTGGCCCTTCGAAGCACC 
TTCATGGCCCGCTCCATGGTTCCTGATGGCTGTTGAAGTTTCAGGCCTGTACTTAGTCTAGGTTAGAAACCAGTCCATTCAGAA 
AGACTAAATCAGAGCATGGATGAAGTGGATCCTCCAACCGTGTAGATGAGTCTCTTGATTCATAATAAGAATCTTCCATTTTAATT 
GAAGGGTCATGCCTAAGTGTAGAAAACAAGTTCCCTAACTGTATGGAGTAACCAAAGGATAGTTCTGTATTGAAGTTGACTTAAA 
GTATCAAAGATCACTCCCCACATGATTTAGCAGTTAAGTCGGAGGCAGCGCCTCAGCCTGGGCATCCTAACTCTGGACTTTGAT 
TCCCCATTTACAATGTAATACTGAGGTTATATCCTAGTATTACTAGTTCTTAAATGTTTATTTAGGTGTGGTAGACATACATTAT 
TTATTTGC 	 GGTTTATTGAATTGTTTCAAGAGATTTGTCTTGCA 
Consensus AU-rich instability element 
262 
Appendix B Mdmx Est sequences with exon 6 spliced out 
Species Tissue/cell type Accession number 
Rattus norvegicus Placenta CV103442 
Homo sapiens Embryonic stem cells CN409878 
Homo sapiens Testis DR007225 
Homo sapiens Squamous cell line 1E7 BP353227 
Homo sapiens Synovial membrane BP344167 
Homo sapiens Brain BP310272 
Homo sapiens Fetal muscle BP231576 
Homo sapiens T cell Jurkat cell line BX383381 
Homo sapiens Chondrosarcoma tissue cell line BU619731 
Homo sapiens Bone marrow cell line K562 BP282772 
Homo sapiens Myeloma cell line KMS-5 BM848342 
CV103442 
CTGTGCAGGCCTTAGGACCTTCAACTGCCACCCCTCCCCCAGCTAGGAGGGGGGAGCGACTCATGGAGCGGCCGTAAG 
TTGCTAACTGAGTTTGGAATCT TCACTGCCAAAATGACATCACAT TCCACCTCTGCCCAGTGTTCAGCATCTGACAGT 
GCTTGCAGAATTTCTTCGGAACAAATCAATCAGGTACGACCAAAACTGCAGCTTCTCAAGATTTTGCAAGCAGCAGGT 
GCTCAGGGGGAAGTTTTCACCATGAAAGAGGTAATGCACTATCTAGGCCAGTATATAATGGTGAAGCAGCTCTATGAT 
CAACAGGAGCAACATCTGGTGTACTGTGGTGGAGACCTTTTGGGAGATCTACTTGGATGTCAGAGCTTTTCTGTGAAA 
GATCCAAGCCCTCTGTATGACATGCTAAGAAAGAACCTTGTTACGTCAGCCTCTGTTAACACAGCACGGTGCAACAGA 
GTGCTCCAACCCCAGAAAAAGAACTGAAGAAGATGATACTCACACACTGCCTACCTCACGACGTAAATGCAGAGATTC 
CAGAGCAGATGAAGACTTGATAGAACATTTATCTCAAGATGAGACATCTAGGCTTGATCTTGATTTTGAGGAGTGGGA 
TGTTGCTGGCCTGCCTTGGTGGTTTCTAGGGAATTTGAGAAAACACTATATACCTAGAAGTAATGGCTCAACTGATTT 
ACAGACAAATCAGGATATAGGTACTGCCATTGTTNCAGACACTACGGACGATTTGTGGTTTTTAATGAGACCGTGTCA 
A 
CN409878 
TCGGCACGAGGATCTTTTGGGAGAACTACTGGGACGTCAGAGCT TCTCCGT GAAAGACCCAAGCCCTCTCTATGATAT 
GCTAAGAAAGAATCTTGTCACT TTAGCCACTGCTACTACAGCAAAGTGCAGAGGAAAGT TCCACTTCCAGAAAAAGAA 
CTACAGAAGACGATATCCCCACACTGCCTACCTCAGAGCATAAATGCATACATTCTAGAGAAGATGAAGACTTAATTG 
AAAATTTAGCCCAAGATGAAACATCTAGGCTGGACCT TGGATTTGAGGAGT GGGATGTAGCTGGCCTGCCTTGGTGGT 
TTTTAGGAAACTTGAGAAGCAACTATACACCTAGAAGTAATGGCTCAACTGATTTACAGACAAATCAGGATGTGGGTA 
CTGCCA.TTGTT TCAGATACTACAGATGACTTGTGGT T TT TGAATGAGTCAGTATCAGAGCAGTTAGGTGTTGGAATAA 
AAGTTGAAGCTGCTGATACTGAACAAACAAGTGAAGAAGTAGGGAAAGTAAGTGACAAAAAGGTGATTGAAGTGGGAA 
AAAATGATGACCTGGAGGACTCTAAGTCCTTAAGTGATGATACCGATGTAGAGGTTACCTCTGAGGATGAGTGGCAGT 
GTACTGAATGCAAGAAATTTAACT 
263 
DR007225 
GCACGAGATTTCAAAATGCTGCCGAGGCCCTAGGATCTGTGACTGCCACCCCTCCCCCCACCCGGGCTCGGCGGGGGA 
GCGACTCATGGAGCTGCCGTAAGTTT TACCAACAGACTGCAGTTTCTTCACTACCAAAATGACATCATT TTCCACCTC 
TGCTCAGTGTTCAACATCTGACAGTGCTTGCAGGATCTCTCCTGGACAAATCAATCAGGTACGA.CCAAAACTGCCGCT 
TTTGAAGATTTTGCATGCAGCAGGTGCGCAAGGTGAAATGTTCACTGTTAAAGAGGTCATGCACTATTTAGGTCAGTA 
CATAATGGTGAAGCAACTT TATGATCAGCAGGAGCAGCATATGGTATATTGTGGTGGAGATCT T TTGGGAGAACTACT 
GGGACGTCAGAGCTTCTCCGTGAAAGACCCAAGCCCTCTCTATGATATGCTAAGAAAGAATCTTGTCACTTTAGCCAC 
TGCTACTACAGCAAAGTGCAGAGGAAAGT TCCACT TCCAGAAAAAGAACTACAGAAGACGATATCCCCACACTGCCTA 
CCTCAGAGCATANATGCATACATTCTAGAGAAGATGAAGACTTAATTGANAATTTAGCCCAAGATGAAACATCTAGGC 
TGGACCTTGGA.TTTGAGGAGTGGGATGTAGCTG 
BP353227 
ATTTCAAAATGCTGCCGAGGCCCTAGGATCTGTGACTGCCACCCCTCCCCCCACCCGGGCTCGGCGGGGGAGCGACTC 
ATGGAGCTGCCGTAAGTT TTACCAACAGACTGCAGTTTCTTCACTACCAAAATGACATCATTT TCCACCTCTGCTCAG 
TGTTCAACATCTGACAGTGCTTGCAGGATCTCTCCTGGACAAATCAATCAGGTACGACCAAAACTGCCGCTTTTGAAG 
ATTTTGCATGCAGCAGGTGCGCAAGGTGAAATGTTCACTGT TAAAGAGGTCATGCACTATTTAGGTCAGTACATAATG 
GTGAAGCAACTTTATGATCAGCAGGAGCAGCATATGGTATATTGTGGTGGAGATCTTTTGGGAGAACTACTGGGACGT 
CAGAGCTTCTCCGTGAAAGACCCAAGCCCTCTCTATGATATGCTAAGAAAGAATCTTGTCACTTTAGCCACTGCTACT 
ACAGCAAAGTGCAGAGGAAAGTTCCACTTCCAGAAAAAGAACTACAGAAGACGATATCCCCACACTGCCTACCTCAGA 
GCATAAATGCATACATTCTAGAGAAGATGAAGACTT 
BP344167 
ACTCGCCATTTCAAAATGCTGCCGAGGCCCTAGGATCTGTGACTGCCACCCCTCCCCCCACCCGGGCTCGGCGGGGGA 
GCGACTCATGGAGCTGCCGTAAGTTTTACCAACAGACTGCAGTT TCT TCACTACCAAAATGACATCAT TT TCCACCTC 
TGCTCAGTGTTCAACATCTGACAGTGCTTGCAGGATCTCTCCTGGACAAATCAATCAGGTACGACCAAAACTGCCGCT 
TTTGAAGATTTTGCATGCAGCAGGTGCGCAAGGTGAAATGTTCACTGTTAAAGAGGTCATGCACTATTTA.GGTCAGTA 
CATAATGGTGAAGCAACT T TATGATCAGCAGGAGCAGCATATGGTATATTGTGGTGGAGATCTT TTGGGAGAACTACT 
GGGACGTCAGAGCTTCTCCGTGAAAGACCCAAGCCCTCTCTATGATATGCTAAGAAAGAATCTTGTCACTTTAGCCAC 
TGCTACTACAGCAAAGTGCAGAGGAAAGTTCCACTTCCAGAAAAAGAACTACAGAAGACGATATCCCCACACTGCCTA 
CCTCAGAGCATAAATGCATACATTCTAGAGAAGATG 
BP310272 
ACTCTCGCCATTTCAAATGCTGCCGAGGCCCTAGGATCTGTGACTGCCACCCCTCCCCCCACCCGGGCTCGGCGGGGG 
AGCGACTCATGGAGCTGCCGTAAGTTTTACCAACAGACTGCAGTTTCTTCACTACCAAAATGACATCATTTTCCACCT 
CTGCTCAGTGTTCAACATCTGACA.GTGCTTGCAGGATCTCTCCTGGACAAATCAATCAGGTACGACCAAAACTGCCGC 
TT TTGAAGATTT TGCATGCAGCAGGTGCGCAGGGTGAAATGTTCACTGTTAAAGAGGTCATGCACTAT TTAGGTCAGT 
ACATAATGGTGAAGCAACTTTATGATCAGCAGGAGCAGCATATGGTATATTGTGGTGGAGATCTTTTGGGAGAACTAC 
TGGGACGTCAGAGCTTCTCCGTGAAAGACCCAAGCCCTCTCTATGATATGCTAAGAAAGAATCTTGTCACTTTAGCCA 
CTGCTACTACAGCAAAGTGCAGAAGGAAAGTTCCACT TCCAGAAAAAGAACTACAGAAGACGATATCCCCACACTGCC 
TACCTCAGAGCATAAATGCATACATTCTAGAGAAGA 
BP231576 
ATTACTCGCCATTTCAAAAGCTGCCGAGGCCCTAGGATCTGTGACTGCCACCCCTCCCCCCACCCGGGCTCGGCGGGG 
GAGCGACTCATGGAGCTGCCGTAAGTTTTACCAACAGACTGCAGTT TCT TCACTACCAAAATGACATCATTTTCCGCC 
TCTGCTCAGTGTTCAACATCTGACA.GTGCTTGCAGGATCTCTCCTGGACAAATCAATCAGGTACGACCAAAACTGCCG 
CTTTTGAAGATTTTGCATGCAGCAGGTGCGCAAGGTGAAATGTTCACTGTTAAAGAGGTCATGCACTATTTAGGTCAG 
TACATAATGGTGAAGCAACTTTATGATCAGCAGGAGCAGCATATGGTATATTGTGGTGGAGATCTTTTGGGAGAACTA 
CTGGGACGTCAGAGCTTCTCCGTGAAAGACCCAAGCCCTCTCTATGATATGCTAAGAAAGAATCTTGTCACTTTAGCC 
ACTGCTACTACAGCAAAGTGCAGAGGAAAGTTCCACTTCCAGAAAAAGAACTACAGAAGACGATATCCCCACACTGCC 
TACCTCAGAGCATAAATGCATACATTCTAGAGAAGAT 
BX383381 
CTGCCACCCCTCCCCCCACCCGGGCTCGGCGGGGGAGCGACTCATGGAGCTGCCGTAAGTTTTACCAACAGACTGCAG 
TT TCTTCACTACCAAAATGACATCATTTTCCA.CCTCTGCTCAGTGTTCAACATCTGACAGTGCTTGCAGGATCTCTCC 
TGGACAAATCAATCAGGTACGACCAAAACTGCCGCTTTTGAAGATTTTGCATGCAGCAGGTGCGCAAGGTGAAATGTT 
CACTGTTAAAGAGGTCATGCACTAT T TAGGTCAGTACATAATGGTGAAGCAACTT TATGATCAGCAGGAGCAGCATAT 
264 
GGTATATTGTGGTGGAGATCT TT TGGGAGAAC TAC T GGGACGTCAGAGCT T CTCCGTGAAAGACCCAAGCCCT CTC TA 
TGATATGCTAAGAAAGAATCTTGTCACTT TAGCCACTGCTACTACAGCAAAGTGCAGAGGAAAGTTCCACTTCCAGAA 
AAAGAAC TACAGAAGAC GATATCCCCACACTGCCTACCTCAGAGCATAAAT GCATACAT T CTAGAGAAGATGAAGAC T 
TAAT T GAAAATTTAGCCCAAGATGAAACAT CTAGGC TGGACCT T GGAT T T GAGGAGTGGGATGTAGCTGGCCTGCCTT 
GGT GG T T TT TAGGAAACT TGAGAAGCAACTATACACCTAGAAGTAATGGCTCAACTGATTTACAGACAAATCAGGATG 
TGGGTACTGCCATTGTTTCAGATACTACAGATGACT TGTGGTT TTTGAATGAGTCAGTATCAGAGCAGT TAGGTGT TG 
GAATAAAAGT TGAAGCTGCTGATACTGAACAAACAAGTGAAGAAGTAGGGAAAGTAAGTGACAAAAAGGTGATTGAAG 
T GGGAAAAAT GAT GAC T GGAGGAC 
BU619731 
TTTTTTTTTTTTTTTTTTCAAAATGCTGCCGAGGCCCTAGGATCTGTGACTGCCACCCCTCCCCCCACCCGGGTCTCG 
GCGGGGGAGCGACTCATGGAGCTGCCGTAAGT TT TACCAACAGACTGCAGT TTC T T CAC TACCAAAATGACATCAT T T 
T CCACCTC T GC TCAGT GT TCAACATC T GACAGTGCT TGCAGGATCTCTCCTGGACAAATCAATCAGGTACGACCAAAA 
C TGCCGC T T T TGAAGATTT TGCATGCAGCAGGTGCGCAAGGTGAAATGTT CACT GT TAAAGAGGTCATGCACTAT T TA 
GGTCAGTACATAATGGTGAAGCAAC T TTAT GAT CAGCAG GAGCAGCATAT GGTATAT TGTGGT GGAGAT CT T TTGGGA 
GAACTACTGGGACGTCA.GAGCT TCTCCGTGAAAGACCCAAGCCCTCTCTATGATATGCTAAGAAAGAATCTTGTCACT 
T TAGC CAC T GC TAC TACAGCAAAGT G CAGAGGAAAG T T CCAC T T C CAGAAAAAGAAC TACAGAAGAC GATAT CC CCAC 
ACT GC C TACC T CAGAGCATAAAT GCATACAT T C TAGAGAAGAT GAAGAC T TAAT T GAAAAT T TAGC C CAAGAT GAAAC 
ATCTAGGCTGGACCT TGGATTTGAGGAGTGGGATGTANCTGGCCTGCCTTGGTGGT TTTTAGGAAACTTGAGAAGAAC 
TATACACC TAGAAG TAT GGCTCAACT GAT TTACAGACAAT CAGGATGTGGGTAC TGCAT TGT T TCAGATAC TACAGAT 
GAC T T GT GGT T T T T T GATGAGT CA 
BP282772 
AT T TCAAAATGCTGCCGAGGCCCTAGGACCTGTGACTGCCACCCCTCCCCCCACCCGGGCTCGGCGGGGGAGCGACTC 
ATGGAGCTGCCGTAAGTTTTACCAACAGACTGCAGTT TCTTCACTACCAAAATGACATCATTTTCCACCTCTGCTCAG 
TGT TCAACATCTGACAGTGCT T GCAGGATCTCTCCTGGACAAATCAATCAGGTACGACCAAAACT GCC GCT TT T GAAG 
AT T TTGCATGCAGCAGGTGCGCAAGGTGAAATGT TCACTGT TAAAGAGGT CATGCAC TATT TAGGT CAGTACATAAT G 
GT GAAGCAAC T T TATGAT CAGCA.GGAGCAGCATATGGT T TAT T GTGGTGGAGAT CT T T T GGGAGAACTAC T GGGACGT 
CAGAGCTTCTCCGTGAAAGACCCAAGCCCTCTCTATGATATGCTAAGAAAGAATCT TGT CACT TTAGCCACTGC TACT 
ACAGCAAAGTGCAGAGGGAAAGTTCCACTTCCAGAAAAAGAACTACAGAAGACGATATCCCCACACTGCCTACCTCAG 
AG CATANAT G CATACAT T CTAGAGAAGATGAAGACT 
BM848342 
GCCACCCCTCCCCCCACCCGGGCTCGGCGGGGGAGCGAC TCAT GGAGC TGCCGTAAGT T TTACCAACAGACTGCAGTT 
TCT TCACTACCAAAATGACATCATT TTCCACCTCTGCTCAGTGTTCAACATCTGACAGTGCT T GCAGGATC TCT CC TG 
GACAAATCAATCAGGTACGACCAAAACTGCCGCTTTTGAAGATTTTGCATGCAGCAGGTGCGCAAGGTGAAATGTTCA 
C T GTTAAAGAGGTCATGCAC TATTTAGGTCAGTACATAATGGTGAAGCAACT TTAT GAT CAG CAGGAG CAG CATATGG 
TATATTGTGGTGGAGATCTTT T GGGAGAACTACT GGGACGTCAGAGCT TCT CCGTGAAAGACCCAAGCCCTCTC TATG 
ATATGC TAAGAAAGAATC TTGT CAC T TTAGCCAC TGCTAC TACAGCAAAGTGCAGAGGAAAGT TCCAC T TCCAGAAAA 
AGAACTACAGAAGACGATATCCCCACACTGCCTACCTCAGAGCATAAATGCATACATTCTAGAGAAGATGAAGACT TA 
AT TGAA 
265 
Appendix C The first 20,000 bp of genomic sequence 3' to the CJBS TATA 
box 
DNA segment immunoprecipitated using c-Jun antibody (c-Jun binding sequence, CJBS) 
ATGAGTCAT = AP-1 Site 
Largest ORF (324 bp) 
5' 
AGTCTGTTGTCAAGATAAAGCTAATGCACCTTAGCAATTIGTTAAAATTGGTCCTTTGICTTAGGGTTTCTGCTGCAGGAACAAAC 
CACCATGACCAAAAAAAGCAAATTGGGGAGGAAAGGGTTIGTTCAACTMACACTGTTCATCACCAAAGGAAGTCAGGACAGG 
AATTCAACAGTACAGGATCCTGGAGGCAGGAGCTGATGCAGGAGCCATGGAGGAGTTCTGCTTACTGGTTTGTTICCCATGGCT 
TACTTGAATGTGCGCTCTCGCGCTCTCTCTCACACTCACTCACACACACGTTTTAAAAACTTCTTATTTGTTAATTTCACATCATAC 
ACTCGAATTCCACTCATCTCCAGTCCCTICATACCAGCCTCTGTCCTTGCAATATCCCCTCTTAAAGAAAAAAATGTGGAAGTTGT 
AGTGTGTGACAGTGTGTCCCACAGTTATTICCTTGTGTTCACACTTTACTTGCAAATGTTCATTGCTATGAGTCATTGGICTGATT 
TGAGGCCTCTGTCTTCTGCTACTCTATAAATACTGGGT 
CCTCAATAGGACTCCTCACAGATACCCTGTIGTIGTCCTGIGTCATGGAGATCCTTCAGCTITGGATCTGCAGGACCAGCCCTT 
CACATCCTCCAGTTCACTGATTGGGTAGAAACCTIGGATCTGGGCTGGTTGAACTGGTGAGCCTGTTAACTCTCCTGTACCTAC 
ACCATCAGGGAAAACCCICTAGTCCIGTCCCGGGTAGCT 
CACCCAATGCTGCAGCTGAGCTGGCAAGGGGTGGACCCATTICTCCTCTAATGCTTTGGGCCATCTCACCCATTTCCATGCCGG 
CAGGACCAGCTCTAATGTTCTGCCCAGGTGAATGAAGTACAGGGCCTGCTCTCCTTGAGTGCTGCAGCACAGCCTGCTTTCTTA 
TAGAACCCAGTAATAGCGCTACCCACAATGGGCTGTGCCTICTTCCACTGATCACTAATTGAGAAAATGCGTTATAGCTGGATCT 
CATGAAGGCATTTCCTAAACTGAGGCTTTTTCCTCTATAAGAGCTCTAGTTTGTGTCAGAGTGAAACAAAACCAGCTAGTGCAAC 
TGAATCCTTGTGAACTTGATACACAAGCACATCACAACCCTTCCTGTCTTATATCCAAATATCTTAAGTCCCATAGICTTCACAAA 
TTCAAACATTACAATTTCAGTCCCTTTAAATAGCCAATTTCTTCAAAATCCAGTCTTTTAAAATCCGAACTCTCTCAATTGTGGGCT 
CAAATAAAATAAAATAAACTTTCTTACTCCAAGAGGGAAAAATTAGGACACAGTTGCAAAGCAAAATCAAATTCCAACCATCCTAG 
TGICTGGGATCCACTCACCATCTTCTGTACTCCTCCAAAAGTGTTGGGTCTCTICTCCAGCTTCATTCCACTGTTGCTGCTGTTC 
TTGGITGGCATGICATGGGGCCAAACCTIGGCAATTCTCTCCAATTGGTTCATACCTTCAAAACTATTAACACTTGGATGACTTAT 
ATAGTACTGAGTCTGGCTGACAGCAGAAGATACAACCTTGGTCACCTGCTGACTTTCATGAAACACTTCCTGAAAGATTTGATTC 
AGTGTTGCTGGTCTCCTCTCAATCATCACTAATTTCTTAGCTACAGCTAACCAATGICAATTGTTCAGTAATGCAAAAGTTTCACT 
TCAGTGATGCTGGTCTCTTGTTAAGCTCAGCTGACTCTAGCTCCAGCTGACTAGAATGGCAGAATCTTAATTCAAAATAGCAAAC 
AGCCCTGATAGAAACTCTAAACTTCCTCTGAAACTTCAGTTAGGCCTCCATCTITTACACTGCTCTCAACATTGTTACTGICCAGG 
TTECTGAATAACATCCCACTGAGCTCTTAACATTTAATGGCTCAGATAGGCCAAAGTTCTGAAGCTCCTCCACATGTCTCCACAAA 
ACATGGCCAAGICTGICACTACAACACCCAACTATGCTGGTACCAACTTGICTTTGGGTTTCTATTGCTGGGACAAAACACTATG 
ACCAAAAAGCAAGTAGGGTAGGAAACAGTTTATTCAGCCTACACTTCCACAATACTGITTGTTCATCACCAAAGGAAGTCAAGAT 
AGCAACAGGGCAGGAACTTGGAGGTAAGAGCTGATTCAGAGGCCATGGAGGAGTGCTGCTTATIGGCTTGCTTTCCCTGGCTT 
GCTCAACCTGCTTCCCTATAGAACCCATGCTGGACTGGGCCTTGCCCCACTGACCACTAATTGAGAAAATGCCCTGCAGCTGGA 
TGGATCTCATGGAGGCATTICTTCAACTGAAGCTTITTTTTCTCTGATGGCTCAAATTIGTGTCAAGTTGACACAAAAACAGCCAG 
TACAGTTCTATTGTCCAAAACTGTTCTGCTTAACATAGCATGCTGAGAGAAAAGGGAGTAGGAACTGGATTAGCCTTAAGAAATA 
ATATAGCTATCAAACTGCAGTGATTAGTMTGTTCAGAGATAAGGAAGAAAAACTGAATCAAAAATTTGTTGGTAGTTTGACTAAA 
TTATGGACTITTCTCTGTTCCICTAACAGGGAAAAGAGACCAAGCAGAGGGAATGTAGGAAATTTCTCCAGTGTATTAGATATTTA 
AGCAATGTAGAACAAAAATAATTTTAAGTACATAGTGAGACTTMAAAAATGACTTATTACTCTAAATTTAATGATCATTCTTTTAA 
AAGCAAATAGTGGAAGTGTATTACTAATACCAGTTGATCATCATATAGTTTATACATCTTATTICCTTGTTCCTGGAATGAGCATTA 
TTAAAGCTTACTGIGTCTGGAATGGTGCCTITGGCATAAGCATTAAGAAATATATAGACAGGAAAGTITTGTGCAGATGGAAATT 
CTGCTTTCCTCATTTTAGTACCATTACTGCTATTTTTCTCCATTTCTTGACCACAAACAGGAAAAAACAAGAATATTTTTAGATTTAA 
GCTTTGITTATAGTAATTAGATTAATTITGTTATCACAGGATGGCCAGATGTGCATGAAAACCACTITGTGTTTCCCAACACAGAT 
CATATTAACCTCCATTITTTITCCCTITTGGACCAAGCAAGTGGTGACCAGACGATCTAGTCTGGAAAAGCTTAATTGCCAACTCT 
GAATTTAGTGGGGGTGGAGAAATTCCTTAGAGGGAAATGGGAATTTAGTTTCAAGATAGTAGTTICCATGTGCAAATGAGCTITG 
AATTCTCCTAAGGAGAAAAATGAATATTAGAAAAAAAGCTGCAAAAAAACCCAAAAGATTTAGGATAAGITTATTTITAAGGAAAC 
TATTTAAAATAAGTTACGATATAACTCACATAGTTTTGTAGGACTAAAAATAATGAACTTTTTTGCAGACCTTAAAGTTTCTCATCAA 
CACTTGAAAGGAGTTAAATGAGCTGACAGATTTAATTACTCAAAGTAGTCTGTATCATTTITTATTTCACTITGACATAAGACTTGG 
CACAAATCTATTATAAGCTGTGCTCATTTATTGCTGCACTTCTAAGTTATAAATCTGGTTTATATCTATGGAAAATGTAGTATAGTA 
TTGAAGACATGTCCAGTTATCTGGGCAATTIGTTITATGAGTTTATACCAAATTAAGTAGAAAGCATTTGGAGAATTTGTTTTTCCT 
CTGTGGGTTGCAAGTCAGTTAGAAAAAGACCTTTTTGAGCAAGGGAGTTCAGAGTTCTGGCTCTTTAGTCTATTTCCTGAATAGA 
TCTGATTAAAACATGATCTAAAAGICTGATTGATGGTGTCCATTTCCCMTCAATGTAACAGATACATTCAGAATGTTGACATCTA 
266 
TGAAAGGTAGAAACATTGATGCTGTATTGCATTCCCCTAGTATTTCTTACTAGTGGAGGAAATGAMAGTCAAGAGACAGGCAA 
AGCTAGTTTICTCAGGTAATAATTTCTGAAAMATAATATTTTATATAGTATACTTTTAGACTTTTAGAATGGCTTAGCCAAATTAG 
ATACAATATGTTCAAATAAACAGMG GTTGCTGATAATGAGGGTAATGTG GAGAGAAAGCMGTCATAACTG GGTATAAAGGA 
GGGGGAAGTGTTAACTGTTTCCTTCTTTAGTTCTCTGTTTTGGGAAGGGAGATTTCTTAGAAAGATGGACAAGAGG GAGAGAAAA 
GGAGACAGATCAAGAGATTTCTAAGGAAAAAGTTATGAATGGATTGTG TATGGCTG GACMTCCTC C CTCTTTGGGATTGGGGA 
TGGATTGACGTTTTTTCCTCTTAAAGGTATAG CAAATMTG TTTTAGTACTACAG GTGTTTTCTTTACCTTTTAATGCTGTACTTAG 
TTTTTTGAG CAGGGTCTCATTTAAGCTAAGCTG GATTCAGATTG GCTATATAGTTAAGGATGATCTTGATCTTCATATTCTTCTGC 
CTCTGCCTCATAATTG CCGGAATTATAGGCACACCACACAGCTGGCCTAAATTATATACTGTTAAAATGTTACACTTACTTCAAGT 
TAGCTCTGATTTATTTTATCAGCTCTTTCATTTTGGAG GGTAGGGTTTATACCTTMTGTTGGITTGCTTIGTMGTTCTGTTTTA 
TTTCCTIGGTGATACTGAGTCATGACTGTGTATCAAAACC1TTTTGGITTGGITTTGAGATTATGTAGTTATATAATTTCTACATTT 
CCITTCCTCCMAAATCTCTCCCCATGCCCCGTCTTTGTTCTTTAAATTCATGGTCTTMTTCGTTAATTGTTGTTACATGTGTG 
TATGTATGTGTACTCC TAAATATAAC C TGGTCAATTTG TATAATATTAC TTG TATCTGTTTTCTGAG CTGACCACATG GAATTGATA 
ACCAGTG GAGCGCTTTTCTCTG GGGAAGACTTAG TT CTTCCACTCTCTACATTCCTTICITTAACAMTATMTCTTG GATACTT 
TATGTATTTACATTTTAAATGTTATCCCATTTCCCCCTTAMGCCTGTAGTTTCTTGTTTAGAGTTGAGGCCCCATGATCTTACAG 
TGCCITTCAACTTGGGCGTGTTTGTTGGTGTTCTTGATCAG CTGATGTTAGACACTTTTGTGATGAGAATTTACAGGTGCAGCTT 
CTGATGCTACTGAGAGACTCACAGTAACCTTCCTGATTCTCTAGCTCTTAAATTTTTCTGTCCCCCTTTCTACACTGTTCCCTGAG 
ACTTACGTGCAG GAGCTGTMATGTATGTAGCCATTGGGACTGGGTTATACAAGTCTGCAMTGATTTGTTGTTTGTAGAGGA 
ATTTTAAACCAGCAGTGGATCACATCCAAAGGACTTCTAGGTATATATGATCCAGTTGGAATGCAGATATACTTTGGATTACAATA 
TGATCTGG TTGAATTC GACACACC CTTAATG TACCCTTAGTTCAGGATCATGCTAG TTCTACAAAG TG GTTATAGGTTCTTCTCCA 
AGATCCATGACTTCACTG TC CTTGGGAACTTTGCTAGGTTTCTGGTTTGCAGGCCTG GTTTCCCTCTGGTTGACTCGTCTGAAGT 
CTAGTTAGAGGTGCTCAGGACTGTTG GTTCCITCCTCCTGIGGCAGCTTACATGGTGCTTCGTGGTACATACMCITAG GTGAG 
TAAACAACAGTGTGATTCCTTATGACTTMCAGATGTTTTCACTATTCTTTCCACTTTICTGGTTTCAGTTATTCCAGGATATGTT 
CATGGTTATTITTGGGCGAGTTATGAGTTCMGTATATTTTGAATATTAATCTMATCAGATGTTTACCTTGCAGAGCTTCMCT 
CATTCTCTGG G GATTCTCTTG GTTAACTGCTTTMAGCTGTGCAGAAG CTITTTAGMTATGAAGTCCTACTTGTTAGTTGTTG 
G CCTTAATACTTAGGCAAATGAAGTCCTATCCAGAAAATTCTTTCCTGCACACATATAGGGTTTTACCTATATTTTTTTCTAGCAGT 
TTCCATGTTTTAGGITTTATATTTAAGTCMTGATCTAMG GAGTAGTMTTITTTCTTTTTTTTCTTTTTTCTTTMCTTTTTTTT 
CGGAGCTG G GGACCGAACCCAGGGTCTTGGGCTTG CTAG G CAAGCGCTCTACCACTGAGCTAAATCCC CAGC CC CTATTTGGA 
GTAGITTTATGCCAGGTGAAGCTGTAGTTAMTTCTATTGCMGAGGAGACATCATGACAAGACCAACTTAGAAATCATTTAGT 
TGGGGGCTTGCTTAAAAGTTTCAGAG GGCTAGTCTATAGCCATAATG GCAG GGAGTATGGTAGCAGCCAGTCAGG CAGTAGGC 
ATGGCGCTG GAGAAGTAGCTGAGCTTAAAGCTCATCTAAGGGAAACACCTCTTCCTACAAGGCCAGCGGTCCTGATCCTTCTCA 
AACAATTTTATCTGTGICAGAAGCATTCAAATGTGAATCTATGTGGGITTGCAGCTTTATCATAATG CAAGATGCACTTAGTCCAA 
CTTTAAAAGTACCCACAGTCTTTCAACGTCTGAATACACATTAAAAACCAAAGTCTTTGGAGAATCAATACAATCTCTGAACTGTA 
ATACTCTGTAAAATCAAAAAGTAAATTAATTCTTCCAGTGTACAGTGACATAGACTATAAATTACMTCCAACAAGGGAGGAAAG 
CAAGCATAATAATGAAATGCTGGACCAAAGCAAGACTGAACATAGCAAACCGCACTCTAAGTCTTGAAACTCTATATCTGATGTC 
AAAGGGTGTAACTCTTCTAGCTTTGCAGACTGCAACATCTCTCTTTGAAGAAGATTCTTTGAACAACATTCAATTGTTTTTCTAGT 
CCAAAGCCCCAAAGTCTTCCACAG CMGTATACCTGTCACAGTACTCCATTCCTGGCACCAATCTCTTAGTTGCTTTTCTGTTGC 
TGTAAAGACAACATTTAAAAGAAAAGCAATTAATTGGGGGTGTG GCTTACAGAGG GTACAGTAGACATGCATGCAAGTAGGAGT 
GACACTAAAAAAGTACCTGAGATTACATCTG CTCCATAAGCACAAGG GAGAGAGAGAGAGCGAATTGGGTATAGCACAGACM 
TGAAATCTCAAAAGTGACACTAATAAGGTCATACTTCCTAATACTTCCCCAGAAGTTCCACAAACTATGGCAGAAGCACAAACATA 
TGAACTTATGGGGACCATTCTTATTTAAAATCTCAAAGTGAGAGATAATGTGICTAATTTTGTACTTCTACATGTGAATGTACAGTT 
TTCCCAGAACCATTTTTTGATGCTTTCTTTTCTCTAGCTTACAATTTTGGCATCTTTGCTCAAGTATTAGGIGGCAGAAATTACATG 
TACTTACAMGGTTCTATAATTTTGTTCCATTG GGCTATATGTTTGTACTGG TACCATATTGMTTTATTACTATTGCTCTGTAAC 
GTATMAGGATCTACTGCAACAAGGCCACCCCTCTTAATAGTGCTACTCCCTATGGGCCAAGAATTTAGATATAGGAGTCTCAG 
GGTGGAGGCATATCATTTCAAACCACCCGTTCTACTCCATGGTGCCCATAAACTTGTAACCATAAAGTAATGCAAAAACGCATTT 
GGICCAACCTCAGAAGTCCTTATAGTCTATAACAGACTCAACACTAMAAAAATCTAATGTTCAAAGTCTCTTCTGAGATCCAGG 
CAATCTGTTAACTGTAATCTGTTATAAAATTAAAATTAAAGATCACATACTTCCAACATATAATGGCACAGGATATACATTATCATT 
CAAGCAAAATGTAG GGAAGGGAGCATAATAATGAAATAC TGGACCAAAGCAAGACTGAAAAACAGCTGGACAGACTTCAAGCTC 
TGCATCTCCATGTCCG CTG TCAGAAG TCTCTCCG GCTCTCCATCCCITTTCAGCTTTGIGGACTGCAACACACTTTTCTCTCTTA 
G GCTGGCTC CACTC CCTATTGGCAGCTCTCCTTGACAGGTACCTGTGGCCGTG GCATATCGGGGTTTCCAAG GCACTG CAGGT 
TCTATCTTCATAGCTTCCCACAGTGG CC CCTCGGGG CTTC CGTGAAGGAACAACACCCTTGC CAC GTGC CTGGTCTCAGACTTT 
TCTTAGTTGTGGAGGACAGTTCCATAACCCTTGACTCTTTTGTATGTCTGATAAGATCAAACTACATCCCGTGTGCCTCTAGATTA 
AGGTGTAGAACTCTCAGTTCCTTCTAGCACCGTGTCTGCCTGCGTGCTGCCATGATTCTTAACTCTTGCTTCACAGAGTACTCTT 
GGCTCTAAAGTCAGTACTACATGGCCAAAGCTGCCATGTTCTGCTGCTTGCTAGGACTGGAACATGGCCTCCTTGCTGAATCAA 
GGCMACTTCATCACCTAAG C1TG GCT GTC CTGGAATTTGCTTTGCAGATCAGMGAC CTTGAATTTAGATCTCTCCTGAG TG C 
TGGGATTAAGGTTGTCTACCATTTCGGAACCTAAACTGTTTTTTAATATCTTTTCAAAAACTGGAAGCTTAGCTTGGTGG GATTCC 
GCCTTGAGGTTTACATTTTGAAAGGTTTAGTCCATTGACTGATGGTAAAGGAGCTGAGGGTTCTACATTTTGATTTAGAG GTAGC 
AGAAAGAGACTGGGCCACACTGGATGTAGCTTGATGATATCAGACATTAAAGCCTGCCTCTACAGTGACATACTTCCTCTAAAAA 
GGACACATG GCAACAAGGTCAGTAATAGTGCTATTCCCTATGGGCCTACCATTCAAAACCCATGAATCTATGGGGGTTATTCCTA 
TATTAACTAGTCAAACCACCATAGCAACCCAGGGATTTTGTTTGMGTTTTTAC 	1 1 1 1 1 1 GGTTTCATGTGAATGTTAGTATTGTC 
TTTTCTATTTCTGTGAGGAATGAGATGGGGATTTTCATTTAGATTGTATTGAATTCAATCTGTCATGATTCTTACCATGACAATAAT 
GAACTAACCCTCTCAAAATGTAAGCTAGCCCCAGCTAAATGTTTCCTTTATAAGAGTTGTATTATG GGTCATG GTATTTTTCACAA 
CAATAGAAACCCTAAGACAGAAGTTG GTACCAGGGATGGATAATCCAGCAATAGGTCTAACCTTGTTTTTCTTTAGAAGAATGTG 
GACMGGGACTCTGAACTAGG AAAGTAGTTGGACAATTTAAGCTCAGCTTAATGGGCCATATTG CATTGAATATATATTCTGCAA 
ATAGCMTGTTAATMCATAGTTACTTCTATCACTTCATGAACATGG GATAG CTTTCTATTTTCTAGCACCATAAATATATAATCA 
ACAAATTGTAMGTTGATTCTTTGTACCTTCTCCCCTTGTTTCCACTTTATTTGTTTCTGCTCTTAATTGTAATATTTTTGAATGTC 
AAGTGGAMGGAGGCMGMTATTTTTCCAAAMTTGAGTTGCATCATTAAGTTATTTGTGTACCTAATTTITTATTTTTTCTA 
AATGTAGGGACTACTTTGAATACTGCTCTGAGTGTATCCCTGATGTTCTGTTGTG C TTTTG TTTTCATTTAGCTTCAGAATTTTT TT 
ATCTGTCTTGATTTATTCTTTCATTCATGAATCATTCAGTGATTAGTTCTATGAGTTTGTGMCAATCTCTGTGAGTTTCAATTAGA 
GACTTATTTGCTGTCAATTTTAAGTTTTCCTGCCTTGTGGTGAGATAGGGTTCAATGAGTCCTTTCAACCTTTTTGAATTTGTATAG 
ATGTGTTTTGTATTCCAG GCMCTTGTGCCGCTGTGCAGAATATG CATTCMTCTGTTTCAGTGGAACGTTCGTTCTGTAGATA 
TTGATACATGATAC CAATTAATTCTGATGAATCTCTTTMTTTTG TCCAGATAACTTGTCTG TTGGAGAAAGTG GGGTATTG GAAT 
CACCAATTATTAATGGATTGTGTTAATCTGTTICATTAGTTCTAGAAGTAAAMTTTAATATAAAATTGGGTGTTCCAGAATTTGAT 
ATATACATGCTTAGCACAGTAATGTCTTG GTTAACTGCTCCCTTGAAGITTGTTACATATTAGGATGAAGGCTTATGCTTGCTTTC 
TGGTCCCATTTGATTGAGGTACTTTTATTTTTGAGCATTCTATTATGCTAAGGCAGTTTCCATCTTTAAAG CTAAGACCTGTTTCTT 
267 
CCAGAGAACAGAAGTATTTCATTTCTTGATTTATTCAGTCAGTATGTTAATTGTGACTTCATGTTGACTTTTTTTGTTTGTAGAGAT 
AATTIGTGTTTTAATAATTATGGTTTGATATTTCTATCCATATAGTCMCTGCTGTGACCATTCCTCTCTTGAGTATGAAAGATTGT 
CTTCTGTATTTTMTAGATTTTGATTGTTAGATATTACATTTTTAAGGCTTITTATACTGTGCAATGTTTTTTTMTTCAATTATGG 
CAGTTMATAGGTATATTAGACTAGGCTGGCCTGTCATAGTCTITTAGGATTCCCCGGGGGGAAAAAGCCTTGTTCCAGGATTA 
TAAGGGTTCTAAGMCCATTGAGAAATCATCTGTTATTCTGATGGGTTITTCTTTATATGTGACTTGTAGTCTTTITCTTGTAGTTT 
CAGTACTCAGACTTTCTTACATATATTTAGTGTTTTAACTATGATATGCTATGGAAGTTTTCTTTCTGGTCTNGTCTAGTTGGTGTT 
CTGCCAGCTTCATATGAGGATGTGTTTTCTTCATTTGGTGAAGTTTTCTTCTATGATCTTGTTGAAATGTGGTCTACGCCATTGAC 
TTCATATTGTTCTCCGTCATCTATGCCTAAAATCTGAAGGTTATATCTrTTTATGATGCCCAACATTCGTCTGTTGGTTCCCTATGT 
GGTTAAATTTMCATATTCGTTATTTAGTTGGTCTAGCTGTTGAGTCCTTATATCTTTCACTTGAGGAGTCTCAGCTAGAGATTCA 
TCTTTTAGATGCTCTGGGGCTTCTGAATGCATGTTTGTTTATTGACTTTTTTTCTTATTCTGGGTACTTCCTCTTGTGCATGGGGT 
GGACAGTTGCTTGTGATTGTGGGGACAAGCTCCAAAACTTATCTTCAGGTTTCGCCGCAGATATCTGGAAAGGCCAGCTTGCCT 
GACAGGTCTTTCATGCTTAGAAGTTATAATTGTTTACAGGCTGGAAGGACCACAGTGGACTCTTGAGGTCTTAGTGTTGITTATG 
CCITGCATTGICTATGATCCATGTCTATGGTCCAGCCTGTATTTCCCATCATTCTCTTATCTTGCAGGGAGTCATATACTTTCTGA 
TTTGTGAACAGATTCTCATTTATATATATTATTATATGTTCATTCCAGTAAAGTACATTTTMTGTCATTTGTAGAGATTCACATTG 
CTTATGCTGACAGATTGAGTTAAATCCACATCCCMTGGGCTTTAGGTAGTATGGCTTGCTTGGGATTTTCACTAAGTCTCCTCA 
TCTTGAAAATTCACCAAMTCTCMATTGTTGATATTTACGTCATGAATATCTGAAGAGGTATTAGAAGGGAACCAAAATACAGT 
GAAATTATCACTATAACGAAAAACATTAAAAATTATTTCAGCTCCTITAGTGTACAAAGTATTAAGTCTCATATTATATTTTCATATT 
GGICCTTATATTTITCTCCTTATTGCCCTCTCCAGTCCCCTGCGCCCTCTGACATGTTCTTTTCTITTCTCCATGTATTACCTGTCT 
TTTICTATGGCATTGGGAATTGAACTCATGACCTTCTGTATATTTTATAAGCATCATACCATTGAGCTATGTTTCTTACCCCTATTT 
TATAACCMAACCATCCTAMAGAAATCTCAAGGACACATGTTGAAATAATCAATCACTCAATGITTTCCCCATTTATATATGATT 
ATTAGGACTTACAGATAACTGCTTTGTCCTTTAAAGGAGTCATAATAGATGAGAAGAAACAGTCATTGAAAAAATTTGTGAACTTA 
ATGCTTCAGATAATTAGTTAATTATAAACACACAGATTTATGGTCACGGTCATAGATGGGAAATGTGAGTTGCACAAATAGATTTA 
GAAAATGGTCTTTTTATTAGAAGAATATAATTATTTGATAAAACTAATTTATCTTTATCAGTGAGGATTTTTTTTCCTTTGAACTCAT 
GAGAACCAAACTCTGCAAGTTGTCCTTGGCCTTCACATGCATTCTCTCTGTCACACACACACCACACATACACATACACACACAC 
ACACACACACACACACACACACACACACACACACACACACCACAGCACAGGGAAATAGAATAAATTATAATAAATTGTAATAACA 
ATTTTAAATAATTATTGGTGAAAACAGGTCTTACTCATAAAGGTAAACTTAAGTATAAGGATGTACAAATACCATTTATATTAAAGA 
ATGACCTCTTAGAAAACATTTGGGCCAAAACTTAATACAAAGAAATTGATATAATTTTTAGTTTTATTACTATATTCACATCCTATTC 
TKITGTTAATAACATAGTTCTGTTAAATATCCIGGTATTTATTCATGCTAAGGTCTGTCAACATTTATGTTCAGGITACTTAATACA 
GATTTATAAGAGATGAATTIGTAGGCGCCACATTGCTTTGTCAAAATAAATTCCATAATTGTAAAAATGCATGATAAAGCAATTACT 
TTCTGAAAACGTGCTTTCTTTGCTAAGTCGCTCCTGTATTTTTACCTAGACATTGTCCCTTATTCCTGTCATTGTTTTAGAAATATT 
ATMACTACACAATAGTTGACTACTTICAGACTGTGCGGATTTTAACACTCTATTTCCTTTATATTGGTTCTGTTAATCTAGTTATT 
GTCAAAAGACCTGATAATGTTAATGCATTTCTTCTCGTAGTGTCCTGGTAATGTGTACATTTATTCTGTGTGTCTAAAATGTATGTA 
ATGAATTCAGCAGTIGTGAGTGAATGAAGGGTAGITTATGAGCCAGTAACAAAAAGGAGGGCTCTTCAAAGAAAAAGATATTAGA 
TTGAATAAAAGAGTGAAAGAGAGAAGAAAAGAAGGGGGTGGGGAAGAGAGGAAGGGATCCAGAAGGAGGAGGAAGAGGAGAA 
GAAGACATCACTCGGATAGCACGTCAGTTACTGGAATTTATGGTCATTGGATTTAAAAATAGCTTGGTGGITCTCCAGGATACCT 
CAGTGTCCTGAGAATGTGATAATCTGGATTIGTTTACTGTTTGTCATTGCCATTGTCATTGTTATTTCTCATGAATGCGTATATTTA 
TATCTATGATAATGGCAAACTTGGAAAACATGGTATACGTTCAAACATAAAATTCATCATCAAATTATAATTATMTAAGATTACTA 
ATAGAAAAGAAACTITTATTGGCTTTGTCAAAAACAAAATCAAAATGTAAGMTCTCAGCTACGGCTTGAGCACCATGCCTGCCT 
GCCTGTCTGTCTGCTGCCGTTCTTCCCGCCATGATTGTCATCGGTTCATCCCCTCAGACTGTAAGCAAGCCCCCAGTTAAATGC 
TCTGAAATTTGAAGTATATTGAAATGCTGTGAGAACMCAGATGTTGGCATTTGGGTTTTCTTCAGTGGGTTGGACTTACAACTG 
TAAAATATGTCATGAGGCATGCTTGCAGAGTTTGCCTCCGAGAAACCTAAATATTCCTACTGTTTTTAAATATGTTGATGGAATTA 
CTTAGTTGICAAAATGAGCMACACTCGTTCCTACAAAGGCTTCACTACTTTGGAAGTTAGTTATTAGAAACTAACCTTCCACTG 
CAGCCTTCTTCTAAGAGTGTTTGTATGAACCTCTCTTATAATAAAATGCAGTGTTCTCAGTTCTGTGTTGACATGGAAACAACCTG 
CTTAAGAGAAAAGTAATTAAAAGGCGTTAGCATAATACTGAATATCACTTGAAAAATATGTAGCMCTATAAGGATTTAAGAACAA 
TGTGCCAATAACTITTAGGATTCCAGTAATCMTCCTGACTTAGCCACCATTTGGAATAGIGGGAAATAAAACTTACAAGGTCTA 
GAACATTITCCTTTTGGTATTGGAAATTGAGCTCAGGGTCTTGAACATTACTAGGCAAGCATACTGTCACTGAAATATGTCTTGAG 
CCCTTCATTTTITTTTCATTTTGAGGTAGTATCTTGCCAGCTTTCTTAAACTGGITTTGAAGTAGCACTGTAAGTCAGATAGGCCTT 
GAACTAATAATTCTACCGCTTCATCCTCTCTAGTAGCTAGAAATACAGGTCTACTCAGCAATTCTTACTTACAGTTAATATTTTAAA 
CTACTITTAATTACAATGGCTGTGCAGTCTATTTTGTGAGAATAACCAAACAAAGGTTGAATATTGTCATTAACACAGGTATCTTA 
GTTACTACTTCTATGACAAAGCATCCTCACCAAAGCAACTTATAAAAGAAAGCACTTAGTTGGTGCATACTTAACAGTTTGAGGG 
GGTGAACCGATGACCATCATGGCGGGAAGCACAGCAGCAGGCAGACAGGCAGGCAGACAGGCAGGCAGGCAGACAGACAGG 
CAGGCAGGCAGGGAGGCAGGCATGGTGCTCGAGCCGTAGCTGAGAAACTTACGTGTGTGTGTGTGTGTGTGTGTGTGTGTGC 
CTGTGTCTGTGTTGTGGGGAGAAGGTGGGGGTGAAGAAGGAGGAGAGAGGTCCTGTACTGGAAAACTGGAAAGAGCTGCTAT 
GCTTGCAGAGAAGTAGAACTGGATACTTGTTTGTAGTATTCAAGTCCCACACAATTTCTAATTITCCTTCATCTGTTGCTAGCTCT 
ATAGTCGCTTGCTCTGGAGTTCTGGCTTTTGTTCAAATTTGTTCTGTCCTGTCTTGTTICTACCAACCTATGTCTATGGCATATTC 
CATTATCCTCAAMCTGACACTGGCTTATACCCAACTTTAATATTGCTCCTTCTTGTCTICAGGGTTGAAATCTCAAAGCAACTG 
CAGTTCACATGTCATTTATTTCTTAGTTTTCTTAGGGAAATATTAAAATCAGMTCAAAATTACACACACACACACACACAGGAGG 
GGGGAGGGGGAGGGGGAGGGGGAGAGGGAGAGACACACACACACACACACACAGACAGAGACATACACATATGCTTCACATA 
AGTAAATTTACATCCCMCAGGAATCTGATATATTTGAGGATTTTCAATAGGTTGAGATTGGGTGGATCATCCTGAGGAAATAGT 
TAGCAAAGATGGATAGAAAGCTTGGGATGGTTTGAGAGATGATATAACCATTTATATGTAAGGCAATATTTTTCTGCATATATCTT 
TCTCCCAATAATGAGACTICACATTTAAAAAAGGCGATTTTTAAAAAAAATGTATACGTATTTCTGTGTGTATATGAACTTTTGGGC 
ACTTGCAGAGCCCAGGAGAAGTTGAATTCCGTGTAG CCAGAATTACAGGAACCTGATGGTGGGGCCTGATCTCCAGTTCTCTG 
GTAGAGTAGCAAACACTTTTAACTGCTGAGCAAMCTACAGCCAAAAGATTTTGTTTITTAAAAATAACTCACTTAAATATTAGAC 
AATTGATTGCAAAAGTCATTICAATAAAAACATGAACATTTGAAGTGAGGCTICTGAGGAATGAAGGAGAACTITATTCACTTGAC 
CTCCCTTTGGAATATGAAGGGAAGGACGCAACTGAGACTCTTCTGCAGATTTCTGGTTTAGTGTTTCTGAGTGGTCGGGAATAT 
GACTTACAGAGCAGGGTAGTTAGAAGAGCTAATAGGTTCTGAAGGCACAGATGATGGTGATTTCCTGTCACTTCTAATCCAAAAG 
GAGCTATCTAATCGAGAATTAAATGCTTCACTTGGAACTCAGAIGGAGACTGGGGATCCACATTATTCCAGITTITAAAGAGGTA 
AAGTGTGGAACGTGCTATAGAGAAGATAGAAAAGACTATTAAAAAACAGTAGTGCCATGGAAGGCTGGAGAATGTGGACTGCAA 
AGGGGGCTGCATAAGCCTTTGCATGTTGCAGTTCTGTGGCATGATGTAGCTAGAAGAGAGGGATACAAAGTCAGAGGAGTTGTT 
CATTGCCTCTGTCGGGAATTTTATCACAGTGGCTICTCACTGTAATCCCAATAATGCCTTTGAATAGAATGICTGTAGGCTACTGA 
AGGCTACCTAAGGCATGCTGAGACTTAACATCCTTCCTTITCTTGCATAATTAGAGAGTTTTCTGTAGTCACTTGCAATGTTCATG 
ACATATTCACATTICACTGTCATGGTCTGGAAAACATCTCTAAATACAAATTTGTTTTTACTTCTCTTTTTATCCTCCCCCITGAGA 
CAGTTCCTTATGIGTGTACAGGTGTGCCTGCAGCTCCTTAATGTGTGATTCCCAGACCGCAGCATCTTAAGATTTGGGATTGCAG 
GTATGTTCTACCATATACAGATTAATTTCTTCTCCCAGTTCCTGGGCTGGGAATTAAATCTCGGTCTTTACACATGATAAGCCTGT 
268 
GCTCTATCACAGGACTGCAATTCCAGCTAGAAAGTAACTICTGAGCCCCTAAAGATACTCTCITTGIGTGTACATTTGCCGCAAC 
ATTTTTATAGTAGCTCAAAGTTAGTTGTTTCTGCAAGAAATCATACTTGAATGTAACTTGGAATACATTACTTTGGATATAGCTTGT 
GTTAACTCTGCAAATGTCAAACACATAAATGATATAACTGAAGATGGCTTCCTATGTTTGTTGGTCTTGACATAACTCTTAGGATG 
TTGATTGATGTAAACGTGTTTATTATATGCATGGGGAGGCAACTACTCACTTCTACATCTAAATTCTATAGATTAGTTCTCATTTTA 
AAGTGAATTCAGTCTITGAGGTGAGGCTGGTAGTTAAATAAAGTAAAAACTGATGAGTTGAGTGAATAAAACATTGAACTTAAGC 
ATCTCTGTCCTTGGTAAATTTAGTGAGAATTTICAGCTTAAAACTCTGGAAAACTGAGTGCACTTGGAATTGGGCCATTGCTCTGT 
TTIGTGCTTCTAGTTTTTGTAAATTGGAGCACATATTGAATTTCAGAGTTCCCAAGCCAAAAATATATTAAAAACTACATATGCTCT 
TTCCTAGTGGAAAAACAGAGTGATCTCCAGTGGAGAGGGACTCCCTCTTCCGAGTTTTTCTGCAAAACGAGTTATTTATATATGA 
GCTCAGAACCACTGCCAAAAAGGTGATCATGACGTATCCTATCAATAAATTTGTTCTTTTGTTAAGATTATTTITATGCTTATAGGA 
ACATAAATCATATTTATTGCCTTTAAATATTCATGCAGATTCATATATTAACATCTTCATGTTTTTGTTGTCATAATTTGTATATTTGA 
ATTAAAAGCCTCTATAATTTATATGTAAACCAGCTGACTCCATAAATATAAACTGGATTCAGTCAAGCCGCCAGCGTGAAGACAC 
CTGAGTCAAGGTAGGTTGTTTTGGAAGTAGATATTAGTTGCTACTAGATGAGACCTGTGTCTTTTAGAAAAGGACAGATTAGGAT 
AATTAGAATAGTCCAATTACATCATCATACAGTTTGTTCTGTACGTGATAGAGGCAACTAAACTCTGTGAAGACTTGTGGACTGAA 
CATCGGTGCCTACTCAAGGTCTTTATCATTCCGACAAGTTCATATGATCCTGTGACAAGTTTATAAGCAAAGCATTTGAAATTATT 
AAGTATTATATGTGATGCCTGTAGGATAATGTGGAAAACTGAAGGACAATTAGGAAAGAMCCTTTTAGATCTGTTGICAAGAAT 
GAAGTGTTTTGGTTATGAGAAGTCAGGGAAGAATAGGAAATGGCCATCTCATTTTTTTTGTGTGTATTATAACTTTGTTGCATATT 
TTAAATACTCAGTAGAAACAATCGAAAAGGAAGAGATGATGTTAGTTTTTTTGAATTGAGTAGGAATGGAGAGGGGCTTTAAAGT 
TATTAAATTTCACTGATATTGTATAAACAGTTTTTAAAAAGTCAAGACACTTAAAGCTGGATCAAGTTTTGAAAATGGCGATTCCTA 
GTTATAAAGTCTACATTAGTAACTTATATTCTTACTCTATCTTCTAGTGTTGGATCACAAACAATCTTCCAGGATTTCTAAGTTCTG 
TAGCATCTACATTTACTCGTTGAATGTCTCTATAGAAATAGTCTAAGGAACTGTAGATGGATTTGAGAAGTCATGCTAATCTGCCA 
GAGTGTAGGGTTTTATTTCTACTGAGTAAGTTGAGGTCTAACCTITGGTGCCAGATTICTGCCCCAATTTCCTGGCTGAAACTGA 
AAACGTAGTTGGCAGTATCATGGGGTGGTTCAGGGAGCCGGGGGCAGAGACTATGTTTGCTGTGTTCATAAACCCTCATGGAAT 
ACATGCGGGCTCCAGTCACCCTTCTCTCTGCTCCACACGATTGCCTGCAGCAGGAAGGAAGGATCGTTTTCATCTCCTGGTACA 
CGGAAAGCTCTGAGCATCCAGTTACAATATCCTTTAGCAAATGGAGTCCCAGAAGGGCCTGCATGAACTTAAAGTGTACATGCA 
TTCTCTGGCTTTTCTTITTCAGACAAATATCTGCTCTTTAAATTATTCATTGCTTTGCAGAGGAAGTATTAATTACAGGACTGTAAG 
CTTAGATCAAGTTGGGATGTAATTACAGGGCTTGCTTTGTCTCTGTTGTCCAACAGAATCAGCCAGGAAGCATTCATGATGCCAG 
CAGGAGAAGGTGITTTAAAGCCCATTATGTCTTCGGTTCTCTCAAGAACTCAAGCCTGGATCAAGTGACAMCTGCTGCCCAGT 
TGTCTGGGAAAACAAAGCAGCAAGTATTAACAAGTTACATTITTATAAGTTTATAATGTTCATTGGTAGACTATGTAAATATGTTAT 
GTGTAACAATGAAAATGGATTTGTCTGTATCCTCATTCTTAATTTTTGATTTTCTTCTGTTTGTAGATGTGTGAGGGTATTCTTGGC 
TGTACATTTGTCTATC 
ATGTTAAAAACGATGAATAAAATGATAAATAGGIGTTTGTGCTACACAGTTTTATTTCTTTTTCCCCCCAC 
AGTTAATTTITTTACATTACATCACACTCCTGCCCCTGCAGATCTCTCCCCTTCCCCTGCTCTAACTCATACCCTGCTCTTCAGCG 
AAGGGGAAGCCCTTGCCCCCACCTGGGTGCCCCTCCACCCTGGGGGTCAGTCTCAGCAGGACTATGCGTCTTGTCTTCCACTG 
AGGCCCAGCCAGGAAGTCCAGGTAGGAGAAGGGGATGCAGTGGCAGGCCACAGAGTCAAAGACAGTCCCCGCTTCAATTGTT 
AG 
GGGATCCATATGAAGACCAAGCTGCACATGTGCTGCGTGTGTGTGTGTGIGTGTGTGTGTGIGTGTGIGTGTGTGTGTGTTGCT 
GGGGCTAGGICCATCTTGCATCCTGTGCATGTTCTTCGGTTGGTGGTTCAATGTCTGTGAGCCCCCATGGGCAAAAGCTAGTTG 
ACTCTCTAGGTCATCATGTGGTUTTCTGGCCCTTGGGCTTGCTCAGTTCTATTCCCGACTCTTCCAAGATTCCCTGAGCTCTGC 
CTGACGTTTGACTGTGGGTCTCTGCTGCTGGATCTGGCAGCATTGCATCACATCACAAAGCCTCCCCGGAGACAGCTATGCTAG 
GCTCCTGICTGCAAGCATAAAAGAGCATCATTACTAATGICAGGGGTTGGCTCTCTCCCACAGAAAGAGCCTCAAGTTGGGCCT 
TACTGCTTTTTAACAGCACTTTCATTTAAAATTGTTTTTTTAAACGTCTAATTTCATATTGAAATTTAGGATAAAAGCACCCACTTCA 
GTATTGATTTACTTIGTTATTTCTTATATTGTGAATTTTCATTATTCTCACAAAGTTTAATGTTATTTTTACTTTGGTAGTTTCCTCCC 
AAGTTCTCACTCAATGACTACCTTTAGCTITTAAGCTCTCTTCTCAATGAAAAGTTAAAACA'TMTCTACCATCTTCCGTCATTGG 
AGGTGTGAGACCTGAGAATTCTGTCCGCTCTCCCATCTGAAGTAGATTAGTGATTCTGTCATCGCTGCTGGGCAAGCTGTCCTC 
CCATCTTTACTCTTAGGTTTCCACCTTGCTAGCTTGCTTCACGTTAACTCCTGICACACGGTGAGCTGCAAGCACATTGTCCTTG 
GAGCACGTGITTCTAGGAACATCACGGTCACCTCAGTCCAGGCTGGGGGGGCTGCTCTTCCTGTTGTCCTCCACTGTCTGCAT 
GATGICTTGTTTCATTTTTCTATCTTTCCGCCATAAACCAGATGGGGAGAGGIGAGGCTCTGGGTTTCATCCTGCTCCCTTTCTC 
ATCCTACGCATAAGAAAAGTTCAACGAAACACAGGCCTGCCTGAAAATATCTTAAGAAAAAATTATTTTIGTATACCAACAGAATA 
ACCAATAAAACATATTAAAAGAAAGTAGATTAATAGAAACCATTACTTCAAGGACAGAAGCTTATATTTTGACAAACATTTTAATTG 
TGTGATAGGAGAACAACACTTCCTGTGATTGTTTGCTTTGTTTCTGGAACCAGTGGGAGATTATATATAGTGAATTACACAGCTCA 
AGACAGGGTAAACTGGCTTATTAGGAACAAACAAAGATATTCAGTGAGAACACAGTGIGTCGTAAAAGACTCATGTAATGAACAG 
AAGGAGCAGTGTTCCAAGGTCCAG 
3' 
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Appendix D 
D i) Comparison of rat and murine CJBS 
1 	10 	20 	30 	40 	50 	60 	70 	Bo 	90 	100 	110 	120 	130 
1...--.......---4,---..-4.----4 ------4.-----4.-------4.-------+------4-----4----4---4------- I 
Rat T66C818TCUIT6CITTICCITUT6611MICATHR6CRUT6HTIWITOATTICATATARRAGGRAATRARGETT6CAGTIRTATCUATTCT6A6TUTTORTRUNITARRACRTRIBERT 
Hurine TAGETTRICCOTETTITETTUTWARRACATTAR6C0CTERTWRIOCTITUTOTARGAGERATRWITHER6TTATATRCITITTCTGAGTITURRRGCTACRARTUR8811----016T 
131 140 150 160 170 180 190 200 210 220 230 240 250 260 
Rat 	TCTRCREARATACTFICKFIGATCMITTA161166FITGTHITCCIGATC —CMG --C16660811111T-6116TCT6TTliTCAMITIRI6CHRTGDICCIUGCADTTT6TTHINTIGGECT 
Marine TRIA-66ARATICTOCIERMITCCIECTATRA806TIAT6CTANTAGOCACATT606TCIATTCETCTIGHTETUT6TC88611Tflflfl6CTARTGTACTITITSCEITTIGITRAMITTETCCT 
261 270 280 290 300 310 320 330 340 350 360 370 380 390 
I............1".•••••••••••+".....••••••"4••••••••••.•+•+.•••••••••.h.........1.......4...................1.....................•••••••-+•••••••••...4..""--'. I 
Rat TT6TCIT6666TTET6CT6C966REMCCACCAT6GCCRAM-ARGUARIT65661166W656TTT6TEMITTITIER---------CTUTCOTCHCCM61186T0166110166RATTC 
Marine TTUCTIRGECTETATT6CEMACRARACACTAT6RECRIVIRCUR6CARATT6566865RAMOTTRITCRACTIMICTITCRUCT6CHTICRTC6COMINUC866KRAGARCTC 
391 400 410 420 430 440 450 460 470 480 490 500 510 520 
Rat OFIC-0611066ATECT66116601661:16CHRTGC116606CCAIGGI166A6TICTUTTACT6GITTEITTCCCITIG6MACTTSFIT6TEGCTUCGC6CTGET-CTUCHCTG8----
Marine ARATIECKAGGIITCMGAGGC116611GCTGATR6116116CCATG-116GAGTTCTGETTEICTETTT6TTTGCORTG6CTGRICCAGTGTERCTCCECCCECCCOICCUCTITTRIMMETTM 
521 530 540 550 560 570 580 590 600 610 620 630 640 650 
Rat 	-- --CT --......--CACIEFICREGUTTRAMACTTETTR-- -----TTIGITHATTRACRICATACACTCGRATTCCRCTCATCTCCRUCCUTTCRTflCVECCITTGICCITGCWITTCCC-...----
murine GITTCTUGTTOCITACKFIGTTITTGARRACTITTTACT6TTTUTTGTTRATGACACRTCOTACKCCCRATTCCACTCRET---6TCCUTCATMCMCCET6TCTIT6CARCECCCTCCCTO 
651 660 670 680 690 700 710 720 730 740 750 760 770 780 
Rat -CTCTTRIMAARRflAT61.661186TT0TR6T6T6T6RCAMT6TCCUCR6THTTECTT6I6TTCRCACTI---TACTT6CFRIT6TTUTT6CTRTGREICATT66TCTGRITT6666CCUT61 
Marine ECCC88886110660flAT6T668116TT6TRUGT5T6M6T6T6TCCUCH6T-RTATIITTCHTCCOTACTICTITKIT6C886T6TTRATTGCT--6116TCHTT66TCHATTT6116MICT66 
781 790 	0 810 820 830 840 850 860 870 880 890 900 910 
Rat CUCT6CTROTTRIAGATACT666TCCTCARTRURCTCCIDERGATRUCT6TTUTSUCT6T6TC8T6GAGATECTTCHUTTMATCT6CA66ACCANCCTRIERTCCTCCAGTERCTGR 
Marine CTICTUTACTCTATCNTACTUATCTICARTGURCICTETDIGATOTCCCATTGC---CCHT6TCRTGOICATUTTCHCIT-60TCTICA66ACCA6CCUTUIC8T6CTCCfl6TICACTGA 
911 920 930 940 950 960 970 980 990 1000 1010 1020 1030 1040 
Rat TT6661068------------------flflUTT668TCT6G6CHUTGROCT66T6R6CCT6TIRKTCTCCT6TACCTRUCCATCAGERMUCTUUTCCTUCCC666TUTCACCOM6 
Marine TT6G6TIERT61TAT66T6R6CMICOGCC11666TCT6660IGTTAR6CT661606CCT81166CTCTCTTGGRCCTRUCCRCUI6667686CCUCCIM8CT6TCCCE6TEATTACTCRATG 
1041 1050 	1060 	1070 	1080 	1090 	1100 	1110 	1120 	1129 
Rat CT6CAGCTIACTWAR666611611CCUITTICTCCTURITGETTT66-6CCRTETCACCCATITCCAT6CCECAURCCAETCT 
Marine CT6CIECT6-----6CCA6666CADETTRECTUTTICTOT6CCATMGCCCTCTCORCOTTICCflT6CCAGC11666CCAGETCT 
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D ii) Comparison of the sequence 5' to the TATA box in rat and 
murine CJBS 
1 	10 	20 	30 	40 	50 	60 	70 	BD 	90 	100 	110 	120 	130 
Rat 	T6RIZITCGC611011GTETWITRGEBRINITGBIT6HCRECTITEGBENTET6CARGG6C1CTIR1161RATINKOIRTEGGIVIC86113G11C1211111GEGGTEGT THERG203111GREDGRS6CT6DEIVEL 
!brine CTIETCCFMTGEISITNICCIGIRGG—TTTGATTGITGF211611111ECT-1111---IFRATIT£116T66/1116111CHTBRIEFITERIDIFITEGUTIRCITERMGDETHEEACTRECIFEBal- 
131 140 150 160 170 180 190 200 210 220 234 240 250 260 
Rat 81111161116116AFORIERGT1161181691113TTAIGGE1FITIVIATNETTIMINCIIIIIC9EDFIRITIRGTATUTGITITGGIGEEKTNICF166GET618DIGRGNMENCATITE169/SITEUTT611 
Nurine 031618CfNITMEFIRLIMET6111161CTREAIXERTGETT-NERTGED1ACC111-6410116g1GGREEMBRITRIMIR61111116686----11111GFIGT61P2TIKEITAT-ENTICLIGT112 
261 Z70 280 290 300 310 320 330 341) 350 360 370 380 390 
I 4--.• .....4 	4-• --4 	.... 	4-• 	• 	....4-. 	+ 	-4- 	I 
Rat 666611C1TIECTTINEINDGEERGRRGUTE1161111116116111-TECI1116611FIGUTGGIGGIGAREGENTEXCAGGIMIGGCEITNIGTEEGINITGIIGTGETIGflIGCRGTAGIT6TC13--MT 
!urine INIFITENTTICINGTINFIGTGIGT-696GiTITTRTMTIVIART6TICNEFITACRINATRIGRUASTIC11611--CIITTEIGITIETIFICT-TCIGTCHTTIRGPITCMIITTIMCBMGENX13 
391 400 410 420 430 440 450 a 470 480 490 500 510 520 
Rat 	TE1 166118111CC111111ACFCA MITT6RRINTGCERIELT13 1GETT1111COCCEIRGIMITIFITCEIGNIKIICOGCNIGICRITREIGCREFIRIVIRGEAIRRIMGCT6GGCT ROTATE 
'Wane 11211121ENT6TCTIIFITIGGC11C66CrfM661.18226M4166161111I1G6E12--GR6162616GOITC6111C1C6GRTG-GCCIIIIITT1C11E6261I-1611166I6111GGREAT1CTICCCEIG6T 
521 530 540 550 560 570 580 590 600 610 620 630 640 650 
Rat 1UREECTITATCETIMICTURT6111611116116114ACCCIGCCTC1161610112BCCITC1111176611111ACHTINSIIITGIIICCERTTE1111---11CLIC666CITC11111111CTATCRIIGFIETIC 
!urine ESTGEEtEdIT-4:111CRICTE1-661116111TTCC9---CEIGGITGINEGTCTIGCCGTIGIRICATELECEICCITINTGCCEMERTCTIGE6TR2611T611CDITGRECTERG676C81MCGUTE 
651 660 670 680 690 700 710 720 730 740 750 760 770 780 
Rat 81612CTITGTGENCIPME/TIGT61161I-CIVE TGOGRCITIGNEBEEDEKATTITCREACBUIGFIGGFIFINTEOIMISIGTEATIVRATUDITCC1611TINIRRICRGICT0164111I 
!urine Cli11661DECGTEECTICTTECETITC1C8811CGCTIG-fIGENTEMIGC11CCITCOUIGGCCACNITCFSG66CC6CCTUGMG6E6C16111111fitTECFITEMETERTR6GTICAI 
781 790 BOO 810 820 830 840 850 860 11/0 880 890 900 910 
Rat 	6---86111116121EHTECIFINITRERROACTUICRITCREECGTFIA 	11161-11C1INEW16111111ICKfll 101-11C1111GTEITT1C6ERFICTITTITIIIIIGITT C1 T1GCTECTRIC 
Suring LICGD6GTCTIICIWCRECEITENT6611C116CEGA1166TCCGCTTCTItIT1T6CTITACTIFIGGCCATCITEGCTIG1TBETD36A1111116661C111111GRITC11TDECITTRICTEITTECCETTGAT 
911 920 930 940 950 860 970 SOO 990 1000 1010 1020 1030 1040 
Rat 	111TMCTIG6CflICKNITIOTECIITC16101118811181111111E111162CATTGArf CMCITIGGCTCCIEGTGI I IGTIMIGTIATGE TC11616I I C•••••••41PCMIDITCRGECCTEGFICIG 
!urine TINITECUGGCOICIIERRETTERITCCITCHIRCINICADETIFICENTCECICAFICCATCGTITIEFICT6FINGIGTITGTERCEIGIIKTECATCRATUTC16TTENTERIFITCRUICCT6GFIG1G 
1041 1050 	1060 	1070 	1080 	1090 	1100 	11.10 	1120 	1130 	1140 	1150 	1160 	1170 
Rat 	GIGETT6111111161ENCETGITEKTIESIGREPATERCCIRDSGTIRIIERBECCIBACTEFIGGITAT TECCTEERMITATIG1X1111 TGLOTTITC1161120TMCREIITTITTRETHITT61111113 
Nimble GTGETI1GTTITT611211CITEADICF1113106136TEFICCTURTIGROGINTECTI6RCTNGGERTT6EETECITTAGINGGETGIITGGTRTEITCRT6GCMAMICREAT811TRCTRATTIFIDAT 
1171 1180 	1190 	1200 	1210 	1220 	1230 	1240 	1250 	1260 	1270 	1280 	1290 	1300 
I 4— —4 4- ••••• 
Rat 	RI T6T---111; 611666tEt MCC CIE IGINOT 66121EBT EL WIGWAG...1 IGGTMEGG1GIB1110.••••-••G111GC10 GSCH 	CUICGIBIGCOBGCCRGOIlliFlTGTAfl1TTCTTLTTGRTCiT 
11urine INITIGTIGTAGGAGGGERRECCE1C161611616GTG1CITITELTAGGEAGGTAGGTETTEGG1711111114668116111GCTIIGGEARGECCUKIGOGCHTIGEDIGTFOTIZETITTICKCCTEGIC11 
1301 1310 	1320 	1330 	1340 	1350 	1360 	1370 	1380 	1390 	1400 	1410 	1420 	1430 
1 	•••• .--4 F.. 	•-•4 4-. • ..4-.- 	•-.4 --.4.• • + I 
Rat TICITC111111TGTACCTIC11661TECICT116121TECTITMEG 
*rise TT rill AGIT TCTGC CIACTIGGI TT C ICE] 1116111TCCT TTETIEG T rICECT IFIRT6CTEIGLIC TatECT88116111CCTITTECOCIIIGGAGSTMERGE110611i1ITC TENCIN1C rounsc 
1431 1440 	1450 	1480 	1470 	1400 	1490 	1500 	1510 	1520 	1530 	1540 	1550 	1560 
1--------4•••••-••••••••+••••••”•••••••••4,.......••••••••••••••••••••••••••••.............•+•••••••••••••••••••.••••••••••••••••-•••••••4-•••••••••,1 
Rat 41ACEAGNT6111116GETAFIT1ITTNIGT668111111611111116E116TICCTIFIRTC136811011ACTERTOGIIR6GRIECIE6110E6TGC111111111611ITICTIMECCIETETCTRCITTECCC1C 
!urine 111911TC116116611CCIEGET ADM 1111161GREfill TEEM111160161ICEITTNITERGKIIDIT6CCC11 TREGINEORIDIRDTEGFIEll TEX1111TITIrdll 1E1 TEACCCHTETCCRE1 1 TECCC1E 
1561 1570 	1580 	1590 	1600 	1610 	1620 	1630 	1640 	1650 	1660 	1670 	1680 	1690 
Rat ECATRCATTEIRTEICTED4CATC1FICCI(666128ICITGRFITTIGCE—CiFICTIFIDIFITTEIGGEGCTERGITIGTEGCMGCGT6C6CGCEPCCRIIGCTGGICITECTGOTEAGC1IATETC11111 
!urine CC n GT11811181 CTENICCE116111CCI CG661611161161111111TEIGT1 ICCE1GET If TEIGGEGC TEDG EICOTAG--GC1116 CIIE-4/1 CCDEGETTGGNICCI G DT11116C1IGT1IEBT 
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1691 1700 	1710 	1720 	1730 	1740 	1750 	170 	1770 	1780 	1790 	1800 	1810 	1820 
I 	 I 
Rat 	PART TGRTG1TRIFIRT0fITTCRTIITC6TECITAGTERTITIIRGGIIR0666ThRTIC16111FINGATTRGIITICIRRTIICT IttGTRGTITIGCGTITT6GGGICCT6TRUCICCRMCTTECCTC1 
!!urine flTATTECT6M-TNINITCATATRUCGC88610G99189666C9P0-611111CCIT1CTUIADOTCT6CO6191GTUT1CG6681---C869161GGITCTURCECTECAT11CRTUTTET 
1821 1830 	1840 	1E0 	1860 	1870 	1800 	1090 	1900 	1910 	1920 	1930 	1940 	1350 
Rat 	CEGGITIGTECIVITGCUCTEERRTIEC 66GCTEGRREGFITEGRMACC011C1166T01061ILTEERGUITUGG611G5ECTIIGGGGIGRRUCGTAGIGGGGRIGGG----GERGSETIEGRANC 
Marine EGGTGIGICCRIATGTCRCTURNECGEGCGRGIIDGGIITGGEFFITIZRCEGG MCAT TCCGIRMATELGET1 	1656116T-TZHIGTEGCT66111116TGTGNINICTIGRCRCRZCIGGA 
1951 1960 	1970 	1980 	1990 	2000 	2010 	2020 	2030 	2040 	2050 	2060 	2070 	2080 
I--+ 4— 	..4 4... 	-.4 ....I -4- # -+- • -4- I 
Rat 	Cl ICTC15166GICIGLI1 I IT 1068 TGE6G6CCITTICT01101ITTEETRFIRTICHGCICTC1CIPTIITCT T-fIGLITGITIFIDITRTITROITICITIT---KGC1366GTGGE1 IGT11CRCHT 
&rine ITIFITC090006611GCTTCRGITGAGGIVINGUTC13110611MG110151111GGCATMCTORTIAGARMITGGGGGIVIIIGGCCCLITGTEGTEWICRNICTGGGCTGG111GETT 
2081 2090 	2100 	2110 	2120 	21.30 	2140 	2150 	2160 	2170 	2180 	2190 	2200 	2210 
1 	 -4 4- I-- -4 
Rat 	RERTITTRTERET6TRETGCGSCIRTI10016111CCTIG6100166gEGMGMTICT1RDIIGTGAAUTICATIG6CIGEFICTIGCTTEREIIIITCGSERIC---IXICRIT 1051-613 
Karim 666TTRTIIT6f1-611GCMGCTGAG-CRRGICCRLPG61111661----RVETRETTITICATCCCICCITIGMCTCTGCRTERSCTCCTGCTITCTUCCTGCTIGTETTTCOGICCIGRETTOCITTGG 
2211 2220 	2230 	2240 	2251) 	2260 	2270 	2280 	2290 	2300 	2310 	2320 	2330 	2340 
I --.4 II* .... h. .-.4 4-. ..--4 .4.• + .4-. 4 .4- I 
Rat. Wif16611ATTICRERKT1611661161118111EKCIEGG6MIT66698I1ITHEINNENNO1000110011001111NRIMNNIINNIIINNHINN10110111INIONNONNI91141111100110181110M 
Wine T6ATEAMC116I11-1659116161811----riCARGTIVVIC--CtliftClITCCREITTGUTCHGLICATGATERIGTGDAGGIVIIFIGAAKCCTUCTREGRCGGSTC11911181811T611 
2341 2350 	2360 	2370 	2380 	2390 	2400 	2410 	2420 	2430 	2440 	2E0 	2460 	2470 
Rat IDINMENtODINRIDINE/INENNRETIORN11011601110119IREHRIENNIWIRENENNENNINTRIIINITIENTE010110110110110100911NE101311911110411120110110(0191 
Karim 666TEGGEGGGIIRERTIGGCCTICILT6116681CTURT611016C1CMCRGIUGT666CCITGICTRATIRTICTICKITGEACTIMICTURERTGATCTERGETIGT6TROTRIXTT181 
2471 2480 	2490 	2500 	25101 	2520 	2530 	2540 	2550 	258 	2570 	2590 	2590 	2600 
Rat IIINIIENETINE10111101110111100INNHONONNININENN010111N104111114011NNININENN08/91110011NRONIRRINNHEN011110130411109048014110149011411101 
&rine T1166606660T6TRUICITIACRITITITIICT6R616110611666CIFTIRT/TRTGARIXT0061161668100611TITC11666GT6ART1111CRIIGECTGAGGCTITIROTRT16166-- 
X01 2610 	2620 	2630 	2640 	2660 	2660 	2670 	2680 	2690 	2700 	2710 	2720 	2730 
Rat 	111P901000011109CCICEIGTR6CRITEGTEPRORMICITICR61166 11 TITITGROIRRIGICIXCGT1CITIETTICETIVISTCTIITTITGRITRFICCITTGICTIITTCCITTGGCRCGTREC 
Marine ------FITRECTUITINCRTGRE/1116TEGR6CCT6IF1---TITCECREFGTIGIGT--611IITICICCRETRGRIITAT6GGEIGGITTICCCAGIITC1166--CTRETIRP2GGRTI- 
2731 2740 	2750 	270 	2770 	2780 	2790 	2800 	2810 	2820 	2831) 	2840 	2850 	28160 
Rat 	IITTREfltilltfiTGIARTIAITT6ICCGREGT1181 T f 11 TRORDGCC111CTIETITIGUICRGGRISTRITTIETTGCTI 'UMW( TIMICTIGC111 MCCFOITRIGGIMPTIIIIIIRER 
Nurine —6CCECRTIRIEflEiRRIACIETECICCII-- —1 T TIGTREIGEC--------TCRGERRECTGIGCTIGRATGGTIIGRIMICIVICCT--CRI IREGTIG6T6— —FEICRITRIIT(IOR 
2861 2870 	2880 	2850 	2900 	2910 	2920 	2930 	2940 	2950 	2960 	2970 	2989 	2990 
Rat 	FITGORFITIRT 11 TINT IIIITGGIIFIRTRGRCAGGLICTAC RITGC GET Gt1111191111CT 1 C ITICR6TIGRT Gn TCC 11111161TGT IRTRIT6C11111 TCCIITTGAGM1C1 TGGCC TIC T 
Marine 116-----TGITTTIIIITTRTT111111BITT-----TRITTRTTRC11169TIGCTIFIRITIRTTICTITICRIDIGIITRRKTRIIGTTGITRTRITCCHITITTCCFIRCG6T--TREIRITTGR----GT 
2991 3000 3010 3020 3030 3040 3050 300 3070 300 3090 3100 3110 3120 
I ...4 4... * ••-• ...I I- -4 4- 4 -4- 4--.. f. I 
Rat 111111911THITRUIRICTCTOGTGCRTAIGGIGGG6TTGECTTRITTIATRIERFIGITICIIIIEGTCRECCTIRFIliTGITTRCTIIREIGUITIITGICTICRGIRETORCCITTC1GRTGTRIC 
Karim TAGRTITCTC---TERTTC1C1C1 GTGCITTRIZIGTFITHGCTITRI TTIGTATITIIRCEICEIRETCRECCURRITI 1 GTEIGC161111110111RNICITCRGIRICTCRIET TITGGRERTRCC 
3121 3130 	3140 	3150 	3160 	3170 	3180 	3190 	3200 	3210 	3220 	3230 	3240 	3250 
Rat 	TG TOITITCRFIGT ITT TGEGACRICCCHT66118611GGI1 TTC1TGITETEMICLGTDCTID1CRITUGC-------161001CATTATIGTIGT6CGGICICCGMATCHCCIIIGGCAG 
Marine TG 11/1 1 TIIGIGI ITT TGEGCGRICCOCIABREAGGIGITC1TCTIRCCIGITICCIVITICTIGCTECICHLT4610ERTTTGCREGTEflICTAI16C1C11C6.1111ractrairraminccut 
3251 3260 3270 3280 3290 3300 3310 3320 3331) 3340 3350 3361) 3370 3380 
I -'4 4- + 4- .-.4 4-.. -4 4- 4 -4- 41.- 4- I 
Rat 	RFFITTFCHT6TDITTTCRTTCCETAITTTIGTCGFIT6IGTGRRTITTRREFICICCGCCECTUICCCITRT161GGIGCTRIMGTTICTRCTARCIT TtERGITIKIZTITC6T0611611TCREGITTR 
Marine MDT THRRITTG Mill TTCRIGGCGTCfl OTT !GI( 111T6IGTG116T 1 ITFICTICTI1 ITICGCC 1 CITCCITIITIGIGGIRCIGIGICT TETIITT filICT 1 1 TO GIFIKET ITCRIGE6110 KEG 1 TER 
3381 3390 	3400 	3410 	3420 	3430 	3440 	3450 	3460 	3470 	3480 	3E0 	3500 	3510 
Rat -CGCTERTTGINGTRIRCRTATGRCTTOCTCCUICGCGGCrfITCUIRCTC116166TERT1061111GTEITGTGRKRCARTICIITICIIIRRTITTEIRIMITTIFICTITRTITUTRECTKIR 
Nur Jae Tfl GCTEGTT TITHGCCII6C10 TUC T I TO CNC CKFIGGG C RT 11118111116511F11011116 TR I GG6TIITAGIOTARTIIT 11111 raannit13999111111191111111111619CCI9619 
3511 3520 	3530 	3540 	3550 	3560 	3570 	3580 	3590 	3600 	3610 	3620 	3630 	3640 
Rat TCRGTECIICACEITCCITTRIGTTICTT1TCRITTITG6800T1TTEICTTCGTGICRTEGRIITTEARGLFIRTFRGCMGRAGREGGC-ICTETTGTACCTCCCTGIMIGRSCRTGITTIGFITTI 
Nur 'ine MAGI GCTCCTICTIGI ECCRITIIITAIR-1 TITC-TCT1 TERM T TC1CITIRTfilf 11105CITT811/16CRA TIMGC(11(20GTAGGIXICICCIGGICCICCCTGICC I 	T %MITT 1 
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3641 3650 	3660 	3670 	3680 	3690 	3700 	3710 	3720 	3730 	3740 	3750 	3760 	3770 
Rat 	TIT TTICTIFFITTI-110111MGRACATTI IGII6101T1RICTET6CIVITC1C-31I TECATITICTITCGICT ICICCICITE1 TUGGTGACURCTIT TR111--11111111115TCUT TAT--
*rine 1TCTTTCTTARTTTCRAIITTGGMIATT1fGITGRRTTATTTCTGEG111TTTTiRTTTIP.tAATTCTTtTGTCTTCTCCTCTT6TRCTGGTTATCCATT1iiRRRRAIITR11TRAITTTTCTTATCITT 
3771 3780 	3790 	3800 	3810 	3820 	3830 	31140 	3850 	3860 	3870 	3880 	3890 	3900 
Rat 	-- - -T660114161CRIMIRRIIGIIKTICOMITCTRI --DUO - -TIICCATMCIFE- 	 - ----------- 	---GTOT1CI-- -------- - --TT 
Miring TRIIIT6fiGTHIGTATCRIGTETWITTRIRTTITCIIIITTICTIIIIMIGICIFITTINTITTGICTGTRITTCITITTEMTITRARIVITATTIITITIRTTITZTATITTCCICKTIRCITTIIT 
3901 3910 	3921) 	393l 	3940 	3950 	3960 	3970 	39 	3999 	4000 	4910 	4020 	4030 
1 --. 4- -4 4- .--4 .4... 	..-.4 -1-... ....4 ...-4 I 
Rat 	CRY,MI TUC CH ----TIC TT TIREFIIIIITT UFA T AT-- -11 TIM T FIT I TRI1T I T-----------1 T11311 TPST CI TT CRIIIIITTA911016 FOB T------1T GIITGIC G 
Marine CAATECTFIECC11110561019CM111/19R9811111116100111111MTRITCRIITITORIVITAMMITFITITP2IITUTATFIREITTEARTRIFIT6TGT11111115T666IMIT1116166 
4031 4040 	4050 	4060 	4070 	4080 	4090 	4100 	4110 	4120 	4130 	4140 	4150 	4160 
I --'.4 4.... 4.... 	.....4 .4. .4.... 	...-4 ..-4 .4..... I 
Rat 516TGIGCECIIDECRPECTIG6TREIGIRGRGGICEATIGKa6TC-4111C16C1166110FRAITUITTIGTIGGCCRIG-C16111611161G6TIGCTGGACTUTCOGGICITTGCRXII 
Marine 6CINGT6CIVITCTIGT8CREI6FICIGTGGAZICITCMG6TIGITSTICflICCTTRASAFIC11151XICATIGGIGKIITLIGC151TTGFITGIGITITC1656.11fICTUICIETTEICTGTGGGR 
4161 4170 	4181) 	4190 	4200 	4210 	4220 	cno 	4240 	4750 	4260 	4270 	4280 	4290 
Rat GEFIGTHIGT6FITTITECTGall5ECCCICITTETM1616TGICTIIMARTEITGT166TCATRTTINTRRERICERTFITCCHTUINTRI1FIR91111191111101CCRE11111TACKAT6CITIICI 
Marine GCAGCCiGTGR1TTiRACTGTCAGGCCCTCT----RACTTCTRTGTCCTTTiTAATIIIGTTCRTTTTill IG6TIMIIIIEGIRTC167666011111f16111111K6 	 KT MAT 
4291 4300 	4310 	4320 	4330 	4340 	4350 	4360 	4370 	4380 	4390 	4400 	4410 	4420 
I.•••-....•.••••••••••••i...••••••-•.-•4•••••••••.••••+•..........•••-••4•.....••••••.+••••••••••••••...••••••••••••••4•••••••••••+.....•••••••••........+•....-....-...1 
Rat TUITTITTECCITAFITGICRTIATICTRITCRARCTI---ICTITICTT1CMAAFITITUTICTCCT1111T6IIREMETATITICO110TPOCIEGROTTITVICTOTITARTHATITCORTGAG0-- 
Nur ine T-- 	IIITCC11111GICT111111111RICCMARTIGT TI CT CTI IRE 	11--C15C111916TTRGRAXITGTITUIRTITPCCTEGRIATTITEAT0TC11011111611116160111911 
4421 4430 	4440 	4459 	4460 	4410 	4480 	4490 	4500 	4510 	4520 	4530 	4540 	4550 
Rat 	MGT --- -811CTRICTIIICTIGTREGRGRGARECIGECTCCITECTIGTIAG6TROCTEXITCCACTEITTTEGICEGIDRHOCOCCRIGITIGOTTIITITITCCRICERGRTC11111.11191 
Merin TEGICATTATICTITICTRACTIGIGE66IPPIRECIGETICCIFIUIR5TIC---------CICUCTGITTEGIRE6TWIICTKITAICCRIGITIG6TRITRITTI1CCUCCRERTUIFTICTUR 
4551 4560 	4570 	4500 	4590 	4600 	4610 	4620 	4630 	4640 	4650 	4660 	4670 	4689 
Rat 	fin TGITTP6RTTITCT/15911111CflATTPITITCOMCCHCCRGGIUGIC1111111C166116CIGICIIT11169010611111flARREAGGITURGAGITC-fITG1ITTEATGIRTITICTEGCARGA 
Marine RH T----11611TICTC111611611171FINTRIRTECIITTTICHCC116519XGTEIGNIICTE-TUUTIERG1111606656611811114917011611156115F11TERFIT61 ITCF0T616C111C156 TM) 
4681 4690 	4700 	4710 	4720 	4730 	4740 	4750 	4760 	4770 	4780 	4790 	4800 	4810 
I .- 	...-.4 .4.. 	....4 .4..... 	......4 ....Hi .......... 	.4., I 
Rat 	tIII1T ICICLIGT616ITITGI6M TT MITT TITICTUIT TUITTTIC1111(1610661111111CCICCI TITCMCICITG 	----CIGIGITTGI RAT T ATGTRTIICGT11C11A111111f11111 
Uterine GATITICT—GIGIGTECIGT61 TTICTITIACI 1 1 TETC96111 TCAGCLICTIII 116111666110CCRITATITCTRITCRGNIGGIVIIRETGIGCTGTFIFIT I ATEMTURT1 ICTIGIRG11161 T 
4811 4820 	4830 	4940 	4850 	4060 	:70 	4880 	4890 	4900 	4910 	4920 	4930 	4940 
I -4 4-.. 4- .-4 .....4 ....4 -$ I 
Rat CERCTCITTIGTTAIGSBIECT-660TIMEGIGG6101ITTEGTINCITURTITICTITETCCIERRI1TIC1CTRIGGIIGITTICAITRITITHFABITTATTITTTERTItTa111TRCTIIIC 
Marine CFRCITITTIGTIATUATRECICRGENTERGIGEGT6IITTRGRRICIT----------------918T1ITCITIRTUTIGCTIITIVITATIMARATATT1ITTE-TrETTRITTFICETTC 
4941 4959 	4969 	4970 	4980 	4990 	5000 	5010 	5020 	5030 	5040 	5060 	5060 	5070 
I-4 4-. 	...4 4- 	...qr. 	4- 	...4 ....4 ..4.. 4 I 
Rat 	Ti TRECIITE115110I8111GCETOTTITIRTITIFITGCT6116T1t1TC11 ICCIGGEGIMICPCTIGT1IIITGIGHT 1 11111TilalfTflflF111RICT6ART1111111111611111611111T TH1161601111CRROGTG-
Nur ine 11 IfINCICIGITI1 I 1111GCCIATR9611E6T6T650 61111TCT 1 TCTIGGI611111111C11 GC1----GICMIT 109111101109CCT6G111116T TRIRTERFITIIRGATflI TEGGRAGF11111CREIGAGT6T 
5071 5080 	5090 	5100 	5110 	5120 	5130 	5140 	5150 	5160 	5170 	5180 	5190 	5200 
I -•4 4- 	-4 1...... 	-4- .4... 	....4 1.... 	...-.4 4 -4- I 
Rat -CTITUTTURRECTRTARRCRGITTROICCHITTERRIECC1060111TOITAICTRIARRCCIITEATCATTT---TRUCT6RITIRRUCAS6GROICREARTECIGERGOITTECRUIRETRA 
Wine OCIMOITTGIRRACTMECRWITOTMITC61131flinfifigiltirrantiRRIARMIGMTTATIDGRORRIGTTGACTICRSIATEGBUIRACARIICTUSTOTITGCNINTGR 
5201 5210 	5221) 	5230 	5240 	5250 	5260 	5270 	5280 	5290 	5300 	5310 	5320 	5330 
Rat AINIRCIRPHIFINITICRIEFITAT---CTUICITCCTITGAITUCCIXT1991019811CCCOCRECTTPAFICCICTRITAX1GTIARMIICITACTCCITT1119110151110111CTICITCTIIIIGTUITGTG1IIT 
Marine TflifillITICSIORCUSICt6ICUCCITCCECCCCCR0611111KCPIRPACCIACRITTICREFIT TECITTIICTS0R1161511ARRIIGTRECTICT I TSIGRTC66111RTET1111 TCTIII 161(11%010C 
5331 5340 	5350 	5360 	5370 	5380 	5390 	5400 	5410 	5420 	5430 	5440 	5450 	5460 
Rat 1111TFITGICECT1111110111C117036661111-1XWITITICTC61X11591111191CUTIC1111116111tP,CTIIPSCTITTIFITART11111165111616CCARAIXATC1CCRACT6T06061311111111 
*wine 2010TGCCTET T11110361CATGMEGR3IIIMOMIC1 CGGCOGINCTIGITCUICIIC1 inrinn MAT Ti TIIIIET TlIfIT61116C-116611151GC1:7111111111TCICCHTIC TECIISCIGUIT ANC 
5461 5470 	5481) 	5490 	5500 	5510 	5520 	5530 	5540 	5550 	5560 	5570 	5580 	5590 
Rat. ttflUCTGEKICITI ICI 1 	 ---ITICTTIITTIFITC01666C11f1511111111TAGIICRCIGC11111171GTIMGTERGIUTCIFIRUTGP31-111161116 
Marine GC116TC1561111CRI TETTICCAGUCCNITIIITITTITIIIITOTCROGTIGTRIIMICCR1T11111M6011611TOTRITRGIICTICITETT11441G1TATIGT11------C1110T111111141fli TT TMCG 
273 
5591 5600 	5610 	5620 	5630 	5640 	5650 	5660 	5670 	5380 	5690 	5700 	5710 	5720 
1 --4 4.- 4,-. ....4 4.. 4- ......1 4- ....• -4- I 
Rat 	668111IGC1OTT1AUTG--11CGRST111VATT1 TITIG16111GRCGTITUICUICG8-------113611111662C cat aucill:C1 111GRUCCT6RGITCCTII--------11 TIFC6GRCTC 
Marine 6611$1111GGHITTINCTGTGIEGIVillIVIGTIGACHTGRCGTITGIICT6CGT16117111116f111111686C1116()%flaRCCATEGAMTTTCGROCIICEC6TITITEGGRCTTOTITTTITAGGRETC 
5721 5730 	5740 	5150 	5750 	5770 	5780 	5720 	5800 	5810 	5820 	5830 	5840 	5850 
1 	 4-- 4- 4 
Rat TGGGCCTACCRGTCTGTITTTRCTT1fiTTTTI11111GTTCGTCTRGCTATCTGICTATTiATTTAGAGATEC6TCATGTflGCCRAGATGRSTTTCRARGTT6CTiIGTCGGCTCatfiGTGCTTTGRRCI 
Marine T6GGECCRTICGIC161111-1---TFICTTNITITITGIGT1CFITCTMIATtl--11TT68111111G8TECGTTITGT6GC1f6f111113GRSITTCIIRRGITIICTCT6t6(ITMGT6TC161311111I 
5851 5860 	5870 	5880 	5890 	5900 	5910 	50 	5930 	5940 	5950 	5960 	5970 	5980 
Rat 	TEIGTIUTTCERECTCTGACTIGT1R66311111)161111CIXIC IC TCTECC TtICT6111MT I TTICKI8T6111T66 TCCC TC6CT TIM TEC CRT TORMCG6f11:61CCICCIIRTGGIX COGEGEGIC 
!trine IXTUICCII1CITECTCIGKEIG-------GC3t6CTETCCECCOCICT-fal I 1-CCC111---GGCCCCICGCRTEAFITACC3ITREFICUMG1CCITCHWASCCMGEGIC 
5981 5990 	6000 	6010 	6020 	6030 	6040 	6050 	6060 	6070 	6080 	6090 	6100 	6110 
1 	 •••••4 
Rat 6(6Fff---111.11138111FLIKTIG-4111666••••••-..-CC111111690CT161TTTC611GCGCGTIVICGTC1111TCCIIGGTICITTATFITIGIC611106LIGGGCGIITGIUCTISK6(16 
Hurine FICICCCCIXCITOSCITCCGCCCCEMFTEGGIZAGGGIGERGEMICCTITTGTIFINGC6CETT6TICGTOCTTCC11GGICCCIITIITTIGIIMENGGIART6TGANCTOGGT6G 
6111 6120 	6130 	6140 	6150 	6160 	6170 	6180 	6190 	6200 	6210 	6220 	6230 	6240 
1 	-4 I- 4.... 	......4 4- 	......4. .4.. .....4 4- I 
Rat 6316116GCT6C1116CT-CTG--1616fFr--CITT-G2G6CTERGICITCCTIC6166TCCT6C5C(11Gt6GLITCt66301366GCT6t1:67636116GTINCITMGCOSACC6fifigiRECC 
Marine 6CCGTI6GCTGCTIZCISCIGEICITGIGTX6GGCTICECCMGGETC(361CMCI6CGTiXTTCT6I6C(11EACCITCMG--------------CTT—C6611613GIVECTGICC 
6241 6250 	6260 	6210 	6280 	6290 	6300 	6310 	6320 	6330 	6340 	6350 	6360 	6370 
Rat 6-GCC61666C661G6C86CTGGICUICIVIRFKITC6C6T6TCHRGCTIGGIRAC611GRETITIGCCURN6CUMGCT6GURGOGAGCCTETEGGCCCITIGCGTECTERGET6G60161.68 
Hurine GTGC-C6ICr----116TTGr3TCT-----ITC11:116668860E866-631iGCCE-Ilt6CCI1663a6P-GUKC-866TT6T1IGTEEICTIIMERC-C1G'TTGC-A6T-- 
6371 6380 	6390 	6400 	6410 	GO 	6430 	6440 	6450 	6460 	6470 	6480 	6490 	6500 
Rat faCTITCCECTMG-TICUCTIGGCT6GGCE6COSTECCTITEGCCTTAGEGICCEICGGITG6ICCRECGMGCCTIFIGTCCTMCIZET6GCMCIGEGINCIAGGCCTACC6CRTITEMII 
*rine ---11C1CCIGTUINCGTINCII6MCIV116%6CCITMCCCTICAGIVC1:61CCATEGGC111361:66CCTIT--CC----6CTITTITiGG----11CCECCCITG.-- 
1501 6510 	6520 	6530 	6540 	6550 	6560 	6570 	6580 	MO 	6600 	6610 	6620 	5630 
	
Rat 	CCCIEGGC116161166C1C11611611ITIT6C6CECCRAGGTVIGC0GT6EIGGECTIKCGT611 TEGGICCCCITGUTMC6fr--TGAGGCCIT611611CCITEGCMCCM6GCMCFIGUIRGGC 
Nur ine .{1TGEGT66GGIIGGDCTTMEICCITrIECUCCATEGGC11-63C86131GGCLIfit-----6GCC£CCIC116016%01X68/134GGCCTT-fIGICCIDGCTICTIGTIGGETKIC11616066( 
6631 6640 	6650 	6660 	6670 	GAO 	6690 	6700 	6711) 	6720 	6730 	6740 	6750 	6760 
1 	 4- 	..•4 4- 4- 4 -4- ..... 	,....4 f. I 
Rat 	ET ACTICIAXCIDIG(NG61016Cliffilla 11116I6C1 I 11K51ICCITTIGCT6G6TIIGC---5116GCCII TWO 1113EFICCTC1166C I1651:861611GGCT 136061IFIGGCC Ift MECUM, 
Marine tilICTGCS---- 	 -TT TECGCCERINGACTIGGITIGCF1f16.rd1661-0 TO6ICCTER6C6CCUTTE6CTTG6116-- CERGSCCTRECKCITTEC 
6761 6770 	6780 	6790 	6800 	6310 	6820 	6030 	6840 	6850 	6860 	6070 	6880 	:• •0  
Rat 	CCULTIGI7CT6GECKG6RGIICITTFIGGCCIT6T6-CCECT 1661116ERIGTHRGICCHITETICC111616CICITGGGIGGNIEGC1)11611CTITTEICrIGTSGTITEGIGETIT6T(dTICITG 
)(urine GICC-TTGIXTGEGCTIGGGAGATIT6GTICCMG6TECCCTIG6CRITEG811G6GRETCCICTERCCITTGT6C TCTIGGGIGGTA61166C13GRECTICCACITGT661TTIGTECT 11616C1 TEM 
6891 6900 	6910 	6920 	6930 	6940 	6950 	6960 	6970 	6980 	6990 	7000 	7010 	7020 
Rat TEIGG61:011£63TACCTIACTITTET6firal€C161-GTGCT-T13116fiTECC6CCIXTRE11666(C1CCCECCETF1IGE116ICIICTTITG661111GTHCRISTOTGIGUATCT6TCTGOTICTT 
Marine 	 GCR6CGAGGGCCTCTCAG(TICiTdiGGfiCCTTTTGT6CiT:TTiTTIGRTGGCCKCTCTRCRCGGCCiCCCAGCCCTATGCRG(CAC(T1[GGGARGRAGCRGIGTGTGCCR(CTGTCTG611T IATTT G61  
7021 7030 	7040 	7050 	7060 	7070 	7080 	7090 	7100 	7110 	1120 	7130 	7140 	7150 
1 -4 4- -4 4..... .....4 4- 4 4- 4- -4 -4- I 
Rat TRAGGACCCEGT6TCCTITTGECIGTGGGOICR2CITC161XGEMG16161611CCOIGC1616%6C111166%,GRTGE18111GGRECGTIRACCGCCTGCT6INAGRICREGICTITTTAIGIMITTIG 
*rine 11111GGIICUE6TGIC CAI TA 1G161,601C11/1C 1 TET6CCOZOGTGTGECCCII6CTGIGGEGUIT.GGUIGFIT6116016GRECGUEICTIGUTGC1-616CM6C6UTCHTCOIG11%11116 
7151 7160 	7170 	7180 	1190 	7200 	7210 	7220 	7230 	7240 	7250 	7260 	7270 	7280 
1••••••••*4..............•••••••••••••••••••••••••••••4•••••••••••••••4•••••••••••"•••.•••••.••••••40.**••••••••• 
Rat TTICIITAGG11008811CRGERGGEMCKfRCCGRGUICIITGCTIOC6CIGUCTUICIIT8SEC8T11611968COTCa6C19110GRUCTGIGTUGFITUTUGG491683ERCT6G8801 
Marine TTICTTOGGITICP.CCGESCEIGG0G----CIECCIC6611Z11016CINVICTIGIGGGICCGICI1TRX(0111G11316C0ICIYAGC1191611311CTCTGCGT6EGRIVICGFGG11116113611Efrfifilitfl 
7281 7290 	7300 	7310 	7320 	7330 	7340 	7350 	1360 	7370 	1380 	7390 	7400 	7410 
Rat 	GT 111109t6Firi6GTROTGACCIGIMIT ERGGGI T ITCCE)131311FIGMATGRACITECCCCRCITRIMCCRECRITIFICCflICKTRIGGCCGAIRCCUIEfl-----CC61CCEIGM T 
Marine GT 1 filtflfi6ATTGGITCRTGACC161101I TFLGGIITTICCETIR1168GfIG1IT6AFiXtCCWICTMIC&CCRCCTIGHCCITTCOGITTEGTOCCIACGIVITC6CCIKC6CCACCUCCERTCT 
7411 70 	7430 	7440 	7450 	7460 	7470 	7480 	7490 	7500 	7510 	7520 	7530 	7540 
Rat CC6Cf616GICCUCRUITITACCTG1GC6TGEGCRECTCTATCCACifITGCDCGFICCIICEICTCCRTITCGINTORICTCCITCCICGETTICATTCTCCFCCTailifilIGTTCICCECCTCGTCCC 
*rine CCIUSTMICTICEFICIITCC6CCTGIUGICG6CFMCICTATWIGRECCEGG6TICCTICTURCIIT---GCCOG6TTCCTCC11------CfrOT6ECC0613TTECITCTURCETCG6IIC 
274 
7541 7550 	7560 	7570 	7580 	7590 	7600 	7610 	7620 	7630 	7640 	7650 	7660 	700 
I ...4 .....4... 4-, 4.- 4 -4- 	• 4- • 4..... I 
Rat 	fl(fl MC REGTC11(111I MCC fICARTECC RA MI CRTIICCIMIGTCGCRGI ITIC GRECCUI ITECFal GIXCRICAT G6 T[C111 fl rfin t T(GCCR RI116Ci II TftS6CC111(11128 MOAB 
)(urine NACCIICIIGGICTIRECita(GCNTECCVADICITUCENGICGCRUMCGRECCRIIITTECRIXTGIXCIIMITGVICIIMITAATTC6CCEGOTTTECI1TRCTC(31TGBB6CTIGNAR 
7671 7680 	7690 	7700 	7710 	7720 	7730 	7740 	7750 	7760 	7770 	7780 	7790 	7800 
Rat 601166---1111(1IFITGI1NPANC-TEGRIX1CTECilliTGRNIBIONNFIGOCHTC16181111IGT611111INTICC116CBCCIICERRIBTRACIIRHIGIIIGCCHIEGGBIGEB111NTTIIR 
hurina ECITGIGLICTFOIRTGANNUCCTNONICITCAGTAANTAGEBRUBRUCC(I6TUTA-1161GTGICTENTICCHMIEN83111RT6(181011111GCUITTGEATGARG11111TAR 
7801 7810 	7820 	71130 	7840 	7850 	7860 	7370 	7880 	71190 	7900 	7310 	7920 	7930 
1 	-4 4.-- 	-4. 4...• 	....-11 4- 	-II -.41--. 	....... -4- 4 I 
Rat. 11----CREGG6CARIINAR-------TGEGRRATCTRIFIBTRCTIGGCNICTENT6C1ffCCCAGEITIT6G66961191TRINTFITTC01BEITIT-11TCNIGCCTEFICCITIA 
Marine PARRINNEGRKFIRBBCRIACRANCERINFINICTUGERCI THIFIDTPCR11MNICIENTGCTIIICCOIGTIIIEANNGN1 MINN ICIENITITDITINTGCCIGCNCTIT8 
7931 7940 	7950 	7960 	7970 	7980 	7990 	8080 	8010 	8020 	8030 	8040 	8050 	8060 
I--•-••••••••••••••••••••4••-.....-.....+••••••••••••••11............4-...-...--4-.....-......--..............4.................••+••••••••••••••••-••-....-.4.--.-,— 1 
Rat 	811111168111813961AGTHSTFITRItit TCF11186---CERATGCTIGMGCCTIIGCEI6111CRTCICINFICTITUTGTITRTTITGENTERTUCGITCHRECITCFIGT1ITNGFiNTRT111 
Marine 181111419-111180161111-11111111GETCNINTffiriailiNT161116(tTRGC1116----CCCCCI1MilifiArf 	ITCNIINTBEC IfITCANG TCRGT1TTREG111111111Tin 
8061 8070 	8080 	8090 	11100 	81.10 	8120 	8130 	8140 	81.50 	8160 	8170 	8180 	8190 
Rat STCCITIGTTETATTNCTERGRITT110111TMEITG866/1118BETGCTEIGLITBSCITEFIGRATTINGC171CREBACTGA9TflM1NIGRNCITITATITNICTETITIERTRTITT1G 
lir 'be tiCC111G1T(iLMITRG(INKFIRTT IfITIF6TNEMNFIGNIFIfIti BUM] INC 1 Tifif1P6111666 C ITT CRERFICT6111116IMCBTOGCC 16618TI IGC1111111 'NNW TT T TG 
8191 8200 	8210 	8220 	8230 	8240 	8250 	8260 	8270 	Eno 	8290 	8300 	8310 	8320 
Rat 	FiG6176ITIIIINCIVIIITN1KFIT6CIllfiTBIER31--TI6TEN1-111811161811T6CC111111:11111G111111111GUIAREGIEGARRIIGT MI MN IFIC1 GMT BTURTIG1GGIIT 
Marine RC 6 ITGITIIT TF1BC INT T UNCUT nrocillilTNEfilltT8161C811 (Nit 1.11111161811161(11---6111111186CIRNGTIGNI11(11 TG1 C11110TACKIGINTRTC T-6 T NAT 
8321 8330 	8340 	8350 	8360 	8370 	8380 	8390 	8400 	8410 	8420 	8430 	8440 	8450 
Rat. TRC ITIGGF1111 ICI ICRE ri TIT TEIGICT-"IFIRNIREAHNI16111( GCT1f1GT1 Cl/E6111GC (CT 1611/1681616EfiNIC iTiCKR16f iTlIGUAN1C111A11611N116510111RRN11 
Marine T6CMGGNATCTICKGMT-T6TCBCTRTFINCTRE6RRENTFITGLIIRET1CREATITGCMTGIRMTAGNFINTCMCRIIT6111.11111T661ETARNTICCTTfiriTCRTIARNA 
8451 8460 	8470 	8480 	8490 	8500 	8510 	0520 	8530 	8540 	8550 	8560 	8570 	8580 
1 	—4 1....• 	-4 -4 .1- 	4 • 4- 4 4- I 
Rat 	GEBICTEIRTICRECATITGDITANNIN181X81111611011CUIRMIROC 1 TGNINTGBENTAT 69118CITIGINFMT1B11BRC Filif161C811/11 TIIIVINCT6118916EXTGliCCUX/1 
Marine GilfiCT6CITITCRECCITTTGGIIRKARTICCR1111111flOGNEXERTEfiffiNITGPMINGBRABITTGBEACTTI691111911I11911PCMCR----- CO611831ICP6166(CCT6R 
8581 8590 	.00 	8610 	20 	NN 	40 	8650 	0660 	8670 	0 	8690 	8700 	8710 
I -4 -4- ''-'0 4..... • -4- • 4- • -+-...-. I 
Rat Efl.468111878GCCRROTACTRAMITIT1GTTGIGNGTIMEANCARECITCCUMINGLAGINTATIURGRIATIIIGT1-8GROTICHAINPARGIGCLIBRIIITGTIGSCUMARCCA 
Marine 69111-66C861ANCRIBINTIRACATTITIGT1616NGTMITENGCARNCITUCRAIIRCUG-6IFITATE61111111GMPLIG1111(1111111111111811GCM1111(611GMC----- 
0711 8720 	0730 	8740 	8750 	8760 	8770 	8780 	8790 	8800 	8810 	8820 	8830 	0840 
Rat IINITANNERGRITCRINATB1T8TATC11TWITTIIRGENT8111M9111118TGGITITTCATTATURDNITTERTECTIINTflTCP61GTNITTNIC81111111XT-ECICTEGTER 
Marine ----(1116101CCNRT1111101111111111111C111111/11118110118ffiffillifiREIRBIGUITTICAHATERENITIMIN ITENTFICIITIGTACMGClifilllIITUCECICT8TD11111 
8841 8850 	61/ 	8870 	8880 	8890 	8900 	8910 	8920 	8930 	8940 	8950 	8960 	8370 
Rat CTITTC1CCTIIRTflGICITTIIITCATATT61111611101TEGRTACRININTIACTARMETRPAITtTF1311GGGRARTCC611—TIIITIITCATIKCCITICIT-ERIIC1CCAITC1CCIICCCI 
Marine CHICCICCCIICHIGICTCT111TERTRICKEINTGIDIC11111€111121111111IRCIRGCCIREAITCIBINGE1111C1111(01111101CCIIIIIICC1TICITGC1111CNIflittITC1 !Cal 
8971 8980 	8990 	9000 	9010 	9020 	9030 	9040 	9050 	9060 	9070 	9080 	9090 	9100 
I -4 4...... 	...4 .4... 	.4.4 -4 -4-- 	• 4- • 4- I 
Rat. TT ADRUCCICC1TITECTBIGIRG1TCCtCTICHTNATGCCFIT TITERGINFIRTHECCTIGRFIT8 TUDIGFOlfi f NII-NGT66IGTGITTCIECANITRERRATCT111111I--GTEGUTT 
Marine 1.1 fiGAG( CTC6-111 TECT66611161CCART1(11--816( TAll MN GrilfliiNCIREIT-111111T FCA(all RINI T TR6 GTGGIGTGI (TM CRI1G11112 A 1191CIG1GIGT6G111G Hi i 
9101 9110 	9120 	91.30 	9140 	9150 	9160 	9170 	9180 	9190 	9200 	9210 	9220 	9230 
Rat GNEINATRBOTGIGITTCBCCITG1IMICTTIRC11811183GTICENDIFIGN11111611141TTTRRITC86TGF1116MINCIFIGARRCT1F1FITGB—RAC1161—ARCIGICEBTUR 
Marine GAGN6f1TERAT6TGTITCRECITG1C(.2611-11111C16911141(16TGCEN-NOCI--611111----NEICTIFICTGITTTGRE1/11181111CTIRREGAGRAFICIT6T6361111111C111111111TUR 
9231 9240 	9250 	9260 	9270 	9280 	9290 	9900 	9310 	9320 	9330 	9340 	9350 	3160 
Rat MIRT6(111111DATIT01111(01B11146116011111161ITCIG1111111111-11CIXIIGC1111111111flUGGRACUOICI--1ARTIGCIIG1TARRAGINC1111B61111flTIGT8111/0 
Nurine 611I 8111.11116C1111 TOT MTCBG1TTICrIll1611I1 T---CT GTIETT1111111C11116C1T1611(11ACTG6REMORBC 16111181GCCT IC 111191111GIGFC TIN GIII111( 1GTAT 11111 
9361 9370 	9380 	9390 	9400 	9410 	9420 	9430 	9440 	9450 	9460 	9470 	9480 	se 
I ..........4 M. 	...11.• ....4 4- • ..... 4- 4 -.4... I 
Rat TECROATECOUNRSO(811141184111CRCNTGRMIGCTIB11118TCTGEMPHRFRICTI1A1flfl--11RBBUGAIMBIGBAR811181111108(BIOWN8161IGERRMOGNII 
Marine TRENTATLEMITABBRICE11(1BAGTECBCAGIGHCfl1GE11811TFITC16FAIRNGT-BITTIRRBIATTIROGRQUIBBRIBEN811(11111TRORREARTEINT61iGNOMIGT-- 
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	9491 9500 	9510 	9520 	9530 	9540 	9550 	9560 	5570 	9500 	9590 	9600 	9610 	9620 
-.4 1.... 	-4 4- 	...4 -4-- 4 4 -4- I 
Rat TI6DICREIRTTGRTUIRRAIRIGITERICTIFBRIMICTIfflT0TC8VIGCTI6CRIVIRGIBTECCT611166fIGRSTAIICIGTIACCTIVATTFORICC------TCUITTECTUGGICGT 
Ulm ------------41GRT6111CURNIRTIVITEITFITCANGCCT6C8661REIRTGCCITTFEINCRSTEIRETATTRICTARET95611107611 176Gt1THIIITIXTGTGERSI 
9621 9630 	4640 	9650 	9660 	9670 	9680 	9690 	9700 	9710 	9720 	9730 	9740 	9750 
Rat 	1 -16991 FRU TEGUAT GIEIVIGTGGTRCIRT1116EVIRTGICGT6TTGITGGRZI1G5T1f16TUICTGICEGGCTGGPIT ITRAGSTCCliTETIFIG---FICCOGIEC0611fIGSGGISIIICETC 
&rine TT fffililliCITEUCTIT 65611115166TITICNAGCCFRIGTC---1 IGG116166fIR7T TGGIGICTGITEGGGIGGECT T TERGGICCTIICTIC161616111XACCCAG-GCFIGIIIITARTRITCETr, 
9751 9760 	9770 	9780 	9790 	9000 	9810 	9820 	9830 	9840 	9850 	9960 	9870 	0 
I "4 'F- 	-4- 4.. 4 -..-4- 4.. 4 4 -1- I 
Rat TTGITECCTWICRIWRITCTICTGGCTGEtTITEGRICARtifITC16611XTITTGICTCITCCR6TGCRIGTEIGICTIOTGCTGICTITGETTCCTRUTTGOTGRTFIITGIIRCTAlifICEICT5A 
Marine CIGTIMIGC66111111261161CTTTIGGTIGCCIT-GGRTC1111611TREMS111161CTCTTCCR616CalIGTCIGItIRGRIGSTGICIIIGCTICCIGCCTINITGIITORTGlifICT6fICTICTEA 
9881 9890 	9900 	9910 	9920 	9930 	9940 	9950 	9960 	9970 	9980 	9990 	10000 	10010 
Rat 	PET—FIRGECRECCC-flATTIIRFIT-ITGICCTITGTRARGUICCTTGATIIICFSCHXGRIECCTTARCTIIERCHT TCCT-GREFIRCEFICRAT ICT691:11C119-ITTC66TGIRRGREG 6266 
Nur ine RAC TC1 Rau C FEC 	RITIITTGIf CTT TRTIIAGRGI TGECT T CA Itfi f FIRCf161691IIICC 11011--511C RAT T CCIAGITAMICC fl (1111T ICI FlartliC I TrIl T CTIRSGTRI1139 NIG UR 
10011 	10030 	10040 	10050 	10060 	10070 	10080 	10090 	10100 	10110 	10120 	10130 	10140 
Rat 	TfiGTTOICITICKTGT TT ITRIRGD-RXIICIGRITIICTGRGGaiRR---GGilliffECATR-TRIGC111IRTIRECTRGEFIRCEAR7CC IIRRTOCIMIRICIRTERRIIIRCRC--11GIRCI 
Merin TfIGTTRACIIICRCT6TTITIRIRrIEGRUCTCTGRflilCURGMCTRKTORGGITRREGGGITOTRIGNRIOTTRCETG%RRDCARUTTTERGT6CREFIIRTETRTFIIRCRACEFICTICIRCT 
101411 10160 10170 10180 10150 10200 10210 10220 Iona 10240 1050 10260 10270 
I ...4 	4-- 	4- 	• 	........ 	1.. 	4 	 4 	..4.. 	I 
Rat C----CACTSTGCATIECAFIREFRIRGOIVIACCRMITGETCEGfiliRATGEGAUGITFAIGFACTGIICTRARR1IIIIIGCTEAT--4110111GTGGCRTAICCETGC11ITCCTTGITGEARRIIC 
Marine CITIFIC(111111T6tfliRGUIRIXAMIGUITAGGIRFIFilliTEC ICAGFORIGGGNIIICCT6GIFIRGATET TURTIEGTXGCTIVT8881241FLITGTIECRIIIICIIITGCT 1T TECTTGT 166111126C 
10271 	10290 10300 10310 10320 10330 10340 10350 10360 10370 10380 10390 10400 
Rat 	AT 111R6C6C11611T A TRIM! 1 IC.11161611611611111111106TC1 HMG! TRIIIITCATICTEIIGTE1 T61106011111111161111X11611611311TICTIICKAF1111 FICTRCFICAGIIFCC1191 T6T1111 
Marine RTIEGUEITGRTATITIFICTITUITRT11111196609111011211TTTIGCRGITIITATIERFITICTEFIGTTITT8806CIIKAMIT6f1R269--CRIITRIA-TSAFIRIICTIICKAGFITCCITIIRTIII 
1041)1. 	10420 	10430 	10440 	10450 	10460 	10470 	10480 	10490 	10500 	10510 	10520 	10530 
I—4 	4— 1..- 	-4 -4-- 1- • 4 .4.. I 
Rat 	66-FIT61 TERM TEII1C----CTGIG--C TREGCSMIRT-GRUCT6TIGTCRUAIRRIIGC169TEVICCI TRECIVIT 1 [GT TARR I 1E5 TUT I T6TC1166661 T TET6CTITIXGRX119XC 
'lariat 86111-61 1 6T6C116GCTI166C8CRT161161C11111ETETC1TGRSICTGTIGTCRKfITE8CiCIFIRTGIRCTITRECTRT 1 ICTIRMIT MUCCI ITGICTTAGMC ITCHITTGCTGGNITAFFIK 
10531.1 	10550 	10560 	10570 	10580 	10590 	10600 	10610 	10620 	10630 	10640 	10650 	10660 
Rat IXCBTERIXRARRII-926C0RfITT6EGGEGGRINGGIT1161TWICTIllfiltfl-----CT6TMATCIECINGYSIGTOIGSIICRVIIFITTCRIX-66TfICREGIITECT11611GgfiGOGCT611 
*wine RCIRTGRCERFIEICCREGCMITTEGGCJIGG0161666111111TWICTIII6X1IMICKTGCTGTICRTC6CCRRAGFORAGTOIGDIC686f1FCICAR0166CIICKGRICTIGGIIMAGGIGCTER 
10661 	10680 	10690 	10700 	10710 	10720 	10730 	10740 	10750 	10760 	10770 	10780 	10790 
I '1.'4 	4- 1-, 	...4 .4... 	....14 4- 4 • .1... I 
Rat TGCRIERGIIRIGGRURGTICIGUIRLIGGITIGTITCCOTEGETTREITGRRIGIGC6CREGMTETCT-CTERCRCTCR-----CT---CRCRCRERMITTRAftIRC 
Morin 11169111f1GtC11T6-110GT I CTGCI IXIGST 1 IGT1TGCC fITEGCTDIC TECNG1GialiC TECCIXCC MCC C6C MC ITT 16111IRRINI111116T110116TIGCREACREfIG171116AffIC 
10791 	10810 	10820 	10830 	10940 	10850 	10960 	10870 	10890 	10090 	16900 	10910 	10920 
Rat 	TTCTIT----1 T TUT IITACRTERTRtfICTC 61311TICCACTC11 ICTCCfETECCTIDITRIXIIGCCIC MINT TGEllflifff CCC--CETTEf1117.60RARFITGIGGC9G1T6T661 
Ilurine TTITTRIGITTCTTIGTIRIITGROICRICOTTMCIIIIITCOICTCATET---EKCCITC11TROCRGCCICTGICTITGC1111CTICCUTDIT6MCFC093fifillrfffilITGIGMIGTTGT261 
10921 	10940 	10950 	10960 	10970 	10980 	10990 	11000 	11010 	1.1020 	11030 	1.1044 
4- I 
Rat 	MID C 6 T6T CCU (MT IFITTICETTGT6TTE6CRET T— T Ril T6Cf1119161 TDI t TEC T816061011 f.)6 TCT GMT MGM I CTGICTIC TGCT ACT( Till ARAI RC% GGT 
Marine 61616PCIETGTGICCOIC66T-IITAITSTICTGICCAT0CTICTITFITIGCHREGTIBITTECT—G1161CITTIGGTC169TI1666GUTETEGCTICIM1RCTCTRICRRIfICTGGIIT 
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D iii) Comparison of the sequence 3' to the TATA box in rat and 
murine CJBS 
1 	10 	20 	30 	40 	50 	60 	70 	80 	90 	100 	110 	120 	130 
1------4----...----4.---f.--.4------4----.4..............4.--4.--1.----4------4.----- I 
Rat 1CTATRARTACT6G6TECTERATIEGACTCCTUICRUTACCCT6TTGTUTECT6TGICATOWITCCITUIETITHATC16CAG6FICCRUCCTICIERTCCTCCRUTCACTUITTEGURGA-
Hurine TCTOTCARTACTGGATCTTCRATUGACTCTICTCRGURTCCCATTE---CCTGIGTCRTGCRCATCCTICIECTT-66ATCTICAGGFICCAGCCCTICACHT6CTCCRGITCACTGflTTEGTAGFIT 
131 140 150 160 170 180 190 200 210 220 230 240 250 260 
Rat -----------------RflUTT6GRICT6UCT66TT6RACTUT6R6CCT6TIRACICTCCT6TRETACACCATC11666119RACCUCTIETCCIGTCUMGTFIGCTCACCUMTGCT6CRETGR 
!brine 6TTRT66T6R6CCIFICCII6CCTT6GIITCTG6GCT6GTHR6CT6GTHGCCIATT66CTC TCTT6C1ICCTFIGICCIICCAGG6T1116CCCI CCIENCIGTECCIIGOTRGIITTACTORTGCTO DIET& 
261 270 280 290 300 310 320 330 340 350 360 370 380 390 
Rat GCTGGC11066G6T6GIECCATTICTCCICTIFT6CITT6G-GCCATCTUCCUTTICCATGCC6GCAGGflOGCTCTARTUTCHCCUIGGTOITGRAGTFICIEGGCCTGCTCTCCITGAGTGCT6 
urine ----GCCAGGOERGACTECCICTITTCTCAT6CCIIIGGIGCCUCTCRACCATTICCRTGCCR6CAGG6CCRETCTARTGIETECCAGGTHARTGRAGTRUIG6GCCTURCTCCITHGTGCT6 
391 400 410 420 430 440 450 460 470 480 490 500 510 520 
Rat CAGUICAGUTGUITICTIAIRMACCUGURTROCUTACCUICARTGGGETMCCTTCTICCACTGATCACTRATTGRGURATGC6TTATAGCT6G0TUCATURGUNTICCTRARCTGAGG 
urine CAGTICAGCCTETITCTICTAGARCCUGGARTWACTATTCACRATMGCTAGG-----------MTC-----TTGERMATGCCITACROOTCTUTUAGGCATTTCCITARCT6A6G 
521 530 540 550 560 570 580 590 600 610 620 630 640 650 
Rat CHTTICCTCTIITIVIGIECICTIETTTEGICAGIC6191111DIRMCCAGCTIVGCARCTRITUTTGT6PETTGATIICACIIIIMICRICKRACCCTECTECTTflTATCCflAnIIRTTflf1-11 
urine CTETTCATEXTRATAGOTTAGTTICTOTTRGCRTGACIICARMTAKTAUGURCT6FIRUCTT6T6flACTTRFITITHEMERUITTERACCITTUTTICTTIRTCCAMTECTIECIE 
651 660 670 680 690 700 710 720 730 740 750 760 770 780 
Rat TCCCATflGTCTICIICAMITTCARACIITUICflfliTTCOGICCUTTARFITAGCCARTTICTTC-IMICCHGTCTITTIVIR9TCCSARCTCTCTCRATTGTGGGETCRRIITARARTARRIITR110--
Hurine TCCEATIETCTIMCANTICAGWITTRCINTECOGECCITTIMTAGCCR6TTICITCCREHTCCRUCTITTAARATCCIIIIIICTCTC—flATTGIGGGETCHIMARIVICARIFICRARFINICRfl 
781 790 800 810 820 830 840 850 860 870 	:,1 890 900 910 
Rat -------------------------CMCITACTCCAFINGWIRATTAGGKRAGTT6CAINGC1111RfliCARATTCCIIRC 
urine FNICIERCUMBROCCIVIIRIMICARACMCIVNICARIMACCCII 0801118CRWROTACTITCTTACTCCAMIGGARANCTAGGERCASTOUVINCAMITCARflTICCOAC 
911 920 930 940 950 960 970 980 990 1000 1010 1020 1030 1040 
I••••••••••••••+•*.*.........4.••••••+•••••••••............+.•••••••••••••••4••k•."•'4•••••••••••••••i• F•. + I• .. .F 1 
Rat CflECTItT6TCT66611TIXACICACCIITCTICTOICTECTCCRANGT6TTGHTCETTCTCCAGETTCA--ITCDICTEITGET6CTUTCTT6GTTGGCRT6TCATG666CCOICE 
urine CflICCCHRTRTIT66GATERCTCARCATCT---660TTCCICURfl6T6CTIGHTC6CTICTCCA6C1TCRECTG6CITCATCCCRTT6TTGET6CTGTTCTT66TTGEDITUTATG666CCRfl6TC 
1041 1050 	1060 	1070 	1080 	1090 	1100 	1110 	1120 	1130 	1140 	1150 	1160 	1170 
Rat TIGGCRATTCTCTCCRATTG6TTCATIECTT-00RAMTATTAMICTT6VITGA--CTUITIITA6TACTOGITIGGCTUCROCRGARUITRCRACCTI6G1CRUTGCTGIETTTCRTMACACTT 
urine TIGUAGTTCTCCCTGACCUTTCATGCCITTCARTACCAGTAATACCTGGATUITTCTUICATRITIITGUIGICTIECTGRTGUTERGGTIERACCIT661TRCCTOTTGIETTTGRTURITACTI 
1171 1180 	1190 	1200 	1210 	1220 	1230 	1240 	1250 	1260 	1270 	1280 	1290 	1300 
Rat CCTGRARGATTT-GATTCRGTUTGCT6GT---CTCCICTCRATCATCRETRATTTCTIROMMGCTIFICCINITUDIOTTGITC116111fiTGCRARAGITTERCITCRGT6RTGC1GGICTCTI6TTA 
urine CCTGRARGOTTITGRCTERRTG0T6CTAGIRGCCTUTCTERATCCURTCRATTICTIT--------------------TTITTICCIERAT61161WITITTFITTEITT--TTOT6ITARRITTITT 
1301 1310 	1320 	1330 	1340 	1350 	1360 	1370 	1380 	1390 	1400 	1410 	1420 	1430 
Rat RGCTUIGCT6fiCTCMGETCCII6CT6RCTR6RFITM0611ATCTTRATTCARA-FITfl6CANCA6CCCTUT8611flAtICTARRCTICCETOMITCAUTRGECTCCATCUTTRUICTETCTC 
',urine 13--TT116--6T0TTT 116C TCIITTERCAMCCWITGCTIITA CallIFINTCTIXCFITIICCCMCDICCCCCfl—LICCCCTFICCCEICCCACTCUCC1I—TTTGGCC-CTGGCGTT-CCMGMCT- 
1431 1440 	1450 	1460 	1470 	1480 	1490 	1500 	1510 	1520 	1530 	1540 	1550 	1560 
Rat 	AflOTT GTIKT6TCCAGGITTCHAFITAIDITCCUICTRIETCTTARCHTTRIITECTER6ATAGGCCINGTICTGARGCTCCTCCIICHTGICICCACIHIFIRCHTUDIRGETGICKTEICARC 
urine --GG6GUITATORA GHT6CGTGICCARTGGGCCT--CTCTITCCRGT-G0TGGC-GFICTAGGCCIITC-TITTOT ACIITATERGIT AGFIGHIHIGfl 6CTCCGC— 	ACT66TT 
1561 1570 	1580 1507 
Rat ACCCARCTIIT6CT6GTACCARCTTUC 
urine GTICATR-ATGITG-TTCCACCTATflG 
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Appendix E Reagents 
Supplier Reagent 
AB Gene 10x Buffer IV (PCR) 
0X174 RF DNA Hae III digest DNA ladder 
Taq polymerase 
Alexis 
Biochemicals 
GF109203X 
LY294002 
Microcystin 
SB203580 
Amersham 151.1Ci [y32P]ATP triethylammonium salt 
Hyperfilm 
Poly di-dc sodium salt 
Rainbow molecular weight marker (RPN 800) 
BD Biosciences Chromaspin columns pore size 10 
BDH Acrylamide 
Benzamide 
Bis-acrylamide 
Boric acid 
EDTA 
Ethanol 
Glucose 
Glycine 
Glyerol 
Glycerophosphate 
HEPES 
Isopropanol 
MgC12 
MgSO4 
Methanol 
Methylated spirit 
Nonidet® P40 (NP40) 
KC1 
NaC1 
NaF 
Na2HPO4 
Na3VO4 
Sodium dodecyl sulphate (SDS) 
Sucrose 
Tris 
Triton X100 
Tween 20 
Beckton 
Dickenson, 
Primaria culture dishes 
Biogenesis RNAzol BeeTM 
BioRad Bradford Reagent 
BOC gases Liquid N2 
DAKO Horseradish peroxidase-conjugated secondary antibodies 
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Harlan Neonatal (two day old) Sprague-Dawley rats 
Invitrogen 100 bp DNA ladder 
Agarose 
dATP, dCTP, dGTP, dTTP 
DNase I Amp Grade (1 U / pl) 
DNase I reaction buffer 
Dulbecco's modified Eagle's medium (DMEM) 
M199 
Foetal Calf serum 
Horse Serum 
M-MLV reverse transcriptase 
Penicillin and streptomycin 
Phosphate buffered saline (PBS) (10x) 
RNaseOut® 
5x 1St strand buffer (cDNA synthesis) 
Trypan blue solution 
MWG Biotech PCR primers 
New England 
Biolabs 
Primary antibodies 
Promega 10 x kinase buffer (EMSA) 
Random hexamers 
T4 polynucleotide kinase (EMSA) 
Qiagen QlAquick PCR purification kit 
QlAquick gel extraction kit 
Santa Cruz 
Biotechnology 
Chemiluminescence reagents 
p53 EMSA probe 
Primary antibodies 
Schleicher and 
Schuell 
Nitrocellulose membrane (Protan®) 
Sigma Actinomycin D 
Ammonium persulphate 
Bovine serum albumin 
Bromophenol blue 
Chloroform 
Cycloheximide 
Dithiothreitol (DTT) 
EMSA probe oligonucleotides 
Endothelin (ET-1) 
Ethidium bromide 
Gelatin 
H202 
Leupeptin 
Pancreatin 
Phenylmethylsulfonyl fluoride 
Protein A-Sepharose 
Sonicated salmon sperm DNA 
SP600125 
TEMED 
Trans-epoxysuccinyl-L-leucylamido-(4-guanidino) butane 
U0126 
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Waitrose Non-fat milk powder 
Worthington Collagenase 
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